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1 
Summary 
Atopic eczema (AE) or atopic dermatitis is an inflammatory skin disease 
characterised by chronic relapse and remission associated with severe pruritus and skin 
lesions. The prevalence of AE has increased globally over the last three decades. In Australia, 
a 12-month period prevalence of AE was 17.2% in school students aged from six to seven 
years and 24.8% in children aged eight to 11 years. The pathogenesis of AE is yet to be fully 
elucidated; the risk factors associated with the increasing prevalence of AE are better 
understood.  
Clinically topical administration of corticosteroids or calcineurin inhibitors is the 
standard first-line pharmacotherapy for mild AE. Systemic medications including oral 
corticosteroids or immunosuppressive drugs are used for more difficult-to-treat or refractory 
moderate or severe AE patients. However, application of systemic medications over a long 
time can lead to unwanted adverse events. Therefore many AE sufferers have chosen to use 
alternative therapies including Chinese herbal medicine (CHM) to manage their AE.  
In spite of long-term use of CHM in clinical practice and the recently increasing 
clinical literature concerning the benefit of CHM treatment for AE, the current state of 
evidence for topical and oral CHMs has not been systematically evaluated. It should be noted 
that despite such evidence gaps, a series of CHM formulae for AE has been included and 
recommended in the Chinese Medicine Guidelines 2011 and Expert Consensus 2013 
(publication 2).  
The present thesis aimed to address this by evaluating the current literature and 
identifying priority targets for generating new clinical evidence. Specifically, this research 
aimed: 1) to systematically evaluate the current state of clinical evidence with respect to 
benefits and safety of CHM for patients with AE; 2) to identify new clinical research 
 
2 
priority(ies) and develop a protocol for a randomised, double-blind, placebo-controlled 
clinical trial; and 3) to conduct a pilot study to determine the feasibility of the trial protocol 
and to gather preliminary data for the efficacy and safety of Pei-Tu-Qing-Xin granules 
(PTQX), a CHM preparation for children aged six to 16 years with moderate to severe AE. 
To address research question 1), two systematic reviews with meta-analysis were 
conducted and published (publications 4 and 5). The first systematic review included 10 
randomised controlled trials (RCTs) involving 1,058 participants who were treated topically 
with CHM or positive pharmacotherapy control interventions. Meta-analysis of these 10 trials 
shown an overall effect in favour of CHM in terms of “total effectiveness rate” when 
compared to topical conventional medications. However, caution should be given to these 
finding due to the high “risk of bias” and significant methodological flaws of the included 
trials. The second systematic review was a Cochrane Systematic Review which included 28 
RCTs involving 2,306 children and adults. In most of the included studies, a higher number 
of participants were reported to reach clinical remission and significantly lower scores of 
itching in CHM groups when compared with the control groups. Again, most of the included 
studies were assessed as high “risk of bias”. Hence findings need to be interpreted with 
caution. The above two systematic reviews concluded that while promising overall benefits 
were shown, well-designed, adequately powered RCTs were needed to determine the clinical 
efficacy and safety profile of the key CHM interventions for AE. 
To address research questions 2) and 3) based on the key findings from the two 
systematic reviews, a trial protocol for an RCT was developed and approved by the RMIT 
Human Research Ethics Committee (HREC) in 2014 and published in 2015 (publication 3).  
Using this published protocol, a pilot study was carried out between August 2016 and 
September 2017 in an out-patient clinical setting. The pilot study was a parallel design, 
randomised, double-blind, placebo-controlled, prospective clinical trial. It aimed to determine 
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the feasibility of the protocol and to gather preliminary data concerning efficacy and safety of 
a common Chinese herbal formula (PTQX) for children aged six to 16 years who were 
diagnosed with moderate or severe AE. The trial medications were given to participants for 
oral ingestion with a dosage of four grams of trial medications twice daily (total of eight 
grams) for six to seven year olds and six grams twice daily (total of 12 grams) for eight to 16 
year olds, for 12 weeks and cessation of medications for four weeks during the follow-up 
period. The trial protocol was successfully implemented. All mean scores of eczema area and 
severity index (EASI), patient-oriented eczema measure (POEM) and children’s dermatology 
life quality index (CDLQI) in the PTQX group were lower than those in the placebo group at 
the end of follow-up. Furthermore, a more obvious trend of decrease in total dosage of topical 
corticosteroid creams which were routine medication (concomitant medication) used by 
participants in both groups was recorded in the PTQX group although no statistically 
significant between-groups differences were detected. This may be due to the small sample 
size (n=30, 16 in PTQX group) involved in the pilot study. The feasibility of the trial design 
and the overall positive trend demonstrated in the outcome measures support the conduct of a 
full-scale trial to address the clinical evidence gap (publication 1). 
In conclusion, the present research employed rigorous methodologies and applied 
evidence-based approaches to determine the current state of clinical evidence for the efficacy 
and safety of CHM in AE. While recognising the methodological weakness of the included 
studies in the two systematic reviews, the promising positive findings have enabled us to 
identify research priorities and to develop a trial protocol for an appropriately powered RCT 
to generate new clinical evidence that will support sound clinical decision making. Further, a 
completed pilot study, which was designed to overcome the weaknesses and risk of bias 
inherent in the published literature, demonstrated the feasibility of the trial protocol and 
showed a positive trend for the benefit and safety of the CHM preparation. Given the clinical 
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challenges to offer effective and safe therapeutics for the patient population, an adequately 
powered trial on this herbal preparation is warranted as a priority to deliver evidence 
appropriate for the development of Chinese medicine therapy for AE.   
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Chapter 1  Introduction 
1.1 Rationale of the Study 
 
Atopic eczema (AE) or atopic dermatitis (AD) is a chronic inflammatory skin disease 
with feature of chronic relapse and remission associated with severe pruritus (itchiness) 
(Reitamo, Luger, & Steinhoff, 2008). Other clinical manifestations of the condition include 
poorly demarcated redness of the skin with surface changes such as scaling, swelling, 
accentuation of the hair follicles and lichenification as a result of long time scratching (H. 
Williams et al., 2009). The visible appearance of AE can negatively affect a person’s self-
esteem, with the disease often being associated with poor quality of life (QoL). AE has a 
major impact on QoL with patients experiencing adverse psychological and social 
consequences (Schmid-Ott, Burchard, Niederauer, Lamprecht, & Kunsebeck, 2003; van 
Valburg et al., 2011). 
Current conventional medical treatment for moderate and severe AE is not 
satisfactory. Patients with mild AE are treated with topical application of corticosteroids and 
emollients, while refractory moderate or severe AE are managed with systemic 
immunomodulating medications including oral ingestion of corticosteroids or 
immunosuppressive drugs such as azathioprine, cyclosporine, mycophenolate and 
methotrexate. However, long-term application of corticosteroids can lead to adverse reactions 
such as suppression of the hypothalamic–pituitary–adrenal axis (HPAA), osteoporosis, 
aseptic necrosis of the hip, hypertension, ocular changes and altered immune function 
(Walling & Swick, 2010). Side effects from immunosuppressives have raised concern, 
particularly the risk of hepatosplenic T-cell lymphomas with connection of azathioprine 
(Denby & Beck, 2012). Therefore, many AE sufferers have chosen to use Chinese herbal 
medicine (CHM) for treatment of their AE (Hon, Ma, Wong, Leung, & Fok, 2005). 
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The history of CHM can be traced back in the 2
nd
 century A.D. when Shennong’s 
Classic of Materia Medica (Shen Nong Ben Cao Jing 《神农本草经》 in Chinese) the 
earliest CHM monograph was published. Unlike conventional medicines, CHM has been 
used in the way of compositing different botanical resources such as barks, seeds, flowers, 
roots or mineral substances into a formula and administered in forms of decoctions, pills, 
washing lotions, or ointments for diseases. As more and more clinical research of AE 
managed with CHM have been conducted worldwide, it is critical to systematically assess the 
efficacy and safety of CHM for management of AE. The findings of this study will provide 
crucial evidentiary basis for policy making and the use of CHM for clinical management of 
AE. 
1.2 Objectives and Research Questions 
 
1.2.1 Primary Objective 
The primary objective for this study was to review relevant knowledge of AE from 
published literature in order to address the following research questions: 
1) What is the definition of AE? 
2) What is the prevalence rate of AE in the past decades? 
3) How does AE impact patients and their family? 
4) What are the risk factors and pathogenesis of AE? 
5) What are the main clinical features of AE across different age groups? 
6) What are the diagnostic criteria, differential diagnosis from other itchy skin 
diseases and scales for measuring severity of AE? 
7) What are the theory and practice in Chinese medicine for AE? 
8) What are the currently available conventional medical and CHM treatments for AE?  
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1.2.2 Secondary Objective 
The secondary objective was to systematically evaluate the existing efficacy and 
safety evidence for use of CHM in treating AE by addressing the following research 
questions:  
1) What is the best available clinical evidence for topical application of CHM for AE? 
2) What is the best available clinical evidence for oral ingestion only or in 
combination of oral and topical application of CHM for AE? 
1.2.3 Tertiary Objective  
The tertiary objective was to develop a protocol for a randomised, double-blind, 
placebo-controlled clinical trial (RCT). 
1.2.4 Quaternary Objective  
The quaternary objective for this study was to conduct a clinical trial to evaluate 
efficacy and safety of a Chinese herbal formula for children aged from six to 16 years 
old with moderate to severe AE, in order to address the following research questions: 
1) What is the efficacy of the Chinese herbal formula for children aged from six to 
16 years old with moderate to severe AE? 
2) Is this Chinese herbal formula safe for children aged from six to 16 years old with 
moderate to severe AE? 
1.3 Outline of This Thesis 
 
The thesis consists of seven chapters. Chapter 1 provides a general introduction to the 
rationale, objectives, and research questions presented in this thesis.  
Chapter 2 reviews the published literature of AE from the conventional medical and 
Chinese medicine perspective for answering the primary research questions (see Chapter 
1.2.1). It covers the prevalence, socio-economic burden and impacts, risk factors and 
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pathogenesis, clinical features, diagnosis, and differential diagnosis, severity measurement 
and treatment of AE. A discussion on the advantages and short-comings of conventional 
medical and CHM for treating AE is provided. As evidence of CHM for AE collected in this 
chapter had not been evaluated systematically, systematic reviews were conducted, one for 
topical application of CHM and another for oral and combination of oral and topical 
application of CHM for AE. These are presented in Chapters 3 and 4 respectively.   
Chapter 3 describes the detailed findings from a meta-analysis and systematic review 
of topical application of CHM for AE in children. As the finding in this chapter suggested 
that a more comprehensive pre-protocol systematic review such as Cochrane Systematic 
Review of Interventions was required for further evaluation of CHMs in both oral and topical 
administration for AE; thereby such a review was conducted.  
Chapter 4 reports the findings and recommendations from a Cochrane systematic 
review. This chapter focuses on collection of data by pre-specified set criteria, quantitative 
analyses of data with meta-analysis and critical appraisal of risk of bias among the included 
RCTs with domain-based evaluation as well as assessment of the quality of the evidence. No 
conclusive evidence that CHM taken by mouth or applied topically to the skin could reduce 
the severity of AE in children or adults and well-designed, adequately powered RCTs were 
recommended to evaluate the efficacy and safety of CHM for managing AE presented in 
Chapter 4. Building on the findings presented in Chapters 3 and 4 a trial protocol was 
developed to address this knowledge gap. 
Chapter 5 provides the derived RCT protocol. Key elements for conducting a high-
quality RCT, such as randomisation, sequence generation, allocation concealment, blinding 
methods, proper sample size, compliance with protocol, determination of baseline and 
endpoint as well as adequate outcome measures have been included; thereby addressing the 
objective outlined in Chapter 1.2.3.  
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Chapter 6 reports the results of a pilot study. Findings of this chapter have provided 
feasibility of a full-scale of RCT which addressing the objective in Chapter 1.2.4.  
Chapter 7 provides a concluding discussion with recommendations based on the 
evidence presented in the previous chapters.  
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Chapter 2  Literature Review 
 
 
The contents of this chapter have been published in the international peer-reviewed 
journal: Sherman X. Gu, Anthony L. Zhang, Meaghan E. Coyle, Dacan Chen & Charlie C. 
Xue (2016) Chinese herbal medicine for atopic eczema: an overview of clinical evidence. 
Journal of Dermatological Treatment, 28:3, 246-250, DOI: 10.1080/09546634.2016.1214673 
Section I: Conventional Medical Viewpoint 
2.1 Terminology 
 
The term eczema stems from the ancient Greek word “ékzema” meaning “to boil out” 
(ek, “out of”, zema, “boiling”) and applies to inflammatory skin disorders with rashes and 
redness. The term dermatitis (“derma”-skin, “-itis”-inflammation) also refers to inflammatory 
skin disorders; therefore, eczema and dermatitis are synonymous (Sehgal, Srivastava, 
Aggarwal, & Sharma, 2010). The term atopy or idiosyncrasy was coined for the human 
hypersensitiveness which has the following feature: it is inherited, limited to a small group of 
patients, differs from ‘‘anaphylaxis’’, occurs only in particular individuals that have suffered 
from hay fever and bronchial asthma and associated with immediate-type (wheal-and-flare) 
skin reactions (Coca & Cooke, 1923). The term AD was first posited by Wise and Sulzberger 
in 1933 (Reitamo et al., 2008); however it took almost another 50 years for the diagnostic 
criteria for AE to be presented (J.M. Hanifin & Raika, 1980). Although the term AE is 
frequently used, not all those afflicted with typical AE are truly atopic; that is, they do not 
demonstrate specific immunoglobulin E (IgE) antibodies to common environmental allergens 
such as house dust mite, pollens, grass, and foods (Flohr et al., 2008). This cohort of AE 
patients is identified as “intrinsic AE” in some European countries including Germany, 
Netherlands, Hungary and Italy and the term is also popular in Asian countries such as South 
Korea and Japan in order to distinguish from “extrinsic AE”, those who have significantly 
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high levels of IgE when exposed to environmental and food allergens (Tokura, 2010). AE is 
frequently observed during infancy, with infants or children less than 16 years old diagnosed 
with “eczema” being considered as an AE; therefore, infantile eczema or childhood eczema is 
regarded as equivalent to AE (Carbone, Siu, & Patel, 2010; Maloney & Sicherer, 2006; 
Musgrove & Morgan, 1976). In accordance with the World Allergy Organisation 
recommendations on nomenclature, the term “eczema” should be used for cases where 
immunological mechanism of the disease is unclear (Johansson et al., 2004). AE is often used 
in the United Kingdom (U.K.) while AD is more popular in the United States of America 
(USA) (H. Williams et al., 2009). In short, the terms AE, AD, infantile eczema, childhood 
eczema or eczema are interchangeable denoting the same condition and this is reflected in 
this thesis.  
2.2 Prevalence  
 
The prevalence of AE has increased over the last 30 years globally, especially in those 
aged six to seven years (Watson & Kapur, 2011; H. Williams, Stewart, von Mutius, Cookson, 
& Anderson, 2008). A systematic review of epidemiological studies from 1990 to 2010 
reported that the incident rate of AE was increasing in Africa, Eastern Asia, Western Europe 
and parts of Northern Europe such as the U.K. (Deckers et al., 2012). For instance, the 12-
month prevalence rate of flexural eczema symptoms in children aged 13 to 14 years increased 
from 1.7% (1994–95) to 2.2% (2001) in Guangzhou City, China (H. Wang, Zheng, & Zhong, 
2006). In the U.K., the prevalence of AE in boys and girls aged six to seven years old 
increased from 17.8% to 21.0% and from 18.7% (1995–96) to 22.5% (2001–02), respectively 
(Shamssain, 2007). Almost one in nine of English children and adults have experienced AE 
with an estimate of 5,773,700 English population had the condition from 1999 to 2005 
(Simpson, Newton, Hippisley-Cox, & Sheikh, 2009). AE also affected 8.3% of children aged 
three to six in China, up to 17% of children and 10.2% of adults in the USA (Silverberg & 
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Hanifin, 2013; Spergel, 2010; Xu et al., 2012). In Australia, a 12-month period prevalence of 
eczema was 17.2% in school students aged from six to seven years and 24.8% in children 
aged eight to 11 years (Robertson, Roberts, & Kappers, 2004; Toelle et al., 2004). The 
incidence rate (35.1%) of AE in Australian born children aged four to six years was 
significantly higher than those born in non-English speaking countries (Ponsonby et al., 
2008). A survey reported that about one in three infants had eczema by one year old in 
Australia (Martin et al., 2013). 
2.3 Socio-economic Burden and Impact of QoL  
 
 As AE is a chronic inflammatory skin condition with severe itchiness and it is a very 
common disease in children (as outlined in Section 2.2), the socio-economic burden 
associated with AE should not be under estimated. A study conducted in the USA showed 
that the average monthly personal cost of AE was US$ 274 with US$ 75 from direct costs 
which were directly related to the treatment and US$ 199 from indirect costs such as sick 
leave from work or school, transportation for medical care, and childcare costs (Filanovsky et 
al., 2015). In Asia and Pacific region, annual overall costs related with AE ranged from 
approximately US$ 1,000 to 6,000 in developed countries such as Australia, South Korea and 
Singapore. Costs were lower in developing countries including Philippines, Indonesia and 
Malaysia, where outlays ranged from US$ 199 to 743 per patient per year over the period 
1997 to 2013 (Lee & Detzel, 2015). The ongoing burden is highlighted by a study from the 
Netherlands where they report that 12% of adult patients interviewed with moderate to severe 
AE took sick leave due to their skin condition in the previous two weeks (van Os-Medendorp, 
Appelman-Noordermeer, Bruijnzeel-Koomen, & de Bruin-Weller, 2015).  
AE is characterised with symptoms of pruritus, general skin dryness, facial 
involvement, and sleep disturbances. All of these are associated with reduction of QoL. A 
study from nationwide cohort of AE patients in Germany showed that AE patients expressed 
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more markedly reduction of QoL than other chronic skin diseases such as rosacea, psoriasis 
and vitiligo (Beikert et al., 2014). A recent study suggests that a holistic approach with 
integration of psychotherapy, behavioural therapy and dermatologic therapy should be used 
for management of AE as impairments of QoL correlate with disease severity, skin lesion, 
depression, anxiety and stress in young patients with AE (Hon et al., 2015). 
2.4 Risk Factors and Pathogenesis  
 
The causes of AE are still vague, but risk factors that are associated with prevalence 
of AE have been identified. They include deficiency of vitamin D, climate factors such as 
combined high humidity and precipitation, prenatal or psychological stresses and genetic 
alterations, in particular loss-of-function mutations of the filaggrin gene (FLG) (Baiz et al., 
2014; Buske-Kirschbaum et al., 2013; H. M. Cheng et al., 2014; Silverberg & Hanifin, 2013; 
S. S. Wang et al., 2014). Genetics are critical in AE pathogenesis as most patients with AE 
display “AE march” which is a progression of food allergy, rhinitis and asthma in certain 
ages (Spergel, 2010). FLG encodes profilaggrin which can be dephosphorylated and cleaved 
by serine proteases into filaggrin. Filaggrin is crucial for formation of a healthy intact skin 
barrier. The skin has two sets of barrier: stratum corneum and tight junctions. Filaggrin 
deficiency in AE leads to decreased hydration of the stratum corneum and increased 
transepidermal water loss, consequently general dry skin occurs in patients with AE. Tight 
junctions seal adjacent stratum granulosum keratinocytes that is just below the stratum 
corneum and research showed that patients with AE have lower level of tight junction 
proteins claudin-1 (Cldn-1) and claudin-23 on their nonlesional epithelium. A recent study 
reports that down-regulation of Cldn-1 could be triggered by skin inflammation in AE 
(Gruber et al., 2015). Once the skin barrier is breached, initially the rapid innate immune 
response then an adaptive immune response must be initiated to prevent further invasion of 
foreign pathogens. Increase of T-helper cell (Th) 2 cytokines including interleukin (IL) 4, IL-
 
14 
13 and IL-31 and the Th22 cytokine (IL-22) are observed in patients with AE. Therefore, AE 
is often known as a Th2- and Th22 mediated inflammatory skin disease. IL-4 and IL-13 
promote IgE and eosinophilic responses in atopy and IL-31 can give rise to severe pruritus as 
well as inhibit epithermal differentiation. Additionally IL-4, IL-13, and IL-31 induced a 
down-regulation of Cldn-1 which in-turn is down-regulated in keratinocytes and brings about 
abnormal epithermal differentiation (Berger, 2000; Gruber et al., 2015; Kim & Leung, 2012; 
D. Y. Leung, 2013; Malajian & Guttman-Yassky, 2015; Miyagaki & Sugaya, 2015; Osawa, 
Akiyama, & Shimizu, 2011; Spergel, 2010). Skin barrier dysfunction from FLG mutations 
supports the “outside-in” AE pathogenic hypothesis while secondary immunologic activation 
leads to further stress on the barrier is considered as “outside-to-inside-back-to-outside” AE 
pathogenesis (Thyssen & Kezic, 2014). AE develops in those who are filaggrin-deficient with 
exposure to risk factors such as insufficiency of vitamin D, climate changes or psychological 
stress and those who have innate and adaptive immunologic responses to these factors at the 
same time. Although filaggrin plays a key role in AE pathogenesis, further study is warranted 
as only about 20-30% of FLG mutation carriers develop AE (Malajian & Guttman-Yassky, 
2015). 
2.5 Clinical Manifestations  
 
AE is a pruritic (itchy) chronic inflammatory skin disease with pattern of relapse and 
remission of skin lesions. It occurs most frequently in infants and children, persisting into 
adulthood in some cases. AE is typically associated with personal or family atopic conditions 
such as asthma or allergic rhinitis (DaVeiga, 2012). Clinical features of AE are different in 
infants, children and adults although pruritus, eczematous rashes, loss of sleep and impact on 
psychosocial wellbeing of patients are seen in all age groups (Baron, Cohen, & Archer, 2012; 
Eichenfield, Tom, Chamlin, et al., 2014; Lyons, Milner, & Stone, 2015; NICE, 2007).  
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2.5.1 Atopic Eczema in Infants (New Born to One Year Old) 
AE can begin in children as early as in the age of two or three months of age, with 
skin erythema (redness) and induration/papulation (rashes) appearing on the scalp and face, 
especially on the cheeks (Figure 1)Figure 1. The affected skin may be dry with bleeding, 
oozing, cracking and oedematous. The child may scratch the pruritic area by rubbing against 
the clothing or other accessible items in their environment and have difficulty in falling 
asleep or shown restless at night due to severe itchiness. Excoriation from scratching can also 
be associated with localised flaring. 
Figure 1 A 10 months old boy with atopic eczema 
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2.5.2 Atopic Eczema in Children (Two to 16 Years Old)  
AE in the this age-group is characterised as a rash on the creases of the elbows, knees 
(flexural surfaces of the limbs) or buttock associated with general dry skin and intense 
pruritus (itchiness). The skin may look darken or thicken as a result of repeated excoriation 
from scratching. Figure 2 demonstrated a three year old child with rashes and excoriation on 
the creases of the buttock and popliteal fossae. 
 Figure 2 A three years old boy with atopic eczema 
 
 
 
2.5.3 Atopic Eczema in Adults 
In addition to the above features of AE in infants and children, AE often covers all 
over of the body in adults. An extremely pruritic, dry and scaly skin is also common in adult 
patients. Impetiginisation may secondary to Staphylococcus aureus infection. Thickness 
(lichenification) of affected skin may be seen in chronic cases. Figure 3 presents an adult with 
AE which covers all of the body. Figure 4 shows lichenous rashes behind the knee (i.e. 
popliteal fossa) on the same patient.  
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Figure 3 An adult with atopic eczema 
 
 
Figure 4 Lichenous rashes behind the knee of an adult with atopic eczema 
 
 
To identify the heterogeneity within the natural courses of AE a German study 
recruited 725 patients with AE (Garmhausen et al., 2013). Patients were classified into five 
subgroups according to the age of onset and further subdivided into 31 different course types 
depending on the condition during five different lifetime periods. One third of all patients 
was type 5 and demonstrated an early childhood onset and persisting chronic course till 
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adulthood. Type 5 patients with AE had the highest total serum IgE level, higher rate of food 
intolerance, more often flexural eczema, more vulnerable to be impacted by psychological 
factor and much noticeable atopy signs than the other types of AE. In contrast to type 5 AE, 
more type 31 patients reported non-allergic variants with a late onset of the condition. These 
findings were consistent with features of extrinsic or intrinsic AE and support the need for 
stratification of AE patients based on different phenotypes of AE in the future research and 
clinical practice (D. Y. Leung, 2013; Tokura, 2010). 
2.6 Diagnostic Criteria  
 
There are a number of published and validated diagnostic criteria for determination of 
AE over the past decades. These are summarised below and presented in Table 1. 
2.6.1 Hanifin and Rajka’s Diagnostic Criteria  
Hanifin and Rajka introduced the first diagnostic guidelines for AE in 1980 (J.M. 
Hanifin & Raika, 1980). These include at least three major criteria such as pruritus 
(itchiness), typical dermatitis or eczema that has a history of relapses, typical distribution of 
the skin rashes and the patient or any of the family members suffering from allergic diseases. 
Besides the major criteria, three or more minor criteria have to be present according to the 
Hanifin and Rajka diagnostic criteria. These minor criteria are: dry skin, cataract, lip 
dermatitis, recurrent eye inflammation and irritation, pale or red face, food intolerance, hand 
eczema, elevation of IgE levels, Immediate type I skin test reactivity, recurrent infections, 
itching on sweating, ptyriasis alba, white patches on the face and exposed area, showing mild 
scaling, white dermographism (on stroking, skin becomes white and raised, instead of red line 
typically seen), keratinous (cone shaped cornea seen between 20-40 years of age in very 
severe cases of atopic eczema). Others conditions such as keratosis pilaris (hair follicle 
oriented hard bumps), nipple dermatitis, dark eye circles, wool intolerance, linear marks on 
 
19 
the palms are also the items of minor criteria included in the Hanifin and Rajka’s diagnostic 
criteria. 
2.6.2 Kang and Tian Diagnostic Criteria 
Kang and Tian diagnostic criteria collected clinical and laboratory findings from 372 
Chinese patients with AE (K. Kang & Tian, 1986; K. F. Kang & Tian, 1987, 1989). Kang and 
Tian suggested the diagnosis of an AE should have two basic features (chronic/chronically 
relapsing dermatitis with pruritus or personal/family history of atopy) or one basic feature 
plus three minor features (genetic, immunologic or pharmaco-physiologic associations). The 
Kang and Tian’s diagnostic criteria have been widely used in the clinical studies in China 
since they have been published in 1986 but were not be recommended by the Guidelines for 
diagnosis and treatment of atopic dermatitis in China (2014) authorised by the Chinese 
Society of Dermatology as the guidelines’ authors indicated that the U.K. Working Party’s 
diagnostic criteria were more appropriate (H. Gu & Zhang, 2014). 
2.6.3 Schultz-Larsen’s Criteria 
Schultz-Larsen’s criteria setup in 1992 utilises 24 questionnaires based on typical 
eczematous lesions; onset age and duration of the condition; and personal or family history of 
atopy (Schultz Larsen & Hanifin, 1992). Each question was allocated a certain point value 
and 60 or more points donated definite AE. 
2.6.4 The U.K. Working Party’s Diagnostic Criteria 
Due to the complexity and lack of validation of the Hanifin and Rajka’s diagnostic 
criteria, the U.K. Working Party’s diagnostic criteria were developed in 1994 by a working 
group of 13 dermatologists, two family medical practitioners and a paediatrician from the 
U.K.(H. C. Williams, Burney, Hay, et al., 1994; H. C. Williams, Burney, Pembroke, & Hay, 
1994; H. C. Williams, Burney, Strachan, & Hay, 1994). According to the U.K. Working 
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Party’s diagnostic criteria, a person must have: a pruritic (itchy) skin condition in the last 12 
months plus three or more of the following conditions: onset under the age of two; history of 
flexural involvement; history of a generalised dry skin; personal history of other atopic 
disease such as asthma or hay fever (in children under four years old, history of atopic 
disease in a first degree relative may be included); and visible flexural dermatitis. The U.K. 
Working Party diagnostic criteria are the most thoroughly validated among those six 
diagnostic criteria for AE although the Hanifin and Rajka diagnostic criteria were often used 
in clinical trial (Brenninkmeijer, Schram, Leeflang, Bos, & Spuls, 2008). In addition, the 
criteria of Hanifin and Rajka or Kang and Tian or the U.K. Working Party have demonstrated 
similar diagnostic efficiency in a survey based on out-patient hospital setting in Chinese 
population (H. Gu et al., 2001). It has been reported that the U.K. Working Party criteria were 
easier to apply without invasive tests. 
2.6.5 The International Study of Asthma and Allergies in Childhood (ISAAC) 
Questionnaire  
ISAAC questionnaire incorporated recommendations from Hanifin and Rajka’s 
diagnostic criteria and the U.K. Working Party’s diagnostic criteria for assessment of the AE 
prevalence (Asher et al., 1995). It is comprised of six questions for children aged between 13-
14 years old and seven questions for children aged from six to seven years old. Children with 
three scores or more of the “core questionnaire for eczema” were considered AE. 
2.6.6 Diepgen’s Criteria  
Thomas Diepgen and his team developed and validated diagnostic scores for AE in 
1996 (Diepgen, Sauerbrei, & Fartasch, 1996). An objective model (atopic features such as 
allergic asthma or rhinitis without subjective features), a simplistic model (no laboratory 
measures and subjective features), and a model without constraints of objective or subjective 
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features were listed. A patient scoring 10 points or more from the combination of the first two 
models is considered an AE. However, the Diepgen diagnostic scores have not been used in 
published studies. Table 1 summarises the diagnostic criteria sets.  
 
Table 1 Published and validated diagnostic criteria for atopic eczema 
 
Criteria  Year of publication Requirements 
Hanifin and Rajka diagnostic 
criteria 
1980 At least 3 major features 
plus 3 or more minors  
Kang and Tian diagnostic criteria 1986 Two basic features or 1 
basic plus 3 minor features  
Schultz-Larsen’s criteria 1992 ≥ 60 points 
U.K. Working Party diagnostic 
criteria 
1994 Pruritus plus at least 3 
conditions  
ISAAC questionnaire 1995 Score ≥ 3 
Diepgen’s criteria 1996 ≥ 10 points 
Abbreviation: ISAAC, International Study of Asthma and Allergies in Childhood. 
2.7  Differential Diagnosis 
 
AE is an itchy inflammatory skin disease that needs to be differentiated from skin 
disorders characterised by itchiness or other inflammatory signs.  
2.7.1 Scabies  
Scabies is an intensive nocturnal pruritus (itchiness) infestation skin disease caused by 
scabies mite (Shimose & Munoz-Price, 2013). Diagnosis of scabies is mainly reliant upon 
collection of patient history and physical examination. Concurrent infection in patients and 
their family members is very useful hint for diagnosis of scabies. However definitive 
diagnosis depends on direct observation of the mites by microscopy. Other signs of scabies 
include thread-like “tunnels” or burrows, red papules (bumps) on the involved web between 
the fingers, wrists, elbows, knees and the axillary folds or the buttocks. 
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2.7.2 Allergic Contact Dermatitis  
Allergic contact dermatitis is a pruritic skin condition with rash caused by contact 
with a foreign substance (allergen) (Usatine & Riojas, 2010). It occurs some hours after 
contact with the allergen and settles down over some days if the skin is no longer in contact 
with material responsible. The most common substances that cause allergic contact dermatitis 
include metal such as nickel and gold in jewellery; poison ivy and fragrance mixture. 
Erythema (redness), swelling and scaling with visible borders could be seen on the affected 
skin. Diagnosis of allergic contact dermatitis is also depended on the medical history and 
physical examination. 
2.7.3 Seborrhoeic Dermatitis  
Seborrhoeic dermatitis is a common chronic inflammatory skin condition with or 
without itchiness (Berk & Scheinfeld, 2010). It appears as erythematous patches with yellow-
grey scales. It most often affects sebum-rich areas, such as the scalp, face, upper chest, and 
back. The diagnosis of the condition is based on patient’s history and clinical findings.  
2.7.4 Psoriasis  
Psoriasis is a chronic inflammatory skin condition characterised by pruritus 
(itchiness), pain and bleeding with clearly defined erythematous patch or plaques that are 
seen as silvery-white micaceous scales (Johnson & Armstrong, 2013). It affects scalp, torso, 
and extensor surfaces of the limbs such as the knees and elbows bilaterally. Auspitz 
phenomenon in which pinpoint bleeding is seen when removal of scale is unique for 
psoriasis. As there is no specific laboratory finding for detection of psoriasis, diagnosis of this 
skin disease rests on thorough history taking and physical examination(s). 
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2.8 Instruments for Measuring Severity  
 
Similar with diagnostic criteria for AE, there are many either validated or invalided 
published measurement scales or instruments including Eczema Area and Severity Index 
(EASI), Nottingham Eczema Severity Score (NESS), Patient-Oriented Eczema Measure 
(POEM), Severity Scoring Atopic Dermatitis (SCORAD) and Six Areas, Six Sign Atopic 
Dermatitis severity score (SASSAD) for measuring severity of AE. These are summarised 
below and presented in Table 2. 
2.8.1 Severity Scoring Atopic Dermatitis (SCORAD) 
SCORAD was developed and published by a group of experts from European Task 
Force on Atopic Dermatitis in 1993 (Stalder & Taieb, 1993). It has been extensively used by 
many randomised controlled trials (RCTs) since the objective component of SCORAD was 
validated in 1997 (Kunz et al., 1997; Oranje, Stalder, Taieb, Tasset, & de Longueville, 1997; 
Rehal & Armstrong, 2011). SCORAD incorporates the objective (extent and intensity of the 
skin lesions) and subjective (pruritus and sleep loss) components. Extent and subjective 
symptoms make up about 20% respectively in the total score and intensity items account for 
60%. The maximum objective score is 83 and the subjective score is 20 with a total 103 of 
SCORAD. The severity of AE can be graded into “mild” (less than 15 objective score), 
“moderate” (between 15 and 40 objective score) and “severe” (more than 40 objective score) 
on two baseline measurements at a minimum of two weeks interval. 
2.8.2 Six Area, Six Sign Atopic Dermatitis Severity Score (SASSAD) 
SASSAD was published in 1996 (Berth-Jones, 1996). The score is obtained by six 
clinical signs of disease intensity (erythema, exudation, excoriation, dryness, cracking and 
lichenification) and measured at six defined body regions (arms, hands, legs, feet, trunk, head 
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and neck) with a maximum score of 108. Its reliability, however, is in doubt as the score is 
subjected to significant inter-observer variation (C. R. Charman, Venn, & Williams, 2002). 
2.8.3 Eczema Area and Severity Index (EASI) 
EASI was published in 1998 based on the initiative of providing a reliable and easy to 
use tool for evaluating extent and severity of AE in adults and children (Tofte et al., 1998). It 
was validated in 2001 and 2004 (Barbier et al., 2004; J. M. Hanifin et al., 2001). In EASI, 
body is divided into four regions: head and neck, upper limbs, trunk and Lower limbs. The 
intensity of skin lesions (erythema, induration/papulation, excoriation and lichenification) of 
an involved area of eczema is scored as none (0), mild (1), moderate (2) and severe (3) by 
using a 4-point scale. Half scores are accepted. Then, the percentage affected region is 
calculated respectively. In each region, the area is expressed from 0 to 6 as: nil (0), 1-9% (1), 
10-29% (2), 30-49% (3), 50-69% (4), 70-89% (5) or 90-100% (6). An index of proportionate 
areas was multiplied to the intensity and percentage of the affected area. The index of 
proportionate areas on head/neck is 0.1 for eight years old above, 0.2 for zero to seven years 
old; upper limbs is 0.2 for all age groups; trunk is 0.3 for all age groups and lower limbs is 
0.4 for eight years old above, 0.3 for zero to seven years old. EASI is the sum of above four 
regions score which ranges from zero to 72. EASI severity degree could be divided into 
0=clear; 0.1-1=almost clear; 1.1-7=mild; 7.1-21=moderate; 21.1-50=severe and 50.1-72=very 
severe AE (Leshem, Hajar, Hanifin, & Simpson, 2015). The EASI user guide, training video, 
scoring tables and calculator were developed by an international group of stakeholders 
including clinical experts, consumers, editors of USA and European dermatology journals, 
and regulatory agency representatives who are interested to work together to agree a core 
outcome set for AE RCTs. These tools are available for download 
athttp://www.homeforeczema.org/research/easi-for-clinical-signs.aspx (accessed on 21 May 
2018).  
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2.8.4 Nottingham Eczema Severity Score (NESS) 
NESS was developed in 2000 and is a simple and standardised population-based 
research instrument for evaluating disease severity into mild, moderate and severe in 
childhood AE (Emerson, Charman, & Williams, 2000). The assessment of AE severity is 
based on clinical duration of AE; intensity as measured by average sleep disturbance and 
extent of disease involvement. The minimum score is three and maximum is 15. The 
instrument is available for download at 
https://www.nottingham.ac.uk/research/groups/cebd/resources/ness.aspx (accessed on 21 
May 2018) and its Chinese version was validated in 2003 (Hon et al., 2003). 
2.8.5 Patient-Oriented Eczema Measure (POEM) 
POEM was published and validated in 2004 (C. R. Charman, Venn, & Williams, 
2004). This instrument records the AE symptoms experienced by the patients and encourages 
the patients to participate the management of AE more actively. POEM was recommended as 
one of the core measure outcomes in AE research (C. R. Charman, Venn, Ravenscroft, & 
Williams, 2013). Table 2 outlines published instruments for measurement of severity of AE. 
 
Table 2 Instruments for evaluation of severity of atopic eczema 
 
Instruments Year of Publication  Interpretation of severity degree 
SCORAD 1993 Mild: <15 objective score 
Moderate: 15-40 objective score 
Severe: > 40 objective score 
SASSAD 1996 Not available 
EASI 1998 Mild: 1-7 
Moderate: 7.1 -21 
Severe: 21.1-50 
Very severe: 50.1-72 
NESS 2000 Mild: 3-8 
Moderate: 9-11 
Severe: 12-15 
POEM 2004 Mild: 3-7  
Moderate: 8-16  
Severe: 17-24  
Very severe: 25-28 
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Abbreviations: EASI, Eczema Area and Severity Index; NESS, Nottingham Eczema Severity Score; 
POEM, Patient-Oriented Eczema Measure; SASSAD, Six Area, Six Sign Atopic Dermatitis severity 
score; SCORAD, Severity Scoring Atopic Dermatitis.  
2.8.6 Core Outcome Domains (CODs) for AE Trials 
Among the 20 published instruments, only EASI, SCORAD and POEM have been 
adequately tested and validated and were recommended for use in a RCT of AE as outcome 
measures. EASI and SCORAD were further recommended for assessment of clinical signs of 
AE (Schmitt et al., 2013; Schmitt, Langan, & Williams, 2007). A consensus has been reached 
under the organisation of HOME (Harmonising Outcome Measures for Eczema) in which 
international multi-disciplinary working groups including clinicians, nurses, patients with AE, 
careers of AE patients, methodologists, representatives from pharmaceutical companies, 
officers from regulatory agencies and journal editors have joined together to develop CODs. 
They suggested that an RCT in AE should include the following CODs: clinician reported 
signs, patient reported symptoms, QoL and long term control of flares (Schmitt, Langan, 
Stamm, Williams, & Harmonizing Outcome Measurements in Eczema Delphi, 2011; Schmitt 
et al., 2012). Each of the CODs should be measured by a core outcome measurement 
instrument (COMI) (Schmitt et al., 2015). EASI is recommended as a validated COMI for 
measuring clinician-reported signs and the POEM is a COMI for measuring patient reported 
symptoms (Chalmers et al., 2016; Schmitt et al., 2014; Spuls et al., 2016). COMIs for 
measuring of QoL and long term control of flares are under developed 
http://www.homeforeczema.org/ (accessed on 21 May 2018).  
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2.9 Conventional Medical Treatment  
 
Conventional medical guidelines for management of AE have been well developed in 
Europe, the USA, China and Asian-Pacific region including Australia, Singapore, Malaysia, 
Indonesia, Philippines, Taiwan, India and Hong Kong (Eichenfield, Tom, Berger, et al., 2014; 
Eichenfield, Tom, Chamlin, et al., 2014; H. Gu & Zhang, 2014; NICE, 2007; Ring et al., 
2012; Rubel et al., 2013; Sidbury, Davis, et al., 2014; Sidbury, Tom, et al., 2014). 
Conventional medical treatment for AE can be categorised into applications of topical agents, 
systemic administration of medications or combination of both topical and oral ingestion of 
medications (Eichenfield, Tom, Berger, et al., 2014).  
2.9.1 Topical Application of Moisturisers 
These agents are beneficial for children and adults with any degree of severity of AE 
as moisturisers can protect and maintain the integrity of affected skin consequently reducing 
xerosis (skin dryness). Usage of moisturisers has been considered as an important non-
pharmacologic intervention for management of mild AE and it can be used in conjunction 
with other medications for moderate and severe AE although no evidence supports whether 
moisturisers are better than other medications (Arkwright et al., 2013; T. N. Leung & Hon, 
2015). It has been recommended that more RCTs are needed to clarify the role of 
moisturisers in the treatment of AE (Schmitt, Apfelbacher, & Flohr, 2011). 
2.9.2 Occlusive Therapy (Dry and Wet-Wrap Therapy) 
This is an alternative option for treatment of AE in children. Wet-wrap dressing on 
the involved skin area for 8-24 hours with moisturisers or topical corticosteroids has been 
considered as a “rescue” therapy for acute flares of AE as it may reduce the skin itchiness; 
cool the inflamed skin, protect skin damage from scratching; increase skin hydration and 
increase penetration of topical agents. However, there are many disadvantages associated 
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with this therapy, i.e. risk of skin allergy, dysfunction of temperature control, increased 
corticosteroid side effects and increased risk of skin infections. No convincing evidence 
support that occlusive therapy is superior to conventional open application of medicinal 
agents (Braham, Pugashetti, Koo, & Maibach, 2010).  
2.9.3 Topical Antimicrobial Products 
These medications have been used to treat AE in patients with associated 
Staphylococcus aureus infection isolated from 90% of AE skin lesion. However, reduction of 
the amount of Staphylococcus aureus with topical usage of antimicrobial agents does not led 
to convincing clinical benefit of AE patients when compared with other non-antimicrobial 
products (Bath-Hextall, Birnie, Ravenscroft, & Williams, 2010). 
2.9.4 Antihistamine 
As AE is a pruritic (itchy) skin condition, topical or oral antihistamine drugs such as 
doxepin hydrochloride cream, chlorpheniramine and hydroxyzine have been widely used to 
treat itchiness by their sedative action. However, no evidence has been found that 
antihistamine drugs are efficacious for the condition and topical antihistamine agents are 
indeed not recommended for AE (Apfelbacher et al., 2013; Eichenfield, Tom, Berger, et al., 
2014).  
2.9.5 Topical or Systemic Immunosuppressive Regimen 
This is the mainstay of treatment for AE. Topical administration of corticosteroids 
with adequate potency or calcineurin inhibitors such as pimecrolimus, tacrolimus is the 
standard first-line treatment for mild AE (Sidbury, Davis, et al., 2014). Systemic medications 
including oral corticosteroids or immunosuppressive drugs such as azathioprine, 
cyclosporine, mycophenolate and methotrexate are used for more difficult-to-treat or 
refractory moderate or severe AE (Slater & Morrell, 2015; Tan & Gonzalez, 2012). 
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Cyclosporine is further recommended as a first-line treatment for short-term use and 
azathioprine as second-line option for moderate to severe AE (Roekevisch, Spuls, Kuester, 
Limpens, & Schmitt, 2014). However, long term use of oral corticosteroids can lead to 
unwanted adverse reactions such as suppression of the HPAA, osteoporosis, aseptic necrosis 
of the hip, hypertension, ocular changes and altered immune function (Walling & Swick, 
2010). Reported side effects of immunosuppressive medications e.g. azathioprine, include 
increased risk of hepatosplenic T-cell lymphomas (Denby & Beck, 2012).  
 
Section II: Chinese Medicine Perspective 
2.10 Aetiology, Pathogenesis and Experts’ Opinions 
 
The Chinese medicine nomenclature Jin Yin Chuang (浸淫疮 in Chinese characters) 
was first used in an ancient Chinese medicine classic Synopsis of the Golden Chamber (Jin 
Kui Yao Lue Fang Lun 《金匮要略方论》) in 300 A.D. Symptoms of Nai Xuan (奶癣) 
were detailed in General Treatise on the Causes and Symptoms of Diseases (Zhu Bing Yuan 
Hou Lun《诸病源候论》) dated 610 A.D. Condition named as Si Wan Feng (四弯风) 
recorded in A Comprehensive Summary of Surgery (Wai Ke Da Cheng 《外科大成》) in 
1665 had clinical features of involvement of skin lesions on the fossae of the legs and ankles 
with severe itchiness and monthly relapse. “Jin Yin Chuang”, “Nai Xuan” and “Si Wang 
Feng” in Chinese medicine nomenclatures were officially standardised as “eczema”, 
“infantile eczema” and “atopic eczema” respectively by Chinese medicine authority, the State 
Administration of Traditional Chinese Medicine (SATCM) in 1994 (SATCM, 1994). The 
terms of “eczema”, “infantile eczema”, “atopic eczema” or “atopic dermatitis” in this thesis 
refer to the same skin condition, as stated in Chapter 2.1. 
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2.10.1 Bingnan Zhao 
Based on the available published literature, AE has been treated with CHM formulae 
according to syndrome differentiation (Bian Zheng 辨证) by Bingnan Zhao (赵炳南), 1899- 
1984,  a renowned senior Chinese medicine dermatologist and founder of the modern Chinese 
medicine dermatology since 1983 (Zhao & Zhang, 1983). Zhao was the Director of 
dermatology and surgery department, Beijing Hospital of Chinese Medicine 
(https://baike.baidu.com/item/%E8%B5%B5%E7%82%B3%E5%8D%97 accessed on 14 
February 2019).  Zhao believed that AE was a result of congenital insufficiency of the spleen 
with retention of dampness heat in interior of the body; the condition was induced by 
invasion of wind, dampness-heat pathogens which retained on the skin. In a chronic case, 
reoccurrences and relapses of the condition led to further damage the spleen function and 
manifested as spleen deficiency with blood dryness of the body.  
2.10.2 Zhili Zhang  
Zhili Zhang (张志礼) 1930-2000, was an integrated Chinese and Western medicine 
medicine dermatologist and Director of the national Chinese medicine dermatological 
medical centre, SATCM. He was also an academic heir of Bingnan Zhao 
(http://www.bjzhongyi.com/yxjy/article/12320.html, accessed on 14 February 2019). Zhang 
further explored the causes of AE and pointed out that the underlying of the condition (the 
root) was spleen deficiency with stomach heat and indigestion of food; while clinical features 
such as itchy skin, rashes or oozing caused by invasion of wind, dampness-heat pathogens 
were considered as the branch of the condition (F. Zhang & Wang, 1998).  
2.10.3 Renkang Zhu  
Renkang Zhu (朱仁康) 1908-2000, was was a Chinese medicine dermatologist and 
Director of Chinese medicine dermatological and surgery department, Xiyuan Hospital, 
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Academy of Chinese Medicine 
(https://baike.baidu.com/item/%E6%9C%B1%E4%BB%81%E5%BA%B7/18994 accessed 
on 14 February 2019). Zhu divided the causes of AE into congenital or acquired origins 
(Xing, 2007). In congenital origin, the heat pathogen was inherited from parents who 
consumed excessive amounts of spicy food. Acquired origin was due to improper diet, which 
weakened the spleen and stomach function and led to internal dampness.  
2.10.4 Tugen Yu  
Tugen Yu (余土根) is a Chinese medicine dermatologist and Director of Chinese 
medicine dermatological department of Zhejiang Provincial Hospital of Chinese Medicine 
(https://baike.baidu.com/item/%E4%BD%99%E5%9C%9F%E6%A0%B9/3280978, 
accessed on 14 February 2019). Yu suggested AE had diverse pathology in different age 
groups (Zheng, 2005). Wind-heat with dampness was the main pathology in infants; 
excessive dampness-heat and spleen deficiency with dampness was more commonly seen in 
children, and adults had deficiency of blood as well as wind-dryness.  
2.10.5 Dacan Chen  
Dacan Chen (陈达灿) is a Chinese medicine dermatologist and Principal of the 
GPHCM (http://www.familydoctor.com.cn/Topics/chendacan.html accessed on 14 February 
2019). Chen analysed the clinical features of AE in infants and children from the theory of 
Zang-fu organs (Sun, 2006). Flaming up of the heart fire was considered the cause of 
itchiness and skin redness which are the paramount symptom and sign of AE in infants and 
children. The spleen was relatively weaker due to rapid growing of the body and the digestive 
system was not mature in children. Thereafter deficiency of the spleen was the underlying 
pathology of AE in children. This postulation was affirmed by Chen’s clinical finding that a 
pale and flabby tongue with soft pulse (Ru Mai濡脉) was observed in most of AE children. 
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2.11 Syndrome Differentiation  
 
2.11.1 The Chinese Medicine Guidelines 2011 
An evidence-based Chinese medicine guideline for management of AE was published 
in 2011 (Chinese medicine guideline 2011) (CACMS, 2011). The guideline recommended 
CHM, acupuncture, paediatric Tuina, dietary therapies and regimen for management of AE. 
Chinese medicine diagnoses of AE differ according to the age of the patient. Differentiation 
of syndrome is made based on clinical findings and these are outlined below. 
1) AE in infancy and childhood: 
a. Dampness-heat syndrome: the child is usually obese. Erythema (redness) and 
rashes and blisters could be seen on the scalp and eyebrows with oozing, cracking and 
crusting as well as intense itchiness. In severe case, the skin lesions could spread out 
to the trunk and extremities. Associated symptoms and signs include dry stools, deep 
colour and shortage of urination, red tongue with greasy yellow coating, slippery and 
rapid pulse. 
 b. Foetal heat syndrome: the child is skinny, a large area of erythema and rashes with 
scales or crusts, scratching and itchiness could be seen. Associated symptoms and 
signs include indigestion, red tongue with scanty coating, leisurely and slippery pulse. 
c. Deficiency of the spleen with wind-dryness syndrome: reoccurrence of skin lesions 
is seen on the same involved area. The skin lesions are rough with flakes and crusts 
and remarkable itchiness. Scratching and pigmentations could be found around the 
skin lesions.  
2) AE in adults 
a. Retention of wind-dampness on the skin syndrome: the skin lesions could be seen 
on the surface of the whole body but the cheek and extremities are most common 
affected. Rashes are loose or intensive with dry desquamations and itchiness that are 
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aggravated with exposure to wind. Associated symptoms and signs include dry month, 
itchy throat, red eyes, constipations, red tongue with scanty or dry coating, and rapid, 
floating and slippery pulse. 
b. Integration of dampness and heat syndrome: erythema, rashes and blisters with 
oozing and erosion after scratching. Associated symptoms and signs include dry 
stools with deep colour urination, red tongue with yellow greasy coating, slippery and 
rapid pulse. 
c. Deficiency of the spleen with retention of dampness: chronic relapse and remission 
of the condition, dry and itchy skin, rashes with scales or crusts, erosions, blisters and 
oozing. Associated symptoms and signs include pallor complexion, lethargy, poor 
appetite, abdominal bloating, loose stools, pale tongue with greasy coating, thready, 
deficient and deep slippery pulse. 
d. Blood deficiency with wind-dryness syndrome: a chronic prolonged course of AE 
with thickness, dryness and rough of the skin lesions, intensive itchiness with 
lichenification and pigmentations are seen. Associated symptoms and signs include 
dry mouth but absence of welling to drink, slight red tongue with scanty saliva and 
lack of coating, deep string taut pulse.  
2.11.2 The Expert Consensus 2013 
Additionally, fifteen members from dermatology speciality committee of the China 
Association of Chinese Medicine published an expert consensus guideline for diagnosis and 
treatment of AE in 2013 (the Expert consensus 2013) (D. Chen et al., 2013). AE could be 
classified into the following different syndromes according to the Expert consensus 2013:  
1) AE in infants is identified as accumulation of heat in the heart and spleen. The heat 
in the heart and spleen is induced from accumulated foetal heat and toxin in new born 
at this syndrome. 
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2) AE in children with acute relapse is considered as heart fire with spleen deficiency. 
A prolonged heart fire could disturb the mind which turns to lower the function of the 
spleen. Dampness-heat is generated by dysfunction of the spleen with flaring up of the 
heart fire at this syndrome. 
3) A remission of AE in children is thought as deficiency of the spleen with 
accumulation of dampness at this syndrome.  
4) AE in adolescents and adults is regarded as deficiency of blood with wind-dryness. 
A study used cluster analysis for 200 children who have been diagnosed with AE and 
treated with CHM reported that the most common seen syndromes for AE based on Chinese 
medicine syndrome differentiation are Deficiency of the spleen syndrome (18.0%); 
Deficiency of blood with wind-dryness syndrome (15.5%) and Accumulation of dampness-
heat syndrome (12.5%) respectively (Jiang, Jing, Diao, Xiong, & Shi, 2014). Findings of this 
study have supported the Chinese medicine differentiation syndrome for AE in children 
proposed in the Chinese medicine guideline 2011 and the Expert consensus 2013. 
2.12 Chinese Herbal Medicine Treatment and Common Used Chinese Herbs  
2.12.1 Chinese Herbal Medicine Formulae for Atopic Eczema 
Oral ingestion of CHMs usually is under the guidance of the Chinese medicine 
syndrome differentiation, whilst topical administration has been devised with little or no 
consideration of syndrome differentiation (Xiao & Song, 2014). Table 3 summarises the oral 
ingestion CHM formulae endorsed by the Chinese medicine guidelines 2011 and the expert 
consensus 2013 and Table 4 outlines the topical application CHMs recommended by the 
Chinese medicine guidelines 2011(CACMS, 2011; D. Chen et al., 2013).  
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Table 3 Chinese herbal medicine formulae for atopic eczema based on syndrome 
differentiation 
 
CHM Formulae Syndromes Ingredients 
(CHMs in Pin Yin) 
Xie Huang San 
(泻黄散) 
Dampness-heat 
syndrome  
(AE in infancy and 
childhood) 
Huoxiang, Huangbai, 
Fulingpi, Huangqin, Shigao, 
Shanyao, Fangfeng, 
Shanzhizi, Gancaoxiao 
San Xin Dao Chi 
San  
(三心导赤散) 
Foetal heat syndrome 
(AE in infancy) 
Accumulation of heat in 
the heart and spleen 
syndrome 
Lianqiao, Zhizi, Lianzi, 
Shengdihuang, Xuanshen, 
Chantui, Shanyao, Baizhu, 
Baishao, Maiya, Guya, 
Gancao, Dengxincao 
Bu Pi Run Zao 
Tang  
(补脾润燥汤). 
Deficiency of the spleen 
with wind-dryness 
(AE in childhood) 
Huangqi, Chenpi, Baishao, 
Fangfeng, Gancao, Danggui, 
Danshen, Jixueteng, 
Beishashen, Shanyao, 
Baibiandou, Fuling 
Qing Xin Pei Tu 
Fang (QXPTF) 
(清心培土方) 
Heart fire with spleen 
deficiency syndrome 
 (AE in children with 
acute relapse)  
Danzhuye, Lianqiao, 
Dengxincao, Shengdihuang, 
Baizhu, Shanyao, Yiyiren, 
Gouteng, Muli, Fangfeng, 
Gancao 
Xiao Er Hua Shi 
Tang 
(小儿化湿汤) 
Deficiency of the spleen 
with accumulation of 
dampness syndrome 
(AE in childhood) 
Cangzhu, Fuling, Maiya, 
Chenpi, Zexie, Huashi, 
Gancao, Baizhu, Yiyiren 
Xiao Feng San 
(XFS) 
(消风散) 
Retention of wind-
dampness on the skin 
(AE in adults ) 
Jingjie, Kushen, Zhimu, 
Cangzhu, Qianghuo, Chantui, 
Fangfeng, Niubangzi, 
Shengdihuang, Huomaren, 
Fuling, Shigao, Danggui 
Bi Xie Shen Shi 
Tang 
(萆薢渗湿汤); 
Integration of dampness 
and heat syndrome 
(AE in adults) 
Bixie, Yiyiren, Huangbai, 
Huangqin, Mudanpi, Zexie, 
Huashi., Tongcao 
Chu Shi Wei 
Ling Tang 
(除湿胃苓汤) 
Deficiency of the spleen 
with retention of 
dampness syndrome 
(AE in adults) 
Bixie, Yiyiren, Chifuling, 
Baizhu, Cangzhu, Houpo, 
Chenpi, Zexie, Baixianpi, 
Difuzi 
Dang Gui Yin Zi 
(当归饮子) 
Blood deficiency with 
wind-dryness syndrome 
(AE in adolescents and 
adults) 
Danggui, Shengdihuang, 
Shudihuang, Huangqi, 
Baishao, Jingjie, Fangfeng, 
Chuanxiong, Baijili, 
Danshen, Chantui, 
Tianhuafen, Difuzi, 
Baixianpi 
Abbreviations: AE, atopic eczema; CHM, Chinese herbal medicine.  
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Table 4 Topical application of Chinese herbal medicines for atopic eczema 
 
Indications CHM formulae Ingredients 
(CHMs in Pin Yin) 
Acute relapse of AE Ma Chi Xian mixture 
（马齿苋合剂） 
Machixian, Zicao, 
Baijiangcao, Daqingye 
San Huang lotion  
（三黄洗剂） 
Dahuang, Huangbai, 
Huangqin, Kushen 
Sub-acute relapse of 
AE 
Huang Lian Oil 
(黄连油) 
Huanglian, Sesame oil 
Qing Dai ointment 
(青黛膏)  
Qingdai, Vaseline  
Chronic stage of AE Shi Du ointment 
（湿毒膏） 
Qingdai, Huangbai, 
Kufan 
Bo Fu Zhi Yang lotion 
（薄肤止痒洗剂） 
Tougucao, Xixiancao, 
Danggui, Shengdihuang 
Abbreviations: AE, atopic eczema; CHM, Chinese herbal medicine.  
 
Of the CHM formulae recommended by the Chinese medicine guidelines 2011 or the 
Expert consensus 2013, only one formula, Xiao Feng San (XFS), was assessed for efficacy 
and safety via a RCT. Cheng et al. recruited 71 children with severe intractable AE and 
treated with XFS granules (n=47) or placebo (n=24) for eight weeks in 2010 (H. M. Cheng, 
Chiang, Jan, Chen, & Li, 2011). They reported that XFS significantly lowered the AE 
severity and skin itchiness as well as improving sleep No severe adverse events were reported 
in this RCT.  
2.12.2 Common Used Chinese Herbs for Atopic Eczema 
A government funded study using data mining analysis reported that there were 20 
most frequently orally ingestion CHMs under five categories were prescribed from 186 
papers published from 1978 to 2012 (B. Zhang, Liang, Wu, Li, & Xuan, 2014). The five 
herbal categories were: 
 
37 
1) Herbs under the strengthening the spleen and eliminating dampness category 
include Huangqi (Radix Astragal), Yiyiren (Semen Coicis), Fuling (Poriae Cocos), 
Baizhu (Rhizoma Atractylodis Macrocephalae);  
2) Herbs under the nourishing blood and cooling the blood category include 
Shengdihuang (Radix Rehmanniae), Danggui (Radix Angelicae Sinensis), Baishao 
(Radix Paeoniae Alba), Chishao (Radix Paeoniae Rubra) and Mudanpi (Cortex 
Moutan);  
3) Herbs under the category of eliminating dampness are Huangqin (Radix 
Scutellariae), Kushen (Radix Sophorae Flavescentis), Cangzhu (Rhizoma 
Atractylodis), Zexie (Rhizoma Alismatis);  
4) Herbs under the category of expelling the wind and stopping itchiness are 
Baixianpi (Cortex Dictamni), Fangfeng (Radix Saposhnikoviae), Baijili (Fructus 
Tribuli),  Jingjie (Herba Schizonepetae),  Chantui (Periostracum Cicadae) and 
5) Herbs under the category of clearing heat and removing toxins are Jinyinhua (Flos 
Lonicerae Japonicae) and Gancao (Radix Glycyrrhizae).  
The most common used of Chinese herbs for topically are Kushen (Radix Sophorae 
Flavescentis), Shechuangzi (Fructus Cnidii), Huangbai (Cortex Phellodendri Chinensis), 
Huanglian (Rhizoma Coptidis), Huangqin (Radix Scutellariae), Gancao (Radix Glycyrrhizae), 
Difuzi (Fructus Kochiae), Machixian (Herba Portulacae) and Baixianpi (Cortex Dictamni). 
These findings are consistent with the ingredients contained in the formulae proposed by the 
Chinese medicine guidelines 2011 and the Expert consensus 2013. 
2.13 Discussion  
 
Both the ancient Greek and Chinese medicine convey the same inflammatory skin 
disorder with rashes and redness or ooze (discharge with clear fluid) with the term ‘eczema’ 
being created in ancient times. The clinical features of the skin condition called “Wind of the 
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four fossae” firstly recorded in 1665 on a Chinese medicine surgical monograph were 
corresponded with the disease tagged with atopic dermatitis in 1933 by conventional 
medicine. There is a trend of increased of AE incidence rate globally in the past decades with 
no known reason. AE brings about significate socio-economic burden and impact of QoL for 
the patients and their family. As a result, the condition has attracted much attention with 
various diagnostic criteria, instruments for measuring severity of the condition and 
therapeutic agents have been evolved. The U.K. Working Party diagnostic criteria, the EASI 
and POEM have been considered for deployment in clinical practice and future clinical trial 
design to identify the condition and measure AE treatment outcomes. Although the causes of 
AE are unknown, risk factors of AE have been obtained. Filaggrin deficiency from FLG 
mutations play a key role in AE pathogenesis based on findings from a series of research. As 
conventional medications for moderate and severe AE draw dissatisfaction due to unwanted 
side effects, many AE patients have sought for alternative approaches and CHM has provided 
an option to complement the needs of these patients. 
CHM is one of the important constituents in Chinese medicine system for prevention 
and treatment of diseases. The term CHM in this thesis is used loosely to refer to any 
medicinal substances employed within the paradigm of Chinese medicine practice. History of 
treating eczema with a single Chinese herb could be traced back to year 300 A.D. Over time 
CHM interventions for AE have been extended into greater complexity where CHM formulae 
with several CHMs are prescribed based on Chinese medicine syndrome differentiations. 
Administration of CHMs for AE has also been expanded from topical use to oral intake or 
combination of topical and oral ingestions. A series of CHM formulae for AE has been 
recommended by the Chinese medicine guidelines 2011 or Expert consensus 2013. Such 
development has made the CHMs a complex intervention for management of AE as a CHMs 
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formula may contain several interacting categories of herbs and each of the herbs has 
multiple components (Flower et al., 2012).  
Investigating a complex intervention involves with process of development, feasibility 
or piloting, evaluation and implementation (Craig et al., 2013). One of the questions on 
developing and reporting such a complex intervention is whether the existing evidence 
collated from a systematic review suggests the intervention is likely to be effective. An initial 
Cochrane systematic review of CHM for AE was published in 2004. The review only 
included four studies, and all included studies used a same CHM product Zemaphyte, which 
is no longer available (W. Zhang et al., 2004). As the review neither pooled data for meta-
analysis nor included study with topical application of CHM for AE, there was a need to 
conduct a systematic review in a broader scope to identify the existing evidence base in 
regarding the CHM for AE. Moreover, the existing clinical evidence of CHM for AE from 
the Cochrane systematic review 2004 was incomplete and inconclusive, and the effects of 
topical CHM formulae for AE proposed by the Chinese medicine guidelines 2011 have not 
been systematically assessed. This gap in the literature was addressed by a systematic review 
with meta-analysis for topical application of CHM for AE, the methodology being presented 
in next chapter. 
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Chapter 3  Systematic Review with a Meta-analysis of 
Topical Application of CHM for Children with AE  
 
The contents of this chapter have been published in the international peer-reviewed 
journal: Gu, S., Yang, A. W., Li, C. G., Lu, C., & Xue, C. C. (2014) Topical application of 
Chinese herbal medicine for atopic eczema: a systematic review with a meta-analysis. 
Dermatology 2014; 228: 294-302. DOI: 10.1159/000360526 
3.1 Aim and Methods of the Systematic Review 
This systematic review aimed to evaluate the effect and safety of topical application 
of CHM for AE in form of RCT and followed the methods specified by the Cochrane 
Handbook for Systematic Reviews of Interventions Version 5.1.0 (the Handbook) (Higgins & 
Green, 2011).  
3.2 Search Strategies 
3.2.1 Online Search  
The following electronic databases were searched from their respective inceptions to 
18 June 2013 with the key words of combination of “atopic eczema”, “atopic 
dermatitis”, “Chinese herbal medicine”, “randomised controlled trials” and their 
synonyms:  
o Cochrane Skin Group Ongoing Skin Trials Register;  
o PubMed;  
o The Cochrane Central Register of Controlled Trials (CENTRAL); 
o CINAHL (EBSCO); 
o SCOPUS; 
o AMED; 
o LILACS; 
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o EMBASE; 
o HERBMED; 
o ProQuest;  
o mRCT;  
o VIP Information; 
o China National Knowledge Infrastructure and 
o Wanfang Data.  
3.2.2 Hand-search 
In addition, the following Chinese medicine journals and conference proceedings 
were hand-searched for potential studies:  
o The Journal of Chinese Medicine (1999-2012); 
o Chinese Journal of Integrated Traditional and Western Medicine (1995-2012); 
o Journal of Traditional Chinese Medicine (1995-2012); 
o Congress proceedings of the First World Congress on Chinese Medicine 
(Melbourne 2003); 
o Congress proceedings of the Third International Congress of Traditional 
Medicine (Toronto 2006) and 
o Congress proceedings of the Sixth World Congress of Chinese Medicine 
(Melbourne 2009). 
3.3 Inclusion and Exclusion Criteria 
The study was planned to include RCTs published in English or Chinese languages in 
this review. Participants of any age and gender with AE or diagnosed with infantile eczema 
by physician were also included. Included clinical studies or trials were permitted with 
topical application of single Chinese herb or Chinese medicinal formulae in comparison with 
 
42 
the following comparators: placebo, no treatment or conventional medications of any 
dosages. Excluded were trials using oral CHM or as a combined treatment intervention. 
3.4 Outcome Measures  
 
For the included studies the following outcomes measures were used. 
3.4.1 Primary Outcome Measures 
1) Proportion of participants experienced clinically significant or marked or effective 
improvement based on self-administered symptom (i.e. itching or sleep loss) scores;  
2) Proportion of participants experienced clinically significant or marked or effective 
improvement based on self-rated signs (i.e. dryness and erythema);  
3) Proportion of participants experienced clinically significant or marked or effective 
improvement based on assessments by clinicians. 
3.4.2 Secondary Outcome Measures 
1) Proportion of participants with improved rating of EASI; SASSAD; SCORAD;  
2) Proportion of participants with improved rating of QoL and adverse events. 
3.5 Data Extraction and Assessment of Risk of Bias for the Included Studies 
Data was extracted from potential included studies by two reviewers independently 
and recorded data on a pre-designed data extraction form. Extracted data consisted of study 
setting, sample size, treatment and control interventions, outcome measures and adverse 
events. Two reviewers separately assessed the risk of bias in the included studies with the 
domains of random sequence generation; allocation concealment; blinding of participants, 
personal and outcome assessment; incomplete outcome data; selective outcome reporting and 
other sources of bias including usage of published and validated scoring system for AE. The 
third party (supervisor and consultant) provided additional insight to resolve any 
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disagreement between the two reviewers. The corresponding authors were contacted of all 
included studies for clarification of the data such as study design, randomisation method and 
statistical data. 
3.6 Data Analysis 
The meta-analysis was performed using RevMan 5.2 software to test the overall effect 
and potential heterogeneity across the included studies. Heterogeneity of the studies was 
interpreted through the characteristics of the intervention(s). Effect size analysis was 
performed to explore the differences between intervention groups. Dichotomous data were 
expressed as risk ratios (RR) with 95% confidence intervals (CI). Statistical method of 
inverse variance with random effects analysis model was used for testing continuous data 
which were expressed as mean difference (MD) where all included studies used the same 
outcome measurement scale or standardised mean difference (SMD) where different outcome 
measurement scales were mixed (Deeks, Higgins, & Altman, 2011). P < 0.05 was regarded as 
statistically significant. 
3.7 Results  
A total of 516 potential studies were identified according to search strategies outlined 
on Section 3.2. Of these, 10 studies met the inclusion criteria and were included in this 
review. Table 5 lists the study identifier (ID) and citation for the studies included. No study 
conducted outside of China or published in English met the inclusion criteria. The study 
selection process is shown in Figure 5. 
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Table 5 Study ID and citations of the included studies 
 
Study ID Citations 
Chao 2003 Chao, Q., & Xiao, J. G. (2003). Research of Chinese herbal medicines 
for infantile eczema. (Master’s thesis), Qingdao University, Qingdao, 
China (in Chinese). 
Chen 2011 Chen, H. (2011). Clinical observation of Huanglian Qingdai cream for 
infantile eczema. Journal of Sichuan of Traditional Chinese Medicine, 
(in Chinese), 29(6), 88-89.  
Dong 2012 Dong, M. (2012). Efficacy of external use of Jingfang mixture in the 
treatment of children with eczema. Medical Journal of Qilu, (in 
Chinese), 27(1), 75-78.  
Huang 2010 Huang, Z. K., Chen, P., & Wei, W. N. (2010). Observation of efficacy 
of Chushi Zhiyang cream for atopic dermatitis. Modern Journal of 
Integrated Traditional Chinese and Western Medicine, (in Chinese), 
19(21), 2647-2648.  
Ma 2007  Ma, X. Q., & Li, Q. Y. (2007). Observation of effectiveness of external 
application of zicao oil for treatment of 38 cases children with eczema. 
Shandong Medical Journal, (in Chinese), 47(35), 78. 
Wang 2008  Wang, P., Cai, L., & Xu, J. J. (2008). Observation efficacy of Chushi 
Zhiyang ointment for infantile eczema. Journal of Sichuan of 
Traditional Chinese Medicine, (in Chinese), 26(9), 92-93.  
Xu 2012 Xu, X. C., & Guo, Y. C. (2012). Clinical observation of Kouqiang 
Xiaoyan powder for infantile eczema. Strait Pharmaceutical Journal, (in 
Chinese), 24(10), 210.  
Yang 2012 Yang, S. Q., & Yan, J. D. (2012). Clinical observation of Shirun 
Shaoshang ointment for atopic dermatitis in children. Paper presented at 
The 8th Academic Conference for External Therapy, Nanning, China, 
(in Chinese). 
Zhou 2011 Zhou, Y. Z. (2011). Observation of clinical efficacy of Canger Kushen 
lotion for 88 cases with infantile eczema. Guide of China Medicine, (in 
Chinese), 9(25), 115-116. 
Zou 2011  Zou, G. M., & Xie, B. (2011). Clinical study of Fufang Sanhuang lotion 
for infantile eczema. Liaoning Journal of Traditional Chinese Medicine, 
(in Chinese), 38(2), 297-299.  
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Figure 5 Flowchart of study selection process
Records identified through database 
searching  
(n = 513) 
Additional records identified 
through other sources  
(n = 3) 
Records after duplicates removed  
(n = 516) 
Records screened  
(n = 516) 
Records excluded  
(n = 455) 
Full-text articles assessed 
for eligibility  
(n = 61) 
Full-text articles excluded 
(n = 51) with reasons 
- 13 used oral 
interventions 
- 15 mixed with oral and 
topical interventions 
- 23 non-RCTs 
Studies included in 
qualitative synthesis  
(n = 10) 
Studies included in 
quantitative synthesis 
(meta-analysis)  
(n = 10) 
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3.7.1 Characteristics of Included Studies 
All the included studies were conducted in China and published in Chinese. 
Their characteristics are summarised in Table 6. Among them, the sample sizes 
ranged from 50 to 195 with a total of 1,058 participants with the age ranging 
from new-born babies (12 days of age) to 27 years old adults. All participants 
were recruited from Chinese medicine or general hospitals. The U.K. Working 
Party’s diagnostic criteria of AE were used in three studies (Huang 2010; Zhou 
2011; Zou 2011). One study diagnosed the condition with AE but no criteria 
were provided (Yang 2012). Children with infantile eczema were recruited in six 
studies (Chao 2003; Chen 2011; Dong 2012; Ma 2007; Wang 2008; Xu 2012). 
No studies subcategorised the condition based on Chinese medicine syndrome 
differentiations. Treatment durations ranged from one to three weeks. Four 
studies reported follow-up periods ranging from 12 to 48 weeks after stopping 
the treatment (Huang 2010; Ma 2007; Zhou 2011; Zou 2011).  
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Table 6 Characteristics of the included studies 
 
Study ID Study 
Design & 
Setting  
Diagnostic criteria Sample size Intervention 
Treatment 
(n, age) 
Control 
(n, age) 
Treatment Control 
Chao 2003  Four-arm 
parallel 
group, 
controlled 
study. 
Patients were 
recruited 
from 
outpatient 
dermatology 
department of 
general 
hospitals 
Infantile eczema: 
clinical symptoms 
and signs of the 
individual 
participants  
CM subcategory: not 
stated 
 
1
st
 arm: 30, 1 to 
28.5 months 
2
nd
 arm: 30, 1.5 
to 25 months 
 
3
rd
 arm: 30, 1 
month to 31.5 
months 
4
th
 arm: 30, 1 
to 32 months 
1
st
 arm: Huangbai Zicao Diyu cream 
(5%) 
 
2
nd
 arm: Huangbai Zicao Diyu 
cream (10%) 
Ingredients and dosage: Huangbai 
(Cortex phellodendri) 50 g, Zicao 
(Radix arnebiae) 50 g, Diyu (Radix 
sanguisorbae) 100 g 
Administration: twice daily 
topically 
 
Duration of treatment: 2-3 weeks 
 
Follow-up: not stated 
 
3
rd
 arm: Compound 
Econazole nitrate cream 
(Econazole nitrate and 
Triamcinolone 
acetonide) (Pevisone) 
Topical use twice daily 
for 2 to 3 weeks 
4
th
 arm: Petroleum jelly 
(Vaseline) 
Topical use twice daily 
for 2 to 3 weeks 
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Chen 2011  Parallel 
group, 
controlled 
study. 
Patients were 
recruited 
from 
outpatient 
department of 
CM hospitals 
Infantile eczema: 
clinical symptoms 
and signs of the 
individual 
participants 
CM subcategory: not 
stated 
 
50, 58 days to 2 
years old 
50, 65 days to 
2 years old 
Huanglian Qingdai ointment 
 
Ingredients and dosage: Huanglian 
powder (Rhizoma coptidis) 0.6 g, 
Qingdai (Indigo naturalis) 0.3 g, 
Huangbai powder (Cortex 
phellodendri) 0.3 g, Mingfan (Alum) 
0. 3 g, Bingpian (Borneolum 
syntheticum), did not provide 
dosage, Niaoshuang (Urea cream) 
40 g 
 
Administration: 2-3 times daily 
topically 
 
Duration of treatment: 2 weeks 
 
Follow-up: not stated 
 
Mometasone furoate 
cream 
Topical use once daily 
for 2 weeks 
 
Dong 2012  Parallel 
group, 
controlled 
study. 
Patients were 
recruited 
from 
outpatient 
dermatology 
department of 
Infantile eczema: 
clinical symptoms 
and signs of the 
individual 
participants 
CM subcategory: not 
stated 
 
48, 0.5 to 5 
years old 
47, 0.5 to 5.5 
years old 
Jingfang mixture solution (a CHM 
product manufactured by a 
pharmaceutical company) 
 
Ingredients and dosage: Qianghuo 
(Rhizoma seu Radix notopterygii), 
Duhuo (Radix angelicae 
pubescentis), Qianhu (Radix 
peucedani), Zhiqiao (Fructus 
aurantii), Fuling (Poria), Gancao 
(Radix glycyrrhizae), Fangfeng 
Hydrocortisone 
butyrate cream  
Topical use twice daily 
for 2 weeks. 
Moist dressing twice 
daily with Boric acid 
solution for cases with 
severe exudates 
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a general 
hospital  
(Radix saposhnikovia), Jingjie 
(Herba schizonepetae), Jiegen 
(Radix platycodi), Chuangxiong 
(Rhizoma chuanxiong) 
Did not provide dosage of the 
ingredients. 
 
Administration: topical use twice 
daily, moist dressing or bath with 
the CHM solution twice daily for 
cases with severe exudates 
 
Duration of treatment: 2 weeks 
 
Follow-up: not stated 
 
 
 
Huang 
2010  
Parallel 
group, 
controlled 
study. 
Patients were 
recruited 
from a 
general 
hospital 
AE: The U.K. 
Working Party’s 
diagnostic criteria 
CM subcategory: not 
stated 
98, 3 months to 
21 years old 
 
97, 4 months 
to 22 years old 
 
Chushi Zhiyang ointment * 
 
Ingredients and dosage: Baixianpi 
(Cortex dictamni), Shechuangzi 
(Fructus cnidii), Huanglian 
(Rhizoma coptidis), Huangbai 
(Cortex phellodendri), Kushen 
(Radix sophorae flavescentis), 
Huzhang (Rhizoma polygoni 
cuspidate), Zihuadiding (Herba 
violae), Bianxu (Herba polygoni 
avicularis), Yinchen (Herba 
artemisiae scopariae), Cangzhu 
(Rhizoma atractylodis), Huajiao 
Clobetasol propionate 
ointment 
Topical use 3 times 
daily for 2 weeks 
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(Pericarpium zanthoxyli), Bingpian 
(Borneolum syntheticum) etc. No 
dosage of the ingredients provided. 
 
Administration: 3 times daily 
topically 
 
Duration of treatment: 2 weeks 
 
Follow-up: 12 weeks after 2-week 
treatment period 
Ma 2007  Parallel 
group, 
controlled 
study 
Patients were 
recruited 
from a 
general 
hospital 
Infantile eczema: 
clinical symptoms 
and signs of the 
individual 
participants 
Grade I: erythema 
with millet sized 
papules. Grade II: 
bleeding, ulcer and 
discharges. Grade 
III: crustae and 
decrustation 
CM subcategory: not 
stated 
 
38, 2 to 24 
months 
30, 2 to 24 
months 
Zi Cao oil 
 
Ingredients and dosage: Zicao 
(Radix Arnebiae) 200 g, Mayou 
(Oleum Sesami) 500 g. 
 
Administration: external application 
of the oil 3-5 times per day 
 
Duration of treatment: 1 week 
 
Follow-up: 6-12 months after 
stopping the treatment 
Calamine lotion 
Topical use 3 to 5 times 
daily for 1 week 
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Wang 2008  Parallel 
group, 
controlled 
study. 
Patients were 
recruited 
from 
outpatient 
department of 
a teaching 
hospital 
Infantile eczema: 
clinical symptoms 
and signs of the 
individual 
participants 
CM subcategory: not 
stated 
35, 15 days to 
11 months 
30, 12 days to 
10 months 
Chushi Zhiyang ointment (a CHM 
product manufactured by a 
pharmaceutical company) 
 
Ingredients and dosage: Baixianpi 
(Cortex dictamni), Shechuangzi 
(Fructus cnidii), Huanglian 
(Rhizoma coptidis), Huangbai 
(Cortex phellodendri), Kushen 
(Radix sophorae flavescentis), 
Huzhang (Rhizoma polygoni 
cuspidate), Zihuadiding (Herba 
violae), Bianxu (Herba polygoni 
avicularis), Yinchen (Herba 
artemisiae scopariae), Cangzhu 
(Rhizoma atractylodis), Huajiao 
(Pericarpium zanthoxyli), Bingpian 
(Borneolum syntheticum) etc. No 
dosage of the ingredients provided. 
 
Administration: twice daily 
topically 
 
Duration of treatment: 1 week 
 
Follow-up: not stated 
 
Vitamin B6 cream 
Topical use twice daily 
for 1 week 
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Xu 2012  Parallel 
group, 
controlled 
study. 
Patients were 
recruited 
from 
inpatient 
paediatric 
department of 
a CM 
teaching 
hospital 
Infantile eczema: 
clinical symptoms 
and signs of the 
individual 
participants 
CM subcategory: not 
stated 
53, 35 days to 2 
years old 
51, 40 days to 
2 years old 
Kouqiang Xiaoyan powder 
 
Ingredients and dosage: Qingdai 
(Indigo naturalis), Bingpian 
(Borneolum syntheticum) 
Did not provide dosage 
 
Administration: topically use twice 
daily 
 
Duration of treatment: 2 weeks 
 
Follow-up: not stated  
Triamcinolone 
acetonide acetate cream 
Topical use twice daily 
for 2 weeks 
 
Yang 2012  Parallel 
group, 
controlled 
study.  
Patients were 
recruited 
from 
outpatient 
dermatology 
department of 
a CM 
teaching 
hospital 
AE: “Criteria for 
common diseases 
and effectiveness” 
(no reference was 
provided). 
CM subcategory: not 
stated 
42, Did not 
state age range, 
(mean 4.64 ± 
4.26 years) 
42, Did not 
state age 
range, 
(mean 4.89 ± 
4.59 years) 
 
Shirun Shaoshang ointment (a CHM 
product manufactured by a 
pharmaceutical company) 
 
Ingredients and dosage: Huanglian 
(Coptis chinensis), Huangqin (Radix 
scutellariae), Huangbai (Cortex 
phellodendri), Dilong (Pheretima), 
Yingsuqiao (Pericarpium 
papaveris), Mayou (Oleum sesami). 
Did not provide dosage 
 
Administration: topically use 3 
times daily 
 
Duration of treatment: 4 weeks 
 
Zinc oxide ointment 
(15%) 
Topical use 3 times 
daily for 4 weeks 
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Follow-up: not stated 
 
Zhou 2011  Parallel 
group, 
controlled 
study. 
Patients were 
recruited 
from 
outpatient 
dermatology 
department of 
a CM 
hospital 
AE: The U.K. 
Working Party’s 
diagnostic criteria 
CM subcategory: not 
stated 
89, Did not 
state age range, 
(mean age 
12.23 ± 3.31 
months) 
87, Did not 
state age 
(range, mean 
age 11.63 ± 
4.35 months) 
Cang’er Kushen lotion 
 
Ingredients and dosage: Cang'erzi 
(Fructus xanthii) 30 g, Kushen 
(Radix sophorae flavescentis) 30 g, 
Tufuling (Rhizoma smilacis 
glabrae) 25 g, Shechuangzi 
(Fructus cnidii) 15 g, Cangzhu 
(Rhizoma atractylodis) 15 g, Jingjie 
(Herba schizonepetae) 15 g, Zicao 
(Radix arnebiae) 15 g, Huangbai 
(Cortex phellodendri) 15 g 
 
Administration: moist dressing with 
the lotion 3-4 times daily 
 
Duration of treatment: 2 weeks 
 
Follow-up: 24 weeks after the 2-
week treatment period 
 
Calamine lotion 
Topical use 3 times 
daily for 2 weeks 
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Zou 2011  Parallel 
group, 
controlled 
study. 
Patients were 
recruited 
from 
outpatient 
dermatology 
department of 
a CM 
teaching 
hospital and 
another 
teaching 
hospital. 
AE: The U.K. 
Working Party’s 
diagnostic criteria 
CM subcategory: not 
stated 
30, Did not 
state age range, 
(mean age 
18.73 ± 6.96 
months) 
20, Did not 
state age 
range, (mean 
age 15.15 ± 
5.22 months) 
Fufang Sanhuang lotion and oil 
Ingredients and dosage: Dahuang 
(Radix et rhizoma rhei) 15 g, Zicao 
(Radix arnebiae) 15 g, Huangbai 
(Cortex phellodendri) 15 g, 
Huangqin (Radix scutellariae) 15 g, 
Diyu (Radix sanguisorbae) 15 g, 
Shechuangzi (Fructus cnidii) 15 g, 
Wubeizi (Galla chinensis) 20 g, 
Qingdai (Indigo naturalis) 10 g, 
Mingfan (Alum) 6 g 
 
Administration: moist dressing with 
the lotion 3 to 4 times daily and 
topical application with the same 
herbal powder mixed with sesame 
oil 
 
Duration of treatment: 2 weeks 
 
Follow-up: 12 weeks after the 2-
week treatment period 
 
Boric acid solution and 
zinc oxide cream 
Topical use 3 to 4 times 
daily for 2 weeks 
 
Abbreviations: CHM, Chinese herbal medicine; CM, Chinese medicine.  
*A CHM product manufactured by a pharmaceutical company. 
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In terms of treatment interventions, two studies used the same product manufactured by 
a pharmaceutical company (Huang 2010; Wang 2008). Another two studies applied two 
different manufactured products respectively (Dong 2012; Yang 2012). The other six 
studies used clinician self-prepared herbal formulae. For control interventions, five 
studies used corticosteroid creams (Chao 2003; Chen 2011; Dong 2012; Huang 2010; 
Xu 2012). The multi-arm study used petroleum jelly (Vaseline) in its 4
th
 arm (Chao 
2003). Two studies used calamine lotions (Ma 2007; Zhou 2011). One study used 
vitamin B6 cream (Wang 2008). One study used boric acid solution and zinc oxide 
cream (Zou 2011). One study used zinc oxide ointment (Yang 2012). Ingredients of 
CHM interventions were detailed in Table 6. A total of 34 Chinese medicinal 
substances (plants, insects and mineral substances) were used in all the included studies. 
Based on CHM theory, the selected Chinese medicinal substances were under categories 
of “exterior-releasing”, “heat-clearing”, “purgative”, “damp-resolving”, “damp-
draining”, “interior-warming”, “haemostatic”, “phlegm-resolving”, “resuscitative”, 
“tonifying”, “astringent” and “externally applied and miscellaneous” (Li, 2008). Of 
these, Huangbai (Cortex Phellodendri) was the most commonly used herb (found in 
seven included studies). Huanglian (Rhizoma coptidis), Shechuangzi (Fructus cnidii), 
Zicao (Radix arnebiae) and Bingpian (Borneolum syntheticum) were used in four 
included studies. Three studies employed moist dressing of CHM on the skin lesion 
areas (Dong 2012; Zhou 2011; Zou 2011). The rest of seven studies applied oil-based 
CHM preparation or ointment directly on the affected skin areas (Chao 2003; Chen 
2011; Huang 2010; Ma 2007; Xu 2012; Wang 2008; Yang 2012). 
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3.7.2 Outcome Measures 
“Effectiveness rate” was used as primary outcome measure in all included 
studies. Data was pooled, and performed meta-analysis, expressing the primary 
outcome measure as “total effectiveness rate”, which was a sum of effectiveness 
rate reported as “recovered” and “significantly improved” by the trial 
investigators of the included studies. None of included studies used QoL as the 
outcome measure. Published and validated scoring systems i.e. EASI, SASSAD, 
SCORAD for scoring of severity of the condition were only employed by two 
studies (Dong 2012; Huang 2010).  
3.7.3 Assessment of Risk of Bias  
Performance bias was high across the 10 included studies as none of them used 
blinding of personnel and participants. Allocation concealment (selection bias) 
and blinding of outcome assessment (detection bias) were unclear as no studies 
reported. Only one study reported random sequence generation and used 
published scoring system (Huang 2010). Almost half of the studies did not use 
scoring system to measure the severity of the condition (Figure 6). There was 
inadequate information to determine selective reporting bias. Letters requested 
further information were sent to the corresponding authors of all included 
studies; however, no reply has been received. 
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Figure 6 Summary of risk of bias for the of included studies 
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3.7.4 Effects of Interventions  
1) CHM versus Placebo 
There was only one study in its 4
th
 arm used placebo as control intervention 
(Chao 2003). The trial investigators stated that the total effectiveness rate in its 
2
nd
 arm (10% of a CHM cream) was significantly higher than that in the 4
th
 arm 
(petroleum jelly) (RR 2.08; 95% CI 1.31 to 3.32). This data was not used from 
the 1
st
 arm (5% of a CHM cream) of this study in this review as the trial 
investigators stated the effect of the 2
nd
 arm was superior to the 1
st
 arm. This 
study used a clinician-developed scoring system and reported that there was a 
significant reduction of the mean score in its 2
nd
 arm compared to that in the 4
th
 
arm (MD -3.90; 95% CI -5.59 to -2.21). However, it did not measure the itching 
severity score or QoL. 
2) CHM versus Conventional medications 
Nine studies plus Chao 2003 in its 3
rd
 arm used conventional medications as 
control interventions (Chen 2011; Dong 2012; Huang 2010; Ma 2007; Wang 
2008; Xu 2012; Yang 2012; Zhou 2011; Zou 2011). Data was pooled from these 
10 studies (nine studies plus one arm from Chao 2003) and this pooled data 
displayed an overall effect favourable for CHM in terms of “total effectiveness 
rate” (RR 1.19; 95% CI 1.04 to 1.36; Figure 7). Testing for heterogeneity 
showed a high level of inconsistency existed across the 10 included studies in 
terms of the “total effectiveness rate” (I2 = 66%). A subgroup analysis was 
performed to investigate the possible cause of heterogeneity. No statistically 
significant difference was observed in five subgroup studies in which 
corticosteroid creams were used as control interventions (Chen 2011; Dong 
2012; Huang 2010; Xu 2012; Chao 2003) (RR 1.04; 95% CI 0.93 to 1.16; Figure 
7, Analysis 2.1.1). The trial investigators further claimed that the immediate 
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effect of CHM rivalled in the corticosteroid creams. The other five subgroup 
studies showed effects of CHM were superior to non-steroid medications (Ma 
2007; Wang 2008; Yang 2012; Zhou 2011 and Zou 2011) (RR 1.52; 95% CI 
1.30 to 1.78; Figure 7, Analysis 2.1.2). Even though there was no heterogeneity 
in both subgroups, the total subgroup differences were significantly substantial 
(I
2
 = 93.6%; Figure 7). 
 
Figure 7 Comparison of CHM and conventional medications for total effectiveness 
rate (number of participants with recovered and significantly improved) 
 
 
 
Abbreviation: CHM, Chinese herbal medicine; CI, Confidence Interval; df, degrees of 
freedom. 
The trial investigators of three studies stated that there was no difference 
between CHM groups and control groups in outcome measured by the overall 
score of severity of the condition (Chao 2003; Chen 2011 and Dong 2012). 
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Huang 2010 study reported CHM was more effective than clobetasol propionate 
ointment (a corticosteroid drug). The pooled data from these four studies where 
corticosteroid creams were used as comparator interventions. No statistical 
significance difference between the treatment and control interventions was 
observed (SMD -0.05; 95% CI -0.88 to 0.78; Figure 8). A high level of 
heterogeneity (I
2 
= 94%) was found among these four included studies. None of 
the included studies assessed itching severity or QoL. 
 
Figure 8 Comparison of CHM and steroid creams for overall score of skin lesion 
severity 
 
 
Abbreviations: CHM, Chinese herbal medicine; CI, confidence interval; df, degrees of 
freedom. 
 
 
3.7.5 Adverse Events 
Four included studies reported no adverse events observed in treatment or 
control groups (Xu 2012, Yang 2012, Zhou 2011, Zou 2011). Ma 2007 study did 
not report any information on adverse events. Dong 2012; Chao 2003 and Chen 
2011 studies reported minor adverse events such as burning, dryness and scaling 
on the skin in control groups. Huang 2010 study reported five cases with 
pigmentation in the control group. Wang 2008 study reported one and four 
minor adverse events in the treatment and control groups respectively. The data 
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was pooled from Chao 2003; Chen 2011; Huang 2010 and Wang 2008 studies. 
The overall adverse events in the CHM groups were less than those in the 
control groups (RR 0.17; 95% CI 0.05 to 0.66; Figure 9).  
 
Figure 9 Comparison of CHM and conventional medications (drugs) for adverse 
events 
 
 
Abbreviations: CHM, Chinese herbal medicine; CI, confidence interval; df, degrees of 
freedom. 
 
3.8  Discussion and Recommendations 
Topical administration of medicines has the advantages of protecting the skin, 
ceasing the use of medication immediately and user-friendly (Yang, 2005). There have 
been a number of RCTs on topical application of CHM for AE published. Of these, the 
most commonly used Chinese herbs for AE seem to have promising pre-clinical 
pharmacological data to support their application, such as Huangbai (Cortex 
Phellodendri), Huanglian (Rhizoma Coptidis), Shechuangzi (Fructus Cnidii), Zicao 
(Radix Arnebiae) and Bingpian (Borneolum Syntheticum) possess a broad range of anti-
inflammatory effect (Shen, 2000). The efficacy of these Chinese herbs is yet to be 
evaluated via properly powered placebo-controlled RCTs.  
The present review identified 10 RCTs, which met the inclusion criteria set in 
the research plan. However, they were of high risk of bias and associated with 
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significant methodological flaws. For instance, although all included studies used 
randomisation for grouping participants, only one study stated methods of 
randomisation. None of the included studies used blinding methods. When further 
information was requested from their corresponding authors, none of them provided 
information such as random sequence generation, allocation concealment, blinding of 
participants or dealing with incomplete outcome data. Inadequate randomisation could 
be from a trial investigator’s bias for grouping participants, consequently affecting the 
outcome estimation (Liu, 2006). Absence of using or reporting data of validated 
instruments for assessing AE severity such as the EASI, SASSAD or SCORAD in the 
included studies made quantifiable data analysis impossible (Eichenfield, Hanifin, 
Luger, Stevens, & Pride, 2003). Seven included studies claimed that there were 
significant statistical differences in the outcome measures between the treatment and 
control groups. It was observed that other four studies were “equivalence trials” to 
prove CHM was not substantially less effective than corticosteroids and trial 
investigators of these four studies concluded that effect of CHM was equivalent to that 
of corticosteroid creams. Due to high risk of bias existed in included studies; these 
positive claims need to be taken with great caution. High level of heterogeneity was also 
found among the included studies. The sources of heterogeneity may be attributed to the 
treatment factors (e.g. different treatment regime).  
In summary, this review did not find convincing evidence to demonstrate 
superiority of CHM used topically for AE when compared to a range of control 
interventions. Therefore, well-designed, adequately powered, randomised placebo-
controlled clinical trials are warranted to evaluate the efficacy and safety of topical use 
of CHM for managing AE. In addition, a more comprehensive per-protocol systematic 
review such as Cochrane systematic review of interventions is recommended for further 
evaluation of CHM in both oral and topical administration for AE.  
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A Cochrane systematic review to evaluate the effects of CHM in a broader scope 
of administration of CHM including oral ingestion and/or topical usage in children and 
adults with AE was outlined in next chapter.  
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Chapter 4  Cochrane Systematic Review of CHM for AE 
 
The contents of this chapter have been published in the Cochrane Database of 
Systematic Reviews (CDSR). Gu S, Yang AWH, Xue CCL, Li CG, Pang C, Zhang W, 
Williams HC. (2013) Chinese herbal medicine for atopic eczema. Cochrane Database of 
Systematic Reviews 2013, Issue 9. Art. No.: CD008642. DOI: 
10.1002/14651858.CD008642.pub2. 
 
Section I: Introduction  
 
4.1 Background  
 
The initial Cochrane systematic review on oral ingestion of CHM for AE was 
published in 2004 (W. Zhang et al., 2004). It was timely to update this review to taking 
into account new evidence that has emerged in relation to oral ingestion of herbal 
interventions. It was decided that it would be best to review both oral ingestion and 
topical CHM since people with AE are likely to be interested in both types of treatment. 
A new protocol was therefore written to plan for the expanded scope of this review (S. 
Gu et al., 2010).  
4.2 Objectives  
 
To evaluate the effects of oral ingestion and topical applications of CHM for the 
management of AE in children and adults. 
 
Section II: Methods 
 
4.3 Criteria for Considering Studies for This Review  
4.3.1 Types of Studies  
All RCTs with or without blinding, regardless of language. 
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4.3.2 Types of Participants  
Adults or children (from one month to 16 years old) with AE were included. It 
was acceptable that the diagnostic criteria such as the Hanifin and Rajka 
definition or the U.K. refinement when using the terms “atopic eczema” or 
“atopic dermatitis”. (J.M. Hanifin & Raika, 1980; H. C. Williams, Burney, Hay, 
et al., 1994). In the absence of explicit diagnostic criteria, adults diagnosed with 
“eczema” or “chronic eczema” were excluded but children diagnosed with 
“eczema” by physicians or dermatologists were accepted. 
4.3.3 Types of Interventions  
Oral ingestion and topical applications of a single Chinese medicinal herb or 
formula, manufactured or clinician self-designed Chinese medicinal formulae, (a 
clinician self-designed formula is usually composed of different types of 
Chinese herbs prescribed by a Chinese medicine practitioner who determines the 
selection of herbs based on a person’s condition) compared to the following 
control interventions: placebo, no intervention, and active controls including 
acupuncture or conventional medicines. 
Trials with a combination of oral ingestion and topical interventions were also 
included. 
Interventions based on individualised treatment were excluded unless there were 
appropriate control interventions. 
4.3.4 Outcome Measures  
1) Primary outcomes  
a. Percentage of trial participants with at least good or excellent improvement in 
terms of investigator global score. Both short-term (within six weeks) and long-
term (more than six weeks) improvement were included. 
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b. Percentage of trial participants with at least good or excellent improvement in 
terms of participants or parents global score. Both short-term (within six weeks) 
and long-term (more than six weeks) improvement in term of participants or 
parents global score were included. 
2) Secondary outcomes  
a. Changes in participant or parent-rated global improvement in EASI, 
SCORAD, POEM or SASSAD as stated in each of the trials both short-term 
(within six weeks) and long-term (more than six weeks) improvement (Schmitt 
et al., 2007).  
b. Changes in participant or parent-rated global improvement in QoL such as 
Children’s Dermatology life quality index (CDLQI) or DLQI (Dermatology life 
quality index) both short-term (within six weeks) and long-term (more than six 
weeks) improvement. 
3) Adverse events. 
4.4 Search Methods for Identification of Studies  
 
It was aimed to identify all relevant RCTs regardless of language or publication 
status (published, unpublished, in press, or in progress). 
4.4.1 Electronic Searches  
1) The following databases up to 11 September 2012 were searched: 
o the Cochrane Skin Group Specialised Register using the following terms: 
((“Chinese” and (“herb*” or “medicin*” or “traditional” or “plant*”)) or 
“traditional medicin*” or “traditional therap*” or ((“orient*” or “herbal”) 
and (“medicin*” or “therap*”)) or “Phytotherapy” or 
“phytopharmaceutic*” or (“plant” and (“medicin*” or “extract*”))) AND 
(“dermatitis” OR (“besnier*” AND “prurigo”) OR “eczema”); 
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o the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 8, 
2012 in The Cochrane Library; 
o MEDLINE via OVID (from 1946); 
o EMBASE via OVID (from 1974); 
o AMED via OVID (Allied and Complementary Medicine, from 1985)  
o LILACS (Latin American and Caribbean Health Science Information 
database, from 1982), and; 
o CINAHL via EBSCO (Cumulative Index to Nursing & Allied Health 
Literature, from 1981). 
   
Table 7 lists the search strategy of the above mentioned databases. 
 
Table 7 Search strategy 
 
Database Strategy 
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The Cochrane 
Library  
#1 MeSH descriptor Eczema explode all trees 
#2 MeSH descriptor Dermatitis, Atopic explode all trees 
#3 MeSH descriptor Dermatitis explode all trees 
#4 eczema or dermatitis or "besnier* prurigo" 
#5 (#1 OR #2 OR #3 OR #4) 
#6 MeSH descriptor Medicine, Chinese Traditional explode 
all trees 
#7 MeSH descriptor Drugs, Chinese Herbal explode all trees 
#8 MeSH descriptor Plants, Medicinal explode all trees 
#9 MeSH descriptor Medicine, Traditional explode all trees 
#10 MeSH descriptor Plant Extracts explode all trees 
#11 MeSH descriptor Phytotherapy explode all trees 
#12 (phytopharmaceutic*) 
#13 (herb*) 
#14 (traditional or herbal) and (therap* or medicine*) 
#15 "aconite root" or camelia or cayenne or "chinese 
cucumber" or "chrysanthemum flower*" or "cocklebur fruit" 
or "cow dipper" or "croton seed" or ginger or ginkgo or 
ginseng or "goji berry" or "horny goat weed" or rhubarb or 
"thunder vine" or "strychnine tree" or "sweet wormwood" or 
"willow bark" 
#16 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 
#13 OR #14 OR #15) 
#17 (#5 AND #16) 
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MEDLINE via 
OVID (from 
1946) 
 
1. exp Eczema/ or eczema.mp. 
2. atopic dermatitis.mp. or exp Dermatitis, Atopic/ 
3. exp Dermatitis/ or dermatitis.mp. 
4. Besnier$ prurigo.mp. 
5. or/1-4 
6. exp drugs, chinese herbal/ or exp medicine, chinese 
traditional/ 
7. exp Plants, Medicinal/ 
8. exp Medicine, Traditional/ 
9. exp Plant Extracts/ 
10. exp Phytotherapy/ 
11. phytopharmaceutic$.mp. 
12. herb$.mp. 
13. traditional medicine$.mp. 
14. traditional therap$.mp. 
15. herbal medicine$.mp. 
16. herbal therap$.mp. 
17. aconite root.mp. 
18. camelia.mp. 
19. cayenne.mp. 
20. chinese cucumber.mp. 
21. chrysanthemum flower$.mp. 
22. cocklebur fruit.mp. 
23. cow dipper.mp. 
24. croton seed.mp. or exp Croton/ 
25. ginger.mp. or exp Ginger/ 
26. ginkgo.mp. or exp Ginkgo biloba/ 
27. ginseng.mp. or exp Panax/ 
28. goji berry.mp. 
29. horny goat weed.mp. 
30. rhubarb.mp. or exp Rheum/ 
31. thunder vine.mp. 
32. strychnine tree.mp. 
33. sweet wormwood.mp. 
34. willow bark.mp. 
35. randomized controlled trial.pt. 
36. controlled clinical trial.pt. 
37. randomized.ab. 
38. placebo.ab. 
39. clinical trials as topic.sh. 
40. randomly.ab. 
41. trial.ti. 
42. 35 or 36 or 37 or 38 or 39 or 40 or 41 
43. (animals not (human and animals)).sh. 
44. 42 not 43 
45. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 
17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 
or 28 or 29 or 30 or 31 or 32 or 33 or 34 
46. 5 and 44 and 45 
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EMBASE via 
OVID (from 
1974)  
 
 
1. eczema.ti,ab. or *eczema/ 
2. exp *DERMATITIS/ or dermatitis.ti,ab. 
3. atopic dermatitis.ti,ab. or *atopic dermatitis/ 
4. Besnier$ prurigo.ti,ab. 
5. or/1-4 
6. exp oriental medicine/ or exp medicinal plant/ or exp 
Chinese medicine/ or exp traditional medicine/ or exp Chinese 
drug/ 
7. exp herb/ or exp Chinese herb/ 
8. exp herbal medicine/ 
9. (herb or herbs).mp. or herbal.ti,ab. 
10. exp plant medicinal product/ or exp plant extract/ 
11. exp phytotherapy/ 
12. phytopharmaceutic$.ti,ab. 
13. traditional medicine$.ti,ab. 
14. traditional therap$.ti,ab. 
15. herbal medicine$.ti,ab. 
16. herbal therap$.ti,ab. 
17. aconite root.ti,ab. 
18. camelia.ti,ab. 
19. cayenne.ti,ab. 
20. chinese cucumber.ti,ab. 
21. chrysanthemum flower$.ti,ab. 
22. cocklebur fruit.ti,ab. 
23. cow dipper.ti,ab. 
24. croton seed.ti,ab. 
25. ginger.ti,ab. 
26. ginkgo.ti,ab. 
27. ginseng.ti,ab. 
28. goji berry.ti,ab. 
29. horny goat weed.ti,ab. 
30. rhubarb.ti,ab. 
31. thunder vine.ti,ab. 
32. strychnine tree.ti,ab. 
33. sweet wormwood.ti,ab. 
34. willow bark.ti,ab. 
35. random$.mp. 
36. factorial$.mp. 
37. (crossover$ or cross-over$).mp. 
38. placebo$.mp. or PLACEBO/ 
39. (doubl$ adj blind$).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
40. (singl$ adj blind$).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
41. (assign$ or allocat$).mp. 
42. volunteer$.mp. or VOLUNTEER/ 
43. Crossover Procedure/ 
44. Double Blind Procedure/ 
45. Randomized Controlled Trial/ 
46. Single Blind Procedure/ 
47. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 
45 or 46 
48. or/6-34 
49. 5 and 47 and 48 
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AMED via 
OVID (Allied 
and 
Complementary 
Medicine, from 
1985)  
1. exp Eczema/ or eczema.mp. 
2. dermatitis.mp. 
3. Dermatitis/ or exp Dermatitis atopic/ 
4. besnier$ prurigo.mp. 
5. or/1-4 
6. exp Drugs chinese herbal/ or exp Traditional medicine 
chinese/ 
7. exp Plant extracts/ or exp Herbs/ or exp Herbal drugs/ or exp 
Plants medicinal/ 
8. exp Traditional medicine/ 
9. exp Herbalism/ 
10. exp Phytotherapy/ 
11. phytopharmaceutic$.mp. 
12. traditional medicine$.mp. 
13. traditional therap$.mp. 
14. herbal medicine$.mp. 
15. herbal therap$.mp. 
16. aconite root.mp. 
17. camelia.mp. 
18. cayenne.mp. 
19. chinese cucumber.mp. 
20. chrysanthemum flower$.mp. 
21. cocklebur fruit.mp. 
22. cow dipper.mp. 
23. croton seed.mp. 
24. ginger.mp. 
25. ginkgo.mp. or exp Ginkgo biloba/ 
26. ginseng.mp. or exp Panax ginseng/ 
27. goji berry.mp. 
28. horny goat weed.mp. 
29. rhubarb.mp. 
30. thunder vine.mp. 
31. strychnine tree.mp. 
32. sweet wormwood.mp. 
33. willow bark.mp. 
34. (plant$1 or herb$).mp. [mp=abstract, heading words, title] 
35. randomized controlled trial$/ 
36. random allocation/ 
37. double blind method/ 
38. single blind method.mp. 
39. exp Clinical trials/ 
40. (clin$ adj25 trial$).mp. [mp=abstract, heading words, title] 
41. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or 
mask$ or dummy)).mp. [mp=abstract, heading words, title] 
42. (placebo$ or random$).mp. [mp=abstract, heading words, 
title] 
43. research design/ or clinical trials/ or comparative study/ or 
double blind method/ or random allocation/ 
44. prospective studies.mp. 
45. cross over studies.mp. 
46. Follow up studies/ 
47. control$.mp. 
48. (multicent$ or multi-cent$).mp. [mp=abstract, heading 
words, title] 
49. ((stud or design$) adj25 (factorial or prospective or 
intervention or crossver or cross-over or quasi-
experiment$)).mp. [mp=abstract, heading words, title] 
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LILACS (Latin 
American and 
Caribbean 
Health Science 
Information 
database, from 
1982) 
((Pt RANDOMIZED CONTROLLED TRIAL OR Pt 
CONTROLLED CLINICAL TRIAL OR Mh 
RANDOMIZED CONTROLLED TRIALS OR Mh 
RANDOM ALLOCATION OR Mh DOUBLE-BLIND 
METHOD OR Mh SINGLE-BLIND METHOD OR Pt 
MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or 
tw trial) and (tw azar or tw acaso or tw placebo or tw 
control$ or tw aleat$ or tw random$ or (tw duplo and tw 
cego) or (tw doble and tw ciego) or (tw double and tw blind)) 
and tw clinic$)) AND NOT ((CT ANIMALS OR MH 
ANIMALS OR CT RABBITS OR CT MICE OR MH RATS 
OR MH PRIMATES OR MH DOGS OR MH RABBITS OR 
MH SWINE) AND NOT (CT HUMAN AND CT 
ANIMALS)) [Words] and chinese or herb$ or traditional 
[Words] and eczema or dermatitis [Words] 
CINAHL via 
EBSCO 
(Cumulative 
Index to 
Nursing & 
Allied Health 
Literature, from 
1981) 
 
S1 (MM "Eczema") OR (MM "Dermatitis, Atopic") 
S2 (MH "Medicine, Chinese Traditional") OR (MH "Drugs, 
Chinese Herbal") 
S3 TI (Chinese and (herb* or medicin* or traditional or 
plant*)) 
S4 AB (Chinese and (herb* or medicin* or traditional or 
plant*)) 
S5 S2 or S3 or S4 
S6 TI eczema or dermatitis 
S7 S1 or S6 
S8 S5 and S7 
S9 (MH "Clinical Trials+") 
S10 PT clinical trial 
S11 TX (clinic* n1 trial*) 
S12 (MH "Random Assignment") 
S13 TX random* allocat* 
S14 TX placebo* 
S15 (MH "Placebos") 
S16 (MH "Quantitative Studies") 
S17 TX allocat* random* 
S18 "randomi#ed control* trial*" 
S19 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX 
( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 
blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or 
(trebl* n1 mask*) ) 
S20 S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or 
S17 or S18 or S19 
S21 S8 and S20 
 
2) The following databases up to 13 September 2012 were searched: 
o SCOPUS (from 1996) using the terms (eczema or dermatitis) AND 
(Chinese) AND (random$); 
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o HERBMED (from 1998) using the terms (eczema or dermatitis) AND 
(Chinese) AND (random$); 
o ProQuest (from 1938) using the terms (atopic eczema or atopic 
dermatitis) AND (Chinese medicine) AND (random$). 
3) The following databases were also searched in the Chinese language up to 13 
September 2012 by using the strategy in Chinese listed in  
Table 8: 
o CQVIP (Chongqing VIP Information Co. Ltd) Chinese Scientific 
Journals Full-text Database (from 1989); 
o CNKI (China National Knowledge Infrastructure) (from 1979); 
o Wanfang Data (from 1982); 
o Chinese Scientific Journal Net (from 1994). The database has been 
merged into CQVIP, and; 
o China Proceedings of Conference Database (from 1994). The database 
has been merged into CQVIP. 
 
Table 8 Search strategy for Chinese databases 
 
Database Strategy (in Chinese) 
CQVIP “(Keyword_C=异位性皮炎)*((Keyword_C=(中医
药)+Title_C=(中医药)))”, 
“(Keyword_C=异位性湿疹)*((Keyword_C=(中医
药)+Title_C=(中医药)))”, 
“(Keyword_C=异位性湿疹)*((Keyword_C=(中
药)+Title_C=(中药)))”, 
“(Keyword_C=特应性皮炎)*((Keyword_C=(中医
药)+Title_C=(中医药)))”, 
“(Keyword_C=特应性皮炎)*((Keyword_C=(中
药)+Title_C=(中药)))”, 
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“(Keyword_C=特异性湿疹)*((Keyword_C=(中
医)+Title_C=(中医)))” 
“(Keyword_C=四弯风)*((Keyword_C=(中医)+Title_C=(中
医)))”, 
“(Keyword_C=婴幼儿湿疹)*((Keyword_C=(中医
药)+Title_C=(中医药)))” 
“(Keyword_C=儿童湿疹)*((Keyword_C=(中医
药)+Title_C=(中医药)))” 
CNKI (发表时间 between (1979, 2011)) 并且 (( (题名=中英文扩展
(异位性皮炎) 或者 题名=中英文扩展(异位性湿疹))) 并且 全
文=中英文扩展(中医药)) (精确匹配) 
(发表时间 between (2011, 2012)) 并且 (( (题名=中英文扩展
(异位性皮炎) 或者 题名=中英文扩展(异位性湿疹))) 并且 全
文=中英文扩展(中医药)) (精确匹配) 
(发表时间 between (2012-09-14, 2013-06-12)) 并且 (( (题名=
中英文扩展(异位性皮炎) 或者 题名=中英文扩展(异位性湿
疹))) 并且 全文=中英文扩展(中医药)) (精确匹配) 
(发表时间 between (1979,2011)) 并且 (( (题名=中英文扩展(特
应性皮炎) 或者 题名=中英文扩展(特异性湿疹))) 并且 全文=
中英文扩展(中医药)) (精确匹配) 
(发表时间 between (2011, 2012)) 并且 (( (题名=中英文扩展
(特应性皮炎) 或者 题名=中英文扩展(特异性湿疹))) 并且 全
文=中英文扩展(中医药)) (精确匹配) 
(发表时间 between (2012-09-14, 2013-06-12)) 并且 (( (题名=
中英文扩展(特应性皮炎) 或者 题名=中英文扩展(特异性湿
疹))) 并且 全文=中英文扩展(中医药)) (精确匹配) 
(发表时间 between (1979, 2011)) 并且 (( (题名=中英文扩展
(婴幼儿湿疹) 或者 题名=中英文扩展(儿童湿疹))) 并且 全文
=中英文扩展(中医药)) (精确匹配) 
(发表时间 between (2011, 2012)) 并且 (( (题名=中英文扩展
(婴幼儿湿疹) 或者 题名=中英文扩展(儿童湿疹))) 并且 全文
=中英文扩展(中医药)) (精确匹配) 
(发表时间 between (2012-09-14, 2013-06-12)) 并且 (( (题名=
中英文扩展(婴幼儿湿疹) 或者 题名=中英文扩展(儿童湿疹))) 
并且 全文=中英文扩展(中医药)) (精确匹配) 
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Wanfang 
Data 
title:异位性皮炎 keyword:中医药 date:1982-2013 
title:异位性湿疹 keyword:中医药 date:1982-2013 
title:特应性皮炎 keyword:中医药 date:1982-2013 
title:特应性湿疹 keyword:中医药 date:1982-2013 
title:四弯风 date:1982-2013 
title:婴幼儿湿疹 keyword:中医药 date:1982-2013  
title:儿童湿疹 keyword:中医药 date:1982-2013 
 
4.4.2 Trials Registers 
Reports of trials in the following trials databases up to 13 September 2012 were 
searched: 
o The metaRegister of Controlled Trials www.controlled-trials.com. 
o The U.S. National Institutes of Health ongoing trials register 
www.clinicaltrials.gov. 
o The Australian and New Zealand Clinical Trials Registry 
www.anzctr.org.au. 
o The World Health Organization International Clinical Trials Registry 
platform www.who.int/trialsearch. 
o The Ongoing Skin Trials Register on 
www.nottingham.ac.uk/ongoingskintrials. 
4.4.3 Searching Other Resources  
1) Hand searching 
The conference proceedings of the First World Congress on Chinese Medicine 
from 2003 onwards that are relevant to eczema were searched by hand. 
Conference proceedings of the Conference of Skin Diseases: Integrating Chinese 
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and Western Medicine 2007 and the 1st International Dermatology Academic 
Symposium of Traditional Chinese medicine (TCM and) Integrated TCM-WM 
2009 were also searched by hand. 
2) Reference lists 
The reference lists of all identified RCTs and review articles for further 
references to relevant trials were checked. 
2) Adverse effects 
A separate search for adverse effects of the target interventions was not 
performed. However, data on adverse effects from the included studies were 
examined. 
3) Correspondence 
On 13 December 2011, 18 September 2012 and 17 June 2013 the clinicians, 
dermatologists and experts in TCM were contacted and requested information 
on any unpublished RCTs on the topic. 
4.5 Data Collection and Analysis  
 
If the data on the number of participants with each outcome measure was not 
available in the published paper, the study author was contacted for further information. 
Also contacted were all study authors of included trials for their raw data where the 
outcomes had not been reported in such a way that meta-analysis was possible. 
4.5.1 Selection of Studies  
Two reviewers Sherman Gu (SG) and Angela Weihong Yang (AWY) selected 
the trials or studies independently according to the inclusion criteria. Papers 
were screened through reading the titles and abstracts and retrieved full texts of 
the potential included studies for further assessment. Discrepancies of the 
assessments were resolved by discussion between SG and AWY. The other two 
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team members Hywel C Williams (HCW) and Weiya Zhang (WZ) provided 
arbitrating advice when a consensus could not be achieved. 
4.5.2 Data Extraction and Management  
Two reviewers (SG and AWY) independently extracted the data from the 
included studies onto a data extraction form developed by the Cochrane Skin 
Group which has been modified to suit this review. Characteristics of 
participants, interventions and outcome measures were extracted. Data from 
each selected study consisted of the number of events (n) and participants (N) 
for dichotomous data; and number of participants (N), mean, and standard 
deviations (SD) for continuous data. 
Discrepancies in data extraction were resolved by discussion between SG and 
AWY or through other arbitrating team members HCW and WZ when a 
consensus could not be achieved. 
4.5.3 Assessment of Risk of Bias in Included Studies  
The Cochrane Collaboration's domain-based evaluation for assessing risk of bias 
was adopted. It includes the domains of: 
o sequence generation; 
o allocation concealment; 
o blinding of participants, personnel, and outcome assessors; 
o incomplete outcome data (missing data was analysed by worst-case 
scenarios. The funnel plot analysis was tested for potential publication 
bias); 
o selective outcome reporting and other sources of bias. 
An additional quality criterion of whether the study used published and validated 
scoring systems (i.e. EASI, SCORAD, POEM, or SASSAD) was set under the 
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heading of "use of published validated scoring systems" to record the severity of 
the disease (Schmitt et al., 2007). 
4.5.4 Measures of Treatment Effect  
1) The total effectiveness rate and the number of adverse events were 
dichotomous data. As the included studies compared the events in two groups, 
the dichotomous data was expressed as RR with 95% CI. A higher total 
effectiveness rate indicates better improvement of the condition. Expression of 
dichotomous data as number needed to treat (NNT) was planned. Expression of 
NNTB (number needed to treat for an additional beneficial outcome) for 
beneficial outcome and NNTH (number needed to treat for an additional harmful 
outcome) for harmful events was planned as recommended by Cochrane 
Handbook for Systematic Reviews of Interventions (the handbook) (Higgins & 
Green, 2011). The baseline event rate includes the Control Event Rate (CER) 
and the Experimental Event Rate (EER) for calculation of NNT. Use of a 
plausible range of CER from the individual trials was planned. An NNTB range 
of two to four should indicate the interventions are effective which should imply 
a beneficial outcome. 
2) The scores of itching VAS, global symptom improvement scores and QoL 
were continuous data. They were expressed as MD with 95% CI. As outcome 
scales used in the included studies were various, the continuous data as SMD 
with 95% CI were expressed, where different outcome scales were pooled. 
4.5.5 Studies with Multiple Treatment Groups 
For studies with more than two interventions, the comparison group that met the 
inclusion criteria was selected. 
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4.5.6 Unit of Analysis Issues  
Unit of analysis issues was considered if a study involved measurements on 
different body parts such as comparison of a site on one arm versus another site 
on the other arm for topical interventions. In this case, the study was treated as a 
'within patient trial' and a separate meta-analysis was performed as appropriate. 
For cross-over trials where participants were given different treatments in 
random sequence, a separate meta-analysis was planned to undertake. The 
results from the first phase could be combined with those from the parallel trials 
if data were available.   
The data from included parallel studies were planned to combine and the first 
period of included cross-over studies in the meta-analysis. Cross-over studies 
only if their methods were appropriate as suggested in the handbook were 
planned to be included. 
4.5.7 Dealing with Missing Data  
The trial author of a study for more information if there was any missing data in 
the trial was contacted. Intention to treat (ITT) analysis was applied to the 
included studies in which missing individuals were identified. 
4.5.8 Assessment of Heterogeneity  
Heterogeneity (inconsistency) in included studies was assessed by using the I² 
statistic, which describes the percentage of variation across studies due to 
heterogeneity rather than by chance. 
4.5.9 Assessment of Reporting Biases  
Funnel plot asymmetry was tested where there were more than 10 trials included 
in the meta-analysis. 
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4.5.10 Data Synthesis  
1) It was anticipated that the nature of the interventions would be quite diverse, 
and it was therefore unlikely that they would all estimate the same treatment 
effect. It was in fact that the studies in this review estimated different, yet 
related, intervention effects, and for this reason, a random-effects mode was 
conducted when attempting to pool data from several studies. The meta-analyses 
were performed irrespective of the level of heterogeneity for the purpose of 
explanation of potential inconsistency across the included studies. When 
substantial heterogeneity was found (I² statistic greater than 50%), then the 
sources of such heterogeneity were explored by rechecking the data, and by 
subgroup analysis based on clinical and methodological diversity factors. 
2) Meta-analysis was performed by using the inverse-variance method in 
RevMan as outlined in the handbook for effect estimates from the collected data. 
3) Studies relating to adverse events were reported quantitatively. 
4.5.11 Subgroup Analysis and Investigation of Heterogeneity  
Subgroup analyses were performed under the heading of "children (16 years old 
or under) with eczema versus adult with eczema", and "application of 
intervention based on Chinese medicine syndrome differentiation versus non-
individualisation formula" where there were at least moderate levels of 
heterogeneity across the included studies. The sources of heterogeneity were 
investigated including participant factors (e.g. age, diagnosis, sex, race, co-
morbidity), treatment factors (e.g. dosage, formulation), and study factors (e.g. 
concordance rates, quality of reporting), and quality control for the Chinese 
herbal preparations (e.g. source, purity, preparation facilities) to explain such 
differences. 
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4.5.12 Sensitivity Analysis  
Sensitivity analyses of the primary outcomes were planned to perform by 
excluding studies of low methodological quality. Where substantial 
heterogeneity existed between studies for the primary outcome (I² statistic > 
50%), sources for such heterogeneity such as quality of disease definition or 
composition or dose of the herbal medication were to be sought and explored in 
sensitivity analyses. However such analyses were unable to be performed due to 
an absence of data. 
Section III: Results 
 
4.6 Description of Studies 
4.6.1 Results of the Search 
A total of 1740 records were identified through thorough searches. There 
were 1674 records excluded after screening the titles and abstracts. Of the 
remaining 66 records, three were registered trials and they were classified as 
"ongoing studies" (see subheading 4.6.5 Ongoing Studies below). Full texts of 
the remaining 63 records were retrieved. Of these, 20 were excluded as they 
were not RCTs. Another four studies were excluded because their comparison 
interventions did not meet the inclusion criteria of this review (see subheading 
4.6.3 Excluded Studies below). Nine studies require further information before 
their inclusion or exclusion may be determined (see subheading 4.6.4 Studies 
Awaiting Classification below). Of the remaining 30 records, one was a protocol 
for a study which has been completed but no final report has been published, and 
it was added to the three records found that were ongoing trials. There were 28 
studies included (from 29 records; one study was reported twice and these two 
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identical trials were included under the same study ID). The screening process is 
summarised in   
 83 
Figure 10 demonstrates the study selection flow diagram. Table 9 listes 
all 28 included studies ID and their citations. 
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Figure 10 Study selection flow diagram 
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Table 9 Study ID and citations of included studies in Cochrane systematic review 
 
Study ID Citation 
Cao 2009  
 
Cao M, Wei YG. Clinical study of Zhuling Jianpi Huashi decoction 
for atopic dermatitis. Nanjing University of Chinese Medicine; 
Nanjing [Master’s thesis] (in Chinese) 2009. 
Chao 2003  
 
Chao Q, Xiao JG. Research of Chinese herbal medicines for 
infantile eczema. Qingdao University, Qingdao [Master’s thesis] (in 
Chinese) 2003. 
Chen 2011  
 
Chen H. Clinical observation of Huanglian Qingdai cream for 
infantile eczema. Journal of Sichuan of Traditional Chinese 
Medicine; (in Chinese) 2011;29 (6):88-9. 
Cheng 2010  
 
Cheng HM, Chiang LC, Jan YM, Chen GW, Li TC. The efficacy 
and safety of a Chinese herbal product (Xiao-Feng-San) for the 
treatment of refractory atopic dermatitis: a randomized, double-
blind, placebo-controlled trial. International Archives of Allergy & 
Immunology 2011;155 (2):141-8. [DOI: 10.1159/000318861] 
Gong 2010  
 
Gong XH, Kuang L, Liu X. Clinical observation of Liangxue 
Xiaofeng formula for adult atopic dermatitis. Journal of TCM 
University of Hunan (in Chinese) 2010;30(3):61-3. 
Hon 2007  
 
Hon KL, Leung TF, Ng PC, Lam MCA, Kam WYC, Wong KY, et 
al. Efficacy and tolerability of a Chinese herbal medicine 
concoction for treatment of atopic dermatitis: a randomized, 
double-blind, placebo-controlled study. British Journal of 
Dermatology 2007;157(2):357-63. [MEDLINE: 17501956] 
Huang 2010  
 
Huang ZK, Chen P, Wei WN. Observation of efficacy of Chushi 
Zhiyang cream for atopic dermatitis. Modern Journal of Integrated 
Traditional Chinese & Western Medicine (in Chinese) 2010;19 
(21):2647-8. 
Jin 2007  
 
Jin PZ, Ye QH, Shen M. Observation of efficacy of Jianpi Zhiyang 
granules for 32 cases with atopic dermatitis. Henan Traditional 
Chinese Medicine (in Chinese) 2007;27 (12):61-2. 
Lang 2007  
 
Lang N, Yao CH, Bo YJ, Chi HY, Tu YY, Huang YZ. Treatment of 
blood deficiency with wind dryness type of atopic dermatitis with 
combination of Shengui decoction and Shidu ointment. Chinese 
Journal of Dermatovenerology Integrated Traditional & West 
Medicine (in Chinese) 2007;6 (1):22-3. 
Lin 2010  
 
Lin Y, Chen DC. Efficacy of anti-inflammatory moisturising 
washing formula for atopic dermatitis and its biological evaluation. 
Guangzhou University of Chinese Medicine, Guangzhou [PhD 
thesis] (in Chinese) 2010. 
Liu 2005  
 
Liu HC. Investigation of efficacy of Chinese medicine for atopic 
dermatitis. Hua-xia Medicine (in Chinese) 2005;25 (3):208-9. 
Luo 2010  
 
Luo FJ, Wei YG. Evaluation of efficacy of Xiaofengsan with 
modifications for atopic dermatitis. Nanjing University of Chinese 
Medicine, Nanjing [Master’s thesis] (in Chinese) 2010. 
Ma 2010  
 
Ma YB, Sun LY, Wang P, Zhang GZ, Cai NN. Clinical observation 
of combination of Jianpi Runfu decoction and topical application of 
Gancao oil for atopic dermatitis with syndrome of spleen deficiency 
and blood dryness. Beijing Journal of Traditional Chinese Medicine 
(in Chinese) 2010;29 (9):680-2. 
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Rao 2010  
 
Rao MR, Wei YG. Clinical study of Qingxin Peitu method for 
atopic dermatitis. Nanjing University of Chinese Medicine, Nanjing 
[Master’s thesis] (in Chinese) 2010. 
Sun 2009  
 
Sun XD. Evaluation of efficacy and effect of reoccurrence of Jianpi 
Shenshi granules for atopic dermatitis [Clinical effect of 
invigorating spleen and excreting dampness granules in treating 
atopic dermatitis and its influence for recurrence of the patient]. 
Chinese Journal of Dermatovenerology Integrated Traditional and 
Western Medicine (in Chinese) 2009;8 (6):335-7. 
Tian 2005  
 
Tian F, He T. Observation of efficacy of Fuyang granules for 
infantile eczema. Liaoning Journal of Traditional Chinese Medicine 
(in Chinese) 2005;32 (8):810-1. 
Wang 2008  
 
Wang P, Cai L, Xu JJ. Observation of efficacy of Chushi Zhiyang 
ointment for infantile eczema. Journal of Sichuan of Traditional 
Chinese Medicine (in Chinese) 2008;26 (9):92-3. 
Xiao 2008  
 
Xiao M, Ai RD. Observation of clinical efficacy of combination of 
Machixian decoction and topical application of Chinese herbs for 
atopic dermatitis and evaluation of IgE level in serum. Chengdu 
University of Chinese Medicine, Chengdu [Master’s thesis] (in 
Chinese) 2008. 
Xiao 2011  
 
Xiao WM, Li G, Luo B, Zhu QJ. Observation of efficacy of 
Huailian decoction for atopic dermatitis. Journal of China 
Traditional Chinese Medicine Information (in Chinese) 2011;3 
(3):37-9. 
Xue 2011  
 
Xue SQ, Tan JH. Clinical observation of Shengxue Runfu 
decoction with modifications for childhood atopic dermatitis. 
Journal of New Chinese Medicine (in Chinese) 2011;43 (2):94-5. 
Yang 2007  
 
Yang Y, Sun JL, Feng YL, Yang YF, Wang LX. Analysis of 
efficacy of Chinese herbs Jianpi Zhiyang granules with Pibo 
Xiaoyan Xuanshi ointment for atopic dermatitis. Chinese Journal of 
Dermatovenerology Integrated Traditional & Western Medicine (in 
Chinese) 2007;6 (3):135-7. 
Yang 2009  
 
Yang XS, Ye JZ, Li K. Clinical efficacy of Jianpi Yangxue Qufeng 
method for atopic dermatitis and its affect for skin barrier function 
[The effects of the clinical efficacy of method of strengthening 
spleen and enriching blood eliminating wind in treatment of chronic 
atopic dermatitis]. Journal of Yunnan University of Traditional 
Chinese Medicine (in Chinese) 2009;32 (3):5-7. 
Yu 1999  
 
Yu TG, Zhu JT, Xu JL, Zhuang YR, Shen B, Wu BL, et al. Clinical 
and laboratory study of Piyan Xiaojingyin granules II for atopic 
dermatitis. Journal of Traditional Chinese Medicine (in Chinese) 
1999;40 (3):165-7. 
Zhang 2005  
 
Zhang QS, Wei YG. Clinical study of Jianpi Huashi formula for 
childhood atopic dermatitis. Nanjing University of Chinese 
Medicine, Nanjing [Master’s thesis] (in Chinese) 2005. 
Zhang 2009  
 
Zhang XJ, Song XL. Observation of clinical efficacy of Xiao'er 
Huashi decoction for infantile eczema. In: Proceedings of the First 
International Dermatology Academic Symposium of TCM and 
Integrated TCM-WM. Beijing: World Federation of Chinese 
Medicine Societies, (in Chinese) 2009:297-9. 
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Zhang 2011  
 
Zhang CJ. Clinical observation of Zhiyin Qingre method for 30 
cases with atopic dermatitis. Guiding Journal of Traditional Chinese 
Medicine & Pharmacy (in Chinese) 2011;17 (8):22-4. 
Zhou 2011  
 
Zhou YZ. Observation of clinical efficacy of Cang’er Kushen lotion 
for 88 cases with infantile eczema. Guide of China Medicine (in 
Chinese) 2011;9 (25):115-6. 
Zou 2011  
 
Zou GM, Xie B. Clinical study of Fufang Sanhuang lotion for 
infantile eczema. Liaoning Journal of Traditional Chinese Medicine 
(in Chinese) 2011;38 (2):297-9. 
 
4.6.2 Included Studies  
There were 28 studies with a total of 2306 participants included. 
1) Design 
All 28 included studies were randomised controlled parallel clinical studies with 
oral ingestion or topical applications of CHM for eczema except the Lin 2010 
study in which CHM was used topically on a randomised selected arm or leg of 
the participant for comparison with the other non-treatment site on the same 
participant.  
No included studies were cross-over trials but one study (Lin 2010) was a 
within-patient trial and this data was treated as they were obtained from the first 
phase of a cross-over trial (Higgins & Green, 2011).  
The sample sizes of the studies ranged from 25 to 220 with a total of 2306 
participants aged from 12 days to 65 years. 
Details of the included studies are listed in the Table 10 Characteristics of 
included studies. 
2) Setting 
All of the included studies were conducted in public hospitals (most of them 
were in Chinese medicine teaching hospitals) in mainland China, Hong Kong or 
Taiwan where Chinese medicine has a long history of practice and widespread 
applications in the healthcare system. The majority of the included studies were 
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published in Chinese. Two studies were printed in English (Cheng 2010; Hon 
2007). 
3) Treatment duration 
Treatment duration ranged from five days to 16 weeks in the included studies. 
Among the 28 included studies, 13 studies reported follow-up and the follow-up 
periods ranged from four to 52 weeks after stopping the treatment.  
4) Funding 
Eight studies reported receiving funding or support from governments (Cheng 
2010; Gong 2010; Hon 2007; Ma 2010; Sun 2009; Xue 2011; Yang 2007; Yu 
1999). 
5) Interventions 
All of the studies used a combination of CHM originated from plants or animal 
or mineral products as an active intervention. 
1. CHM versus placebo 
There were four studies which compared CHM to placebo (Chao 2003; Cheng 
2010; Hon 2007; Sun 2009). Three studies used oral ingestion of interventions 
(Cheng 2010; Hon 2007; Sun 2009) and one study administered the 
interventions via topical application (Chao 2003). 
The Chao 2003 study was a four-arm parallel RCT. It treated 120 children aged 
from one to 38 months (mean seven months) with 5% (1st arm) or 10% (2nd 
arm) of Huangbai Zicao Diyu cream, or econazole nitrate cream (Pevisone) (3rd 
arm) or placebo (petroleum jelly) (4th arm) respectively for two to three weeks. 
Data from the 1st arm were not used as the 2nd arm showed a higher 
effectiveness rate than the 1st arm. Data from the 2nd arm were used and 
compared to the 4th arm (CHM versus placebo) and the 2nd arm compared to 
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the 3rd arm (CHM versus conventional medicines) in the section: 'Effects of 
interventions'. 
In the Cheng 2010 study, 71 participants with a mean age of 13 were 
randomised in a ratio of 2:1 and were treated with Chinese herbal formula Xiao-
Feng-San granules or placebo for eight weeks. Follow-up assessment was done 
after an 8-week treatment period. A total of 85 participants aged from five to 21 
years (mean 11 years) with moderate-to-severe eczema (objective SCORAD > 
15) were recruited in the Hon 2007 study. Chinese herbal medicine capsules 
containing five Chinese herbs or placebo were used for 12 weeks and follow-up 
was conducted at week 16 of the trial period. In the Sun 2009 study, Jianpi 
Shenshi granules with 10 Chinese herbs or placebo were prescribed to 25 
participants aged from three to 20 years old (mean nine years) for four weeks. 
Follow-up assessment was conducted at 24 weeks after the treatment period. 
Other medicines were allowed in both groups in all four studies. 
2. CHM versus conventional medicines (drugs) 
There were 22 studies plus the Chao 2003 study where one of its four arms 
compared the effects of CHM to drugs. 
a) Oral Ingestion (five studies) 
There were 62 participants aged from 10 to 52 years old with a mean age of 20 
years, randomly assigned to the treatment or control group in the Jin 2007 study. 
Jianpi Zhiyang granules with 12 CHMs or loratadine tablet (an antihistamine 
medication) were given to the participants for four weeks. 
The Luo 2010 study recruited 62 children with a mean age of nine and treated 
with XFS decoction with individualised modifications or loratadine or other 
antihistamine drug for 16 weeks. 
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A formula containing nine herbs was used in the Yang 2009 study in which 60 
children or adults aged from four to 27 years with a mean age of 16 were 
recruited for four weeks treatment. Loratadine tablet again was used as control 
intervention in the Yang 2009 study. 
The Yu 1999 study had the largest sample size (220 participants) among the 28 
included studies. Piyan Xiaojingyin granules II composed of more than five 
herbs were given to participants aged from five to 53 years old (mean 13 years). 
Loratadine tablet was a control intervention and both groups were supplied with 
saline or zinc oxide cream for 12 weeks. Follow-up assessment was conducted at 
52 weeks after the treatment period. 
The Zhang 2011 study reported that a clinician self-designed CHM formula with 
modifications based on individual cases or levocetirizine dihydrochloride tablets 
(an antihistamine medication) were used for treatment of 56 children aged from 
2.5 to 14 years old (with a mean age of seven years) for eight weeks. Follow-up 
assessment was conducted at 24 weeks after the eight-week treatment period. 
b) Topical application (six studies) 
The Chao 2003 study compared the effects of CHM to econazole nitrate cream 
(Pevisone) which was composed of 1% of econazole nitrate (antifungal 
medication) and 0.1% of triamcinolone acetonide (corticosteroid) in its 3rd arm. 
In the Chen 2011 study, 100 children from 58 days to two years old were 
entered into the treatment or control groups randomly and were treated with 
Huanglian Qingdai cream made from six herbs or mometasone furoate cream (a 
corticosteroid) for two weeks. 
There were 65 boys and girls aged from 12 days to 11 months (mean five 
months) in the Wang 2008 study in which Chushi Zhiyang ointment, a 
manufactured CHM product made up of 13 Chinese herbs was used topically for 
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one week, vitamin B6 cream (a moisturising agent) was employed as the control 
intervention. 
The Huang 2010 study recruited 195 patients aged from three months to 22 
years old with a mean age of 12 years and treated with Chushi Zhiyang 
ointment, which was the same CHM product used in the Wang 2008 study, or 
clobetasol propionate ointment (a corticosteroid) for two weeks. Follow-up 
assessment was performed at 12 weeks after the treatment period. 
The Zhou 2011 study treated 176 children aged three to 38 months old (mean 10 
months) with Cang'er Kushen lotion which had 13 Chinese herbs, or calamine 
lotion (an anti-itching agent) which was used topically as the control 
intervention for two weeks. Follow-up assessment was conducted 24 weeks after 
the treatment period. 
In the Zou 2011 study, 50 children aged from three to 36 months with a mean 
age of 16 months were randomised. Moist dressing with a CHM lotion 
composed of nine herbs and topical application with the same herbal powder 
mixed with sesame oil were used for two weeks. Boric acid solution (an 
antiseptic agent) and zinc oxide cream (a moisturising agent) served as control 
interventions. 
c) Combination of oral ingestion and topical application (12 studies) 
The included studies in this group used CHM by oral ingestion and topical 
application in their treatment groups for comparison of the effect to the control 
groups. 
The Cao 2009 study treated 56 children aged from two to 16 years (mean eight 
years) with Zhuling Jianpi Huashi decoction (which could be modified when the 
condition of an individual patient changed) or with oral ingestion of cetirizine 
hydrochloride drops (an antihistamine medication) for one to four weeks. There 
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were 12 herbs in the Zhuling Jianpi Huashi decoction used in this study. The 
same CHM decoction (although the name of the formula was changed) was also 
evaluated by the Zhang 2005 study. 
The Gong 2010 study randomised 56 adults aged from 16 to 65 years old (mean 
37 years) into treatment or control group and treated with Liangxue Xiaofeng 
decoction composed of 13 herbs or oral ingestion of desloratidine (an 
antihistamine medication) for four weeks. 
In the Lang 2007 study, Shengui decoction with eight herbs and Shidu ointment 
were used for the treatment group for four weeks and oral ingestion of loratadine 
tablets and 1% hydrocortisone cream (a corticosteroid) topically as control 
interventions for 72 patients aged from three to 34 years old (mean 17 years). 
The Liu 2005 study recruited 184 children and adults aged from three months to 
42 years old (mean not provided) for four to eight weeks treatment. The 
participants were treated with oral ingestion of Cangyi decoction with 
individualised modifications and Qingdai ointment and Huangbai lotion 
topically in the treatment group or treated with terfenadine tablet (an 
antihistamine medication) and 0.025% dexamethasone cream (a corticosteroid) 
as control interventions. There were 12 herbs in Cangyi decoction and the 
ingredients of the topically used CHM interventions were unknown in this study. 
The Ma 2010 study treated 82 children and adults aged from seven to 33 years 
old (mean 18 years) with formula Jianpi Runfu decoction containing 11 herbs or 
loratadine tablet. The oral ingestion of CHM could be modified based on the 
individual's condition in this study and Zicao oil or butyl flufenamate cream (an 
anti-inflammatory medication) was also used topically in the treatment group or 
control group respectively for four weeks. 
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The Tian 2005 study treated 100 participants (did not report the range of age) 
with oral ingestion of Fuyang granules composed of five herbs and used the 
same formula for topical application or oral ingestion of cyproheptadine tablet 
(an antihistamine medication) plus 3% sulphur cream (an antiseptic agent) 
externally for only five days. 
The Xiao 2008 study used oral ingestion and external application of Machixian 
decoction as a basic formula which was modified according to an individual's 
condition. Chlorphenamine tablet (an antihistamine medication) and 3% boric 
acid solution were used as control interventions. There were a total of 52 
participants aged from three to 23 years old (mean 13 years) in this study and 
treatment duration was eight weeks with follow-up assessment at 12 weeks after 
the treatment period. 
The Xiao 2011 study recruited 60 participants aged from two to 60 years old 
(mean 12 years) and provided four weeks treatment with Huailian decoction 
composed of 12 herbs and loratadine tablet was the control oral ingestion 
intervention. External use of nitrofurazone, calamine, menthol and CHM 
ointment were also provided to both groups 
The Xue 2011 study used Shengxue Runfu decoction composed of 15 herbs. The 
formula could be modified depending upon an individual's condition and 
loratadine was the control oral ingestion intervention for an 8-week treatment. 
There were 63 boys and girls ranged from two to 12 years old (mean seven 
years) in this study. Topical application of CHM ointment and emollients were 
employed for both groups 
The Yang 2007 study used the same oral ingestion of CHM intervention as was 
used in the Jin 2007 study. The two studies were conducted at the same 
department of a Chinese medicine hospital in Shenzhen, China. The Yang 2007 
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study, however, also used CHM ointment topically with a total of 64 participants 
from five to 25 years old (mean seven years) who were treated with Chinese 
herbs or oral ingestion of loratadine tablet and 1% hydrocortisone butyrate 
cream (a corticosteroid) for four weeks. 
A CHM decoction was used for comparison of its efficacy to chlorpheniramine 
tablet for 12 weeks in three groups of participants in the Zhang 2005 study 
where 45 children under 16 years old (mean eight years) were recruited. In this 
study, CHM lotion or CHM ointment were also used topically according to an 
individual's condition in all the groups. 
Finally, the Zhang 2009 study treated 61 children aged from two to 12 years old 
(mean not provided) with Xiao'er Huashi decoction (composed of 13 herbs) or 
loratadine granules for four weeks. External use of CHM lotion and CHM cream 
were provided to both groups. 
3. Combination of oral and topical CHM interventions versus same oral CHM 
alone. 
There were two studies compared effects of combination of oral and topical 
CHM to the same oral CHM formula alone (Lin 2010; Rao 2010). The Lin 2010 
study used Runfu Xiaoyan lotion composed of four herbs applied externally on a 
randomly selected site of the limb (which had received no previous treatment 
regarding the topical intervention) of 23 participants aged from 11 months to 27 
years old (mean 10 years) for two weeks. Oral ingestion of Qinxin Peitu 
decoction was also used for moderate and severe cases in the Lin 2010 study. 
The Rao 2010 study was a three-arm parallel controlled design of 12 weeks 
treatment duration. Thirty participants aged from seven to 25 years old (mean 15 
years) were recruited. The treatment group (the first arm) received Qingxin Peitu 
decoction with individualised modifications plus external use of Qingxin Peitu 
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lotion. The second arm group was treated with the same oral ingestion of the 
intervention but no topical intervention was used, and the third arm group used 
oral ingestion of placebo plus oral ingestion of cetirizine hydrochloride tablet 
and topical application of mometasone furoate cream. Data from the third arm 
group were not used in this review as there was no appropriate comparator for 
this group. 
6) Outcomes 
With regard to the Primary Outcome 1), the trial investigators in most of the 
included studies converted the measure score into effectiveness rate without 
reporting the actual score; acceptance for 'recovery' was set to where there was 
>90% reduction of the investigator global score and a 'significant improvement' 
was >70% reduction of the score as stated by the trial investigator(s). A total 
effectiveness rate was a sum of effectiveness rates expressed as 'recovery' and 
'significant' by the trial investigator(s) of the included studies. A higher total 
effectiveness rate indicates better improvement of the condition. 
With regard to Primary Outcome 2), most of the included studies, measured 
severity of itching score and expressed this as a patient-rated VAS. Thereafter, 
the continuous data extracted was expressed as a mean value, SD and total 
numbers of events assessed at the endpoint of the trial as one of the primary 
outcome measures to replace the percentage of trial participants that were 
planned. 
With regard to Secondary Outcome 3), adverse events have been extracted in a 
data extraction form for all included studies. A severe adverse event was an 
adverse effect that led a participant to withdraw from the study. A minor adverse 
event was one reported by the participant or clinician but which was not serious 
and the person still completed the treatment. 
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With regard to short-term or long-term improvement of a relevant outcome, the 
short-term improvement was an outcome measured within six weeks in the 
follow-up period after stopping the treatment. The long-term improvement was 
an outcome measured more than six weeks in the follow-up period after 
stopping treatment. 
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Table 10 Characteristics of included studies 
 
Study ID Methods Participants Interventions Controls Outcomes 
Cao 2009  
 
Randomised, 
non-blinded, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of a 
university 
teaching 
hospital in 
Nanjing, China 
2. Age: from 2 
to 16 years old 
3. Sex: 
Male/Female 
32/24 
4. Number of 
participants 
randomised: 56 
5. T/C: 32/24 
 
I. Treatment group 
1. Zhuling Jianpi Huashi decoction with 
individualised modifications 
1.1 Ingredients and dosage 
Fuling (Poria) 6 g 
Cangzhu (Rhizoma Atractylodis) 6 g 
Baizhu (Rhizoma Atractylodis 
macrocephalae) 6 g 
Chenpi (Pericarpium Citri reticulatae) 3 g 
Zexie (Rhizoma Alismatis) 6 g 
Baixianpi (Cortex Dictamni) 6 g 
Maiya (Fructus Hordei germinatus) 15 g 
Huashi (Talcum) 6 g 
Gancao (Radix Glycyrrhizae) 4 g 
1.2 Administration 
One package per day, drink the decoction 
twice daily 
1.3 Duration of treatment 
One to 4 weeks 
1.4 Follow-up 
Did not state 
II. Control group 
a. oral ingestion 
2. Cetirizine 
Hydrochloride Drops 
2.1 Ingredients and dosage 
0.5 ml for 2 to 6 years old 
patients, 1.0 ml for 7 to 16 
years old 
2.2 Administration 
Once daily 
2.3 Duration of treatment 
One to 4 weeks 
2.4 Follow-up 
Did not state 
External used of CHM 
lotion and cream were 
applied on both groups 
 
1. Percentage of 
reduction of total 
SASSAD score 
2. Effectiveness rate 
3. Adverse events 
All assessments were 
conducted at baseline, 
week 4 and at the end 
of 8-week treatment 
period respectively 
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Chao 
2003  
 
Randomised, 
controlled, 4-
arm parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
dermatology 
department of 
hospitals in 
Qingdao, China 
2. Age: from 1 
to 38 months 
3. Sex: 
Male/Female 
58/62 
4. Number of 
participants 
randomised: 120 
5. T/T/C/C: 
30/30/30/30 
 
I. Treatment group (A) (1st arm) 
1. Huangbai Zicao Diyu cream (5%). Data 
of this group was not used for comparison in 
this review as the trial investigator reported 
that the total effectiveness rate of the 2nd 
arm (group B) was superior to what in the 
1st arm (group A). 
1.1 Ingredients and dosage 
Huangbai (Cortex Phellodendri) 50 g 
Zicao (Radix Arnebiae) 50 g 
Diyu (Radix Sanguisorbae) 100 g 
1.2 Administration 
Twice daily topically 
1.3 Duration of treatment 
Two to three weeks 
1.4 Follow-up 
Did not state 
II. Treatment group (B) (2nd arm) 
Huangbai Zicao Diyu cream 10% was used 
in this group 
 
III. Control group (C) (3rd 
arm) 
2. Compound Econazole 
nitrate cream (Pevisone) 
2.1 Ingredients and dosage 
Econazole nitrate and 
triamcinolone acetonide, 
did not provide dosage 
2.2 Administration 
Twice daily topically 
2.3 Duration of treatment 
Two to three weeks 
2.4 Follow-up 
Did not state 
IV. Control group (D) (4th 
arm) 
2. Placebo 
2.1 Ingredients and dosage 
Petroleum jelly (Vaseline), 
did not provide dosage 
2.2 Administration 
Twice daily topically 
2.3 Duration of treatment 
Two to three weeks 
2.4 Follow-up 
Did not state 
External use of CHM 
lotion for washing the skin 
lesion was applied to all 
groups 
1. Skin lesion score. 
The scoring system was 
developed by the trial 
investigators. Data were 
expressed as "mean ±" 
by the trial investigators 
and we assumed the " 
±" was SD 
2. Effectiveness rate 
3. Adverse events 
4. Bacteriologic 
eradication rate on the 
skin lesions 
All assessments were 
conducted at baseline, 
week 1, 2 and the end 
of 3-week treatment 
period respectively 
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Chen 
2011  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of a 
Chinese 
medicine 
hospital in 
Changshu, 
China 
2. Age: from 58 
days to 2 years 
old 
3. Sex: 
Male/Female 
59/41 
4. Number of 
participants 
randomised: 100 
5. T/C: 50/50 
 
I. Treatment group 
1. Huanglian Qingdai ointment 
1.1 Ingredients and dosage 
Huanglian powder (Rhizoma Coptidis) 0.6 g 
Qingdai (Indigo Naturalis) 0.3 g 
Huangbai powder (Cortex Phellodendri) 0.3 
g 
Mingfan (Alum) 0. 3 g 
Bingpian (Borneolum Syntheticum) did not 
provide dosage 
Niaoshuang (Urea cream) 40 g 
1.2 Administration 
Topically use 2 to 3 times daily 
1.3 Duration of treatment 
Two weeks 
1.4 Follow-up 
Did not state 
II. Control group 
2. Mometasone furoate 
cream 
2.1 Ingredients and dosage 
Mometasone furoate 
cream 5g/tube 
2.2 Administration 
Topically use once daily 
2.3 Duration of treatment 
Two weeks 
2.4 Follow-up 
Did not state 
 
1. Severity of itching 
score (measured by 
patient-rated score, 
scale 0 to 3) 
2. Skin lesion 
(erythema and papule) 
score (measured by 
clinician-rated score). 
The scoring system was 
developed by the trial 
investigators 
3. Skin lesion area 
score (measured by 
clinician-rated score). 
The scoring system was 
developed by the trial 
investigators 
4. Effectiveness rate 
(rating was developed 
by the trial investigator) 
5. Adverse events 
All assessments were 
conducted at baseline 
and end of 2-week 
treatment period 
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Cheng 
2010  
 
Randomised, 
double-blind 
placebo-
controlled, 
parallel 
clinical trial 
1. Setting: 
Patients were 
recruited from 
department of 
Integration of 
Traditional 
Chinese and 
Western 
Medicine, a 
university 
hospital in 
Taiwan 
2. Age: from 8 
to 23 years old 
3. Sex: 
Male/Female 
37/34 
4. Number of 
participants 
randomised: 71 
5. T/C: 47/24 
 
I. Treatment group 
1. Xiao-Feng-San (XFS) 
1.1 Ingredients and dosage 
Fangfeng (Radix Saposhnikovia) 2.5 mg 
Jingjie (Herba Schizonepetae) 2.5 mg  
Danggui (Radix Sngelicae sinensis) 2.5 mg 
Shengdihuang (Radix Rehmanniae) 2.5 mg 
Kushen (Radix Sophorae flavescentis) 2.5 
mg 
Cangzhu (Rhizoma Atractylodis) 2.5 mg 
Chantui (Periostracum Cicdae) 2.5 mg 
Yamazi (Linum Usitatissimum) 2.5 mg 
Zhimu (Rhizoma Anemarrhenae) 2.5 mg 
Shigao (Gypsum Fibrosum) 2.5 mg 
Chuanmutong (Caulis Clematidis armandii ) 
1.25 mg 
Gancao (Radix Glycyrrhizae) 1.25 mg 
Niubangzi (Fructus Arctii) 2.5 mg 
1.2 Administration 
Three times daily orally, one sachet of 
granules for 3–7 years old, two sachets for 
8–12 years old and three sachets for 13 and 
over. There were 3 grams of XFS 
concentrated particles in each sachet 
1.3 Duration of treatment 
Eight weeks 
1.4 Follow up 
Four weeks after the 8-week treatment 
period 
II. Control group 
2. Placebo 
2.1 Ingredients and dosage 
Placebo was made of 
caramel, lactose and starch 
at a ratio of 2:1:1 and put 
into identical-appearing 3-
gram packs. The placebo 
mixture has no known 
benefit in atopic dermatitis 
but has a similar 
appearance and taste to the 
active treatment 
2.2 Administration 
Same as at 1.2 
2.3 Duration of treatment 
Eight weeks 
1.4 Follow up 
Four weeks the 8-week 
treatment period 
 
1. Improvement of 
clinical lesion score 
from baseline (the sum 
of erythema score and 
surface damage score 
measured by clinician-
rated score) 
2. Improvement of 
itching relief score from 
baseline (measured by 
patient-rated score) 
3. Improvement of 
sleep score from 
baseline (measured by 
patient-rated score) 
4. Adverse events 
5. Full blood count, 
serum bilirubin, 
aspartate 
aminotransferase, 
alkaline phosphatase, 
albumin, urea and 
electrolytes, creatinine, 
calcium, phosphate, 
glucose, creatine 
phosphokinase and 
immunologic markers 
(IgE, eosinophil count, 
eosinophil cationic 
protein, IL-5, IL-13) 
All assessments were 
conducted at baseline 
and week 4, 8 and 12 of 
the trial 
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Gong 
2010  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient and 
inpatient 
department of a 
Chinese 
medicine 
hospital in 
Changsha, 
China 
2. Age: from 16 
to 65 years old 
3. Sex: 
Male/Female 
31/25 
4. Number of 
participants 
randomised: 56 
5. T/C: 28/28 
 
I. Treatment group 
1. Liangxue Xiaofeng decoction 
1.1 Ingredients and dosage 
Fangfeng (Radix Saposhnikovia) 10 g 
Jingjie (Herba Schizonepetae) 10 g  
Danggui (Radix Angelicae sinensis) 10 g 
Shengdihuang (Radix Rehmanniae) 15 g 
Kushen (Radix Sophorae flavescentis) 10 g 
Cangzhu (Rhizoma Atractylodis) 6 g 
Chantui (Periostracum Cicdae) 6 g 
Zhimu (Rhizoma Anemarrhenae) 10 g 
Gancao (Radix Glycyrrhizae) 5 g 
Niubangzi (Fructus Arctii) 10 g 
Zicao (Radix Arnebiae)10 g, 
Chishao (Radix Paeoniae rubra) 10 g 
Mudanpi (Cortex Moutan) 10 g 
1.2 Administration 
One pack of herbs cooked with water and 
drink the decoction twice daily 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
12 weeks after the 4-week treatment period 
II. Control group 
2. Desloratadine tablet 
2.1 Ingredients and dosage 
Desloratadine 5 mg 
2.2 Administration 
Once daily oral ingestion 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
12 weeks after 4-week 
treatment period 
External use of CHM 
lotion for washing the skin 
lesion were applied three 
times daily on both groups 
 
1. SCORAD score 
2. Effectiveness rate 
3. Adverse events 
All assessments were 
conducted at baseline, 
end of 4- week 
treatment period and 12 
weeks after the 4-week 
treatment period 
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Hon 2007  
 
Randomised, 
double-blind 
placebo-
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
the paediatric 
dermatology 
outpatient of a 
university 
teaching 
hospital in Hong 
Kong, China 
2. Age: from 5 
to 21 years old 
3. Sex: 
Male/Female 
46/39 
4. Number of 
participants 
randomised: 85 
5. T/C: 42/43 
 
I, Treatment group 
1. TCHM capsules 
1.1 Ingredients and dosage 
Jinyinhua (Flos Lonicerae) 2 g 
Bohe (Herba Menthae ) 1 g 
Mudanpi (Cortex Moutan) 2 g 
Cangzhu (Rhizoma Atractylodis) 2 g 
Huangbai (Cortex Phellodendri) 2 g 
(a total 9 g of raw herbs) 
1.2 Administration 
Three capsules twice daily 
1.3 Duration of treatment 
12 weeks 
1.4 Follow-up 
Four weeks after the 12-week treatment 
period 
 
II. Control group 
2. Placebo 
2.1 Ingredients and dosage 
Capsule shell, corn starch 
(pharmaceutical grade) 
and caramel (food grade) 
2.2 Administration 
Three capsules twice daily 
2.3 Duration of treatment 
12 weeks 
2.4 Follow-up 
Four weeks after the 12-
week treatment period 
 
1. SCORAD score 
2. CDLQI score 
3. Adverse events 
4. Record of trial 
medications and 
primary Western 
medications usage 
All assessments were 
conducted at baseline, 
every 4 weeks during 
the trial period and at 
the end of the 12-week 
course (visit 4) 
5. Complete blood 
counts; eosinophil 
counts; total IgE levels; 
liver and renal function 
were obtained before 
treatment (visit 1), and 
at the end of the 12-
week course (visit 4) 
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Huang 
2010  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from a 
hospital in 
Mianyang, 
China 
2. Age: from 3 
months to 22 
years old 
3. Sex: 
Male/Female 
96/99 
4. Number of 
participants 
randomised: 195 
5. T/C: 98/97 
 
I. Treatment group 
1. Chushi Zhiyang ointment (a CHM 
product manufactured by a pharmaceutical 
company) 
1.1 Ingredients and dosage 
Baixianpi (Cortex Dictamni)  
Shechuangzi (Fructus Cnidii) 
Huanglian (Rhizoma Coptidis) 
Huangbai (Cortex Phellodendri) 
Kushen (Radix Sophorae flavescentis) 
Huzhang (Rhizoma Polygoni cuspidati) 
Zihuadiding (Herba Violae) 
Bianxu (Herba polygoni Avicularis) 
Yinchen (Herba Artemisiae scopariae) 
Cangzhu (Rhizoma Atractylodis) 
Huajiao (Pericarpium Zanthoxyli) 
Bingpian (Borneolum Syntheticum) etc. 
Did not provide dosage of the ingredients 
1.2 Administration 
Three times daily topically 
1.3 Duration of treatment 
Two weeks 
1.4 Follow-up 
12 weeks after 2-week treatment period 
II. Control group 
2. Clobetasol propionate 
ointment 
2.1 Ingredients and dosage 
Clobetasol propionate 
Did not provide dosage 
2.2 Administration 
Three times daily topically 
2.3 Duration of treatment 
Two weeks 
2.4 Follow-up 
12 weeks after 2-week 
treatment period 
Oral ingestion of 
phenergan syrup and moist 
dressing with 3% boric 
acid solution and infrared 
rays therapy for acute and 
subacute cases in both 
groups 
 
1. EASI score 
2. Effectiveness rate 
3. Adverse events 
Assessments were 
conducted at baseline, 
every week during the 
trial period respectively 
and follow-up 3 months 
after 2-weeks treatment 
4. Full blood counts, 
liver and renal function 
tests 
Conducted after 2-
weeks treatment period 
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Jin 2007  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology of 
a Chinese 
medicine 
hospital in 
Shenzhen, 
China 
2. Age: from 10 
to 52 years old 
3. Sex: 
Male/Female 
40/22 
4. Number of 
participants 
randomised: 62 
5. T/C: 32/30 
 
I. Treatment group 
1. Jianpi Zhiyang granules 
1.1 Ingredients and dosage 
Huangqi (Radix Astragali) 
Baizhu (Rhizoma Atractylodis 
macrocephalae) 
Danggui (Radix Angelicae sinensis) 
Heshouwu (Radix Polygoni) 
Shengdihuang (Radix Rehmanniae) 
Baishao (Radix Paeoniae alba) 
Chuangxiong (Rhizoma Chuanxiong) 
Fangfeng (Radix Saposhnikovia) 
Jingjie (Herba Schizonepetae)  
Baijili ((Fructus Tribuli terrestris) 
Gouteng (Ramulus Uncariae cum uncis) 
Gancao (Radix Glycyrrhizae) 
Did not provide dosage of the ingredients 
1.2 Administration 
Ten grams 3 times daily oral ingestion 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
Did not state 
II. Control group 
2. Loratadine tablet 
2.1 Ingredients and dosage 
Loratadine 10mg/tablet 
2.2 Administration 
One tablet daily oral 
ingestion 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
Did not state 
 
1. SCORAD score 
2. Severity of itching 
score (measured by 
patient-rated VAS, 
scale 0 to 10) 
3. Serum IgE level and 
eosinophil count 
All assessments were 
conducted at baseline 
and end of 4-week 
treatment period 
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Lang 
2007  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
the dermatology 
department of a 
Chinese 
medicine 
hospital in 
Beijing, China 
2. Age: from 3 
to 34 years old 
3. Sex: 
Male/Female 
31/33 plus 8 
dropouts 
without 
statement of 
gender 
4. Number of 
participants 
randomised: 72 
5. T/C: 36/36 
 
I. Treatment group 
a. Oral ingestion 
1. Shengui decoction 
1.1 Ingredients and dosage 
Danggui (Radix Angelicae sinensis) 10 g 
Fuling (Poria) 10 g 
Xuanshen (Radix Scrophulariae) 10 g 
Shengdihuang (Radix Rehmanniae) 10 g 
Shudihuang (Radix Rehmanniae preparata) 
10 g 
Shouwuteng (Caulis Polygoni) 15 g 
Baixianpi (Cortex Dictamni) 15 g 
Baijili (Fructus Tribuli terrestris) 8 g 
1.2 Administration 
50ml for children or under 30 kg body 
weight and 100 ml for adults or body weight 
over 30 kg twice daily oral ingestion 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
Did not state 
b. Topical application 
1. Shidu ointment 
1.1 Ingredients and dosage 
Qingdai (Indigo naturalis)  
Huangbai (Cortex phellodendri) 
Did not provide dosage 
1.2 Administration 
Once daily topically 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
Did not state 
II. Control group 
a. Oral ingestion 
2. Loratadine tablet 
2.1 Ingredients and dosage 
Loratadine. Body weight < 
30 kg:5 mg, body weight > 
30 kg:10 mg 
2.2 Administration 
Once daily orally 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
Did not state 
b. Topical application 
2. Hydrocortisone cream 
2.1 Ingredients and dosage 
1% Hydrocortisone cream 
2.2 Administration 
Once daily topically 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
Did not state 
 
1. EASI score 
2. Severity of itching 
score (measured by 
patients-rated score, 
scale 0 to 3) 
3. Effectiveness rate 
4. Adverse events 
All measurements were 
performed at baseline 
and end of 4-week 
treatment period 
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Lin 2010  
 
Randomised, 
controlled, 
within patient 
trial 
 
1. Setting: 
Patients were 
recruited from 
the dermatology 
department of a 
Chinese 
medicine 
teaching 
hospital in 
Guangzhou, 
China 
2. Age: from 11 
months to 27 
years old 
3. Sex: 
Male/Female 
13/10 
4. Number of 
participants 
randomised: 23 
I. Treatment group 
1. Runfu Xiaoyan lotion 
1.1 Ingredients and dosage 
Jinyinhua (Flos Lonicerae) 10 g 
Bohe (Herba Menthae ) 5 g 
Huangjing (Rhizoma Polygonati) 10 g 
Gancao (Radix Glycyrrhizae) 3 g 
1.2 Administration 
Two to three times daily washing or moist 
dressing externally 
1.3 Duration of treatment 
Two weeks 
1.4 Follow-up 
Did not state 
 
II. Control group 
No external CHM lotion 
was used 
Basic moisturising cream 
was used topically for both 
groups and oral ingestion 
of Qingxin Peitu decoction 
for moderate and severe 
cases. 
 
1. Skin lesion score 
(measured by clinician-
rated score) 
2. Severity of itching 
score (measured by 
patient-rated VAS, 
scale 0 to 10) 
3. SCORAD 
4. Adverse events 
All assessments were 
conducted at baseline, 
week 1 and end of 2-
week treatment period 
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Liu 2005  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of a 
Chinese 
medicine 
teaching 
hospital in 
Changsha and 
specialty 
outpatient 
department of a 
teaching 
hospital in Hong 
Kong, China 
2. Age: from 3 
months to 42 
years old 
3. Sex: 
Male/Female 
98/86 
4. Number of 
randomised: 184 
5. T/C: 92/92 
 
I. Treatment group 
a. Oral ingestion 
1. Cangyi decoction with individualised 
modifications 
1.1 Ingredients and dosage 
Cangzhu (Rhizoma Atractylodis) 15 g 
Yiyiren (Semen Coicis) 40 g 
Baixianpi (Cortex Dictamni) 20 g 
Baijili (Fructus Tribuli terrestris) 30 g 
Huangqin (Radix Scutellariae) 15 g 
Difuzi (Fructus Kochiae) 20 g 
Baimaogen (Rhizoma Imperatae) 30 g 
Zicao (Radix Arnebiae) 30 g 
Chishao (Radix Paeoniae rubra) 9 g 
Rendongteng (Caulis Lonicerae) 30 g 
Kushen (Radix Sophorae flavescentis) 20 g 
Gancao (Radix Glycyrrhizae) 6 g 
1.2 Administration 
One package of herbs daily oral ingestion 
1.3 Duration of treatment 
Four to eight weeks 
1.4 Follow-up 
24 weeks after the treatment period 
b. Topical application 
1. Qingdai ointment and Huangbai lotion 
1.1 Ingredients and dosage 
Did not state 
1.2 Administration 
Three times daily topically 
1.3 Duration of treatment 
Four to eight weeks 
1.4 Follow-up 
24 weeks after the treatment period 
II. Control group 
a. Oral ingestion 
2. Terfenadine tablet 
2.1 Ingredients and dosage 
Terfenadine 
2.2 Administration 
30 mg for children, 60 mg 
for adults twice daily oral 
ingestion 
2.3 Duration of treatment 
Four to eight weeks 
2.4 Follow-up 
24 weeks after the 
treatment 
b. Topical application 
2. Dexamethasone cream 
2.1 Ingredients and dosage 
0.025% Dexamethasone 
cream 
2.2 Administration 
Three times daily 
2.3 Duration of treatment 
Four to eight weeks 
2.4 Follow-up 
24 after the treatment 
period 
 
1. Effectiveness rate 
2. Adverse events 
Assessments were 
measured at baseline 
and end of 4 to 8-week 
treatment period 
3. Recurrence rate 
Conducted at 24 weeks 
after the treatment 
period 
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Luo 2010  
 
Randomised, 
non-blind 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
department of 
Chinese 
medicine and 
department of 
dermatology in 
a teaching 
hospital in 
Taiwan 
2. Age: from 7 
to 14 years old 
3. Sex: 
Male/Female 
36/26 
4. Number of 
participants 
randomised: 62 
5. T/C: 34/28 
 
I. Treatment group 
1. Xiao Feng San with individualised 
modifications 
1.1 Ingredients and dosage 
Fangfeng (Radix Saposhnikovia) 3 g 
Jingjie (Herba Schizonepetae) 3 g  
Danggui (Radix Angelicae sinensis) 3 g 
Shengdihuang (Radix Rehmanniae) 3 g 
Kushen (Radix Sophorae flavescentis) 3 g 
Cangzhu (Rhizoma Atractylodis) 3 g 
Chantui (Periostracum Cicdae) 3 g 
Humaren (Semen Sesami nigrum) 3 g 
Zhimu (Rhizoma Anemarrhenae) 3 g 
Shigao (Gypsum Fibrosum) 3 g 
Niubangzi (Fructus Arctii) 3 g 
Chuangmutong (Caulis Clematidis 
armandii ) 1.5 g 
Gancao (Radix Glycyrrhizae) 1.5 g 
1.2 Administration 
One package of the herbs daily oral 
ingestion 
1.3 Duration of treatment 
16 weeks 
1.4 Follow up 
12 weeks after the 4-week treatment period 
II. Control group 
2. Loratadine tablet and 
antihistamine tablet 
2.1 Ingredients and dosage 
Loratadine: 5 mg for body 
weight < 30 kg, 10 mg for 
body weight > 30 kg 
Did not provide ingredient 
and dosage of 
antihistamine 
2.2 Administration 
Once daily oral ingestion 
2.3 Duration of treatment 
16 weeks 
2.4 Follow-up 
12 weeks after the 4-week 
treatment period 
 
1. Percentage of 
reduction of total 
SASSAD score 
2. Effectiveness rate 
3. Adverse events 
Assessments were 
conducted at baseline, 
week 4, 8, 14 and 16 of 
the treatment period 
4. Full counts of blood, 
routine tests of urine 
and stool 
5. Electrocardiogram, 
liver and renal function 
tests 
Did not state 
assessment time points 
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Ma 2010  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
the outpatient 
and inpatient 
department of 
dermatology in 
a Chinese 
medicine 
teaching 
hospital in 
Beijing, China 
2. Age: from 7 
to 33 years old 
3. Sex: 
Male/Female 
42/40 
4. Number of 
participants 
randomised: 82 
5. T/C: 42/40 
 
I. Treatment group 
a. Oral ingestion 
1. Jianpi Runfu decoction with 
individualised modifications 
1.1 Ingredients and dosage 
Danggui (Radix Angelicae sinensis) 10 g 
Fuling (Poria) 10 g 
Shengdihuang (Radix Rehmanniae) 10 g 
Cangzhu (Rhizoma Atractylodis) 10 g 
Baizhu (Rhizoma Atractylodis 
macrocephalae) 10 g 
Chenpi (Pericarpium Citri reticulatae) 10 g 
Dangshen (Radix Salviae miltiorrhizae) 10 g 
Jixueteng (Radix et Caulis Jixueteng) 10 g 
Chishao (Radix Paeoniae rubra) 10 g 
Baishao (Radix Paeoniae alba) 10 g 
1.2 Administration 
One package, drink the decoction twice 
daily, half dosage for children under 14 
years old 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
Did not state 
b. Topical application 
1. Gancao oil 
1.1 Ingredients and dosage 
Gancao (Radix glycyrrhizae) 
Did not provide dosage 
1.2 Administration 
Twice daily topically 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
Did not state 
II. Control group 
a. Oral ingestion 
2. Loratadine tablet 
2.1 Ingredients and dosage 
Loratadine: 5 mg for 
children under 14 years 
old, 10 mg for > 14 years 
old 
2.2 Administration 
Once daily oral ingestion 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
Did not state 
b. Topical application 
2. Butyl flufenamate 
cream 
2.1 Ingredients and dosage 
Butyl flufenamate 
Did not provide dosage 
2.2 Administration 
Twice daily topically 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
Did not state 
 
1. EASI score 
2. Severity of itching 
score (measured by 
patients-rated VAS, 
scale 0 to 10) 
3. Adverse events 
All measurements were 
conducted at baseline 
and end of 4-week 
treatment period 
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Randomised, 
placebo-
controlled, 3-
arm parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology in 
a Chinese 
medicine 
teaching 
hospital in 
Nanjing, China 
2. Age: from 7 
to 25 years old 
3. Sex: 
Male/Female 
20/10 
4. Number of 
participants 
randomised: 30 
5. T/C/C: 
10/10/10 
 
I. Treatment group 
a. Oral ingestion 
1. Qingxin Peitu decoction with 
individualised modifications 
1.1 Ingredients and dosage 
Taizishen (Radix Pseudostellariae) 
Lianqiao (Fructus Forsythiae) 
Danzhuye (Herba Lophatheri), 
Shanyao (Rhizoma Dioscoreae) etc. 
Did not provide other ingredients and 
dosage 
1.2 Administration 
One package of the herbs per day, drink the 
decoction twice daily, one dosage for body 
weight < 40 kg, two dosages for body 
weight > 40 kg 
1.3 Duration of treatment 
12 weeks 
1.4 Follow-up 
24 weeks after the 12-week treatment period 
b. Topical application 
1. Qingxin Peitu lotion 
1.1 Ingredients and dosage 
Jinyinhua (Flos Lonicerae) 
Gancao (Radix Glycyrrhizae) etc. 
Did not provide other ingredients and 
dosage 
1.2 Administration 
Once or twice daily washing or moist 
dressing 
1.3 Duration of treatment 
12 weeks 
1.4 Follow-up 
24 weeks after the 12-week treatment period 
 
III. Control group B (Data 
of this group were not 
used for comparison in this 
review) 
a. Oral ingestion 
2. Placebo plus Cetirizine 
hydrochloride tablet. 
2.1 Ingredients and dosage 
Did provide ingredients of 
placebo 
Cetirizine 5 to 10 mg 
2.2 Administration 
Once daily oral ingestion 
2.3 Duration of treatment 
12 weeks 
2.4 Follow-up 
24 weeks after the 12-
week treatment period 
b. Topical application 
2. Mometasone furoate 
cream. 
2.1 Ingredients and dosage 
Mometasone furoate 
Did not provide dosage 
2.2 Administration 
Once daily topically 
2.3 Duration of treatment 
12 weeks 
2.4 Follow-up 
24 weeks after the 12-
week treatment period 
 
1. SCORAD score 
2. Investigators' global 
assessment score (IGA) 
3. Effectiveness rate 
Assessments were 
conducted at baseline, 
every four weeks 
during the trial period, 
end of 12-week 
treatment period and 24 
weeks after the 12-
week treatment period 
4. Patient's self-
experience 
Assessment was 
conducted at baseline, 
every two weeks during 
the trial period and end 
of 12-week treatment 
period 
5. CDLQI or DLQI 
score 
Assessment was 
conducted at baseline, 
end of 12-week 
treatment period and 24 
weeks after the 12-
week treatment period 
6. Full counts of blood, 
routine tests of urine 
and stool 
7. Electrocardiogram, 
liver and renal function 
8. Adverse events 
Assessments were 
conducted at baseline 
and end of 12-week 
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Sun 2009  
 
Randomised, 
double-blind 
placebo-
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology of 
a Chinese 
medicine 
teaching 
hospital in 
Guangzhou, 
China 
2. Age: from 3 
to 20 years old 
3. Sex: 
Male/Female 
12/13 
4. Number of 
participants 
randomised: 25 
5. T/C: 14/11 
 
I. Treatment group 
1. Jianpi Shenshi granules 
1.1 Ingredients and dosage 
Dangshen (Radix Codonopsis) 
Zexie (Rhizoma Alismatis) 
Fuling (Poria) 
Yiyiren (Semen Coicis) 
Baizhu (Rhizoma Atractylodis 
macrocephalae) 
Dazao (Fructus Jujubae) 
Shanyao (Rhizoma Dioscoreae) 
Chenpi (Pericarpium Citri reticulatae) 
Baibiandou (Semen Lablab album) 
Jiegen (Radix Platycodi) 
Did not provide dosage of the ingredients 
1.2 Administration 
Six grams for 3 to 11 years old, 12 grams for 
12 to 20 years old, dissolved the granules 
with boiling water, oral ingestion three times 
daily 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
24 weeks after the 4-week treatment period 
II, Control group 
2. Placebo 
2.1 Ingredients and dosage 
Did not provide 
ingredients and dosage 
2.2 Administration 
Five grams for 3 to 11 
years old, 15 grams for 12 
to 20 years old, dissolved 
the granules with boiling 
water, oral ingestion three 
times daily 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
24 weeks after the 4-week 
treatment period 
Both groups applied non-
medicinal moisturising 
cream topically and oral 
ingestion of 
cyproheptadine tablets for 
cases with severe itchiness 
1. SCORAD score 
2. Severity of itching 
score (measured by 
patients-rated score, 
scale unknown) 
3. Sleeping disturbance 
rate 
4. Skin lesion area 
5. Severity of skin 
lesion 
6. Effectiveness rate 
7. Adverse events 
All assessments were 
conducted at baseline 
and end of 4-week 
treatment period 
8. Recurrence rate 
Conducted at 24 weeks 
after the 4-week 
treatment period 
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Tian 2005  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology in 
a hospital in 
Yingkou, China 
2. Age: children, 
did not state age 
3. Sex: 
Male/Female 
71/29 
4. Number of 
participants 
randomised: 100 
5. T/C: 58/42 
 
I. Treatment group 
a. Oral ingestion 
1. Fuyang granules 
1.1 Ingredients and dosage 
Cangerzi (Fructus Xanthii) 
Difuzi (Fructus Kochiae) 
Chuangxiong (Rhizoma Chuanxiong) 
Honghua (Flos Carthami) 
Baiying (Herba Solani lyrati) 
Did not provide dosage of the ingredients 
1.2 Administration 
oral ingestion 2.25 to 3 g of the granules, 
twice daily 
1.3 Duration of treatment 
Five days 
1.4 Follow-up 
Did not state 
b. Topical application 
Used the remain solution of oral ingestion 
intervention for external application 
 
II. Control group 
a. Oral ingestion 
2. Cyproheptadine tablet 
2.1 Ingredients and dosage 
Cyproheptadine 0.25 mg 
2.2 Administration 
Three times daily oral 
ingestion 
2.3 Duration of treatment 
Five days 
2.4 Follow-up 
Did not state 
b. Topical application 
2. Sulphur cream 
2.1 Ingredients and dosage 
3% Sulphur cream 
2.2 Administration 
Applied the cream 
topically, did not state how 
often of the application 
2.3 Duration of treatment 
Five days 
2.4 Follow-up 
Did not state 
1. Effectiveness rate 
developed by the trial 
investigators 
2. Adverse events 
Assessments were 
measured at baseline 
and end of 5-day 
treatment period 
 
 113 
Wang 
2008  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department in a 
teaching 
hospital in 
Yichang, China 
2. Age: from 12 
days to 11 
months 
3. Sex: 
Male/Female 
22/43 
4. Number of 
participants 
randomised: 65 
5. T/C: 35/30 
 
I. Treatment group 
1. Chushi Zhiyang ointment (a CHM 
product manufactured by a pharmaceutical 
company) 
1.1 Ingredients and dosage 
Baixianpi (Cortex Dictamni)  
Shechuangzi (Fructus Cnidii) 
Huanglian (Rhizoma Coptidis) 
Huangbai (Cortex Phellodendri) 
Kushen (Radix Sophorae flavescentis) 
Huzhang (Rhizoma Polygoni cuspidati) 
Zihuadiding (Herba Yiolae) 
Bianxu (Herba Polygoni avicularis) 
Yinchen (Herba Artemisiae scopariae) 
Cangzhu (Rhizoma Atractylodis) 
Huajiao (Pericarpium Zanthoxyli) 
Bingpian (Borneolum Syntheticum) etc. 
Did not provide dosage of the ingredients 
1.2 Administration 
External use twice daily 
1.3 Duration of treatment 
One week 
1.4 Follow-up 
Did not state 
II. Control group 
2. Vitamin B6 cream 
2.1 Ingredients and dosage 
Vitamin B6, did not 
provide dosage 
2.2 Administration 
Twice daily topically 
2.3 Duration of treatment 
One week 
2.4 Follow-up 
Did not state 
 
1. Effectiveness rate 
developed by the trial 
investigators 
2. Adverse events 
Assessments were 
measured at baseline 
and end of 1-week 
treatment period 
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Xiao 2008  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient and 
inpatient 
department of 
dermatology in 
a Chinese 
medicine 
teaching 
hospital in 
Chengdu, China 
2. Age: from 3 
to 23 years old 
3. Sex: 
Male/Female 
29/23 
4. Number of 
participants 
randomised: 52 
5. T/C: 26/26 
 
I. Treatment group 
a. Oral ingestion 
1. Machixian decoction with individualised 
modifications 
1.1 Ingredients and dosage 
Machixian (Herba Portulacae) 
Tufuling (Rhizoma Smilacis glabrae) 
Yuxingcao (Herba Houttuyniae) 
Fuling (Poria) 
Mudanpi (Cortex Moutan) 
Zijingpi (Cortex Cercis chinensis) 
Longgu (Os Draconis) 
Jiangcan (Bombyx Batryticatus) 
Gancao (Radix Glycyrrhizae) etc. 
Did not provide dosage of the ingredients 
1.2 Administration 
Oral ingestion 30 ml of decoction for 
children below 12 years old, 100 ml for 12 
to 23 years old, three times daily 
1.3 Duration of treatment 
Eight weeks 
1.4 Follow-up 
12 weeks after the 8-week treatment period 
b. Topical application 
Used the same oral ingestion intervention 
for external moist dressing three times daily 
 
II. Control group 
a. Oral ingestion 
2. Chlorphenamine tablet 
2.1 Ingredients and dosage 
Chlorphenamine 0.35 mg 
per kg of body weight per 
day 
2.2 Administration 
Oral ingestion 
2.3 Duration of treatment 
Eight weeks 
2.4 Follow-up 
12 weeks after the 8-week 
treatment 
b. Topical application 
2. Boric acid solution 
2.1 Ingredients and dosage 
3% boric acid solution 
2.2 Administration 
Three times daily topically 
2.3 Duration of treatment 
Eight weeks 
2.4 Follow-up 
12 weeks after the 8-week 
treatment period 
Sesame oil was used for 
cases with dry skin twice 
daily for both groups 
1. SCORAD score 
2. Adverse events 
Assessments were 
conducted at baseline 
and end of 8-week 
treatment period 
3. Full counts of blood, 
routine tests of urine 
and stool, liver and 
renal function tests, 
serum IgE level 
Assessments were 
conducted at baseline 
and end of 8-week 
treatment period 
4. Recurrence rate 
Assessment was 
conducted at 12 weeks 
after the treatment 
period 
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Xiao 2011  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology of 
a Chinese 
medicine 
teaching 
hospital in 
Guangzhou, 
China 
2. Age: from 2 
to 60 years old 
3. Sex: did not 
state 
4. Number of 
participants 
randomised: 60 
5. T/C: 30/30 
 
I. Treatment group 
1. Huailian decoction 
1.1 Ingredients and dosage 
Maidong (Radix Ophiopogonis) 15 g 
Beishashen (Radix Glehniae) 15 g 
Yuzhu (Rhizoma Polygonati odorati) 15 g 
Tianhuafen (Radix Trichosanthis) 15 g 
Shanyao (Rhizoma Dioscoreae) 30 g 
Heye (Lolium Nelumbinis) 15 g 
Huanglian powder (Rhizoma Coptidis) 6 g 
Ejiao (Gelatinum Asini) 10 g 
Jinyinhua (Flos Lonicerae) 15 g 
Danzhuye (Herba Lophatheri) 10 g 
Fuling (Poria) 30 g 
Gancao (Radix Glycyrrhizae) 6 g 
1.2 Administration 
Oral ingestion of one full dosage of the 
decoction for body weight over 45 kg, 2/3 of 
the full dosage for body weight at 25 to 45 
kg and 1/3 for < 25 kg 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
24 weeks after the 4-week treatment period 
II. Control group 
2. Loratadine tablet 
2.1 Ingredients and dosage 
Loratadine 10mg/tablet 
2.2 Administration 
Oral ingestion, 10 mg once 
daily for > 12 years old or 
2-12 years old with body 
weight > 30 kg, 5 mg once 
daily for 2-12 years old 
with body weight < 30 kg 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
24 weeks after the 4-week 
treatment period 
External use of 
nitrofurazone, calamine, 
menthol and CHM 
ointment for both groups 
 
1. SCORAD score 
2. Effectiveness rate 
3. Adverse events 
Assessments were 
conducted at baseline, 
week 2 and end of 4-
week treatment period 
4. Full counts of blood, 
routine tests of urine 
and stool, liver and 
renal function tests 
Assessments were 
conducted at baseline 
and after the 4-week 
treatment period 
5. Recurrence rate 
Conducted at 24 weeks 
after the 4-week 
treatment period 
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Xue 2011  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from a 
Chinse medicine 
hospital in 
Jiangmen, China 
2. Age: from 2 
to 12 years old 
3. Sex: 
Male/Female 
37/26 
4. Number of 
participants 
randomised: 63 
5. T/C: 33/30 
 
I. Treatment group 
1. Shengxue Runfu decoction with 
individualised modifications 
1.1 Ingredients and dosage 
Danggui (Radix Angelicae sinensis) 6 g 
Ejiao (Gelatinum Asini) 6 g 
Baizhu (Rhizoma Atractylodis 
macrocephalae) 6 g 
Tiandong (Radix Asparagi) 6 g 
Maidong (Radix Ophiopogonis) 6 g 
Taoren (Semen Persicae) 6 g 
Mudanpi (CortexMmoutan) 6 g 
Shudihuang (Radix Rehmanniae preparata) 
10 g 
Huangqi (Radix Astragali) 10 g 
Fuling (Poria) 10 g 
Baixianpi (Cortex Dictamni) 10 g 
Honghua (Flos Carthami) 10 g 
Huangqin (Radix Scutellariae) 10 g 
Gancao (Radix Glycyrrhizae) 3 g 
Shengma (Rhizoma Cimicifugae) 3 g 
1.2 Administration 
Oral ingestion of the decoction 2 to 3 times 
daily 
1.3 Duration of treatment 
Eight weeks 
1.4 Follow-up 
Did not state 
II. Control group 
2. Loratadine tablet 
2.1 Ingredients and dosage 
Loratadine 10mg/tablet 
2.2 Administration 
Oral ingestion 10mg for 
body weight ≥ 30 kg once 
daily, 5 mg for body 
weight < 30 kg once daily 
2.3 Duration of treatment 
Eight weeks 
2.4 Follow-up 
Did not state 
Topical application of 
CHM ointment and 
emollients for both groups 
 
1. SCORAD score 
2. Severity of itching 
score (measured by 
patients-rated score, 
scale 0 to 10) 
3. Skin lesion area 
score 
4. Severity of skin 
lesion score 
5. Effectiveness rate 
6. Chinese medicine 
clinical syndrome score 
All assessments were 
conducted at baseline, 
week 4 and end of 8-
week treatment period 
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Yang 
2007  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology of 
a Chinese 
medicine 
teaching 
hospital in 
Shenzhen, 
China 
2. Age: from 5 
to 25 years old 
3. Sex: 
Male/Female 
35/29 
4. Number of 
participants 
randomised: 64 
5. T/C: 32/32 
 
I. Treatment group 
a. Oral ingestion 
1. Jianpi Zhiyang granules 
1.1 Ingredients and dosage 
Huangqi (Radix Astragali) 
Baizhu (Rhizoma Atractylodis 
macrocephalae) 
Danggui (Radix Angelicae sinensis) 
Sheshouwu (Radix Polygoni) 
Shengdihuang (Radix Rehmanniae) 
Baishao (RadixPaeoniae alba) 
Chuangxiong (Rhizoma Chuanxiong) 
Fangfeng (Radix Saposhnikovia) 
Jingjie (Herba Schizonepetae)  
Baijili (Fructus Tribuli terrestris) 
Gouteng (Ramulus Uncariae cum uncis) 
Gancao (Radix Glycyrrhizae) 
Did not provide dosage of the ingredients 
1.2 Administration 
10 grams 3 times daily, half dosage for 
children < 6 years old 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
Did not state 
b. Topical application 
1. Pibao Xiaoyan Xuanshi ointment 
1.1 Ingredients and dosage 
Shengyaodi (Hydrargyrum oxydatum 
crudum bottom) 
Shenghualiu (Sublimed Sulfur) 
Shechuangzi (Fructus cnidii) 
Zhangnao (Camphora) 
Bingpian (Borneolum syntheticum) etc. 
Did not provide dosage of the ingredients 
1.2 Administration 
Twice daily topically 
II. Control group 
a. Oral ingestion 
2. Loratadine tablet 
2.1 Ingredients and dosage 
Loratadine 10 mg/tablet 
2.2 Administration 
10 mg oral ingestion daily 
for adults and children 2-
12 years old with body 
weight > 30kg, 5mg daily 
for body weight < 30 kg 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
Did not state 
b. Topical application 
2. Hydrocortisone butyrate 
cream 
2.1 Ingredients and dosage 
1% hydrocortisone 
butyrate 
2.2 Administration 
Twice daily topically 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
Did not state 
 
1. SCORAD score 
2. Severity of itching 
score (measured by 
patient-rated VAS, 
scale 0 to 10) 
3. Effectiveness rate 
4. Adverse events 
5. Serum IgE level and 
eosinophil count 
All assessments were 
conducted at baseline 
and end of 4-week 
treatment period 
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Yang 
2009  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
an outpatient 
department of 
Chinese 
medicine 
teaching 
hospital and 
dermatology and 
venereology 
outpatient 
department of a 
teaching 
hospital in 
Kunming, China 
2. Age: from 4 
to 27 years old 
3. Sex: 
Male/Female 
33/27 
4. Number of 
participants 
randomised: 60 
5. T/C: 30/30 
I. Treatment group 
1. Jianpi Yangxue Qufeng decoction with 
individualised modifications 
1.1 Ingredients and dosage 
Huangqi (Radix Astragali) 30 g 
Baizhu (Rhizoma Atractylodis 
macrocephalae) 15 g 
Danggui (Radix Angelicae sinensis) 15 g 
Heshouwu (Radix Polygoni) 30 g 
Fangfeng (Radix Saposhnikovia) 20 g 
Baijili ((Fructus Tribuli terrestris) 30 g 
Wugong (Scolopendra) 10 g 
1.2 Administration 
Oral ingestion of the decoction, did not state 
other details 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
Did not state 
 
II. Control group 
2. Loratadine tablet 
2.1 Ingredients and dosage 
Loratadine 10 mg 
2.2 Administration 
Oral ingestion, 10 mg once 
daily 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
Did not state 
 
1. Skin lesion area 
score (measured by 
clinician-rated score) 
2. Skin lesion severity 
score (measured by 
clinician-rated score) 
3. Severity of itching 
score (measured by 
patient-rated VAS, 
scale 0 to 3) 
4. Erythema score 
(measured by clinician-
rated score) 
5. Transepidermal 
water loss, skin oil and 
skin elasticity 
(measured by a 
multifunctional skin 
testing equipment) 
6. Effectiveness rate 
7. Adverse events 
All assessments were 
conducted at baseline 
and end of 4-week 
treatment period 
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Yu 1999  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient and 
inpatient 
department in 
three hospitals 
in Shanghai and 
Hangzhou, 
China 
2. Age: from 5 
to 53 years old 
3. Sex: 
Male/Female 
112/108 
4. Number of 
participants 
randomised: 220 
5. T/C: 120/100 
 
I. Treatment group 
1. Piyan Xiaojingyin granules II 
1.1 Ingredients and dosage 
Cangzhu (Rhizoma Atractylodis) 
Danggui (Radix Angelicae sinensis) 
Hanfangji (Radix Stephaniae tetrandrae) 
Huangqin (Radix Scutellariae) 
Chaihu (Radix Bupleuri) etc. 
Did not provide dosage of the ingredients 
1.2 Administration 
Oral ingestion, 10 g for age of 5 to 9 years 
old, 15 g for 10 to 14, 20g for 14 above, 3 
times daily 
1.3 Duration of treatment 
12 weeks 
1.4 Follow-up 
52 weeks after the 12-week treatment period 
 
II. Control group 
2. Loratadine (Clarityne) 
tablet 
2.1 Ingredients and dosage 
Loratadine 
Did not provide dosage 
2.2 Administration 
Oral ingestion, did not 
state other details 
2.3 Duration of treatment 
12 weeks 
2.4 Follow-up 
52 weeks after the 12-
week treatment period 
Topical application of 
saline or zinc oxide cream 
for both groups 
 
1. Skin lesion severity 
score (measured by 
clinician-rated score) 
2. Skin lesion area 
score (measured by 
clinician-rated score) 
3. Severity of itching 
score (measured by 
patient-rated VAS, 
scale 0 to 3) 
4. Effectiveness rate 
5. Adverse events 
Assessments were 
conducted at baseline, 
end of 12-week 
treatment period and 52 
weeks after 12-week 
treatment period 
6. Serum CD4/CD8 
ratio and IgE level 
Assessments were 
conducted at baseline, 
end of 12-week 
treatment period 
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Zhang 
2005  
 
Randomised, 
controlled, 3-
arm parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology in 
a Chinese 
medicine 
teaching 
hospital in 
Nanjing, China 
2. Age: below or 
at 16 years old 
3. Sex: 
Male/Female 
Did not state 
4. Number of 
participants 
randomised: 45 
5. T/C/C: 
15/15/15 
I. Treatment group 
1. Jianpi Huashi decoction 
1.1 Ingredients and dosage 
Fuling (Poria) 6 g 
Cangzhu (Rhizoma Atractylodis) 6 g 
Baizhu (Rhizoma Atractylodis 
macrocephalae) 6 g 
Chenpi (Pericarpium Citri reticulatae) 3 g 
Zexie (Rhizoma Alismatis) 6 g 
Baixianpi (Cortex Dictamni) 6 g 
Maiya (Fructus Hordei germinatus) 15 g 
Huashi (Talcum) 6 g 
Gancao (Radix Glycyrrhizae) 4 g 
1.2 Administration 
One package per day, oral ingestion the 
decoction twice daily, half dosage for 
children at age of 10 or below 
1.3 Duration of treatment 
12 weeks 
1.4 Follow-up 
Did not state 
II. Control group A 
2. Chlorpheniramine tablet 
2.1 Ingredients and dosage 
Chlorpheniramine 
2.2 Administration 
Oral ingestion 0.30 mg per 
kg of the body weight 
daily 
2.3 Duration of treatment 
12 weeks 
2.4 Follow-up 
Did not state 
III. Control group B 
No oral ingestion of 
medications. Data of this 
group was not used for 
comparison in this review 
Topical application of 
CHM lotion or CHM 
ointment according to the 
condition of an individual 
in all groups 
1. Percentage of 
reduction of total 
SASSAD score 
2. Severity of itching 
score from baseline 
(measured by patients-
rated VAS, scale 0 to 
10) 
3. IgE and EOS level 
4. Effectiveness rate 
5. Adverse events 
All measurements were 
conducted at baseline, 
four weeks and end of 
12- week treatment 
period 
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Zhang 
2009  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology in 
a Chinese 
medicine 
teaching 
hospital in 
Jinan, China 
2. Age: from 2 
to 12 years old 
3. Sex: 
Male/Female 
Did not state 
4. Number of 
participants 
randomised: 61 
5. T/C: 36/25 
 
I. Treatment group 
1. Xiao'er Huashi decoction 
1.1 Ingredients and dosage 
Cangzhu (Rhizoma Atractylodis) 6 g 
Baizhu (Rhizoma Atractylodis 
macrocephalae) 6 g 
Chenpi (Pericarpium Citri reticulatae) 3 g 
Zexie (Rhizoma Alismatis) 6 g 
Fuling (Poria) 9 g 
Baixianpi (Cortex Dictamni) 6 g 
Maiya (Fructus Hordei germinatus) 15 g 
Huashi (Talcum) 12 g 
Gancao (Radix Glycyrrhizae) 6 g 
Laifuzi (Semen Raphani) 9 g 
Binglang (Semen Arecae) 9 g 
Jineijin (Endothelium Corneum gigeriae 
galli) 9 g 
Shengdihuang (Radix Rehmanniae) 6 g 
Mudanpi (Cortex Moutan) 6 g 
Huangqin (Radix Scutellariae) 9 g 
1.2 Administration 
One package per day, oral ingestion the 
decoction 3 to 4 times daily 
1.3 Duration of treatment 
Four weeks 
1.4 Follow-up 
Four weeks after the 4-week treatment 
period 
II. Control group 
2. Loratadine granules 
2.1 Ingredients and dosage 
Loratadine 10mg 
2.2 Administration 
Oral ingestion 10 mg daily 
for children age 2 to 12 
years old with body 
weight > 30 kg, or 5mg 
per night for body weight 
≤ 30 kg 
2.3 Duration of treatment 
Four weeks 
2.4 Follow-up 
Four weeks after the 4-
week treatment period 
External use of CHM 
lotion and CHM cream for 
both groups 
 
1. EASI score 
2. Effectiveness rate 
Assessments were 
conducted at baseline 
and end of 4-week 
treatment period 
3. Recurrence rate 
Conducted at four 
weeks after the 4-week 
treatment period 
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Zhang 
2011  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology in 
a Chinese 
medicine 
teaching 
hospital in 
Tianjin, China 
2. Age: 2.5 to 14 
years old 
3. Sex: 
Male/Female 
31/25 
4. Number of 
randomised: 56 
5. T/C: 30/26 
 
I. Treatment group 
1. Self-designed CHM decoction with 
individualised modifications 
1.1 Ingredients and dosage 
Shengdihuang (Radix Rehmanniae) 15 g 
Danggui (Radix Angelicae sinensis) 10 g 
Xuanshen (Radix Scrophulariae) 15 g 
Shengdihuang (Radix Rehmanniae) 10 g 
Shouwuteng (Caulis Polygoni) 15 g 
Chishao (Radix Paeoniae rubra) 15 g 
Digupi (Cortex Lycii) 15 g 
Tianhuafen (Radix Trichosanthis) 15 g 
Huangqin (Radix Scutellariae) 10 g 
Zhimu (Rhizoma Anemarrhenae) 10 g 
Maidong (Radix Ophiopogonis) 15 g 
Beishashen (Radix Glehniae) 10 g 
Mugua (Fructus Chaenomelis) 10 g 
Lingxiaohua (Flos Campsis) 15 g 
Danshen (Radix Salviae miltiorrhizae) 10 g 
Jixueteng (Radix et Caulis jixueteng) 15 g 
Gancao (Radix Glycyrrhizae) 10 g 
1.2 Administration 
One package per day, oral ingestion the 
decoction twice daily, half dosage for age 10 
years old or below or body weight < 30 kg 
1.3 Duration of treatment 
Eight weeks 
1.4 Follow-up 
24 weeks after the 8-week treatment period 
II. Control group 
2. Levocetirizine 
dihydrochloride tablets 
2.1 Ingredients and dosage 
Levocetirizine 
dihydrochloride 
2.2 Administration 
Oral ingestion 5 mg once 
daily for 6 years old or 
above, 2.5 mg for 2 to 6 
years old once daily 
2.3 Duration of treatment 
Eight weeks 
2.4 Follow-up 
24 weeks after the 8-week 
treatment period 
 
1. SCORAD score 
2. Effectiveness rate 
Assessments were 
conducted at baseline, 
end of 8-week 
treatment period 
3. Recurrence rate 
Conducted at 24 weeks 
after the 8-week 
treatment period 
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Zhou 
2011  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology in 
Jiangyong 
country Chinese 
medicine 
hospital in 
Hunan, China 
2. Age: 3 to 38 
months old 
3. Sex: 
Male/Female 
95/81 
4. Number of 
participants 
randomised: 176 
5. T/C: 89/87 
I. Treatment group 
1. Cang Er Kushen lotion 
1.1 Ingredients and dosage 
Cang'erzi (Fructus Xanthii) 30 g 
Kushen (Radix Sophorae flavescentis) 30 g 
Tufuling (Rhizoma Smilacis glabrae) 25 g 
Shechuangzi (Fructus Cnidii) 15 g 
Cangzhu (Rhizoma Atractylodis) 15 g 
Jingjie (Herba Schizonepetae) 15 g 
Zicao (Radix Arnebiae) 15 g 
Huangbai (Cortex Phellodendri) 15 g 
1.2 Administration 
Moist dressing with the lotion 3 to 4 times 
daily 
1.3 Duration of treatment 
Two weeks 
1.4 Follow-up 
24 weeks after the 2-week treatment period 
 
II. Control group 
2. Calamine lotion 
2.2 Ingredients and dosage 
Calamine 
Did not provide dosage 
2.3 Administration 
Topical use 3 times daily 
2.4 Duration of treatment 
Two weeks 
2.5 Follow-up 
24 weeks after the 2-week 
treatment period 
 
1. Effectiveness rate 
2. Adverse events 
Assessment were 
conducted at baseline 
and end of the treatment 
period 
3. Recurrence rate 
Conducted at 24 weeks 
after the 2-week 
treatment period 
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Zou 2011  
 
Randomised, 
controlled, 
parallel 
clinical trial 
 
1. Setting: 
Patients were 
recruited from 
outpatient 
department of 
dermatology in 
a Chinese 
medicine 
teaching 
hospital and 
another teaching 
hospital in 
Nanchang, 
China 
2. Age: 3 to 36 
months old 
3. Sex: 
Male/Female 
27/23 
4. Number of 
participants 
randomised: 50 
5. T/C: 30/20 
I. Treatment group 
1. Fufang Sanhuang lotion and oil 
1.1 Ingredients and dosage 
Dahuang (Radix et Rhizoma rhei) 15 g 
Zicao (Radix Arnebiae) 15 g 
Huangbai (Cortex Phellodendri) 15 g 
Huangqin (Radix Scutellariae) 15 g 
Diyu (Radix Sanguisorbae) 15 g 
Shechuangzi (Fructus Cnidii) 15 g 
Wubeizi (Galla Chinensis) 20 g 
Qingdai (Indigo Naturalis) 10 g 
Mingfan (Alum) 6 g 
1.2 Administration 
Moist dressing with the lotion 3 to 4 times 
daily and topical application with the same 
herbal powder mixed with sesame oil 
1.3 Duration of treatment 
Two weeks 
1.4 Follow-up 
12 weeks after the 2-week treatment period 
 
II. Control group 
2. Boric acid solution and 
zinc oxide cream 
2.2 Ingredients and dosage 
3% Boric acid solution, 
zinc oxide cream, did not 
provide dosage 
2.3 Administration 
Topical use 3 to 4 times 
daily 
2.4 Duration of treatment 
Two weeks 
2.5 Follow-up 
12 weeks after the 2-week 
treatment period 
 
1. Effectiveness rate 
2. Serum IgE, EOS, 
liver and renal function 
tests 
3. Adverse events 
Assessments were 
conducted at baseline 
and end of 2-week 
treatment period 
4. Recurrence rate 
Conducted at 12 weeks 
after the 2-week 
treatment period 
 
 
Abbreviation: C, Control; CDLQI, Children’s Dermatology life quality index; CHM, Chinese herbal medicine; EASI, Eczema Area and Severity Index; EOS, 
Eosinophils ; DLQI, Dermatology life quality index; IGA, Investigators' global assessment score; IgE, Immunoglobulin E; IL, Interleukin; SCORAD, Severity 
Scoring Atopic Dermatitis; SASSAD, Six Areas, Six Sign Atopic Dermatitis severity score; T, Treatment; VAS, Visual Analogue Scale.  
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4.6.3 Excluded Studies  
Four studies were excluded because their comparison interventions did not 
meet the inclusion criteria of this review. Details are listed on Table 11 Characteristics 
of excluded studies.  
Table 11 Characteristics of excluded studies 
 
Study ID Citation Reason for exclusion 
Li 2006 Li DH, Mu DS, Liu J, Song WY. 
Observation of efficacy of Jianpi Qufeng 
method for atopic dermatitis. Jilin Journal 
of Traditional Chinese Medicine 2006;26 
(8):18-9. 
Inappropriate 
comparator 
interventions. 
Udompataikul 
2011 
Udompataikul M, Srisatwaja W. 
Comparative trial of moisturizer 
containing licochalcone A vs. 
hydrocortisone lotion in the treatment of 
childhood atopic dermatitis: a pilot study. 
Journal of the European Academy of 
Dermatology & Venereology 
2011;25(6):660-5. [MEDLINE: 
20840345] 
Inappropriate treatment 
interventions. 
Zhang 2010  Zhang YF, Lin ZS. Observation of 
clinical efficacy of Chinese medicine for 
30 cases with infantile eczema. Journal of 
Paediatrics of Traditional Chinese 
Medicine 2010;6 (5):18-20 
Inappropriate 
comparator 
interventions. 
Zhao 2008 Zhao BJ. Clinical observation of Jianpi 
Hewei Xiaoshi Daozhi method for 
infantile eczema. Guangming Journal of 
Chinese Medicine 2008;23 (5):623 
Inappropriate 
comparator outcome 
measures. 
 
4.6.4 Studies Awaiting Classification 
A final prepublication search for this review was undertaken on 6 June 2013. 
Although it has not been possible to incorporate RCTs identified through this search 
within this review, relevant references were listed on the Table 12 Studies awaiting 
classification. They will be incorporated into the next update of the Cochrane 
systematic review.  
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Table 12 Studies awaiting classification 
 
Study ID Citation 
Cai 2012 Cai XZ. Modified Shenling Baizhu formula for 43 cases with 
atopic dermatitis in spleen deficiency and blood dryness. Hebei 
Journal of Traditional Chinese Medicine 2012;34(10):1499-500. 
Chi 2012 Chi HY, Huang YZ. A clinical evaluation of treating atopic 
dermatitis with traditional Chinese medicine. A muti-center 
randomized controlled trial on the treatment of AD with suppress 
the heart and calm the mind method. China Academy of Chinese 
Medical Sciences, Beijing [PhD thesis] 2012. 
Dong 2012 Dong M. Efficacy of external use of Jingfang mixture in the 
treatment of children with eczema. Medical Journal of Qilu 
2012;27(1):75-8. 
Shi 2012 Shi J, Diao YT, Li XW. Compound Chinese medicine treatment 
for patients with atopic dermatitis and curative effect of the 
immune function of regulatory role. Chinese Journal of 
Dermatovenerology Integrated Traditional & Western Medicine 
2012;11(3):143-5. 
Tian 2011 Tian Y. Clinical observation of modified Qushi Zhiyang 
decoction for infantile eczema. Journal of China Traditional 
Chinese Medicine Information 2011;3(2):38-9. 
Xu 2012 Xu XC, Guo YC. Clinical observation of Kouqiang Xiaoyan 
powder for infantile eczema. Strait Pharmaceutical Journal 
2012;24(10):210. 
Yang 2012 Yang SQ, Yan JD. Clinical observation of Shirun Shaoshang 
ointment for atopic dermatitis in children. In: Proceedings of the 
8th Academic Conference for External Therapy. Nanning: China 
Association of Chinese Medicine, 2012:151-5. 
Zhao 2011 Zhao YD, Yao CH, Lang N, She YY, Chi HY, Tian FY, et al. 
Clinical observation of Longmu liquid in treatment of atopic 
dermatitis in youths and adults and the investigation of quality of 
life. Chinese Journal of Dermatovenerology Integrated 
Traditional & Western Medicine 2011;10(4):215-8. 
Zheng 2012 Zheng YP, Xie RB, Chen GF, Zhang L. Clinical observation of 
efficacy of Bupi Qufeng formula for atopic dermatitis. 
Guangming Journal of Chinese Medicine 2012;27(7):1365-6. 
 
4.6.5 Ongoing Studies 
 There were four studies registered on different trial registers. One trial 
(registration number: ChiCTR-TRC-08000156) funded by the Chinese government 
tested the efficacy and safety of Pei Tu Qing Xin Fang (PTQXF), another government 
funded trial (registration number: ChiCTR-TRC-12003174) is testing Pei Tu Qing 
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Xin (PTQX) granules. Both PTQXF and PTQX granules were modified from Qing 
Xin Pei Tu Fang (QXPTF) which was recommended by the expert consensus 2013 
(see subheading 2.12.1 and Table 3) (D. Chen et al., 2013). The corresponding trial 
investigators were contacted for these four studies for more information of the trials 
and only one trial responded (registration number of ChiCTR-TRC-08000156). The 
investigator of this trial indicated that the trial was concluded in February 2011 but 
the report has not been published. Table 13 lists details the four ongoing studies and 
hope that these can be included in a future revision of this review once the trial reports 
are published. 
 
Table 13 Characteristics of ongoing studies 
 
Registration 
number 
Trial register Study name Starting 
date 
ChiCTR-TRC-
08000156 
http://www.chictr.org/cn Clinical trial of 
traditional Chinese 
formula of hilling and 
clearing away heart-
fire (HCAH) for atopic 
dermatitis 
1st October 
2008 
 
ChiCTR-TRC-
09000562 
http://www.chictr.org/cn 
 
Clinical trial of Bu 
Shen Yi Qi Fang on 
treating atopic 
dermatitis in 
Deficiency of Kidney 
Yang and Qi 
Not started 
yet 
 
ChiCTR-TRC-
12003174 
http://www.chictr.org/cn  
 
Effectiveness of PeiTu 
QingXin (PTQX) 
Granules adds on usual 
care to reduce the 
accumulated relapse of 
the atopic dermatitis in 
children: A protocol 
for a multi-centre, 
double-blind, 
randomized controlled 
trial 
1 March 
2013 
 
ISRCTN26218532 http://www.controlled-
trials.com 
 
A clinical study of 
Hwangryunhaedoktang 
in adult atopic 
21 June 
2010 
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dermatitis: a 
randomised, double-
blind, placebo-
controlled, multicentre 
trial 
 
4.7 Risk of Bias in Included Studies 
 
Two reviewers (SG and AWY) independently assessed the risk of bias in the 
included studies and resolved discrepancies of the assessments by discussion. The 
other two team members HCW and WZ provided arbitrating advice when a consensus 
could not be achieved. Risk of bias was assessed and a brief rationale was provided 
for judgment for each study. Overall, the risk of bias in the included studies was high 
for blinding of participants and research personnel and unclear for the other domains. 
The judgements according to the published data about each risk of bias item presented 
as percentages across all included studies were shown in Figure 11. The judgements 
based on the Cochrane Collaboration's domain-based evaluation for "assessing risk of 
bias" about each risk of bias item for each included study were summarised in Figure 
12. 
Figure 11 Risk of bias graph 
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Figure 12 Risk of bias summary 
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4.7.1 Allocation (Selection Bias)  
Almost half of the included studies (13/28) did not state how allocation 
sequences were generated (Chao 2003; Chen 2011; Jin 2007; Liu 2005; Sun 
2009; Tian 2005; Wang 2008; Xiao 2008; Xue 2011; Yang 2007; Yu 1999; 
Zhang 2005; Zhang 2009). Of the 28 included studies, only two studies 
explicitly explained the procedures for allocation concealment of randomised 
codes for avoiding potential selection bias (Cheng 2010; Hon 2007). Both 
studies used an independent party to provide randomised codes which was 
generated by a computer program. The Cheng 2010 study placed the random 
codes in an envelope. The trial investigator did not break the codes of any 
participant until the trial was completed in the Hon 2007 study. 
4.7.2 Blinding (Performance Bias and Detection Bias) 
Blinding of participants, and personnel involved in direct contact with the 
participants is important for minimising bias from subjective outcome 
measures (Tal, 2011). 
One of the most common quoted subjective outcome measures in eczema was 
visual analogue scale (VAS) for itching severity. About 89% of the included 
studies (25/28) did not use blinding either on the participants or on the trial 
investigators which implied the highest risk of bias within the assessed 
domains. Although the Sun 2009 study claimed that the trial was a double-
blind design, there was only one author in the published paper with absence of 
acknowledgment of other personnel. It was not sure how the blinding was 
implemented in this study. Only two studies employed the double-blind design 
and provided clear description of blinding methods (Cheng 2010; Hon 2007). 
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Blinding of the outcome assessors was another overall weakness of 
methodology in the included studies. Most of the included studies (82%, 
23/28) did not state whether they had used the blinding in assessments of 
outcomes. In many situations, the appearance and administration of the two 
compared interventions were different in the trial. For example, Chinese 
herbal decoction versus Western medications, which made the blinding 
impossible even though the study did not particularly state that blinding was 
not used. The Cao 2009; Luo 2010 studies declared that no blinding was 
required. Only three studies appropriately blinded the chief investigators of the 
trials from awareness of the interventions used when they performed outcome 
assessments or used a third party to carry out such assessments (Cheng 2010; 
Hon 2007; Rao 2010). 
4.7.3 Incomplete Outcome Data (Attrition Bias) 
There was unclear risk of bias among the included studies as the numbers of 
participants randomised and analysed were identical in 75% of the included 
studies and it seems that there were no incomplete outcome data in those 
studies. High risk of attrition bias (a bias associated with withdrawal or 
dropout of participants in a study) existed as there were withdrawals or 
dropouts in the studies of Chao 2003; Lang 2007; Lin 2010; Xue 2011 and 
ITT was not used in these studies. The Cheng 2010; Hon 2007; Ma 2010 
studies reported data for withdrawals and dropouts and the ITT principle was 
used in the final statistical calculations; therefore the risk of bias was 
considered at a low level. 
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4.7.4 Selective Reporting (Reporting Bias) 
In the Huang 2010 study, the trial investigators claimed full blood counts, liver 
and renal function tests were performed after the two-week treatment period, 
but find the results of those tests could not be found in their study. It was 
unable to assess the outcome reporting bias due to insufficient information in 
the rest of the 27 included studies. 
4.7.5 Other Potential Sources of Bias 
"Use of published validated scoring systems" was set to assess potential 
sources of bias and found that more than 64% (18/28) of the included studies 
used published and validated scoring systems including EASI, SAASAD or 
SCORAD as outcome measures. Five included studies did not use any 
published and validated scoring system and were considered at a high risk of 
bias (Liu 2005; Tian 2005; Wang 2008; Zhou 2011; Zou 2011). Four studies 
used a scoring system developed by the trial investigator(s) for measurement 
of outcomes (Chao 2003; Chen 2011; Yang 2009; Yu 1999); these were 
unable to be validated and thus the risk of bias was classed as unclear. The 
Cheng 2010 study claimed a "standardised scoring system" was used although 
it could not be determined whether this system had been previously validated, 
so the risk of bias was also classed as unclear. 
None of the included studies used POEM for scoring the severity of the 
condition. 
4.8 Effects of Interventions 
 
4.8.1 CHM versus Placebo 
1) Primary outcomes 
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a. Total effectiveness rate: 
The Chao 2003 study showed that there was a statistically significant increase 
in total effectiveness rate (those participants with “recovery” or “significant 
improvement”) in the CHM group treated with 10% strength CHM cream 
compared to those in the control group using petroleum jelly (Vaseline) at the 
end of the three week treatment period. The full strength (10%) CHM cream 
was included for analysis in this review. The Sun 2009 study recorded no 
effect in the sum of “recovery” and “significant improvement” events in both 
groups at the end of the four week treatment period. 
Data were pooled from these two studies by the statistical method of inverse-
variance with random-effects analysis model and expressed as RR with 95% 
CI for estimating their overall effects which showed a statistically significant 
effect of the CHM intervention (RR 2.09; 95% CI 1.32 to 3.32, see Analysis 
1.1 in Table 14). 
The Chao 2003 study did not report short-term or long-term improvement. The 
Sun 2009 study reported long-term improvement (24 weeks after stopping the 
treatment) assessed with “Recurrence rate”. Further analysis of the data was 
not performed as the “Recurrence rate” was not a pre-specified outcome of 
this review. 
The Cheng 2010; Hon 2007 studies did not report the outcomes as 
“effectiveness rate”. 
b. Severity of itching score measured by VAS: 
The Cheng 2010 study reported the improvement of itching in scores (scale 
from 0 to 4). The score was expressed as least-squares mean ± the standard 
error (SE) change from baseline for each intervention group following the 
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eight week treatment period. The Cheng 2010 study also provided data of 
baseline median (interquartile range [IQ]) per group. The SE provided was not 
used as they were too narrow. Data were pooled by using an alternative SD 
estimated from the baseline data (calculation from baseline IQ range: 
SD=IQ/1.35) and to ensure the least-squares means did not receive too much 
weight in the meta-analysis (Higgins & Green, 2011). The Sun 2009 study 
also used VAS (scale unknown) to assess the severity of itching at the end of 
the four week treatment period but did not report scale. Data were pooled and 
expressed as SMD with 95% CI due to different outcome scales being used in 
these two studies (SMD -1.53; 95% CI -2.64 to -0.41, see Analysis 1.2 in 
Table 14). As the Cheng 2010 study reported improvement of VAS without 
the actual score and the Sun 2009 study recorded decrease of VAS at endpoint, 
the mean in Cheng 2010 study was multiplied by -1 to ensure the two 
outcomes were in the same direction (Deeks et al., 2011). Both studies showed 
favourable results towards the CHM groups. 
The Cheng 2010 study reported short-term improvement (four weeks after 
stopping the treatment) and stated that better scores of itching were seen in the 
CHM group but no details of data were provided. 
No record of severity of itching score was found in the Chao 2003 and the 
Hon 2007 studies. 
2) Secondary outcomes 
a. Overall severity score measured by the scoring system (e.g. EASI, 
SAASAD or SCORAD): 
The Chao 2003 study used a self-developed scoring system and recorded the 
score at endpoint in the CHM group (2nd arm) and control group (4th arm). 
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The Cheng 2010 study reported improvement in clinical lesion scores which 
were expressed as least-squares means ± SE at the end of the eight week 
treatment period. Data were analysed by using an alternative SD as outlined 
above. The Hon 2007 study reported the SCORAD score at the end of the 12 
week treatment period in both groups and stated that there was no significant 
difference between the two groups. The Sun 2009 study also used SCORAD 
to measure the outcomes and claimed that a significant difference in the 
treatment and control groups at the end of the treatment period was observed 
and the effect in the CHM group was superior to the control group. Data were 
pooled from those four studies and a significant difference was recorded 
(SMD -0.88; 95% CI -1.67 to -0.09, see Analysis 1.3 in Table 14). 
The Cheng 2010 study reported short-term improvement (four weeks after 
stopping the treatment) and stated improved clinical lesion scores were seen in 
the CHM group, however no data was provided. The Hon 2007 study reported 
no short-term improvement was observed as there was no difference between 
the two groups four weeks after stopping the treatment (MD 3.40; 95% CI -
5.70 to 12.50, see Analysis 1.4 in Table 14). The Chao 2003; Sun 2009 studies 
did not report short-term or long-term improvement in overall severity score. 
b. QoL index: 
The Hon 2007 study reported improvement in CDLQI score in the CHM 
group at the end of the 12 week treatment (MD -2.50; 95% CI -4.77 to -0.23, 
see Analysis 1.5 in Table 14). The Hon 2007 study also stated that there was a 
short-term improvement in CDLQI four weeks after stopping the treatment, 
but this claim was not supported by the statistical analysis (MD -1.30; 95% CI 
-3.51 to 0.91, see Analysis 1.6 in Table 14). 
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The Chao 2003; Cheng 2010; Sun 2009 studies did not use QoL index to 
measure the outcomes. 
c. Adverse events: 
There were two minor adverse events in the CHM group in the Chao 2003 
study. The Cheng 2010 study reported one participant had transient elevation 
of aspartate aminotransferase; the trial investigators did not state in which 
group the participant was assessed. There were two participants in the 
treatment group who complained of gastrointestinal upset in the first week of 
the treatment but the participants were able to complete the whole trial 
reported by the Cheng 2010 study. The Sun 2009 study stated that no adverse 
events were reported from any participants of the trial. 
Data were pooled from the Chao 2003 and Cheng 2010 studies about minor 
adverse events, no significant difference was seen between the treatment and 
control groups (RR 0.71; 95% CI 0.06 to 8.67, two studies, n=129, Analysis 
1.7 in Table 14). There were a total of 82 minor adverse events reported by 
participants in the CHM group and 47 minor adverse events reported by 
participants in the control group in the Hon 2007 study; the trial investigators 
claimed that there was no significant difference in terms of frequency of minor 
adverse events in the two groups. The frequency of those adverse events was 
treated as “count data” and converted to RR (Deeks et al., 2011). It showed a 
statistically significant difference in the minor adverse events between the two 
groups and the CHM group had a higher rate in the incident of the events (RR 
1.77; 95% CI 1.24 to 2.53, see Analysis 1.8 in Table 14). 
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Subgroup analysis and investigation of heterogeneity 
Substantial heterogeneity (I² = 87%, see Figure 13) was found across the four 
studies in the outcome “overall severity score”. It was planned to perform 
subgroup analyses of "children (16 years old or under) with eczema versus 
adults with eczema", and "application of interventions based on Chinese 
medicine syndrome differentiation versus non-individualisation formula" 
where there are at least moderate levels of heterogeneity across the included 
studies. However, only the Chao 2003 study recruited children aged from one 
to 38 months and the other three studies mixed children with adults and these 
three studies used non-individualised formulae. Thus subgroup analyses were 
not conducted. The subgroup analysis was not able to explain such differences 
by further analysing the following sources of heterogeneity: analysis of the 
participant factors e.g. age (children versus adults, because it was not able to 
identify the difference for the reasons stated above), diagnosis (infantile 
eczema in Chao 2003 study versus atopic eczema in Hon 2007; Cheng 2010; 
Sun 2009 studies), sex (mixed gender in all four studies), race (all Asians), co-
morbidity (not able to identify due to insufficient data), treatment factors e.g. 
dosage (various CHM dosages applied across the four studies), formulation 
(four different CHM formulae used in four studies), study factors e.g. 
concordance rates (all four studies reported high compliance rates), quality of 
reporting (this was overcome by assessment of risk of bias in this review) and 
quality control for the Chinese herbal preparations e.g. source, purity, 
preparation facilities (all four studies reported quality control for the CHM 
interventions). 
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Sensitivity analysis 
It was planned to perform sensitivity analyses of the primary outcomes by 
excluding studies of low methodological quality. Substantial heterogeneity (I² 
= 74%, see Figure 14) was found in the two studies where one of the primary 
outcomes, the severity of itching, was measured by VAS. Sensitivity analysis 
was not performed as there were only two studies in the meta-analysis. 
 
Table 14 Data and Analyses 1. CHM vs Placebo 
 
Outcome or Subgroup Studies Participants Statistical 
Method 
Effect 
Estimate 
1.1 Total effectiveness 
rate (No. of participants 
recovered and 
significantly improved) 
2 85 Risk Ratio (IV, 
Random, 95% 
CI) 
2.09 [1.32, 
3.32] 
1.2 Itching VAS 2 94 Std. Mean 
Difference (IV, 
Random, 95% 
CI) 
-1.53 [-2.64, 
-0.41] 
1.3 Overall severity score 4 239 Std. Mean 
Difference (IV, 
Random, 95% 
CI) 
-0.88 [-1.67, 
-0.09] 
1.4 Overall severity score 
(short-term improvement) 
1  Mean 
Difference (IV, 
Fixed, 95% CI) 
No totals 
1.5 QoL 1  Mean 
Difference (IV, 
Fixed, 95% CI) 
No totals 
1.6 QoL (short-term 
improvement) 
1  Mean 
Difference (IV, 
Fixed, 95% CI) 
No totals 
1.7 Adverse events 2 129 Risk Ratio (IV, 
Random, 95% 
CI) 
0.71 [0.06, 
8.67] 
1.8 Adverse events in one 
study 
1  Risk Ratio (IV, 
Fixed, 95% CI) 
No totals 
Abbreviations: CI, Confidence Interval; QoL, Quality of Life; VAS, Visual Analogue Scale.  
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Figure 13 CHM vs Placebo Outcome: total severity score measured by different 
scales  
 
 
Abbreviations: CHM, Chinese herbal medicine; CI, confidence interval; df, degrees of 
freedom; SD, standard deviation. 
 
 
Figure 14 CHM vs Placebo outcome: severity of itchiness score measured by 
VAS 
 
 
Abbreviations: CHM, Chinese herbal medicine; CI, confidence interval; df, degrees of 
freedom; SD, standard deviation. 
 
 
4.8.2 CHM versus No Treatment 
No included studies compared CHM with no treatment. 
4.8.3 CHM versus Acupuncture 
No included studies compared CHM with acupuncture treatment. 
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4.8.4 CHM versus Conventional Medicines (Drugs) 
1) Primary outcomes 
a. Total effectiveness rate: 
A total of 20 included studies employed total effectiveness rate as the outcome 
measure. In addition, one arm was included in the Chao 2003 study which was 
a four-arm design where CHM was used topically (2nd arm) compared to 
steroid cream (3rd arm) in the current category. Data were pooled from the 21 
included studies by the statistical method of inverse-variance with the random-
effects analysis model and expressed as RR with 95% CI for estimating their 
overall effects. The forest plot of comparison showed that application of CHM 
significantly improved the condition compared to control interventions (RR 
1.43; 95% CI 1.27 to 1.61, see Analysis 2.1 in Table 15). 
The Cao 2009; Chao 2003; Chen 2011; Lang 2007; Ma 2010; Tian 2005; 
Wang 2008; Xue 2011; Yang 2007; Yang 2009; Zhang 2005 studies did not 
report short-term or long-term improvement. The Zhang 2009 study reported 
short-term improvement assessed with “Recurrence rate”. The Huang 2010; 
Liu 2005; Xiao 2011; Zhang 2011; Zhou 2011; Zou 2011 studies also used 
“Recurrence rate” to report long-term improvement. All of them stated that the 
CHM groups had a lower recurrence rate than their comparators. The Luo 
2010 study reported long-term improvement but no data were provided. The 
Gong 2010; Yu 1999 studies reported long-term improvement and stated that 
CHM groups had a higher effectiveness rate than the control groups (RR 1.52; 
95% CI 1.11 to 2.08, see Analysis 2.2 in Table 15). 
b. Severity of itching score measured by VAS: 
2) Secondary outcomes 
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a. Overall severity score measured by the scoring system (e.g. EASI, 
SAASAD or SCORAD): 
The Liu 2005; Tian 2005; Wang 2008; Zhou 2011; Zou 2011 studies did not 
report measurement of overall severity of the condition. The Yang 2009; Yu 
1999; Zhang 2009 studies did not provide data for the scores. Data collected 
from the remaining 15 included studies were pooled and expressed as SMD 
with 95% CI as different outcome scales were used in the studies. The Cao 
2009; Luo 2010; Zhang 2005 studies reported data measured at the endpoint as 
percentage of reduction of total SASSAD score and expressed the data as 
“numbers ±”. It was assumed unlabelled data in these three studies were 
“mean and SD”. The mean was multiplied by -1 to ensure all scales were in 
the same direction in the meta-analysis. The forest plot figure showed that 
application of CHM significantly reduced the severity of skin lesions 
measured by various scoring systems when compared to Western medications 
(SMD -0.97; 95% CI -1.23 to -0.71, see Analysis 2.4 in Table 15). 
No short-term or long-term improvement was reported by Cao 2009; Chao 
2003; Chen 2011; Jin 2007; Lang 2007; Ma 2010; Xue 2011; Yang 2007; 
Zhang 2005 studies. The Gong 2010; Huang 2010; Luo 2010; Xiao 2008; 
Xiao 2011; Zhang 2011 studies reported long-term improvement. Only the 
Xiao 2008 study provided data to support a long-term improvement observed 
in the CHM group (MD -8.50; 95% CI -13.40 to -3.60, see Analysis 2.5 in 
Table 15). 
b. QoL index: 
No studies in this group employed QoL questionnaires as outcome measures. 
c. Adverse events: 
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The Jin 2007; Xue 2011; Zhang 2009; Zhang 2011 studies did not report 
adverse events. The Cao 2009; Luo 2010; Zhou 2011; Zou 2011 studies stated 
that no adverse events were reported during the trial period. None of the 
studies reported withdrawals of participants due to any adverse event. The 15 
studies when combined indicated there were significantly less minor adverse 
events in the CHM than the control groups (RR 0.44; 95% CI 0.32 to 0.61, see 
Analysis 2.6 in Table 15). 
Subgroup analysis and investigation of heterogeneity 
There was substantial heterogeneity (I² = 65%, see Analysis 2.1 in Table 15 
and Figure 15) across the 21 included studies with the outcome measured by 
total effectiveness rate. It was planned to conduct a subgroup analysis of the 
studies of "children (16 years old or under) with eczema versus adults with 
eczema" and identified 12 studies in which the participants were 16 years old 
or under. The other nine studies, however, recruited participants with a mix of 
children and adults; therefore subgroup analysis under this heading was not 
available. 
Difference in the total effectiveness rate between two groups where 
application of CHM was based on Chinese medicine syndrome differentiation 
or non-individualised formula was compared. There was low inconsistency (I² 
= 22%) within the seven sub grouped studies which applied CHM based on 
Chinese medicine syndrome differentiation (individualised modifications) and 
showed that CHM was more effective than the Western medications (RR 1.50; 
95% CI 1.30 to 1.74, (see analysis 3.1.1 in Analysis 2.1 in Table 15). There 
were no subgroup differences (I² = 0) when comparing the individualised 
treatment subgroup to the non-individualised subgroup. Where non-
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individualised formulae were used there was a high level of heterogeneity 
between the studies in this subgroup (I² = 71%, see analysis 3.1.2 in Figure 
15). 
A post hoc subgroup analysis of "CHM versus topical steroid"; "CHM versus 
antihistamines"; and "CHM versus other agents" was performed as the 
different types of comparators could be a possible reason for heterogeneity in 
the studies. There was substantial heterogeneity in the subgroup of topical 
steroid (I² = 72%). Although there were no inconsistencies in the subgroups of 
antihistamines or other agents, the total subgroup differences were statistically 
significant (P = 0.02, I² = 74.4%, see Analysis 2.7 in Figure 16Figure 15). 
The sources of the heterogeneity in this group from participant factors (e.g. 
age, diagnosis, sex, race, co-morbidity), treatment factors (e.g. dosage, 
formulation), and study factors (e.g. concordance rates, quality of reporting), 
and quality control for the Chinese herbal preparations were unable to be 
further investigated as no data was available for appropriate comparisons. 
Sensitivity analysis 
Sensitivity analyses of the primary outcomes by further excluding studies of 
low methodological quality were not performed as all studies in this category 
had similar methodological weaknesses (e.g. high risk of bias in blinding of 
participants and research personnel). 
Assessment of reporting bias 
A Funnel plot (Figure 17) was generated to inspect visually for evidence of 
potential reporting bias including publication bias across 15 included studies 
where effects of CHM and Western medications were compared (Cao 2009; 
Chao 2003; Chen 2011; Gong 2010; Huang 2010; Jin 2007; Lang 2007; Luo 
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2010; Ma 2010; Xiao 2008; Xiao 2011; Xue 2011; Yang 2007; Zhang 2005; 
Zhang 2011). The Funnel plot was tested for bias using the method of Egger 
(Egger, Davey Smith, Schneider, & Minder, 1997). Result of this assessment 
indicated that there were no statistically asymmetrical distributions among 
those 15 studies (Egger test P = 0.2021). 
 
Table 15 Data and Analyses 2. CHM vs Conventional medications (drugs) 
 
Outcome or Subgroup Studies Participants Statistical 
Method 
Effect 
Estimate 
2.1 Total effectiveness 
rate (No. of participants 
recovered and 
significantly improved) 
with subgroup analysis 
21 1868 Risk Ratio (IV, 
Random, 95% 
CI) 
1.43 [1.27, 
1.61] 
 2.1.1 Individualised 
treatment 
7 567 Risk Ratio (IV, 
Random, 95% 
CI) 
1.50 [1.30, 
1.74] 
 2.1.2 Non-individualised 
treatment 
14 1301 Risk Ratio (IV, 
Random, 95% 
CI) 
1.37 [1.17, 
1.60] 
2.2 Total effectiveness 
rate (long-term 
improvement) 
2 276 Risk Ratio (IV, 
Random, 95% 
CI) 
1.52 [1.11, 
2.08] 
2.3 Itching VAS 7 465 Std. Mean 
Difference (IV, 
Random, 95% 
CI) 
-0.83 [-1.43, 
-0.22] 
2.4 Overall severity score 
 
 
15 1062 Std. Mean 
Difference (IV, 
Random, 95% 
CI) 
-0.97 [-1.23, 
-0.71] 
2.5 Overall severity score 
(long-term improvement) 
1  Mean 
Difference (IV, 
Fixed, 95% CI) 
No totals 
2.6 Adverse events 15 1396 Risk Ratio (IV, 
Random, 95% 
CI) 
0.44 [0.32, 
0.61] 
2.7 Total effectiveness 
rate with post hoc 
subgroup analysis 
21 1868 Risk Ratio (IV, 
Random, 95% 
CI) 
1.43 [1.27, 
1.61] 
 2.7.1 CHM vs Topical 
steroid 
6 671 Risk Ratio (IV, 
Random, 95% 
CI) 
1.18 [0.99, 
1.40] 
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 2.7.2 CHM vs 
Antihistamines 
12 906 Risk Ratio (IV, 
Random, 95% 
CI) 
1.58 [1.37, 
1.82] 
 2.7.3 CHM vs Other 
agents 
3 291 Risk Ratio (IV, 
Random, 95% 
CI) 
1.58 [1.31, 
1.90] 
Abbreviations: CHM, Chinese herbal medicine; CI, Confidence Interval; VAS, Visual 
Analogue Scale. 
 
Figure 15 CHM vs Conventional medications (drugs) outcome: total effectiveness 
rate with subgroup analysis  
 
 
 
Abbreviations: CHM, Chinese herbal medicine; CI, confidence interval; df, degrees of 
freedom. 
 
  
 
146 
Figure 16 CHM vs Conventional medications (drugs) post hoc subgroup analysis 
 
 
 
Abbreviations: CHM, Chinese herbal medicine; CI, confidence interval; df, degrees of 
freedom. 
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Figure 17 CHM vs Conventional medications (drugs) Funnel plot outcome: 
overall severity score 
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4.8.5 Combination of Oral and Topical CHM Interventions versus Same 
Oral CHM Alone 
1) Primary outcomes 
a. Total effectiveness rate: 
The Lin 2010 study did not express the outcomes as “effectiveness rate”. The 
Rao 2010 study reported no difference in the effects between the first arm 
(CHM used orally and topically) and second arm (CHM was used by oral 
ingestion only, but no topical intervention was used) at the end of the 12 week 
treatment period (RR 1.13; 95% CI 0.78 to 1.63, see Analysis 3.1 in Table 16). 
The Lin 2010 study did not report short-term or long-term improvement. The 
Rao 2010 study reported long-term improvement (24 weeks after stopping the 
treatment) but no difference was observed between the two groups (RR 1.00; 
95% CI 0.75 to 1.34, see Analysis 3.2 in Table 16). 
b. Severity of itching score measured by VAS: 
The Lin 2010 study reported there was statistically significant improvement in 
terms of itching relief (scale from zero to 10) in the treatment site compared to 
the control site of the limb at the end of two week treatment (MD -1.05; 95% 
CI -1.75 to -0.35, see Analysis 3.3 in Table 16). The Lin 2010 study did not 
report short-term or long-term improvement. The Rao 2010 study did not 
report severity of itching score. 
2) Secondary outcomes 
a. Overall severity score measured by the scoring system (e.g. EASI, 
SAASAD or SCORAD): 
The Lin 2010 study used a self-developed scale (scale zero to 24) for scoring 
the severity of skin lesions and reported a statistically significant improvement 
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in terms of skin lesions at the treatment site of the limb compared to the 
control site, at the end of the two week treatment period (MD -1.59; 95% CI -
2.92 to -0.26, see Analysis 3.4 in Table 16). The score of SCORAD was not 
pooled in the Lin 2010 study as the data provided were recorded at the 
baseline and the end of the treatment period rather than the treatment site and 
control site. The Rao 2010 study stated no difference in the reduction of 
SCORAD between the treatment group and control group at the end of the 12 
week treatment period (MD -3.43; 95% CI -7.01 to 0.15, see Analysis 3.5 in 
Table 16). Data of the two studies for were not pooled for meta-analysis as the 
Lin 2010 study was a within participant trial. 
The two studies did not report short-term or long-term improvement. 
b. QoL index: 
The Lin 2010 study did not use a QoL index for measurement of outcomes. 
The Rao 2010 study used CDLQI as the secondary outcome measure and 
recorded the scores at the end of the 12 week treatment period which indicated 
no difference between the two groups (MD 0.90; 95% CI -2.89 to 4.69, see 
Analysis 3.6 in Table 16). CDLQI scores were also used for measuring long-
term improvement in 24 weeks after stopping the treatment in Rao 2010 study 
but no data were provided. 
c. Adverse events: 
There was one participant withdrawal (a severe adverse event) from the Lin 
2010 study due to exacerbation of the skin condition after using the Chinese 
herbs for two days, and three participants complained of mild to moderate 
burning and pain sensations but they still completed the two week treatment. 
The Rao 2010 study stated that there was one participant with increased serum 
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alanine transaminase each in the treatment and control group (RR 1.00; 95% 
CI 0.07 to 13.87, see Analysis 3.7 in Table 16). 
Subgroup or sensitivity analyses were not performed for this comparison. 
NNT or NNTB 
Due to high risk of bias in most of the included studies, it was not appropriate 
to express dichotomous data as NNT or continuous data as NNTB as these 
additional variations may induce unnecessary misleading implications. 
 
Table 16 Data and Analyses 3. Combination of oral and topical CHM vs same 
oral CHM alone 
 
Outcome or Subgroup Studies Participants Statistical 
Method 
Effect 
Estimate 
3.1 Total effectiveness 
rate (No. of participants 
recovered and 
significantly improved) 
1 20 Risk Ratio (IV, 
Fixed, 95% CI) 
1.13 [ 0.78, 
1.63] 
3.2 Total effectiveness 
rate (long-term 
improvement) 
1 20 Risk Ratio (IV, 
Fixed, 95% CI) 
1.00 [0.75, 
1.34] 
3.3 Itching VAS 1 22 Mean 
Difference (IV, 
Fixed, 95% CI) 
-1.05 [-1.75, 
-0.35] 
3.4 Skin lesion score 1 22 Mean 
Difference (IV, 
Fixed, 95% CI) 
-1.59 [-2.92, 
-0.26] 
3.5 Overall severity score 1 20 Mean 
Difference (IV, 
Fixed, 95% CI) 
-3.43 [ -
7.01, 0.15] 
3.6 QoL 1 20 Mean 
Difference (IV, 
Fixed, 95% CI) 
0.90 [-2.89, 
4.69] 
3.7 Adverse events 1 20 Risk Ratio (IV, 
Fixed, 95% CI) 
1.00 [0.07, 
13.87] 
Abbreviations: CI, Confidence Interval; QoL, Quality of Life; VAS, Visual Analogue 
Scale. 
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Section IV: Discussion 
4.9 Summary of Main Results 
 
This review is an updated version with a new team of authors and a newly 
published protocol. The four studies in the previous version were not included in this 
review as they all investigated a CHM product Zemaphyte which has been withdrawn 
from the market by the manufacturer since 2004 (W. Zhang et al., 2004), and it would 
skew the significance of systematically produced evidence-based medicine if data that 
is not linked to current clinical practice or research were incorporated. 
This review included 28 studies with a total of 2306 participants. Chinese 
herbal medicines and comparators were taken orally or applied topically by children 
and adults with AE. Four studies compared CHM to placebo. Two studies compared 
combination of oral and topical CHM to the same oral CHM formula alone and 22 
studies and one arm of the Chao 2003 study compared CHM to Western medications. 
There was an evidence from one 12 week study of moderate to severe AE 
comparing an oral CHM to placebo of a statistically significant difference between the 
two groups with respect to QoL score (MD -2.50; 95% CI -4.77 to -0.23, see Analysis 
1.5 in Table 14) (Hon 2007). The mean QoL score in the CHM groups was 2.5 lower 
than that in the placebo groups which indicated that oral ingestion of CHM could 
improve QoL. Although the overall effect in the outcomes of “total effectiveness 
rate”, “severity of itching score” and ‘'overall severity score” showed a statistically 
significant difference between the groups in favour of CHM, these findings were 
inconclusive due to the high risk of bias with regard to blinding of participants and 
research personnel and incomplete outcomes or other unclear risk of bias that existed 
across these four studies (see   
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Table 17 Summary of findings CHM vs Placebo). Unexplained high 
heterogeneity (I² = 87%, see Figure 13) among the four studies in the outcome 
measured by “overall severity score” further weakened the strength of the positive 
estimates. 
The majority of the included studies (22 studies and one arm of the Chao 2003 
study) used conventional medicines (Western medications) as comparators which 
included oral ingestion of antihistamine tablets, topical use of corticosteroid cream 
and other agents such as antifungal, antiseptic or emollients. Twenty-one studies 
expressed their primary outcome in “total effectiveness rate” and all reported that 
effectiveness of CHM interventions was superior to the comparators except the Chao 
2003 and Chen 2011 studies where corticosteroid cream was used as the control 
intervention. In addition to these two studies the meta-analyses performed showed no 
statistically significant difference between the CHM and conventional medicine 
groups observed in the studies of Gong 2010; Huang 2010; Lang 2007; Tian 2005; 
Wang 2008; Xiao 2011; Zhang 2009 although the overall effects of the 21 included 
studies favoured the CHM groups (RR 1.43; 95% CI 1.27 to 1.61, see Analysis 2.1 in 
Table 15). The claim of positive effects with CHM intervention needs to be 
interpreted with caution due to substantial heterogeneity (I² = 65%, see Figure 15) 
across the studies. The result from a post hoc subgroup analysis (subgroup differences 
I² = 74.4%) also confirmed there was unexplained heterogeneity. There was high risk 
of bias in the domains for blinding of participants and research personnel, blinding of 
outcome assessment and other potential sources of bias (absence of usage of 
published and validated scoring systems for outcome measures) in this group of 
studies (see Table 18 Summary of findings CHM vs Drugs). All included studies in 
this group were associated with several major methodological weaknesses. For 
 
153 
example, although all studies used randomisation for grouping of participants, none of 
them provided information of the procedure for allocation concealment (see Figure 
12). Inadequate randomisation could give rise to an investigator’s bias for grouping of 
participants which consequently affects the outcomes (Liu, 2006). 
Two studies reported a statistically significant difference in outcomes of “total 
effectiveness rate” or “severity of itching score measured by VAS” respectively and 
overall effects in the combination of oral and topical CHM groups were always 
superior to the oral CHM control groups (Lin 2010; Rao 2010). Data from the two 
studies were not pooled as the Lin 2010 study was a within patient study. The Lin 
2010 study had high risk of performance bias and attrition bias. The Rao 2010 study 
had high risk of bias in the domain of blinding of the participants and research 
personnel and both studies had small sample sizes (a total of 42 participants in two 
studies evaluated). Their claims that overall effects in CHM groups were superior to 
the control groups were in doubt (see Table 19 Summary of findings Combined oral 
and topical CHM vs same oral CHM). 
It is worth pointing out that nearly half of the included studies did not use 
published and validated scoring systems for measuring the severity of the condition. 
Some studies used the scoring system but did not provide continuous data for the 
scores. The absence of these data made quantifiable data analysis impossible and 
downgraded the credibility of the results (Eichenfield et al., 2003). It was unable to 
further estimate if CHM has potential for short-term or long-term improvement of AE 
due to limited data provided by the included studies. 
Chinese herbal medicines' possible association with hepatotoxicity (liver 
toxicity) was discussed when 11 cases of liver damage following oral ingestion of 
some raw Chinese herbal mixtures for skin conditions were reported in the U.K. 
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between 1991 to 1993 (Perharic, Shaw, Leon, De Smet, & Murray, 1995). The 
reporters indicated that the mechanism of toxicity was not clear. The adverse effects 
of those CHM mixtures seemed to not be dose-related and were probably 
idiosyncratic. The safety issue of oral ingestion of CHM has been a concern of 
healthcare professionals and the public (Chitturi & Farrell, 2000). In this review, both 
beneficial effects and adverse effects of interventions from the included studies have 
evaluated. There was only a quarter (7/28) of the included studies had monitored the 
liver and renal function of the participants during the period of the trial (Cheng 2010; 
Hon 2007; Luo 2010; Rao 2010; Xiao 2008; Xiao 2011; Zou 2011). With regard to 
adverse events including liver or kidney dysfunction, there was one withdrawal due to 
aggravation of the condition (a severe adverse event) after using CHM (Lin 2010), no 
severe adverse events were reported in 23 studies and the remaining four studies did 
not report adverse events (Jin 2007; Xue 2011; Zhang 2009; Zhang 2011). Twenty-
four studies reported minor adverse events, in two studies transient elevation of 
aspartate aminotransferase or alanine transaminase in the trial participants was 
observed (Cheng 2010; Rao 2010). Apart from the Hon 2007 study in which a 
statistically significant difference in minor adverse events was recorded with a higher 
incidence in the CHM group, pooled data from other included studies demonstrated 
significantly less minor adverse events with CHM interventions than their 
comparators. Nevertheless the quality of evidence was low. 
There were eight included studies (Cheng 2010; Gong 2010; Hon 2007; Ma 
2010; Sun 2009; Xue 2011; Yang 2007; Yu 1999) which were funded by 
governments. In addition, 75% of the included studies, all conducted in mainland 
China, reported identical numbers of participants randomised and analysed. No 
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incomplete outcome data were reported in these studies. These analyses were not able 
to find out the underlying reasons for such unusually high compliance in RCTs. 
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Table 17 Summary of findings CHM vs Placebo 
 
CHM compared to Placebo for AE 
Patient or population: patients with AE 
Settings: Hospital outpatients 
Intervention: CHM 
Comparison: Placebo 
Outcomes Illustrative 
comparative risk* 
(95% CI) 
Relativ
e effect 
(95% 
CI) 
No of 
Participant
s 
(studies) 
Quality 
of the 
evidence 
(GRADE
) 
Comments 
Assume
d risk 
Correspondin
g risk 
Placebo CHM 
Total 
effectivenes
s rate 
(Analysis 
1.1) 
Clinician's 
rating 
Follow-up: 
2 to 4 weeks 
Low
1
 RR 
2.09  
(1.32 to 
3.32) 
85 
(2 studies) 
⊕⊕⊝⊝ 
low
2,3
 
Two 
additional 
studies did 
not report 
this 
outcome. A 
higher total 
effectivenes
s rate 
indicates 
improvemen
t of the 
condition. 
1 per 
100 
2 per 100 
(1 to 3) 
High
1
 
40 per 
100 
84 per 100 
(53 to 100) 
Itching 
VAS 
(Analysis 
1.2) 
Patient's 
rating. Scale 
from: 1 to 
10 
Follow-up: 
4 to 12 
weeks 
The 
mean 
itching 
VAS 
ranged 
across 
control 
groups 
from 
0.2 to 
7.8 
scores 
The mean 
itching in VAS 
the 
intervention 
groups was 
1.53 standard 
deviations 
lower 
(2.64 to 0.41 
lower) 
 94 
(2 studies) 
⊕⊕⊝⊝ 
low
3,4
 
Lower score 
indicates 
improvemen
t of the 
condition. 
Two 
additional 
studies did 
not report 
this 
outcome. 
Overall 
severity 
score 
(Analysis 
1.3)  
Clinician's 
rating. Scale 
from: 1 to 
80 
Follow-up: 
The 
mean 
overall 
severity 
score 
ranged 
across 
control 
groups 
from 
The mean 
overall severity 
score in the 
intervention 
groups was 
0.88 standard 
deviations 
lower 
(1.67 to 0.09 
lower) 
 239 
(4 studies) 
⊕⊝⊝⊝ 
very 
low
2,3,4
 
Lower score 
indicates 
improvemen
t of the 
condition. 
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2 to 16 
weeks 
5.7 to 
46.9 
scores 
QoL 
(Analysis 
1.5) 
Patient's 
rating. Scale 
from: 0 to 
30 
Follow-up: 
4 to 16 
weeks 
The 
mean 
QoL in 
the 
control 
groups 
was 
10.1 
scores 
The mean QoL 
in the 
intervention 
groups was 
2.5 lower 
(4.77 to 0.23 
lower) 
 85 
(1 study) 
⊕⊕⊕⊝ 
moderate
3
 
Lower score 
indicates 
better 
quality of 
life. Three 
additional 
studies did 
not report 
this 
outcome. 
Adverse 
events 
(Analysis 
1.7) 
Patient's 
report 
Follow-up: 
2 to 12 
weeks 
Low
1
 RR 
0.71  
(0.06 to 
8.67) 
129 
(2 studies) 
⊕⊕⊝⊝ 
low
2,3
 
One 
additional 
study 
reported 
numbers of 
adverse 
events were 
greater than 
the total 
participants. 
Data were 
treated as 
adverse 
event count 
data rather 
than 
participant 
level data 
which could 
not be 
pooled. 
1 per 
100 
1 per 100 
(0 to 9) 
High
1
 
6 per 
100 
4 per 100 
(0 to 52) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is 
provided in footnotes. The corresponding risk (and its 95% confidence interval) is 
based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI). 
Abbreviations: CI, Confidence interval; RR, Risk ratio. 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the 
estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
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Table 18 Summary of findings CHM vs Drugs 
 
CHM compared to Drugs for AE 
Patient or population: patients with AE 
Settings: Hospital outpatients 
Intervention: CHM 
Comparison: Drugs 
Outcomes Illustrative 
comparative risk* 
(95% CI) 
Relativ
e effect 
(95% 
CI) 
No of 
Participant
s 
(studies) 
Quality 
of the 
evidence 
(GRADE
) 
Comments 
Assume
d risk 
Correspondin
g risk 
Drugs CHM 
Total 
effectiveness 
rate (Analysis 
2.1) 
Clinician's 
rating 
Follow-up: 2 
to 52 weeks 
Low
1
 RR 
1.43  
(1.27 to 
1.61) 
1868 
(21 studies) 
⊕⊝⊝⊝ 
very 
low
2,3,4,5
 
A higher 
total 
effectivenes
s rate 
indicates 
improvemen
t of the 
condition. 
20 per 
100 
29 per 100 
(25 to 32) 
High
1
 
90 per 
100 
100 per 100 
(100 to 100) 
Total 
effectiveness 
rate with 
subgroup 
analysis - 
Individualise
d treatment 
Clinician's 
rating 
Follow-up: 4 
to 8 weeks 
Low
1
 RR 
1.50  
(1.30 to 
1.74) 
567 
(7 studies) 
⊕⊕⊝⊝ 
low
2,3,4
 
 
20 per 
100 
30 per 100 
(26 to 35) 
High
1
 
70 per 
100 
100 per 100 
(91 to 100) 
Total 
effectiveness 
rate with 
subgroup 
analysis - 
Non-
individualise
d treatment 
Clinician's 
rating 
Follow-up: 2 
to 52 weeks 
Low
1
 RR 
1.37  
(1.17 to 
1.60) 
1301 
(14 studies) 
⊕⊝⊝⊝ 
very 
low
2,3,4,5
 
 
20 per 
100 
27 per 100 
(23 to 32) 
High
1
 
90 per 
100 
100 per 100 
(100 to 100) 
Itching VAS 
(Analysis 2.3) 
Patient's 
The 
mean 
itching 
The mean 
itching VAS in 
the 
 465 
(7 studies) 
⊕⊕⊝⊝ 
low
2,3,5
 
Lower score 
indicates 
improvemen
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rating. Scale 
from: 0 to 10 
Follow-up: 2 
to 12 weeks 
VAS 
ranged 
across 
control 
groups 
from 
0.3 to 
5.75 
scores 
intervention 
groups was 
0.83 standard 
deviations 
lower 
(1.43 to 0.22 
lower) 
t of the 
condition. 
Sixteen 
additional 
studies did 
not report 
this 
outcome. 
Overall 
severity score 
(Analysis 2.4) 
Clinician's 
rating. Scale 
from: 0 to 103 
Follow-up: 2 
to 12 weeks 
The 
mean 
overall 
severity 
score 
ranged 
across 
control 
groups 
from 
0.3 to 
70.82 
scores 
The mean 
overall 
severity score 
in the 
intervention 
groups was 
0.97 standard 
deviations 
lower 
(1.23 to 0.71 
lower) 
 1062 
(15 studies) 
⊕⊕⊝⊝ 
low
2,3,5
 
Lower score 
indicates 
improvemen
t of the 
condition. 
Eight 
additional 
studies did 
not report 
this 
outcome. 
Adverse 
events 
(Analysis 2.6) 
Patient's 
reports 
Follow-up: 2 
to 52 weeks 
Low
1
 RR 
0.44  
(0.32 to 
0.61) 
1396 
(15 studies) 
⊕⊕⊝⊝ 
low
2,3,4
 
Four 
additional 
studies did 
not report 
this 
outcome. 
1 per 
100 
0 per 100 
(0 to 1) 
High
1
 
60 per 
100 
26 per 100 
(19 to 37) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is 
provided in footnotes. The corresponding risk (and its 95% confidence interval) is 
based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI). 
Abbreviations: CI, Confidence interval; RR, Risk ratio. 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the 
estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
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Table 19 Summary of findings Combined oral and topical CHM vs same oral 
CHM 
 
Combination of oral and topical CHM compared to same oral CHM for AE 
Patient or population: patients with AE 
Settings: Hospital outpatients 
Intervention: Combination of oral and topical CHM 
Comparison: Same oral CHM 
Outcomes Illustrative comparative 
risk* (95% CI) 
Relativ
e effect 
(95% 
CI) 
No of 
Participant
s 
(studies) 
Quality 
of the 
evidence 
(GRADE
) 
Comments 
Assume
d risk 
Correspondin
g risk 
CHM 
(oral) 
CHM 
(combination 
of oral and 
topical) 
Total 
effectivenes
s rate 
(Analysis 
3.1) 
Clinician's 
rating 
Follow-up: 
4 to 24 
weeks 
Moderate RR 
1.13  
(0.78 to 
1.63) 
20 
(1 study) 
⊕⊕⊝⊝ 
low
1,2
 
One 
additional 
study did 
not report 
this 
outcome. A 
higher total 
effectivenes
s rate 
indicates 
improvemen
t of the 
condition. 
80 per 
100 
90 per 100 
(62 to 100) 
Overall 
severity 
score 
(Analysis 
3.5) 
Clinician's 
rating. Scale 
from: 0 to 
103 
Follow-up: 
4 to 24 
weeks 
The 
mean 
overall 
severity 
score in 
the 
control 
groups 
was 
21.02 
scores 
The mean 
overall severity 
score in the 
intervention 
groups was 
3.43 lower 
(7.01 lower to 
0.15 higher) 
 20 
(1 study) 
⊕⊕⊝⊝ 
low
1,2
 
Lower score 
indicates 
improvemen
t of the 
condition. 
One 
additional 
study was a 
within 
patient 
design, data 
were 
analysed 
separately. 
QoL 
(Analysis 
3.6) 
Patient's 
rating. Scale 
The 
mean 
QoL in 
the 
control 
The mean QoL 
in the 
intervention 
groups was 
0.9 higher 
 20 
(1 study) 
⊕⊕⊝⊝ 
low
1,2
 
Lower score 
indicates 
better 
quality of 
life, One 
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from: 0 to 
30 
Follow-up: 
4 to 24 
weeks 
groups 
was 
5.8 
scores 
(2.89 lower to 
4.69 higher) 
additional 
study did 
not report 
this 
outcome. 
Adverse 
events 
(Analysis 
3.7) 
Patient's 
report 
Follow-up: 
4 to 12 
weeks 
Moderate RR 1  
(0.07 to 
13.87) 
20 
(1 study) 
⊕⊕⊝⊝ 
low
1,2
 
One 
additional 
study was a 
within 
patient study 
and data of 
adverse 
events were 
analysed 
separately in 
this review. 
10 per 
100 
10 per 100 
(1 to 100) 
Itching 
VAS 
(Analysis 
3.3) 
Patient's 
rating. Scale 
from: 0 to 
10 
Follow-up: 
1 to 2 weeks 
The 
mean 
itching 
VAS in 
the 
control 
groups 
was 
5.76 
scores 
The mean 
itching VAS in 
the 
intervention 
groups was 
1.05 lower 
(1.75 to 0.35 
lower) 
 22 
(1 study) 
⊕⊕⊝⊝ 
low
1,2,3
 
Lower score 
indicates 
improvemen
t of the 
condition. 
This was a 
within 
patient 
study. 
Skin lesion 
score 
(Analysis 
3.4) 
Clinician's 
rating. Scale 
from: 0 to 
24 
Follow-up: 
1 to 2 weeks 
The 
mean 
skin 
lesion 
score in 
the 
control 
groups 
was 
9.05 
scores 
The mean skin 
lesion score in 
the 
intervention 
groups was 
1.59 lower 
(2.92 to 0.26 
lower) 
 22 
(1 study) 
⊕⊕⊝⊝ 
low
1,2,3
 
Lower score 
indicates 
improvemen
t of the 
condition. 
This was a 
within 
patient 
study. 
*The basis for the assumed risk (e.g. the median control group risk across studies) is 
provided in footnotes. The corresponding risk (and its 95% confidence interval) is 
based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI). 
Abbreviations: CI, Confidence interval; RR, Risk ratio. 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the 
estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our 
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confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
 
 
4.10  Overall Completeness and Applicability of Evidence  
Studies with CHM interventions administered orally or applied topically, or a 
combination of both, for children or adults diagnosed with eczema were included. All 
28 included studies have specifically focused on management of eczema with CHM. 
Based on a Chinese medicine description, the selected Chinese herbs in the included 
studies were under categories of “exterior-releasing”, “heat-clearing”, “purgative”, 
“wind-damp-dispelling”, “damp-resolving”, “damp-draining”, “interior-warming”, 
“Qi-regulating”, “digestant”, “haemostatic”, “blood-activating and stasis-resolving”, 
“liver-pacifying wind-extinguishing”, “resuscitative”, “tonifying”, “astringent”, and 
“externally applied and miscellaneous” (Li, 2008). The top seven most commonly 
used herbs were Gancao (Radix glycyrrhizae) (16 studies), Cangzhu (Rhizoma 
atractylodis) (13 studies), Danggui (Radix angelicae sinensis) (11 studies), Baizhu 
(Rhizoma atractylodis macrocephalae) (nine studies), Baixianpi (Cortex dictamni) 
(nine studies), Fuling (Poria) (nine studies) and Shengdihuang (Radix rehmanniae) 
(nine studies). Studies in which the CHM formulae were modified based on Chinese 
medicine syndrome differentiation as well as the studies which only recruited AE 
patients with a pre-specified Chinese medicine syndrome were also included. Many of 
the included studies were conducted in Chinese medicine teaching hospitals or 
general medical teaching hospitals which are expected to have standardised facilities 
and qualified personnel and represent the standard of clinical practice of the 
profession (MEPRC, 1992). The results have reflected the up-to-date management of 
eczema with CHM. The findings of this review could provide a crucial reference for 
current evidence-based Chinese medical practice and research.  
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4.11  Quality of the Evidence 
 
The Grades of Recommendation, Assessment, Development and Evaluation 
(GRADE) system recommended by the Handbook was used to assess the level of 
evidence on outcome measures reported by the included studies (Schünemann et al., 
2011). Overall, the quality of the included studies was poor except the Hon 2007 
study where the level of quality of the evidence was “moderate” in the outcome 
measured by QoL. The majority of the included studies showed unclear risk of bias 
for allocation concealment and high risk of bias due to lack of blinding, thus the 
strength of evidence was downgraded in these studies to “low level” due to serious 
limitations in the design and implementation (absence of allocation concealment and 
blinding). The total 2306 participants within the 28 included studies were diverse with 
their ages ranging from new-born babies to 65 years and most of the studies had 
mixed children with adults. There were heterogeneous Chinese herbs or formulae with 
regard to the ingredients, dosage and administrations in the included studies. This 
contributed to a high level of inconsistency of the outcomes across the studies 
although such underlying sources of heterogeneity have not been confirmed by 
statistical analyses due to insufficiency of data. 
4.12  Potential Biases in the Review Process 
The RCT is a gold standard to test efficacy of an intervention for a defined 
condition within a population (Kane, 2004). It is debatable, however, whether results 
from RCTs can really reflect the intrinsic effect obtained from an individualised 
treatment which is one of the essential features of Chinese medicine practice. For this 
reason, it has scrupulously aimed to include studies using individualised treatments or 
studies only recruiting AE patients with a specific type of Chinese medicine syndrome 
as far as there was an appropriate control group, i.e. with balanced numbers of 
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randomised participants, in the study. Further subgroup analysis was performed in 
those included studies with individualised treatment. The best effort has been tried to 
search for any studies that match the inclusion criteria but it could be still possible 
that some papers, in particular those published in Chinese could have been 
overlooked. This is because as there is limited access to the printed Chinese medical 
journals in the cases where those journals were not collected by the Chinese databases 
searched. It was unable to rule out the possibility of potential language bias in this 
review as Chinese medicine is also popularly used in other Asian countries such as 
Japan, Vietnam and Korea. It was not able to search databases developed by these 
countries. 
The funnel plot presented in Figure 17 and Egger test did not show statistically 
asymmetrical distributions among those 15 studies where effects of CHM and 
Western medications were compared. However, it could not exclude reporting bias 
including publication bias in those 15 studies because of the relatively low power of 
the Egger test (Sterne, Egger, & Moher, 2011). 
4.13  Agreements and Disagreements with Other Studies or Reviews 
The first Cochrane systematic review of CHM for eczema was published in 
2004 (W. Zhang et al., 2004). Only four studies with oral ingestion of a CHM 
product, which is no longer available on market, were included. These studies were 
not included in this updated review. Poor trial quality and "small study effect" were 
found across the included studies in both the version published in 2004 and this 
review. 
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4.14  Authors’ Recommendations  
In summary, a new clinical research priority was identified and well-designed, 
adequately powered, randomised placebo-controlled clinical trials were required to 
evaluate the efficacy and safety of CHM for managing AE. The conduct of such a 
randomised double-blind placebo-controlled clinical trial to test the efficacy and 
safety of a CHM formula for children with moderate to severe AE was the subject of 
the next two chapters. 
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Chapter 5  Protocol of a RCT  
 
The contents of this chapter have been published in the international peer-
reviewed journal: Gu S., Zhang A., Coyle M., Mo X., Lenon G., Cranswick N., Chen 
D., Xue C. (2015) Chinese herbal medicine granules (PTQX) for children with 
moderate to severe atopic eczema: study protocol for a randomised controlled trial. 
Trials, 2015, 16:294. DOI: 10.1186/s13063-015-0806-y. 
 
Section I: General Information of the Trial 
 
5.1  Title and Rationale of the Trial 
The full title of this protocol is Randomised Double-blind Placebo-controlled 
Clinical Trial of Oral Ingestion of Chinese Herbal Medicine Granules for Children 
with Moderate to Severe Atopic Eczema.  
As stated in Chapters 2, 3 and 4, AE is a common chronic skin disorder and 
incidence rate of AE has been increased globally. Conventional medicine for AE is 
not satisfactory and more and more patients with AE look to CHM for management of 
the condition. Although the Cochrane systematic review of CHM for AE conducted 
by Zhang in 2004 found that a certain CHM product might be efficacious for AE; 
results among the included trials were conflicting and inconclusive. The updated 
Cochrane systematic review of CHM for AE in 2013 (details in Chapter 4) found only 
limited evidence that oral ingestion of a CHM formulation could improvement QoL 
for children with moderate to severe AE but not reduced the severity (symptoms and 
signs) of AE (S. Gu et al., 2013). It further suggested seeking for evidence of efficacy 
and safety of CHM for AE through rigorous RCTs. This protocol was been approved 
by the RMIT Human Research Ethics Committee (HREC). 
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5.2 Description of Intervention Used in the Trial 
This trial aimed to evaluate the efficacy and safety of an oral Chinese herbal 
formulation Pei Tu Qing Xin (PTQX) in granule form for children aged six to 16 
years old with moderate to severe AE.  
5.2.1   Preliminary Study of the Trial Medication (PTQX) 
The trial medication PTQX was developed by Professor Dacan Chen 
(Dermatologist and President of Guangdong Provincial Hospital of Chinese 
Medicine) based on the formula QXPTF which has been used for children 
with AE since 2006 (D. Chen & Liu, 2009; Huang, Liu, & Chen, 2010; Sun, 
2006). The formula was created according to Chen’s understanding of AE 
pathogenesis in infants and children (see Chapter 2.10.5), then it was 
recommended by the expert consensus 2013 (see Chapter 2.12.1 and Table 3 ) 
(D. Chen et al., 2013). The formula in its raw herbs was evaluated via an RCT 
conducted in the Department of Dermatology, Guangdong Provincial Hospital 
of Chinese Medicine between 2008 and 2011. The trial was listed as one the 
four ongoing studies in the Cochrane systematic review 2013 as the trial was 
concluded but no report of the trial was published by the time of completion of 
the Cochrane systematic review (see Chapter 4.6.5 and Table 13). The trial 
report was finally published in 2015 (Liu et al., 2015). It recruited a total of 
250 adults and children aged five to 25 years old with moderate to severe AE 
and treated with decoction of Pei Tu Qing Xin Tang (PTQXT) (n=83) or 
PTQXT combined with topical usage of CHMs which contained with 
Jinyinhua (Flos Lonicerae), Huangjing (Rhizoma Polygonati), Bohe (Herba 
Menthae) and Gancao (Radix Glycyrrhizae) (n=84) or topical usage of 0.1% 
mometasone furoate cream (n=83) for 12 weeks. The trial investigators 
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claimed that PTQXT was effective to decrease the AE severity and improve 
the QoL. No serious adverse event (SAE) has occurred during the 12 weeks 
treatment period and 24 weeks follow-up in the participants recruited. All full 
blood examination (FBE), liver and renal function tests were normal on 
baseline and endpoint.  
The formula was further prepared as CHM granules and were protected 
by patent in 2013; however, its efficacy and safety for AE needs to be 
evaluated through RCTs (see Chapter 4.6.5 and Table 13)(D. Chen, 2013). 
While the main herbs of the formula remain the same; the name of the formula 
was changed from QXPTF to PTQXT and finally to PTQX granules during its 
development. PTQX granules or simply PTQX which has a set of nine 
ingredients was used for the trial medication in the project. Figure 18 
summaries the process of evidence chain of PTQX collected from this project. 
 
Figure 18 Process of evidence chain of PTQX 
 
 
Expert opinion since 
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•Evidence collected 
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5.2.2   Ingredients of PTQX 
PTQX granules include extracts from nine Chinese medicinal substances. 
Table 20 lists the ingredients of PTQX granules.  
 
Table 20 Ingredients of PTQX granules 
 
English Name Pharmaceutical 
Name 
Scientific Name 
(Australian TGA 
Approved Name)  
 
Chinese 
Characters 
and Phonetic 
Writing (Pin 
Yin) 
One Dosage 
(12 grams) of 
PTQX equals 
to raw herb 
(gram) 
Largehead 
Atractylodes 
Rhizome 
Rhizoma 
Atractylodis 
Macrocephalae 
Atractylodes 
macrocephala 
白术 
Bai Zhu 
10 
Heterophylly 
Falsestarwort 
Root 
Radix 
Pseudostellariae 
Pseudostellaria 
heterophylla 
太子参 
Tai Zi Shen 
10 
Common Yam 
Rhizome 
Rhizoma 
Dioscoreae 
Dioscorea 
opposita 
山药 
Shan Yao 
15 
Coix Seed Semen Coicis Coix lachryma-
jobi 
薏苡仁 
Yi Yi Ren 
20 
Lalang Grass 
Rhizome 
Rhizoma 
Imperatae 
Imperata 
cylindrica 
白茅根 
Bai Mao Gen 
15 
Weeping 
Forsythia 
Capsule 
Fructus 
Forsythiae 
Forsythia 
suspensa 
连翘 
Lian Qiao 
10 
Liquorice Root Radix 
Glycyrrhizae 
Glycyrrhiza 
glabra 
甘草 
Gan Cao 
5 
Densefruit 
Pittany Root-
bark 
Cortex Dictamni Dictamnus 
desycarpus 
白藓皮 
Bai Xian Pi 
10 
Pearl Powder Margarita Pteria martensii 
(Dunker） 
珍珠粉 
Zhen Zhu 
Fen 
0.3 
Abbreviations: PTQX, Pei Tu Qing Xin; TGA, Therapeutic Goods Administration.  
 
In CHM theory, Bai Zhu has the function of strengthening the spleen and Lian 
Qiao can clear away the heart fire and remove toxins. These two herbs serve 
as sovereign (jun 君) herbs. Bai Mao Gen is used to cool the blood and reduce 
swelling by promoting diuresis. Tai Zi Shen, Yi Ren and Shan Yao have the 
function of strengthening the spleen and eliminating dampness. These four 
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substances act as minister (chen 臣) herbs to further enhance the effects of the 
sovereign herbs. Zhen Zhu Feng calms the mind and extinguishes the wind. 
Bai Xian Pi has the function of clearing away heat, drying the dampness, 
expelling the wind and easing itchiness. These two ingredients work as 
assistant (zuo 佐) role in the formula. Can Cao is a guide (shi 使) herb as it 
harmonises all ingredients of the formula (D. Chen, 2013).  
5.2.3   In Vivo Studies of PTQX 
Evidence from in vivo studies has shown that Atractylodis Macrocephalae and 
Semen Coicis could improve the immune function by increasing the IL-1 or 
IL-2; Fructus Forsythiae and Radix Glycyrrhizae have the action of anti-
inflammatory in mice (Shen, 2000). A recent pharmacodynamics research 
showed that PTQX can reduce skin itchiness on histamined guinea pig, 4-
aminopyridined mouse and dextraned mouse (X. Mo et al., 2015). Another in 
vivo study that proved PTQX has anti-inflammatory effect by reducing 
swelling of xylened mouse ear, inhibiting abdominal cavity capillary 
permeability in aceticacided mouse and cotton pellet induced granuloma in 
rats (XM. Mo et al., 2015)． 
5.2.4   PTQX Safety 
All of the above medicinal substances except pearl powder are listed on the 
Therapeutic Goods Administration (TGA) Approved Terminology for 
Medicines (TGA, 1999). The pearl powder is listed on Australian Register of 
Therapeutic Goods (ARTG) (http://search-
au.funnelback.com/s/search.html?query=pearl+powder&collection=tga-artg, 
accessed on 23 January 2014). All of the substances are traditional Chinese 
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medicinal substances and have been used safely for hundreds of years. None 
of the substances are within the “Eighteen mutually antagonistic ingredients” 
or “Nineteen mutually incompatible ingredients” based on traditional Chinese 
herbal medicine theory (P. Chen & Zheng, 1997). None of them are listed on 
the Updated listing of restricted Chinese herbs September 2012 issued by the 
Chinese Medicine Board of Australia 
(http://www.chinesemedicineboard.gov.au/Codes-Guidelines.aspx accessed on 
23 January 2014) nor in the Poisons Standard published and updated annually 
by TGA. No adverse reactions have been reported in other clinical studies in 
which the interventions contain these substances(Huang et al., 2010). In 
addition, no evidence has found that individual ingredients of PTQX adversely 
interact after searching TGA’s official website (www.tga.gov.au) for 
“Medicines Safety Update” and databases such as Google Scholar, PubMed 
and cnki.net in Chinese as well as hand searched the monographs including 
“Herbal Supplements : Efficacy, Toxicity, Interactions with Western Drugs, 
and Effects on Clinical Laboratory Tests”; “Stockley's Herbal Medicines 
Interactions: A Guide to the Interactions of Herbal Medicines”; “Herbal-drug 
interactions and adverse effects: A Evidence-based Quick Reference Guide”; 
“Herb Toxicities & Drug Interactions: A Formula Approach” and “Herb, 
Nutrient, and Drug Interactions: Clinical Implications and Therapeutic 
Strategies”.  
5.3 Statement of Compliance 
This protocol was prepared according to the guidelines of Australian Clinical 
Trial Handbook issued by TGA, Department of Health and Ageing, Australian 
Government (TGA, 2006) and followed the Nine CONSORT Checklist Items for RCTs 
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of Herbal Medicines recommended by the Consolidated Standards of Reporting Trials 
(CONSORT) Group(Gagnier et al., 2006). The protocol has been approved by the 
RMIT HREC with approved number: 08/14 (RM: 18633) (Appendix 1). The trial has 
been registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) 
with trial ID: ACTRN12614001172695 (Appendix 2) and a Clinical Trial Notification 
(CTN) has been filed with TGA with file number: 2014/033590 (Appendix 3). This 
trial was conducted strictly in compliance with the protocol, principles of 
International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) Note for Guidance on Good 
Clinical Practice (GCP) and its relevant requirements.  
5.4 Trial Objectives  
The primary objective of this trial was to evaluate efficacy of oral ingestion of 
PTQX in children with moderate to severe AE. It also assessed the safety of PTQX 
for children with AE.  
Section II: Methods 
5.5 Trial Design 
This 16-week randomised double-blind, placebo-controlled; two-arm parallel 
clinical trial includes 12 weeks of treatment and a four-week follow-up period. Figure 
19 illustrates the flowchart of the trial.   
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Figure 19 Flowchart of the trial 
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5.6 Randomisation 
 
Block randomisation method was employed with balanced variable blocks. 
Equal numbers of participants received the real treatment and the inert vehicle (the 
placebo). Randomisation codes were generated by a computer program by an 
independent statistician who was not directly involved with the trial. 
5.7 Blinding 
 
Neither trial participants nor investigators knew whether the treatment was 
real or placebo. The randomisation codes were concealed into individual opaque 
envelopes which will be sequentially numbered and opened only after participant’s 
IDs were written on the envelope. An emergency unblinding envelope with identical 
contents was prepared in case a serious adverse event (SAE) occurs during the 
treatment period. At the time of randomisation (Visit 1, Week 0), each participant was 
asked to choose one sealed envelope from the pack. The envelopes were opened by a 
CHM dispenser, who is a registered CHM practitioner or registered CHM dispenser. 
The CHM dispenser then handed over the pre-packed container of either PTQX or 
inert vehicle sachets to the participant and provided the participant with verbal and 
written instructions of usage of the interventions (Appendix 4). The containers were 
identical in appearance and labelled. The trial medication (both PTQX and placebo) 
was pre-packaged and labelled corresponding to the randomisation schedule prior to 
study initiation. The CHM dispenser recorded information including participant’s ID, 
sequential number of the container and randomisation code on a Record Sheet of 
Dispensary (Appendix 5). The code was not revealed to participants and personnel 
who were involved in data entry and data analysis. In case of a SAE where immediate 
cessation of trial intervention is required, the emergency unblinding envelope will be 
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opened for further investigation of the nature of the event by the trial investigators. A 
partial unblinding for group allocation of the participants applied once all data of the 
trial were collected for statistical analysis and full unblinding for final finding 
interpretation.  
5.8 Preparation of the Interventions 
 
5.8.1   Treatment Intervention 
 
The treatment intervention, PTQX was prepared by Jiangyin Tianjiang 
Pharmaceutical Co. Ltd, an appointed CHM extract granules manufacturer 
with Good Manufacturing Practice (GMP) certificate 
(http://www.tianjiang.com/index.php?ctl=about&id=8 accessed on 17 January 
2014). PTQX was packaged in a paper sachet with a label including the pre-
specified information (Appendix 6).  
5.8.2   Control Intervention 
Placebo granules were provided to participants in the control group. The 
placebo was made of maltodextrins and lactose. The smell, colour and 
packaging of the placebo were as close to PTQX as possible. The placebo was 
also prepared by Jiangyin Tianjiang Pharmaceutical Co. Ltd. 
5.8.3   Administration Dosage and Total Dose of the Interventions 
PTQX was be given four grams twice daily with a total of eight grams for six 
to seven years and six grams twice daily with a total of 12 grams for eight to 
16 years old participants by oral ingestion. Each participant needed eight to 12 
grams of PTQX daily for 84 days. Thus, the total dose of PTQX or placebo 
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was 672 grams for the participants age six to seven years and 1008 grams for 
those who were eight to 16 years. 
5.8.4   Quality Control and Quality Assurance of the Interventions 
The intervention products (PTQX and placebo) were manufactured by an 
appointed GMP licensed manufacturer as mentioned on subheading 5.8.1 
above. This included the identification of products, quality and safety testing. 
The raw herbs were mixed, cooked twice with water, filtered, concentrated, 
spray-dried and mixed with sucralose and pearl powder (Margarita powder) 
and finally forming granules (PTQX). They were packaged in small sachets 
weighing 2g each. A sample batch of PTQX was tested for microorganism and 
was deposited in the manufacturer for traceability. Quantity of phillyrin, one 
of the compounds identified from Fructus Forsythiae, measured by High 
performance liquid chromatography (HPLC) was suggested as a quality 
standard of PTQX (Mo et al., 2013; Xue, Chen, Tan, Liu, & Mo, 2013). In 
addition, fingerprint profile of PTQX has been established by using ultra-
HPLC with high-resolution, multiple stage fragmentation (UHPLC-HR-MS
n
)
 
profiling method for further study of the active compounds of the formula. 
5.9 Selection and Withdrawal of Participants 
 
 Participants were recruited through advertisement (Appendix 7) in local 
papers, posters, via the Internet, schools’ Newsletter and through referrals from 
general practitioners (GPs) or dermatologists. Trial information flyers could be placed 
in offices of GPs or dermatologists who agree to refer patients to the trial. Contact 
details of the potential participants were recorded on expression of interest in the trial 
(Appendix 8). The Participant Information and Consent Form (PICF) and Informed 
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Assent Form with information of the trial including the purpose of the trial, about the 
intervention, potential adverse reaction and ethical issues were given to potential 
participants (Appendix 9). All potential participants or their guardians were provided 
with the PICF (for those children who can read, an Informed Assent Form were given 
to sign) as well as General Information Questionnaires (Appendix 10). The PICF was 
developed in compliance with guidelines issued by RMIT HREC. Potential 
participants were interviewed to assess eligibility against the inclusion and exclusion 
criteria (Appendix 11) in order to select suitable participants for the trial 
(Screening/run-in period). 
 5.9.1 Selection Criteria  
1) Inclusion Criteria  
The U.K. Working Party’s diagnostic criteria and the NESS (Appendix 12) 
were adopted for inclusion in this trial (C. Charman, Chambers, & Williams, 
2003; Emerson et al., 2000; H. C. Williams, Burney, Hay, et al., 1994) 
a. Diagnosis of the condition: 
o History of skin pruritus in the last 12 months plus three or more of the 
any followings; 
o Onset under the age of two;  
o History of flexural involvement; 
o History of generally dry skin; 
o Personal history of other atopic disease such as asthma or hay fever;  
o Visible flexural dermatitis  
b. Severity of AE 
The total score of NESS ≥ 9 (moderate to severe) in baseline 
measurement; 
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c. Age: from six to 16 years old; 
d. Completion of informed consent form. 
 2) Exclusion Criteria  
a. Use of systemic corticosteroids, other systemic immunosuppressives, or any 
preparation of CHM or other herbs for treatment of AE orally in the past 30 
days;  
b. Diagnosis of scabies, allergic contact dermatitis, seborrhoeic dermatitis or 
psoriasis; 
c. Under six years or over 16 years old; 
d. Severe medical conditions such as cardiovascular, liver or renal 
dysfunction; 
e. History of lactose intolerance.  
 5.9.2 Withdrawals and Dropouts 
Without providing reasons, participants were allowed to withdrawal at any 
time during the trial. However, withdrawal (a trial investigator’s decision to 
stop participating) or dropout (a participant or guardian's decision on his/her 
own to stop participating) of participant were followed up to investigate the 
time and reason of withdrawal (Appendix 13). ITT analysis was performed on 
missing data with the Last observation carried forward (LOCF) method. 
 5.9.3 Discontinuers 
Participants would be advised to discontinue the treatment if there was a 
product-related adverse event of a serious nature or if the participant was not 
compliant with the trial procedure i.e. using corticosteroid orally during the 
treatment period. Using topical corticosteroids was allowed for those 
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participants who have been using them before participation in the trial, and 
whose skin condition worsened during the trial treatment period. However, the 
same drug and dosage of the drug should be recommended and medication 
record was well documented. All discontinuers would not be replaced by new 
participants. ITT analysis was performed on missing data from discontinuers 
with the LOCF method. 
5.10 Sample Size 
The following sample size calculation was for a full RCT which will be 
proposed in future. Such a trial will test the efficacy of a CHM intervention by 
measuring the changes of EASI scores between the CHM and placebo groups (J. M. 
Hanifin et al., 2001). The difference of estimated effect between the PTQX and 
placebo groups was set to based on data from a previous published study (Ma, Sun, 
Wang, Zhang, & Cai, 2010) where the outcome measured mean and SD of the EASI 
score was 7.4 ± 3.3 and 9.6 ± 4.1 for active treatment and control group respectively. 
To achieve a 90% power (β = .10), significance level of 0.05 (α) in a 2-tailed test, 
calculated by using GPower 3.1.2, based on an estimated 10% dropout rate, 62 
participants were needed for each group, that is a total of 124 for the trial. Thirty 
participants were recruited in a pilot study to test the feasibility of a full-scale trial. 
5.11 Screening/run-in, Baseline, Treatment Periods and Endpoint 
 5.11.1 Screening and Run-in Period 
Eligible participants undertook a two-week run-in period (Week -2 and -1) 
prior to randomisation at Week 0. The run-in period was also be considered as 
the screening period as only those participants who have met the inclusion and 
exclusion criteria delineated on subheading 5.9.1 could go into the treatment 
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periods. A folder with Case Report Forms (Appendix 14) was set up for each 
participant.  
 5.11.2 Baseline  
EASI score and other baseline outcome assessments were measured for 
eligible participants at Visit 1 (Week 0). 
 5.11.3 Treatment Periods 
Oral ingestion of the trial medication was used twice daily for 12 weeks. The 
products were supplied to participants at Visit 1 (Week 0), Visit 2 (Week 4) 
and Visit 3 (Week 8) respectively. 
 5.11.4 Endpoint 
The endpoint was set at Visit 4 (Week 12) of the trial period.  
5.12 Outcome Measures 
 
As stated in Chapter 2.8.6, a consensus has been reached by HOME that an 
RCT in AE should include the following CODs: clinical sign, symptoms, long-term 
control of flares and QoL and these CODs should be measured with their relevant 
COMIs. This trial adopted these recommendations for its outcome measures. 
5.12.1 Primary Outcome Measure 
The primary outcome measure to test the efficacy of the treatment intervention 
and placebo was the comparison within or between groups at change of 
severity of the condition measured with the EASI score (Barbier et al., 2004; J. 
M. Hanifin et al., 2001) (Appendix 15). 
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5.12.2 Secondary Outcome Measures 
Secondary outcome measures included changes within or between groups in 
symptoms by measuring the score of the POEM (C. R. Charman et al., 2004) 
(Appendix 16). QoL index score was measured by using the CDLQI (Lewis-
Jones & Finlay, 1995) (Appendix 17). Permission to use this instrument for 
the trial has been provided from the original authors. Number of days using 
concomitant conventional medicines such as topical application of 
corticosteroid creams and the total dosage of those concomitant conventional 
medicines were recorded for evaluation of whether PTQX could possess the 
sparing effect of corticosteroids. 
The EASI, POEM and QoL index scores were recorded at Visit 1 (Week 0), 
(before treatment commences); Visit 2 (Week 4) and Visit 3 (Week 8) during 
the treatment period; Visit 4 (Week 12) at the end of the treatment and Visit 5 
(Week 16) which was at 4-week after stopping the treatment (follow-up 
period) respectively. A Daily Medical Record Sheet (Appendix 18) was given 
to the participants or their guardians to record the details of administration of 
the trial medication. This daily sheet also recorded the usage of any other 
concomitant medications with their names and dosage which should be used 
as one of the secondary outcome measures if the two groups have used the 
same concomitant medication. Other secondary outcome measures included 
FBE with eosinophil counts and total IgE (an objective biomarker of AE) 
levels at Week 4, and end of the 12-week treatment period respectively. 
Both primary and secondary outcome measures (except the blood tests which 
only be taken at the screening period, Week 4 and endpoint) were assessed and 
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recorded on an Outcome Measures Sheet (Appendix 19) at each appointed 
time by the trial investigators when the participants visited the trial laboratory.  
5.12.3 Assessment of Safety 
Safety of the intervention products was monitored by way of any adverse 
reactions observed by the participants or their guardians or the trial 
investigator. Blood samples from participants were collected by a qualified 
blood collector at the screening/run-in period, Visit 2 (Week 4), and Visit 4 
(Week 12) of the trial for liver and renal function tests. Blood tests were 
conducted in a credited pathology laboratory, Dorevitch pathology. The 
volume required for the FBE was 4 ml and for the liver and renal function 
tests and IgE is 8.5 ml with a total of 12.5 ml of blood at each session of blood 
collection (Appendix 20).  
Details of the adverse event should be recorded on Adverse Event 
Questionnaires (Appendix 21) and medical advice from a medical officer 
should be given to any case with a SAE.  
In case of any adverse events, the chief investigator would manage such 
events in compliance with the Guidance: Safety monitoring and reporting in 
clinical trials involving therapeutic goods issued by the National Health and 
Medical Research Council (NHMRC) (NHMRC, 2016). The chief trial 
investigator would report any SAE occurs in the locate site to the sponsor 
within 24 hours and all significant safety issues and suspected unexpected 
serious adverse reaction (SUSAR) arising from the local site to RMIT HREC 
within 72 hours. 
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5.12.4 Assessment of Participant Compliance  
Participant compliance was monitored each time when participants re-visit the 
trial laboratory (Appendix 22). Participants were followed up for compliance 
with trial medication usage during the trial period and four weeks after the end 
of treatment period; participants were followed up for further outcome 
measurements.  
5.12.5 Survey of Participation of the Trial 
Participants or their parents/guardians filled in survey questionnaires 
(Appendix 23) for assessments of tolerability of the PTQX, quality of blinding 
method and willingness of re-use the PTQX in future.  
Table 21 summaries the schedule of the trial and provide a summary list for 
primary and secondary outcome measures. 
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Table 21: Schedule of the Trial 
 
Items Title of the Documents Screening/run-in 
Period 
Visit 1 
(Baseline) 
Visit 2 Visit 3 Visit 4 
(Endpoint) 
Visit 5 
(Follow-up) 
Week of the trial  -2, -1 0 4 8 12 16 
Demographic 
information 
taking 
1. Record Sheet for Potential 
Participants  
2. General Information Questionnaires 
+      
Informed 
consent form 
PICF +      
General medical 
history taking 
General Information Questionnaires  +      
Severity of AE 
for inclusion and 
exclusion of the 
participants  
Inclusion/Exclusion Criteria +      
Blood tests Pathology Tests +  +  +  
Clinical sign of 
AE 
Assessment Form for EASI  + + + + + 
Symptoms Assessment Form for POEM  + + + + + 
QoL score CDLQI  + + + + + 
Distributions of 
treatment or 
placebo 
products 
Record Sheet of Dispensary  + + +   
Daily medical 
record  
Daily Medical Record Sheet + + + + + + 
Monitor of 
adverse event 
Adverse Event Questionnaires + + + + + + 
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Abbreviations: AE, Atopic Eczema; CDLQI, Children’s Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; QoL, Quality of Life; 
PICF, Participant Information and Consent Form; POEM, Patient-Oriented Eczema Measure.  
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5.13 Statistics 
 
Data were analysed by using software of Statistical Package for the Social 
Services (SPSS) (IBM SPSS version 22). Data from continuous variables (i.e. EASI, 
POEM and QoL scores) were expressed as mean and SD. Comparisons of difference 
of means between the intervention and placebo group at Week 12 and Week 16 of the 
trial were expressed as MD with 95% CI. Independent-samples t-test (Student’s t-test) 
was performed for normal distributed data and non-parametric tests for skew 
distributed data. Chi-squared or Fisher’s exact test was performed for comparison of 
dichotomised data and will be expressed as RR with 95% CI (Witt & Linde, 2011). 
All comparisons were made in 2-tailed and p-values < 0.05 was considered to be 
statistically significant. ITT analysis was performed on missing data as stated on 
Chapter 5.9. Interim analysis and earlier stopping of the trial would be activated if a 
series of SAE that may potentially affect the safety of all participants was reported.  
5.14 Data Identification and Confidentiality 
 
The participant’s name, gender, date of birth, body weight, body height, 
medical history and contact details will be collected. Participants’ information will be 
retained for 15 years in a secured locked archive in the RMIT clinical trial laboratory 
and will be disposed under the guidelines of “NHMRC (Joint National Health and 
Medical Research Council) / AVCC (Australian Vice-Chancellor’s Committee) 
Statement and Guidelines on Research Practice” (NHMRC, 1997). Digital data will 
be kept in a secured archive (eczema trial H: drive, a unique H: drive allocated for this 
trial) in the RMIT clinical trial laboratory. Only the investigators have access to the 
data. However, the investigators will permit trial-related monitoring by authorities, 
review by RMIT HREC, and regulatory inspection, providing direct access to source 
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data/documents for such monitoring, review or inspection. Data containing 
participant’s personal information will not be sent by email. Only de-identified data 
will be encrypted. Data will not be sent to outside of RMIT for analysis unless 
encryption system is used for prevention of unauthorised access. All personal 
information will remain in trial sites.  
Procedures will be in place to manage, monitor and report adverse and/or 
unforeseen events relating to the inappropriate release of personal information during 
its collection, use or disclosure. All participants will be required to fill out the forms 
including “General Information Questionnaires” and “PICF” accurately in terms of 
personal information. Any correction of personal information must be signed by a 
trial investigator and the original entry must be still visible. Headers containing 
“Participant’s initial”, “Participant’s ID” and “Date” are included on relevant forms 
such as “Assessment form for EASI score” for participant to fill out. The trial 
investigators or supervisors will cross check the correctness of participant’s personal 
information. All data containing personal information will be kept in a secured locked 
archive in the RMIT clinical trial laboratory. A USB memory device with backup of 
digital data will be kept separately from the main computer system (eczema trial H: 
drive) where a password is created for purpose only the investigators have 
authorisation to access the data. The chief investigator will have his obligation to 
report any of the adverse events relating to the inappropriate release of personal 
information during the trial period to the RMIT HREC immediately. 
5.15 Trial Investigators and Other General Information 
 
The trial investigation team members will come from different academic 
backgrounds. The trial investigators, who are in charge of history taking, input of 
inclusion/extrusion criteria questionnaires forms will be registered Chinese medicine 
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practitioners. Two experts, Professor Dacan Chen who is a western medicine and 
Chinese medicine dermatologist and Associate Professor Noel Cranswick who is a 
paediatrician and clinical pharmacologist, are appointed for providing medical expert 
advice. The trial will be sponsored by the China-Australia International Research 
Centre for Chinese Medicine and the School of Health Sciences, RMIT University. 
The trial will be conducted at RMIT University Health Sciences Research Hub 
(Clinical Trial Laboratory) - Building 201 Level 3 Room 201.3.17C, RMIT 
University, Plenty Road, Bundoora Victoria 3083 Australia or in a collaborating trial 
centre who has signed an agreement for RCT with the trial sponsor.  
5.16 Institutional Ethics Approval  
 
The investigators submitted an application to RMIT HREC for approval prior 
to conducting the trial.  
5.17 Publication Policy 
 
Manuscript of the trial report would be submitted to a professional journal for 
publication and/or academic conference once the trial is concluded. None of the 
information related to the privacy of the participants such as their names or contact 
details would be released in any publication or presentation. 
5.18 Financing and Insurance 
The sponsor of this trial arranged financial support for conduction of the trial. 
The RMIT University was responsible for public and products liability insurance 
covering legal liability of the insured to pay damages or compensation in respect of 
personal injury or damage to property as a result of an occurrence happening in 
connection with the trial. No conflict of interest has been identified from the trial 
investigators and the institutions they work for. 
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Section III: Discussion 
 
This protocol outlined the necessity and feasibility for assessing the efficacy 
and safety of oral ingestion of CHM granules (PTQX) for AE in the form of RCT 
with a pre-calculated sample size. A randomised double-blind, placebo-controlled 
parallel groups clinical trial has been well accepted by the research profession as a 
gold standard method for evaluation of efficacy and safety of an intervention (Kane, 
2004; Vincent, Furnham, & Richardson, 1997) Thus this trial was proposed to be 
designed as an RCT with blinding to avoid potential risk of bias in outcome measures. 
The endpoint was set at Visit 4 (Week 12), after the applications of the last dose of 
trial medication. The trial was concluded at Visit 5 (Week 16), the follow-up period 
which was in four weeks following cessation of trial medication.  
Recruitment of participants was restricted to the age of six to 16 years old as 
the prevalence of AE has increased over the last 10 years especially in those aged six 
to seven years. The commonly quoted Hanifin’s diagnostic guidelines were not 
chosen for the diagnosis of AE because its minor criteria require an ophthalmologist 
to determine the condition. This was beyond the research resources at this stage. Only 
those potential eligible participants (PEPs) who were assessed with moderate to 
severe AE for which the total score of NESS was at nine or greater would be 
included. A two-week screening and run-in period was designed for selection of 
participants for purpose of washing out any potential sparing effect of medication that 
eligible participants had token before being randomised. EASI and other outcome 
measures were measured according to the designed time points. The mean score of 
those measures at Visit 1 (Week 0) was used as baseline measure. The EASI would 
also be used as the primary outcome measure to test whether PTQX could improve 
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the severity of AE. Changes of POEM, QoL index and other items within or between 
groups were used as secondary outcome measures.  
This protocol was compiled based on the Nine CONSORT Checklist Items For 
RCTs of Herbal Medicines with emphasis on checklist Item 4 for reporting 
randomised, controlled trials of herbal medicine interventions recommended by the 
CONSORT Group (Gagnier et al., 2006). Checklist Item 4 includes 4A: Herbal 
medicinal product name, 4B: Characteristics of the herbal product, 4C: Dosage 
regimen and quantitative description, 4D: Qualitative testing, 4E: Placebo/control 
group and 4F: Practitioner. All key issues on the Item 4 have been elaborated in this 
protocol.  
The ultimate purpose of this trial was to test the efficacy and safety of PTQX. 
Further evaluation of the pharmacological action of PTQX could be conducted once 
the potential clinical efficacy is proved by this trial.  
 A feasibility study with five participants was conducted in RMIT Clinical 
Trial Laboratory (n=2) and Guangdong Provincial Hospital of Chinese Medicine 
(n=3) for a pilot study with 30 participants recruited in Guangdong Provincial 
Hospital of Chinese Medicine. The actual mean and SD of EASI score collected from 
the pilot study would be used for re-calculation of the sample size for a full-scale trial 
in future. The results of the pilot study are presented in next chapter. 
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Chapter 6  Results of a Feasibility Study and a Pilot 
Study 
  
Section I: Feasibility Study for the Trial 
 
6.1  Preparation  
 
 To efficiently implement the pilot study (trial) protocol (which was approved 
by RMIT HREC), the trial team held a series of meetings over 5 August 2014 to 21 
July 2015 including two video conferences with the trial co-investigators in 
Guangdong Provincial Hospital of Chinese Medicine, China. These meetings 
addressed trial medication labelling; randomisation; emergency unblinding procedure; 
reporting of adverse event including notification of any SAE to HREC and TGA; 
assessment of consistence of packing; labelling and overall differences between the 
herbal granules and placebo; trial medication dispensing and logistic issues; strategy 
for recruitment of participants and dry run (practice) of the trial. As a result a  set of 
standard operating procedure (SOP) were developed, including SAE Report Form 
(Appendix 24), Script of Introduction of the trial (Appendix 25), Task distribution 
checklists for the trial (Appendix 26) and Instruction for recording topical medication 
(Appendix 27). Also discussed was the feasibility of conducting the trial in 
Guangdong, China in case there was insufficient number of participants in Australia.  
6.2 Report of the Feasibility Study 
 
A first round promotion campaign commenced in March and May 2015. In 
order to promote the trial, the campaign issued a media release, placed advertisements 
in local newspapers, in four editions of the weekly local primary school newsletter 
and in Oz Kid magazine, sent a message to the Eczema Association Australasia (EAA) 
and to members of a Chinese medicine association, distributed flyers on RMIT 
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Bundoora campus, participated in an SBS radio interview, and also created a website   
(https://www.rmit.edu.au/news/newsroom/media-releases-and-expert-
comments/2015/march/herbal-trials-a-first-for-psoriasis-and-eczema accessed on 21 
March 2018). A total of 19 enquiries were received (nine from local newspaper, one 
from school newsletter, one from flyer displayed on RMIT campus, five from internet, 
two from members of Chinese medicine professional association, one from SBS 
radio). Among those 19 potential eligible participants (PEPs), there was only one boy 
eventually entered screening stage and eligible for participation of the trial (Table 22). 
 
Table 22 Reasons of exclusion of PEPs at the first round campaign  
 
Number of exclusion Reason of exclusion 
2 Not for attending the trial 
5 Adults 
1 4 years old 
2 Lived in other state and reluctant to 
travel to Melbourne for the trial 
1 Busy and not able to participate the 
trial 
2 Requested for guarantee for allocation 
in the real treatment group 
5 No response after sending out the PICF 
Abbreviation: PICF, Participant information and consent form. 
A second round campaign for the trial commenced in June and July 2015, and 
placed advertisements on larger marking divisions including the local newspapers; 
newsletters issued by the local primary schools (31 primary schools in Bundoora and 
surrounding suburbs were approached for permission to advertise in their newsletter; 
two were agreeable, two rejected the proposition and the rest (27) did not respond); 
sent out message to members of a Chinese medicine association again; posted study 
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protocol and message on social media (WeChat) and sent letters and flyers to one 
dermatologist and six local medical centres (one returned the mail and flyer). 
Advertisements were also placed along with an editorial in the newsletter (Spring 
edition) issued by the EAA. A total of 20 enquires were made (one from local 
newspaper from the one same as at first round campaign, two from internet, one from 
a GP who practises in New South Wales and read message from the trial promotion 
website, three from social media, one from Chinese medicine association, eight from 
a local swimming group, one from RMIT teaching clinic, one from EAA and two did 
not inform). Among those 20 PEPs, there was only one boy met the inclusion criteria 
and eligible to participate the trial (Table 23). Finally, two participants were recruited 
from the RMIT trial centre from the first and second round campaigns. 
 
Table 23 Reason of exclusion of PEPs at the second round campaign 
 
Number of exclusion Reason of exclusion 
7 Not willing to participate in the trial 
2 Adults 
4 2-4 years old 
3 Mild AE 
2 Lived in other state and reluctant to 
travel to Melbourne for the trial 
1 Refused to have blood tests 
Abbreviation: AE, atopic eczema.  
The trial team analysed the low recruiting rate of participants and found that 
there are many reasons that have contributed to the difficulties in recruiting 
participants in Australia. For example the sheer population differences, the awareness 
of CHM as a health intervention, cultural familiarity. Thus the feasibility study was 
extended to Guangdong, China. The GPHCM ethics committee approved the protocol 
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which was developed based on the RMIT HREC approved-protocol on 11 December 
2015 (Appendix 28). A feasibility study was conducted in GPHCM and its other two 
affiliated hospitals referred PEPs to the trial in Guangzhou, China and five 
participants (two in Australia + three in China) age from 10 to 14 years old were 
randomised and four completed the trial by 25 July 2016. 
A SAE occurred on 1 April 2016 in the feasibility study conducted in 
GPHCM. The SAE was reported to the GPHCM Ethics Committee and managed in 
accordance with their rules.  The participant was discharged from GPHCM with fully 
recovery. The participant was an 11 years old girl randomised into the placebo group 
and started to take the trial medications on 6 March 2016. On 1 April 2016, her 
parents requested their child to be treated in the in-patient department (i.e. 
hospitalised) of GPHCM as the child’s AE condition had not been improved after 
taking the trial medications for 26 days. The trial investigator in GPHCM reported 
this as a SAE to the Ethics committee on 5 April 2016 and stated that reasons of the 
no improvement of the skin condition could be: 1). AE is a chronic disease and needs 
a longer period of treatment; 2). The relapse of AE could be induced by living 
environment, diet and emotional factors and 3). The trial medications could be 
placebos. The GPHCM Ethics Committee replied on 5 April 2016 and approved for 
continuity of the trial. The participant was hospitalised on 1 April 2016 and treated 
with both CHMs and conventional medicines and discharged on 9 April 2016 with 
significant improvement of AE. The participant filled in a completion form for the 
trial. For the purposes of this study this participant was considered as a dropout so no 
further action was taken. The SAE was also reported to RMIT HREC. 
Data obtained from the feasibility study were processed with the methods 
outlined in Chapter 5.13. The feasibility study with five participants shown balance in 
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baseline characteristics (Table 24). Calculation of significance level of the outcome 
measures on the feasibility study was indicative only (Table 25). The feasibility study 
also recorded a good compliance rate of taking the trial medications as well as high 
credibility of blinding (Table 26).  
 
Table 24 Demographic characteristics of included participants in feasibility 
study 
 
 
Variable 
PTQX 
(n = 3) 
Placebo 
(n = 2) 
Significance 
Mean±SD 
Age, years 12.67±2.31 11.50±0.71 t = 0.66 p = 0.55 
Weight, kg  49.63±18.19 43.80±11.60 t = 0.39 p = 0.72 
Height, cm 158.67±13.32 147.00±11.31 t = 1.01 p = 0.39 
NESS 12.33±3.06 13.50±2.12 t = 0.46 p = 0.68 
 
Number of participants Significance 
Gender 
Male 2 1 
X2 = 0.14 p = 0.71 
Female 1 1 
Trial site 
China 2 1 
X2 = 0.14 p = 0.71 
Australia 1 1 
Allergies  
Seafood 2 0 
X2 = 2.92 p = 0.23 Other 1 1 
No 
allergy  
0 1 
Parents’ 
history of 
atopy 
No 1 1 
X2 = 0.14 p = 0.71 
Yes 2 1 
Abbreviations: Ness, Nottingham Eczema Severity Score (≥ 9 maximum 15); PTQX, Pei Tu 
Qing Xin. 
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Table 25 Summary of mean differences between groups in feasibility study 
 
Abbreviations: CDLQI, Children’s Dermatology Life Quality Index; EASI, Eczema Area and 
Severity Index; IgE, immunoglobulin E; POEM, Patient-Oriented Eczema Measure; PTQX, 
Pei Tu Qing Xin.  
* Baseline difference between groups, p < 0.05; NA: measurement was not conducted. 
 
Table 26 Compliance rate of taking trial medications, dropout, adverse event 
and credibility of blinding in feasibility study 
 
 PTQX 
(n = 3) 
Placebo 
(n = 2) 
Significance 
Compliance rate, % 
92.0 85.7 t = 0.57 p = 0.66 
Dropout 
0 1 -- -- 
Adverse event 
0 0 -- -- 
SAE 
0 1 -- -- 
Credibility 
of blinding 
at Week 12 
Guessed in the real group 0 0 
-- -- Guessed in the placebo 
group 
0 0 
Outcomes Group 
Baseline 
(Mean ± 
SD) 
End of 
treatment 
(week 12) 
(Mean±SD) 
End of 
follow-up 
(week 16) 
(Mean±SD) 
Comparison between 
groups  
(t value and p value) 
End of 
treatment 
End of 
follow-
up 
EASI* 
PTQX 
19.08 ± 
4.20 
14.47 ± 4.01 19.70 ± 
12.22 
-1.07 
p = 0.47 
-0.73 
p = 0.52 
Placebo 
38.93 ± 
12.62 
29.68 ± 
19.76 
29.78 ± 
19.62 
POEM 
PTQX 
22.00 ± 
5.23 
18.00 ± 7.00 20.00 ± 6.00 
0.51 
p = 0.65 
0.77 
p = 0.50 
Placebo 
16.50 ± 
7.78 
14.00 ± 
11.31 
14.50 ± 
10.60 
CDLQI 
PTQX 
10.33 ± 
5.13 
7.67 ± 3.06 7.67 ± 2.01 
0.11 
p = 0.93 
0.03 
p = 0.98 
Placebo 
11.50 ± 
6.37 
7.00 ± 8.49 7.50 ± 7.78 
Serum IgE, 
kU/L 
PTQX 
2844.67 ± 
2267.49 
2539.33 ± 
1919.67 
NA 
0.14 
p = 0.67 
NA 
Placebo 
1681.50 ± 
361.33 
1841.00 ± 
135.76 
NA 
 
197 
Not sure 3 2 
Abbreviations: SAE, serious adverse events; PTQX, Pei Tu Qing Xin.  
 
6.3 Summary of the Feasibility Study and Its Implication for the Pilot Study 
 The feasibility study aimed at testing the methods and internal validity of the 
study stipulated on the approved protocol. These included the recruitment and 
screening the PEPs; implement of randomisation including sequence generation and 
allocation concealment; outcome measurements; compliance with the trial protocol by 
the included participants; data processing and management. There were three boys 
and two girls age from 10 to 14 years old were randomised and four completed the 
trial and one withdrawal due to hospitalised requested by participant’s parents. 
Although no significant difference between two groups was detected because of the 
small sample size, the feasibility study demonstrated that the trial protocol can be 
implemented, noting only recruitment challenges experienced in Australia leading to 
the pilot study being conducted in China.  
Section II:  Findings from the Pilot Study 
 
The contents of this chapter have been published in the international peer-
reviewed journal: S.X. Gu, X. Mo, A.L. Zhang, J. Liu, M.E. Coyle, S. Ye, Z. Wen, 
N.E. Cranswick, C.C. Xue, D. Chen (2018): A Chinese herbal medicine preparation 
(Pei Tu Qing Xin) for children with moderate-to-severe atopic eczema: a pilot 
randomized controlled trial, British Journal of Dermatology 2018, 179(6), 1404-1405. 
DOI: 10.1111/bjd.16988 
6.4  Participant Flow and Recruitment  
One hundred and twenty one PEPs were invited from dermatology outpatient 
department of GPHCM and its two affiliated hospitals in Guangzhou, China from 
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August 2016 to May 2017 for screening (Table 27). A total of 30 children with 
moderate to severe AE and met the pre-designed inclusion and exclusion criteria were 
recruited. The participants were randomised into PTQX treatment (n = 16) or placebo 
control group (n =14) according to the methods outlined in Chapters 5.6 and 5.7 and 
received 12 weeks of treatment with either PTQX granules or inner granules (placebo). 
A following up assessment was given to participants at four weeks after the treatment 
was completed (endpoint). The last participant completed the follow-up visit on 2 
September 2017. There were three participants did not completed the 12-week 
treatment (dropouts) and six did not turned up for follow-up at Week 16. ITT analysis 
was performed with LOCF method as stated in Chapter 5.9.2 for the missed data. 
Data from the previous feasibility study were not included in the pilot study in order 
to avoid potential bias in the study results. Figure 20 depicts the participants flow at 
each stage of the trial. 
 
Table 27 Data of recruitments in GPHCM and its two affiliated hospitals  
 
 GPHCM  The 2
nd
 
affiliated 
hospital  
The 3
rd
 
affiliated 
hospital 
Total 
Invited PEPs 
for screening 
 
80 14 27 121 
Randomised 
 
27 2 1 30 
Dropouts 
 
3 0 0 3 
Completed 
 
24 2 1 27 
Abbreviations: GPHCM, Guangdong Provincial Hospital of Chinese Medicine; PEPs, 
potential eligible participants. 
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Figure 20 Participants flow at each stage of the trial 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
  
 
 
 
 
 
 
   
 
 
 
  
14  
Allocated to control intervention 
group  
14 Placebo  
 Treatment period 
(12 weeks) 
121 Screened  
Screening/run-in period 
 
30 eligibility confirmed   
Baseline period 
 
30  
Randomised 
16  
Allocated to treatment 
intervention group  
16 PTQX  
Treatment period  
(12 weeks) 
12 Follow-up 
 
12 Follow-up 
 
91 
excluded  
16 analysed 14 analysed 
E
n
ro
lm
en
t 
A
llo
ca
tio
n
 
0 Did not received 
intervention 
0 Did not received 
intervention 
 
2 discontinued  
intervention 
4 lost to follow-up 
1 discontinued 
intervention 
 
2 lost to follow-up 
 
F
o
ll
o
w
-u
p
 
A
n
a
ly
si
s 
0 not analysed 0 not analysed 
 
200 
6.5 Demographic and Baseline Data 
There were nine boys and 21 girls, aged from six to 16 years old in the trial. 
The lowest score of NESS was nine and the highest score was 15 with mean score 
12.56 in the PTQX group and 12.14 in the placebo control group. A minimum nine 
score of NESS was set as one of the inclusion criteria at the screening stage outlined 
in Chapter 5.9.1. No significant differences were seen in terms of personal or parents’ 
history of atopic conditions (AE, allergic rhinitis or asthma) between two groups 
(Table 28).  
The lowest score of EASI was 2.3 and the highest score was 31.5 at Week 0 
(baseline). EASI score was set as a primary outcome measure stated in Chapter 5.12.1 
and both mean scores of EASI in two groups were balanced at the beginning of 
treatment (baseline). There were no statistically significant differences between two 
groups in mean scores of secondary outcome measures including POEM, CDLQI and 
serum IgE (p <0.05) at baseline (Table 29).  
 
Table 28 Demographic characteristics of included participants in pilot study 
 
Variable 
PTQX 
(n = 16) 
Placebo 
(n = 14) 
Significance 
Mean±SD 
Age, years 
8.63±2.22 8.93±3.34 t = -0.30 p = 0.77 
Weight, kg  
29.78±11.46 29.11±9.96 t = 0.17 p = 0.87 
Height, cm 131.56±10.39 133.21±15.35 t = -0.34 p = 0.74 
NESS 
12.56±1.75 12.14±1.92 t = 0.63 p = 0.54 
 
Number of participants Significance 
Gender 
Male 4 5 
X2 = 0.41 p = 0.52 
Female 12 9 
Personal 
history of 
atopy  
Atopic 
eczema 
7 10 
X2 = 2.34 p = 0.31 
Atopic 7 2 
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eczema & 
allergic 
rhinitis 
Atopic 
eczema & 
asthma & 
allergic 
rhinitis 
2 1 
Parents’ 
history of 
atopy 
No 6 10 
X2 = 3.45 p = 0.06 
Yes 10 4 
Abbreviations: NESS, Nottingham Eczema Severity Score ≥ 9 maximum 15; PTQX, Pei Tu 
Qing Xin.  
6.6 Numbers Analysed and Statistical Analysis 
6.6.1 Efficacy 
The mean score of EASI was compared between two groups and no 
statistically significant differences were observed between the PTQX and 
placebo group at the end of the treatment period (Week 12) (MD, 0.08; 95% 
CI, -4.81 to 4.99; n = 30, p = 0.97) or at the end of the following-up 
observation (Week 16) (MD, -2.95; 95% CI, -9.55 to 3.67; n = 30, p = 0.37). 
No trial medications or placebo were administered from weeks 13 to 16 as a 
follow-up period. Similarly no between groups statistically significant 
differences in POEM, CDLQI and serum IgE were recorded at the end of 
treatment period (Week 12) (Table 29). 
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Table 29 Summary of mean differences between groups  
 
Abbreviations: CDLQI, Children’s Dermatology Life Quality Index; EASI, Eczema Area and 
Severity Index; IgE, immunoglobulin E; MD, Mean difference; NA, measurement was not 
conducted; POEM, Patient-Oriented Eczema Measure; SD, standard deviation.  
 
All mean scores of EASI, POEM and CDLQI in the PTQX group were lower than 
than those in the placebo group at the end of follow-up where no interventions were 
given to the participants although no between groups statistically significant 
differences were detected (Figure 21, Abbriveatoins: EASI, Eczema Area and Severity 
Index; PTQX, Pei Tu Qing Xin. 
 
Figure 22 and Figure 23). 
  
Outcomes Group 
Baseline 
(Mean ± 
SD) 
End of 
treatment 
(Week 12) 
(Mean ± SD) 
End of 
follow-up 
(Week 16) 
(Mean ± SD) 
Comparison between 
groups  
MD (95% CI) 
End of 
treatment 
End of 
follow-
up 
EASI 
PTQX 
13.66 ± 
6.96 
6.71 ± 6.32 6.23 ± 6.35 0.08  
(-4.81 to 
4.99); 
t = 0.04 
p = 0.97 
-2.95 
(-9.55 to 
3.67); 
t = -0.91 
p = 0.37 
Placebo 
13.63 ± 
9.08 
6.63 ± 6.79 9.18 ± 11.00 
POEM 
PTQX 
20.00 ± 
5.53 
12.50 ± 7.78 13.56 ± 8.08 -2.57 
(-7.84 to 
2.70); 
t = -1.00 
p = 0.33 
-2.3 
(-8.49 to 
3.90); 
t = -0.76 
p = 0.45 
Placebo 
18.07 ± 
4.94 
15.07 ± 6.04 15.86 ± 8.47 
CDLQI 
PTQX 
12.44 ± 
5.68 
8.50 ± 6.56 8.31 ± 6.98 -1.36 
(-5.83 to 
3.12); 
t = -0.62 
p = 0.54 
-1.90 
(-6.78 to 
2.97); 
t = -0.80 
p = 0.43 
Placebo 
12.79 ± 
4.84 
9.86 ± 5.20 10.21 ± 5.90 
Serum IgE, 
kU/L 
PTQX 
2369.91 
± 
4304.53 
2340.38 ± 
4321.89 
NA 
-520.28 
(-3214.63 to 
2174.07); 
t = -0.40 
p = 0.70 
NA 
Placebo 
2851.84 
± 
2645.90 
2860.66 ± 
2504.29 
NA 
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Figure 21 Trend of EASI mean score 
 
 
Abbriveatoins: EASI, Eczema Area and Severity Index; PTQX, Pei Tu Qing Xin. 
 
Figure 22 Trend of POEM mean score 
 
 
 
Abbrivatioins: POEM, Patient-Oriented Eczema Measure; PTQX, Pei Tu Qing Xin. 
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Figure 23 Trend of CDLQI mean score 
 
 
Abbreviations: CDLQI, Children’s Dermatology Life Quality Index; PTQX, Pei Tu 
Qing Xin. 
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and 13.63 to 7.01 in the placebo group, but there was no between groups statistically 
significant difference at the end of treatment (Week 12) (p = 0.98) nor between group 
statistically significant difference at the end of the follow-up (Week 16) (p = 0.33). 
All mean scores from the secondary outcome measures at the end of the treatment or 
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Table 30 Mean differences before and after treatment/end of follow-up within 
and between groups  
 
Abbreviations: CDLQI: Children’s Dermatology Life Quality Index; EASI, Eczema Area and 
Severity Index; POEM, Patient-Oriented Eczema Measure; SD, standard deviation.  
6.6.2 Use of Concomitant Medications 
 
Among the 30 participants, 21 girls or boys used topical corticosteroid creams 
(TCS) during the trial period. Corticosteroid creams including desonide, mometasone 
furoate, triamcinolone acetonide and hydrocortisone butyrate creams were prescribed. 
The total dosage and days of usage of the corticosteroid creams in the PTQX group 
were greater than those in the placebo group at all three set measure time points 
(Week 4, 8 and 16) despite the fact that no significant differences between groups 
were observed (Table 31). However, a more obvious trend of decrease in total dosage 
of corticosteroid creams was recorded in the PTQX group (from the mean of 43.09 to 
24.91) even though there was no statistically significant difference compared to the 
trend in placebo group at Week 16 (p = 0.428) (Figure 24). 
 
Outcomes Group 
Change 
from 
baseline to 
end of 
treatment 
(Week 12) 
Mean±SD 
Change from 
baseline to end 
of follow-up  
 
(Week 16) 
Mean±SD 
Comparison between 
groups 
 
End of 
treatment 
(Week 12) 
End of 
follow-up 
(Week 16) 
EASI 
PTQX -6.95±7.35 
-7.43±5.79 
t = 0.02 
p = 0.98 
t = -1.00 
p = 0.33 
Placebo -7.01±8.16 
-4.46±10.19 
POEM 
PTQX -7.50±8.05 
-6.44±8.24 
t = -1.66 
p = 0.11 
t = -1.39 
p = 0.18 
Placebo -3.00±6.59 
-2.21±8.39 
CDLQI 
PTQX -3.94±6.29 
-4.13±6.34 
t = -0.45 
p = 0.66 
t = -0.66 
p = 0.52 
Placebo -2.93±5.99 
-2.57±6.56 
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Table 31 Application of TCS 
 
Total dosage (FTU)  Day of usage (days) 
 PTQX 
(n=10) 
Placebo 
(n=11) 
Comp 
between 
groups 
PTQX 
(n=10) 
Placebo 
(n=11) 
Comp 
between 
groups 
Visit (Mean ± 
SD) 
(Mean ± SD)  (Mean ± SD) (Mean ± 
SD) 
 
Week 4 43.09 ± 
46.37 
21.19 ± 
31.15 
t = 1.282  
p = 0.215 
13.10 ± 
10.38 
5.82 ± 
6.00 
t = 1.944 
p = 0.072 
Week 8 34.75 ± 
34.65 
21.66 ± 
37.66 
t = 0.826 
p = 0.419 
13.30 ± 
11.47 
6.45 ± 
5.18 
t = 1.733 
p = 0.108 
Week 12 42.28 ± 
41.20 
24.91 ± 
54.84 
t = 0.814 
p = 0.426 
12.20 ± 
11.20 
9.00 ± 
8.26 
t = 0.750 
p = 0.462 
Week 16 26.75 ± 
48.18 
13.68 ± 
30.39 
t = 0.751 
p = 0.462 
10.20 ± 
13.18 
5.55 ± 
8.17 
t = 0.962 
p = 0.352 
Comp b/w 
Week 4 
and end of 
follow-up 
Week 16 
 
-16.34 ± 
62.29 
t = 0.83 
p = 
0.428 
 
-7.51 ± 27.71 
t = 0.899 
p = 0.390 
 
 
Comp 
b/w Week 
4 and end 
of follow-
up Week 
16 
-2.9 ± 15.32 
 t = 0.600 
 p = 0.564 
-0.27 ± 
11.39 
t = 0.079 
p = 0.938 
 
Abbreviations: Comp, comparison; Day of usage, total number of days of using corticosteroid 
cream; FTU, fingertip unit; PTQX, Pei Tu Qing Xin; Total dosage, total amount of 
corticosteroid cream measured by FTU; TCS, topical corticosteroid creams. 
 
Figure 24 Trend of total dosage of TCS 
 
 
Abbreviation: PTQX, Pei Tu Qing Xin; TCS, topical corticosteroid creams. 
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In addition to the corticosteroid creams, five participants also used tacrolimus 
ointment topically, a calcineurin inhibitor (one of the immunosuppressive agents for 
mild AE as stated in Chapter 2.9.1) for their skin condition, and another five 
participants used topical tacrolimus ointment only as a concomitant medicine with the 
trial medications. There were no statistically significant differences within or between 
groups at all measure time points except the mean of number of day usage in the 
placebo group was statistically significant lower than that in the PTQX group at Week 
12 (p = 0.009) (Table 32). 
 
Table 32 Topical application of tacrolimus ointment 
 
Total dosage (FTU)  Day of usage (days) 
 PTQX 
(n=5) 
Placebo 
(n=5) 
Comp 
between 
groups 
 
PTQX 
(n=5) 
Placebo 
(n=5) 
Comp 
between 
groups 
 
Visit (Mean ± 
SD) 
(Mean ± 
SD) 
 (Mean ± 
SD) 
(Mean ± 
SD) 
 
Week 4 12.20 ± 
21.31 
27.83 ± 
42.04 
t = -0.742 
p = 0.480 
13.80 ± 
13.76 
9.80 ± 
11.37 
t = 0.501 
p = 0.630 
Week 8 13.94 ± 
11.12 
23.40 ± 
32.66 
t = -0.559 
p = 0.591 
18.20 ± 
13.90 
11.40 ± 
11.72 
t = 0.836 
p = 0.427 
Week 12 19.62 ± 
30.99 
6.10 ± 
6.70 
t = 0.952 
p = 0.369 
17.20 ± 
7.19 
4.60 ± 
3.85 
t = 3.455 
p = 0.009 
Week 16 14.42 ± 
26.99 
13.67 ± 
13.60 
t = 0.056 
p = 0.957 
10.80 ± 
11.63 
6.40 ± 
4.04 
t = 0.799 
p = 0.447 
Comp b/w 
Week 4 
and end of 
follow-up 
Week 16 
-2.22 ± 
6.65 
t = -0.75 
p = 0.50 
14.17 ± 
37.76 
t = 0.84 
p = 0.45 
 
Comp b/w 
Week 4 and 
end of 
follow-up 
Week 16 
3.00 ± 
14.39 
t = 0.47 
p = 0.67 
3.40 ± 
12.58 
t = 0.60 
p = 0.58 
 
Abbreviations: Day of usage: total number of days of using tacrolimus ointment; FTU: finger-
tip unit; PTQX, Pei Tu Qing Xin; Total dosage: total amount of tacrolimus ointment 
measured by FTU. 
 
6.6.3 Compliance, Withdrawal or Dropout and Credibility of Blinding 
 
The participants in both groups were highly compliant with the protocol in 
terms of taking the trial medications. The withdrawal or dropout rate were within an 
 
208 
acceptable 10% rate as there were only one withdrawal and one dropout in the PTQX 
group and one dropout in the placebo group. Two dropouts indicated that their skin 
condition had not been improved after taking the medications for eight weeks. One 
withdrawal did not turn up for blood tests at Week 4 and Week 12 for assessment of 
safety purpose planned in Chapter 5.12.3.  Evaluation of the success of blinding by 
testing the accuracy of participants’ guesses as to whether they are in the treatment 
group or the control group is a common process in RCTs (Hrobjartsson, Forfang, 
Haahr, Als-Nielsen, & Brorson, 2007).  Credibility of blinding for the participants 
was high as more than 50% of the participants in the placebo group guessed they were 
on the active intervention group and the correct guess rate was only 7.14% (Table 33). 
A survey was conducted at the end of follow-up (three missing data) and 92.59% 
(25/27) participants were tolerant the taste and colour of the trial medications. There 
were 77.78% (21/27) of participants willing to use the trial medications in future if the 
findings affirm efficacy and safety of PTQX. 
 
Table 33 Compliance rate of taking trial medications, withdrawal and credibility 
of blinding 
 
 PTQX 
(n = 16) 
Placebo 
(n = 14) 
Significance 
Compliance rate at Week 12, % 
(Three missing data) 
94.5 89.4 t = 1.55 p = 0.13 
Withdrawal (dropout) 2 1 -- -- 
Credibility of 
blinding 
at Week 12 
(Three 
missing data) 
Guessed in the 
real medication 
group 
8 8 X2 = 0.30 p = 0.86 
Guessed in the 
placebo group 
2 1 
Not sure 4 4 
Abbreviation: PTQX, Pei Tu Qing Xin. 
 
6.6.4 Adverse Events  
 
 
209 
There were three adverse events and no SAE during the trial period. No 
hepatic or renal function abnormities were found for all participants during the 
treatment period. Table 34 records the details of the adverse events. 
 
Table 34 Record of adverse event 
 
 PTQX 
(n = 1) 
Placebo 
(n = 2) 
Adverse event Skin rash on the chest after 
taking the PTQX for 3 days 
The rash lasted for 2 days and 
disappeared after stop using 
the medications. The event 
was recorded at Week 4. 
Vomiting once due to acute 
gastritis diagnosed by a physician 
in a local hospital. The event was 
recorded at Week 4. 
 
Fever for 1 day due to common 
cold diagnosed by a physician in a 
local hospital. The event was 
recorded at Week 8. 
Abbreviation: PTQX, Pei Tu Qing Xin. 
 
Section III:  Discussion 
6.7 Interpretation  
This pilot study sought to test the viability of an approved protocol for a full-
scale future RCT. No SAE or hepatic and renal dysfunctions were recorded during the 
trial period.  
All mean scores of EASI, POEM and CDLQI in the PTQX group were lower 
than those in the placebo group at the end of follow-up and a more remarkable trend 
of decrease in total dosage of corticosteroid creams was recorded in the PTQX group 
although no between groups statistically significant differences were detected 
probably as a result of a small sample size. Findings from this study provided 
meaningful information for further improvement of a full-scale RCT design. For 
example, the mean score of EASI obtained from this study can be used to estimate the 
effect size and calculation of sample size more accurately for a future full-scale RCT.  
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When the trial protocol was developed, NESS was used rather than EASI for 
determination of severity of AE in inclusion and exclusion criteria for recruitment of 
participants owing to the severity strata for EASI was not available until 2015 
(Leshem et al., 2015). In this study, it was found that participants with moderate AE 
tested with NESS (≥ 9 out of 15 total scores) in screening stage might be defined as 
mild AE by using EASI (1.1- 7 out of 72 total scores) on baseline as “clinical course” 
and “clinical intensity” (disturbs of sleepy by itches of skin) occupied 66.67% of the 
total NESS score (see Appendix 12). Whilst EASI only assessed skin lesions such as 
erythema (redness) and induration/papulation (rash) of AE condition (see Appendix 
15). These data suggest using EASI as an instrument for define the severity of AE at 
screening stage instead of NESS in a full-scale trial in future.  
PTQX was designed to target infants or children who were diagnosed with AE 
and also have a specific TCM syndrome or pattern of spleen deficiency and heart fire 
(see Chapter 5.2.1). A specific TCM pattern was not set as one of the inclusion and 
exclusion criteria because syndrome of spleen deficiency with heart fire were the most 
common seen pattern in cohort of children aged from six to 16 years old in AE (see 
Chapter 2.11.2). Based on the preliminary findings addition of a specific TCM 
syndrome or pattern as one the inclusion or exclusion criteria for a full-scale trial in 
future in accordance with the newly published CONSORT Extension for Chinese 
Herbal Medicine Formulas 2017 is recommended  (C. W. Cheng et al., 2017) . 
It was found that 90% (27/30) of the participants had applied topical 
immunosuppressive agents including corticosteroid creams and/or tacrolimus 
ointment as concomitant medications during the trial period. A different strength and 
potent of corticosteroid were prescribed for these participants to control their skin 
condition. The mean score of EASI fell below baseline at the end of treatment and at 
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the end of follow-up in both groups, thus it was a challenge to identify whether the 
trial medications or concomitant medications led to the improvement of an AE 
condition. It was noticeable that the PTQX group had a greater decrease of topical 
corticosteroid creams usage than that in the placebo group at the follow-up period in 
light of that participants eased to use PTQX for four weeks at the measure time point. 
It is necessary to find out what leads to such a high percentage of using 
immunosuppressive agents for those participants who had moderate to severe AE as 
topical corticosteroid creams and tacrolimus ointment are first-line treatment for mild 
AE only as stated in Chapter 2.9.5. It is further suggested that standardising the potent 
and using short-term effect of immunosuppressive agents may be needed in a future 
full-scale trial.  
Serum IgE was used as an objective biomarker and one of the secondary 
outcome measures in this study. However, recent a finding does not support the serum 
IgE an appropriate biomarker for severity of AE (J. Thijs et al., 2015; Thijs, van 
Seggelen, Bruijnzeel-Koomen, de Bruin-Weller, & Hijnen, 2015). An innovative 
combination of biomarkers called “predicted-EASI (p-EASI)” which consists of 
serum thymus and activation-regulated chemokine (TARC), IL-22 and soluble IL-2 
receptor (sIL-2R) is recommended as a credible and validated objective biomarker 
signature for assessment of severity of AE (Thijs et al., 2017).  
The total mean scores of primary and secondary in the PTQX group were 
lower than those in the placebo group at the end of follow-up (Week 16) considering 
no intervention medications were given to the participants although no statistically 
significant differences were detected between two groups. A statistically significant 
difference is expected for a future full-scale trial.  
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6.8 Generalisability 
 
The participants collectively adhered to the study protocol, taking the 
intervention medications in both groups. Most of the participants accepted the taste 
and colour of the trial medications and willing to use the trial medications if they were 
proved to be effective for AE. In terms of external validity, as PTQX was developed 
through years of clinical practice, the findings of this preliminary study and more 
importantly outcome from the full scale trial may provide important evidence to 
facilitate clinical decision making with respect to the role of PTQX in the treatment of 
children with AE. 
6.9 Overall Evidence 
This was a parallel design, randomised, double-blind, placebo-controlled, 
exploratory, prospective pilot clinical trial following the successful completion of a 
feasibility trial. Findings from this pilot study using PTQX granules and the previous 
study using PTQXT (raw herbs instead of granules used in this pilot study) in 2015 
are not comparable as stated in Chapter 5.2.1.  For instance, the PTQXT study (2015) 
included both adults and children, using a combination of PTQXT and topical CHM 
lotion, and employed outcome measures other than CODs and relevant COMIs were 
not used for outcome measures. 
The aim of the pilot study was to collect preliminary data for a full scale trial 
seeking to test the efficacy and safety of PTQX for children aged six to 16 years old 
diagnosed with moderate to severe AE. There were no significant differences between 
the PTQX group (treatment group) and the control group at the end of the treatment 
period (Week 12).  There was minor difference in total usage of topical corticosteroid 
creams between the PTQX group and control group at the end of the 4-week follow-
up period (non-intervention). It should be noted that such difference was not 
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statistically significant. Although findings were preliminary, the information derived 
from this study provided positive indications for a future full-scale trial. 
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Chapter 7  Concluding Discussion  
 
7.1  Key Findings of Evidence 
 
7.1.1 Evidence from the Literature Review 
The incidence rate for AE in worldwide has been trending to increase over the 
past decades, the reason for which is unknown (Watson & Kapur, 2011; H. 
Williams et al., 2008). These include: deficiency of vitamin D; climate factors; 
prenatal or psychological stresses; and genetic hereditary alterations. AE 
brings about significant socio-economic burden and impact of QoL for the 
patients and their family. The history of treating Jin Yin Chuang (eczema) 
with a single Chinese herb traces back to year 300 A.D. even though condition 
of Jin Yin Chuang might be not necessary equivalent to AE as per the first 
diagnostic criteria was set up by Hanifin and Rajka in 1980 (J.M. Hanifin & 
Raika, 1980). This thesis further identified expert opinion as to the 
pathogenesis of AE. In addition, the Chinese medicine guidelines 2011 or the 
expert consensus 2013 recommended a series of CHM formulae for AE based 
on the Chinese medicine syndrome differentiations. 
7.1.2 Evidence from the Systematic Review and Meta-analysis 
Data from 10 RCTs were analysed with a total of 1058 participants which 
were treated with CHM or control interventions topically. Meta-analysis from 
these 10 studies showed an overall effect favoured to CHM in terms of “total 
effectiveness rate” when compared to topical conventional medications (RR 
1.19; 95% CI 1.04 to 1.36). However, this finding was of high risk of bias and 
associated with significant methodological flaws found in these 10 trials. 
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7.1.3 Evidence from the Cochrane Systematic Review 
Twenty eight studies were included with a total of 2306 participants. Most of 
the studies were assessed as at high “risk of bias” and there was substantial 
inconsistency between the studies.  
Four studies (three oral and one topical) compared CHM to placebo. Pooled 
data from two showed the total effectiveness rate in the CHM group was 
higher (by RR 2.09; 95% CI 1.32 to 3.32; two studies; n=85), and the itching 
VAS in the CHM group was 1.53 lower (by SMD; 95% CI 2.64 to 0.41; two 
studies; n=94) than the placebo group, where a lower VAS score indicates 
reduced itch. One study in 85 participants with moderate to severe AE who 
received an oral CHM formula for 12 weeks, reported a QoL score 2.5 lower 
in the CHM group (by MD; 95% CI 4.77 to 0.23; one study; n=85) than the 
placebo group, where a lower score indicates better QoL.  
Twenty-two studies and one arm from a study with a 4-arm parallel controlled 
design, compared CHM (five oral, six topical and 12 mixed oral and topical) 
to conventional medicines. The total effectiveness rate in the CHM groups was 
superior (RR 1.43; 95% CI 1.27 to 1.61; 21 studies; n=1868) and the itching 
VAS in the CHM groups was 0.83 lower (SMD; 95% CI 1.43 to 0.22; seven 
studies; n=465) than the comparators. These need to be interpreted with 
caution due to substantial heterogeneity across the studies and the high risk of 
bias particularly in blinding of participants and personnel. 
Two studies compared combination of oral and topical CHM to the same oral 
CHM formula alone. The total effectiveness rate in one study was not 
statistically significant (RR 1.13; 95% CI 0.78 to 1.63; one study; n=20). In 
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the other study the itching VAS in the CHM group was 1.05 lower (MD; 95% 
CI 1.75 to 0.35; one study; n=23) than the control group. 
With regard to adverse events, four studies did not mention adverse events. 
The other 24 studies reported minor adverse events which were reversed soon 
after stopping CHM. One participant withdrew from one trial due to 
exacerbation of their condition after using the CHM intervention. 
7.1.4 Evidence from the Pilot Study 
 
Although there were no statistical significant differences between the PTQX 
and placebo group at the end of treatment (Week 12) (MD, 0.08; 95% CI, -
4.81 to 4.99; n = 30, p = 0.97) or the end of the following-up (Week 16) (MD, 
-2.95; 95% CI, -9.55 to 3.67; n = 30, p = 0.37) measured EASI, there was a 
greater trend of decrease in total dosage of corticosteroid creams in PTQX 
group at follow-up period of the trial. Findings from the pilot study were 
encouraging a full-scale trial in future. 
 
7.2  Implication of the Key Findings 
 
7.2.1 Implication of Findings from the Literature Review 
Expert opinion on the pathogenesis of AE provided theoretical foundation of 
devolvement of CHM from single herb to formulae for treatment of AE. The 
Chinese medicine guidelines 2011 and expert consensus 2013 further 
summarised the clinical experience from previous practitioners and 
recommended CHM formulae for different stages or different syndromes of 
AE. These recommended formulae include oral ingestion and/or topical 
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application and it is suggested to assess the efficacy and safety of CHM for 
AE through systematic review for a higher level of clinical evidence. 
7.2.2 Implication of Findings from the Systematic Review of Topical Use 
of CHM for AE 
The evidence of estimate effects of topical application of CHM for AE 
collected through the review was inconclusive. A Cochrane systematic review 
is recommended for further evaluation of CHM in both oral and topical 
administration for AE.  
7.2.3 Implication of Finding from the Cochrane Systematic Review 
1) Implications for practice  
Limited evidence (one study) for oral ingestion of a Chinese herbal formula 
was found for five Chinese herbs may provide therapeutic benefit for children 
with AE from one study (Hon 2007). As duration of oral ingestion of CHM 
could be up to 12 weeks, it is suggested that a longer duration (more than 12 
weeks) treatment strategy is appropriate for oral ingestion of CHM for AE. 
Conclusive evidence was not found that oral ingestion of other Chinese herbs 
or Chinese herbal formulae used in the included studies improved the 
condition. Further, convincing evidence was not be found that topical 
application of CHM, whether used alone or in conjunction with oral ingestion 
of Chinese herbal formula could reduce the severity of AE in children or 
adults. Even though in the included studies there were statistically significant 
differences in the outcome measures where CHM treatment groups were 
compared to those in the control groups, due to a low strength of evidence and 
high risk of bias, these claims cannot be regarded as reliable. 
 
218 
2) Implications for research  
There is evidence that CHM has been increasingly used for the management of 
AE since the publication of the first Cochrane systematic review 2004 in this 
area. The followings outline key facets for conducting a RCT of CHM for AE 
in the future:  
a) Recruitment of participants with similar ages or severity of their condition 
is needed to minimise heterogeneous outcomes within the study. Stratified 
randomisation is recommended if the study recruits both children and adults. 
b) Sample size in the interventional group and control group should be 
balanced. Characteristics of participants in the two groups should be 
comparable. Methods for randomisation must be clearly described on the 
published works. 
c) Blinding should always be used because in most cases, outcome measures 
for AE are subjective. An open-labelled design study could lead to risk of bias 
for outcome assessment. 
d) Application of the intervention should be used alone i.e. oral ingestion or 
topical application with appropriate comparator unless efficacy of the oral 
ingestion or topical application of the intervention has been confirmed 
respectively. Quality control including appropriate toxicology studies and 
quality assurance of Chinese herbs to be investigated should be performed 
prior to the conduct of clinical trials as contamination of any non-CHM 
components detracts from the high standards and tradition of Chinese 
medicine. 
e) Assessment of the efficacy of the intervention should rely on data from both 
objective and subjective outcome measures assessed at baseline and at the 
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endpoint of the trial. Using published and validated scoring systems such as 
EASI, SASSAD or SCORAD as a primary outcome measure may help to 
achieve this and continuous data should always be reported or provided upon 
request. 
f) Adverse events should be adequately reported. Liver and renal function tests 
or blood cell tests should be used as one of the safety parameters in a RCT. 
Both the systematic reviews, first for the topical application of CHM, 
then the more comprehensive Cochrane systematic review suggested well-
designed, adequately powered placebo-controlled RCTs are required to 
evaluate the efficacy and safety of CHM for managing AE.  
7.2.4 Implication of Findings from the Pilot Study 
 
Findings from the pilot study suggest the HREC approved protocol is feasible 
for a full-scale trial in the future. The pilot study provided meaningful 
information for further improvement of a full-scale of RCT design. These 
include more accurate estimation of effect size and calculation of sample size 
by using the data observed from the pilot study; using EASI at all stages 
including the screening stage of the trial; adding a specific TCM syndrome or 
pattern as one the inclusion and exclusion criteria; using standard potent and 
short-term effect of immunosuppressive agents when needed and serum IgE 
should be replaced by predicted-EASI, an innovated combination of 
biomarkers as one of the secondary outcome measures for severity of AE in a 
full-scale RCT. 
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7.3 Innovation of the Project 
The usage of current best evidence with conscientiousness, explicitness and 
judiciousness for decisions making about the medical care of individual is at the core 
of Evidence-based medicine (Sackett, Rosenberg, Gray, Haynes, & Richardson, 
1996). The practice of Evidence-based medicine encourages a clinician to integrate 
their practical expertise with the best available external research evidence as well as 
the patient’s choice for planning the regimen for the patient’s need. The strength of 
external research evidence in Evidence-based medicine rests on the hierarchical level 
of evidence which ranks from the highest “I degree”, in which evidence is collected 
from a systematic review of all relevant RCTs to the lowest one “IV degree” where 
evidence is gained from case series study or expert opinion (NHMRC, 2000). Table 
35 summarises the rank of key clinical evidence collected from this thesis. 
 
Table 35 Hierarchy of evidence collected in this thesis 
 
Hierarchy of evidence Key clinical evidence Chapter 
Systematic reviews The Cochrane systematic review of CHM for AE 4 
Systematic review of topical application of CHM 
for AE 
3 
RCT Pilot study of PTQX for children with moderate 
to severe AE 
5, 6 
Guidelines and expert 
consensus  
The Chinese medicine guidelines 2011 and the 
expert consensus 2013 
2 
Expert opinion  Experts’ opinions of pathogenesis of AE 2 
Abbreviations: AE, Atopic eczema; CHM, Chinese herbal medicine; PTQX, Pei Tu Qing Xin; 
RCT, randomised controlled trial. 
 
This thesis has employed rigorous standard methodologies and an evidence-
based Chinese medicine approach to determine the current state of clinical evidence 
of CHM for AE. It is the first research to address the efficacy and safety of CHM for 
AE from the full range of hierarchical evidence levels recommended by the NHMRC 
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which is the peak Australian government body for promoting the development and 
maintenance of public and individual health standards and sponsoring medical 
research. Findings of the study have identified research priorities in which new 
clinical evidence of CHM for AE is critical to support sound clinical decision making. 
The pilot study complied with the approved protocol and was the first trial in 
CHM for AE to employ CODs and relevant COMIs for outcome measures 
recommended by HOME (Schmitt, Langan, et al., 2011; Schmitt et al., 2012). 
Although there was no conclusive findings from the pilot study to confirm the 
efficacy of PTQX likely due to small sample size, these findings have provided 
meaningful data for accurate estimate of effect size, calculation of sample size and 
recommended proper outcome measure tools and biomarkers for a full-scale RCT in 
future.  It is expected that more high quality of CHM RCTs for AE with minimum 
risk of bias will be carried out under the guidance of Reporting Randomized, 
Controlled Trials of Herbal Interventions: An Elaborated CONSORT Statement 2006 
and CONSORT Extension for Chinese Herbal Medicine Formulas 2017(C. W. Cheng 
et al., 2017; Gagnier et al., 2006).  The pilot study has demonstrated a feasibility to 
conduct a RCT by using scientific methodology to test the efficacy and safety of 
CHM for AE. 
7.4 Conclusions and Prospects 
There has been increasing clinical evidence for evaluation of efficacy and 
safety of CHM for AE gained from RCTs over the past decades. The promising 
outcomes of meta-analyses have added weight to the notion that CHM may be 
effective to AE but these findings need to be affirmed by well-planned, large sample 
size RCTs with minimum risk of bias. The CODs and their relative outcome 
instruments plus the newly innovated combined biomarkers can be used for all AE 
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clinical trials including CHM trials for outcome measurements. There was 
preliminary evidence that the CHM granules PTQX may be efficacious for children 
with moderate to severe AE. The pilot study presented here informs the feasibility of 
an adequately powered trial on this herbal preparation which is a priority for 
evidence-based Chinese medicine development for AE.  
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China-Australia International Research Centre for Chinese Medicine and School of 
Health Sciences 
 
Appendix 4 Instruction of Usage of Trial Medication Granules 
 
Pour the contents of __ sachet(s) into an empty glass; add 100 ml of warm water and 
stir; 
Drink cooled mixture after breakfast; 
Repeat step 1 and 2 and drink the mixture after your evening meal; 
Please return the container, empty sachets and any unused granules to the investigator 
at your next visit. 
Contact phone number for the trial investigator: Mr. Xu Ming Gu (03) 9xxx xxxx 
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China-Australia International Research Centre for Chinese Medicine and School of 
Health Sciences 
 
Appendix 5 Record Sheet of Dispensary 
 
Participant’s 
ID Number 
Sequential 
Number of the 
Container 
Randomisation 
Code 
Date of 
Dispensary 
Dispenser’s 
Signature 
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Appendix 6 Template of Label on the Container  
 
Participants ID__________; Initial ________; Week __________ 
  
PTQX trial for eczema 
For clinical trial use only 
Randomisation No. 1 
Keep out of reach of children 
 
Ethics approval: RMIT HREC 08/14 
ANZCTR registration No.:  
Sponsor: RMIT University 
Manufactured by Jiangyin Tianjiang Pharmaceutical Co Ltd, China (GMP) 
Batch No.: 1305355; Exp.: Apr 2016 
Site: RMIT Building 201, level 3, room 17C 
 
Directions: 3 sachets twice daily after meals dissolve granules with warm water, taken 
orally. 
 
Chief investigator: Prof. Charlie Xue 
Contact: Mr Xu Ming Gu 
03 9xxxxxxx 
 
Please return the container, empty sachets, and any unused granules to the investigator 
at your next visit. 
 
 
 
China-Australia International Research Centre for Chinese Medicine and School of 
Health Sciences 
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Appendix 7 Media Advertisements for Recruitment of Participants 
 
Sample of Trial information flyer 
 Eczema Sufferers Wanted  
 
Are you or your child suffering from eczema or dermatitis? Are you concerned about 
the side effects of steroid drugs? If your child is aged between 6 and 16 years old, and 
has been diagnosed with eczema, or atopic eczema or atopic dermatitis by a GP or 
dermatologist, you might be eligible to participate in this clinical trial which involves 
the oral intake of traditional Chinese herbal granules for 12 weeks. 
The trial has been approved by the appropriate authorities and you and your child’s 
personal information will be absolutely confidential.   
For more information or to register in the trial, please contact Mr. Xu Ming Gu on (03) 
9xxxxxxx or via email eczema.trial@rmit.edu.au 
Mr. Gu is a registered Chinese medicine practitioner in the Divisions of Chinese herbal 
medicine and acupuncture of the Chinese Medicine Board of Australia. 
The clinical trial will be conducted at the following venue: 
RMIT University Health Sciences Research Hub - Building 201 Level 3 Room 201. 3. 
17C, RMIT University Bundoora West campus, Plenty Road. Bundoora Vic. 3083 
 
 
RMIT Website Advertisement 
 
Children (6-16 years) are invited to participate in a study using Chinese herbal 
medicine to relieve itching and skin rash due to atopic eczema (AE) or atopic dermatitis 
(AD). 
Does your child or someone you know suffer from eczema? 
AE or AD is a common, chronic skin condition which is characterised by severe itching 
and redness of the skin. It can result in skin changes such as scaling, swelling and skin 
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thickening. AE can be treated with steroids and other drugs but side effects may occur 
with long term usage of the drugs. 
Chinese herbal medicines (CHMs) have been used to treat AE for many years. Recent 
evidence suggests CHMs may reduce the itchiness and improve quality of life for 
people with AE. 
Recruiting patients now 
RMIT University is conducting a double-blind placebo controlled trial for moderate to 
severe AE or AD. The study will compare the effect of oral Chinese herbal medicine 
granules with placebo in reducing itchy skin and skin lesions. The trial will last 16 
weeks and has been approved by RMIT HREC. Thirty children between 6 and 16 years 
of age with AE will participate. 
The details of the trial can be found on the Australian New Zealand Clinical Trials 
Registry  
Register your interest 
If you are interested in participating in the study, or would like more information, please 
contact Sherman Gu on (03) 9xxxxxxx or email eczema.trial@rmit.edu.au. The study is 
being conducted at RMIT University’s Bundoora West campus. 
 
 
  
 242 
 
China-Australia International Research Centre for Chinese Medicine and School of Health Sciences 
 
Appendix 8 Record Sheet for Potential Participants  
 
Number Participant 
and/or 
Guardian’ 
Surname 
Given 
Name 
Gender 
 
Postal 
Address 
Date 
of 
Birth 
Tel: 
Home 
Tel: 
Business 
Mobile: Email 
Address 
PICF* 
Sent 
out 
Initials 
and 
Signature 
of the 
Recorder  
1            
2            
3            
4            
5            
6            
7            
8            
9            
10            
            
 
*PICF: Participant Information and Consent Form 
 
Participant’s Initials:                                    Participant’s ID:                        Date: 
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Appendix 9  The Participant Information and Consent Form (PICF) 
 
INVITATION TO PARTICIPATE IN A RESEARCH PROJECT 
 
PARTICIPANT INFORMATION 
 
Project Title: Randomised Double-Blind Placebo-Controlled Clinical Trial of Oral 
Ingestion of Chinese Herbal Medicine Granules for Children with Moderate to Severe 
Atopic Eczema 
Investigators:  
Prof Charlie Xue BMed, PhD (Chief trial investigator) 
Head, School of the Health Sciences, RMIT University 
Registered Chinese medicine practitioner 
 
Dr Tony Zhang BMed, MPH, PhD (Co- investigator) 
Head, Discipline of Chinese Medicine, School of the Health Sciences, RMIT University 
Registered Chinese medicine practitioner  
 
Dr George Binh Lenon BHlthSc (Hons), PhD (Co- investigator) 
Lecturer, Discipline of Chinese Medicine, School of the Health Sciences, RMIT 
University 
Registered Chinese medicine practitioner 
 
Dr. Meaghan Coyle, BlthSc(Acup), PhD 
Research Fellow, Discipline of Chinese Medicine, School of the Health Sciences, RMIT 
University,  
Registered Chinese medicine practitioner 
 
Prof Dacan Chen PhD (Co-investigator) 
Dermatologist, Guangdong Provincial Hospital of Chinese Medicine, China 
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A/Prof Noel E Cranswick MBBS, BMedSc, LLB, FRACP (Co-investigator) 
Paediatrician & clinical pharmacologist, Royal Children's Hospital, Melbourne 
 
Mr Xu Ming Gu BMed, MAppSc (Principal research student) 
Complementary Medicine PhD candidate 
Registered Chinese medicine practitioner 
 
 
 
Dear …………., 
You (the term “you” in the contents also includes your child) are invited to participate 
in a research project being conducted by the China-Australia International Research 
Centre for Chinese Medicine and the School of Health Sciences RMIT University. 
Please read this sheet carefully and be confident that you understand its contents before 
deciding whether to participate. If you have any questions about the project, please ask 
one of the investigators.  
 
Who is involved in this research project? Why is it being conducted?  
 
This research project is being conducted as part of Mr Xu Ming Gu’s PhD degree. The 
project is led by Professor Charlie Xue and Dr Tony Zhang. Two experts outside RMIT 
Professor Dacan Chen from Guangdong Provincial Hospital of Chinese Medicine, 
China and Associate Professor Noel Cranswick from the Royal Children’s Hospital, 
Melbourne are medical consultants for this project. The results of this project will be 
presented in academic conference and journal publication. This is a pilot study that will 
inform a large size clinical trial in the future. 
The project has been approved by RMIT HREC. This project is funded by RMIT 
University and the Guangdong Provincial Hospital of Chinese Medicine.  
 
Why have you been approached?  
 
You have been diagnosed with atopic eczema (AE) or atopic dermatitis (AD). You may 
have been referred by your health care provider or you have contacted us in response to 
reading a recruitment poster displayed in a clinic or you have seen a media 
advertisement from our research team.  
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What is the project about? What are the questions being addressed?  
 
This is a pilot study with a total of 30 participants recruited. The project is a double-
blind trial for AE or AD, lasting only 16 weeks. The study will compare Chinese herbal 
granules named “PTQX” with placebo and test if the Chinese herbal formula is effective 
in reducing itchy skin and skin lesions.   
 
If I agree to participate, what will I be required to do?  
 
If you agree to participate in this project, we will provide PTQX – which is a mixture of 
medicinal herbs in granule form, or placebo granules with inert substances that will be 
taken orally (by mouth) for 12 weeks. You will be required to attend the clinical trial 
centre located at the RMIT University Bundoora campus 6 times over 16 weeks for 
about 1 hour on each occasion.  
 
Screening Period (30 to 60 minutes) 
In this stage, you will be interviewed by the research team at the trial centre for 
eligibility. You will be provided with detailed information of this project and have an 
opportunity to ask questions. You will be required to fill out some forms which will 
record your present skin condition and other information. You might be asked 
questions, for instance, “Over the last week, how itchy, sore, painful or stinging has 
your skin been?” The forms will be used at the end of the trial to compare the difference 
of your conditions with the previous information you provided. At this time you will be 
asked to sign this PICF form if you consent to participate. You will undertake a blood 
test in order to test your liver and kidney function. You will then be booked for a 
baseline assessment 2 weeks from this stage. 
 
Baseline period, 1
st
 visit (60 minutes) 
In this stage, you will be assessed by the research team in the trial centre with a number 
of questionnaires. You will then be randomly allocated into either a treatment group or 
control group and be given PTQX or placebo sachets for 4 weeks. You will have to take 
the granules two times a day. You will then be booked for mid-treatment assessment 4 
weeks from this visit.  
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Mid-treatment period, 2
nd
 visit (30 – 60 minutes) 
In this stage, you will be assessed by the research team in the trial centre with a number 
of questionnaires. You will be given the granules for another 4 weeks. You will 
undertake a blood test for testing your liver and kidney function again and you will then 
be booked for mid-treatment assessment 4 weeks from this visit. 
 
Mid-treatment period, 3
rd
 visit (30 – 60 minutes) 
In this stage, you will be assessed by the research team at the trial centre with a number 
of questionnaires. You will be given the granules for a further 4 weeks and you will 
then be booked for endpoint assessment 4 weeks from this visit. 
 
Endpoint, 4
th
 visit (30 – 60 minutes) 
In this stage, you will be assessed by the research team in the trial centre with a number 
of questionnaires. You will be asked to return all forms or dairies in which you have 
recorded information. You will undertake a blood test for testing your liver and kidney 
function. You will then be booked for the follow-up assessment 4 weeks from this visit. 
 
Follow-up, 5
th
 visit (30 – 60 minutes) 
In this stage, you will be assessed by the research team at the trial centre with a number 
of questionnaires. 
 
What are the possible risks or disadvantages?  
 
PTQX has been used clinically in China for years and there is no evidence to show 
adverse reaction of a serious nature in relation to the application of PTQX. If any 
serious adverse reaction occurs in relation to the application of the preparation, you 
should stop using PTQX immediately and you will be treated by prompt medical 
attention. If any symptoms persist please seek medical assistance from your GP or an 
emergency department of a hospital. The blood tests can cause minor pain with 
insertion of the needle. All blood tests will be funded from the research fund and 
performed by qualified personnel . 
 If you are unduly concerned about your responses to any of the questionnaire items or 
if you find participation in the project distressing, you should contact Dr Tony Zhang as 
soon as convenient. Dr Zhang will discuss your concerns with you confidentially and 
suggest appropriate follow-up, if necessary. Similarly you may contact your GP and the 
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RMIT HREC for concerns if you would prefer them handled by someone outside the 
research team. 
You will not know whether you have received PTQX or placebo granules until the trial 
is completed. However, the identity of the granules can be determined immediately if 
any serious adverse reaction develops and you will be contacted and referred to Dr Tony 
Zhang.  
This project will be in compliance with all requirements listed in the ICH Note for 
Guidance on Good Clinical Practice. 
 
What are the benefits associated with participation?  
 
Your condition might be improved once the full course of treatment is completed. Of 
course, this is not guaranteed or promised and you will not receive the Chinese herbal 
granules treatment if you are in the control group.  
 
What will happen to the information I provide?  
 
By signing this form, you consent to provide your personal information and medical 
condition(s) to the research team. However, any personal information you provided will 
remain confidential. No identity of any participant in this project will be disclosed in 
any public reports or publications. However, for the purpose of monitoring, supervision 
and review of the trial, identified data will be seen by a small number of people such as 
the project supervisors, consultants and personnel from RMIT HREC. Any information 
that you provide can be disclosed only if (1) it is to protect you or others from harm, (2) 
if specifically required or allowed by law, or (3) you provide the researchers with 
written permission.  
Results of the project will be included in the PhD thesis and will be held in the RMIT 
Repository which is a publicly accessible online library of research. Results of the 
project will also be submitted to a professional journal for publication or academic 
conferences for presentation once the project is concluded. Data of the project will be 
used for a larger size trial in the future. None of the information related to the privacy of 
you as participants such as your name or contact details will be released in any 
publication or presentation. 
Storage and disclosure of the information in this project will be strictly under the 
guidance of the Australian Government Statement and Guidelines on Research 
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Practice.  The research data will be kept securely at RMIT for a period of 15 years 
before being destroyed.  
 
What are my rights as a participant?  
 
You will have 
The right to withdraw from participation at any time; 
The right to request that any recording cease; 
The right to have any unprocessed data withdrawn and destroyed, provided it can be 
reliably identified, and provided that so doing does not increase the risk for the 
participant; 
The right to be de-identified in any photographs intended for public publication, before 
the point of publication; 
The right to have any questions answered at any time.  
 
Whom should I contact if I have any questions?  
 
Please contact Mr Xu Ming Gu at (03) 9xxxxxxx during business hours for questions 
related with this project. Outside of business hours you should contact your GP or 
emergency department of a hospital if you require urgent health related information or 
assessment. 
 
 
What other issues should I be aware of before deciding whether to participate?  
 
Before deciding to participate in this project, you need to commit to take the Chinese 
herbal granules twice daily for 12 weeks and attend the clinical trial centre 6 times for 
assessment as well as record medications that you use during the trial for completion of 
the project. 
 
Yours sincerely 
 
 
Prof Charlie Xue 
BMed, PhD  
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Dr Tony Zhang  
BMed, MPH, PhD  
 
Dr George Binh Lenon 
BHlthSc (Hons), PhD  
 
Dr Meaghan Coyle  
BlthSc(Acup), PhD 
 
Prof Dacan Chen 
PhD  
 
 
A/Prof Noel E Cranswick 
MBBS, BMedSc, LLB, FRACP 
 
Mr Xu Ming Gu  
BMed, MAppSc  
 
 
If you have any concerns about your participation in this project, which you do not wish 
to discuss with the researchers, then you can contact the Ethics Officer, Research 
Integrity, Governance and Systems, RMIT University, GPO Box 2476V VIC 3001. Tel: 
(03) 9925 2251 or email human.ethics@rmit.edu.au 
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CONSENT  
 
I have had the project explained to me, and I have read the information sheet  
 
I agree to participate in the research project as described 
 
I agree: 
to undertake the tests or procedures outlined  
to be interviewed and/or complete the questionnaires 
 
I acknowledge that: 
 
My participation is voluntary and that I am free to withdraw from the project at any 
time and to withdraw any unprocessed data previously supplied (unless follow-up is 
needed for safety). 
The project is for the purpose of research. It may not be of direct benefit to me. 
(c) The privacy of the personal information I provide will be safeguarded and only 
disclosed where I have consented to the disclosure or as required by law.  
(d) The security of the research data will be protected during and after completion 
of the study. The data collected during the study may be published, and a report of the 
project outcomes will be provided to professional journal or conference. Any 
information which will identify me will not be used. 
 
Participant’s Consent 
 
Participant:  Date:  
(Signature) 
 
Witness: 
Witness:  Date:  
(Signature) 
 
Where participant is under 18 years of age:  
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I consent to the participation of ____________________________________ in the 
above project. 
 
Signature: (1)                                            (2) 
 
Date
: 
 
(Signatures of parents or guardians) 
 
 
Witness:  Date:  
(Witness to signature) 
 
 
Participants should be given a photocopy of this PICF after it has been signed. 
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Informed Assent Form for Children with Moderate to Severe Atopic Eczema 
*
 
 
 (This informed assent form is for children between the ages of 6 - 16 who attend RMIT 
clinical trial center and who we are inviting to participate in research of Chinese herbal 
granules [PTQX].) 
Project Title: Randomised Double-Blind Placebo-Controlled Clinical Trial of Oral 
Ingestion of Chinese Herbal Medicine Granules for Children with Moderate to Severe 
Atopic Eczema 
Investigators:  
Prof Charlie Xue BMed, PhD (Chief trial investigator) 
Head, School of the Health Sciences, RMIT University 
Registered Chinese medicine practitioner 
 
Dr Tony Zhang BMed, MPH, PhD (Co- investigator) 
Head, Discipline of Chinese Medicine, School of the Health Sciences, RMIT University 
Registered Chinese medicine practitioner  
 
Dr George Binh Lenon BHlthSc (Hons), PhD (Co- investigator) 
Lecturer, Discipline of Chinese Medicine, School of the Health Sciences, RMIT 
University 
Registered Chinese medicine practitioner 
 
Dr. Meaghan Coyle, BlthSc(Acup), PhD 
Research Fellow, Discipline of Chinese Medicine, School of the Health Sciences, RMIT 
University,  
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Registered Chinese medicine practitioner 
 
Prof Dacan Chen PhD (Co-investigator) 
Dermatologist, Guangdong Provincial Hospital of Chinese Medicine, China 
 
A/Prof Noel E Cranswick MBBS, BMedSc, LLB, FRACP (Co-investigator) 
Paediatrician & clinical pharmacologist, Royal Children's Hospital, Melbourne 
 
Mr Xu Ming Gu BMed, MAppSc (Principal research student) 
Complementary Medicine PhD candidate 
Registered Chinese medicine practitioner 
  
 
 
This Informed Assent Form has two parts: 
Information Sheet (gives you information about the study) 
Certificate of Assent (this is where you sign if you agree to participate) 
You will be given a copy of the full Informed Assent Form 
Part I: Information Sheet 
Introduction  
 My name is Xu Ming Gu and my job is to research and test Chinese herbal granules 
(PTQX) to see if they work for eczema. We want to know if PTQX will stop children 
from getting itchiness and we think this research could help tell us that.  
 I am going to give you information and invite you to be part of a research study. You 
can choose whether or not you want to participate. We have discussed this research with 
Participant’s Initials:                                    Participant’s ID:                        Date: 
 254 
your parent(s)/guardian and they know that we are also asking you for your agreement. 
If you are going to participate in the research, your parent(s)/guardian also have to agree.  
You may discuss anything in this form with your parents or friends or anyone else you 
feel comfortable talking to. You can decide whether to participate or not after you have 
talked it over. You do not have to decide immediately. 
There may be some words you don't understand or things that you want me to explain 
more about because you are interested or concerned. Please ask me to stop at any time 
and I will take time to explain. 
Purpose: Why are you doing this research? 
 We want to find helpful medicines to control eczema that are also safe. We have 
existing Chinese herbal granules (PTQX) which we are hoping might be better than the 
drugs that are currently being used. In order to find out if they are better we have to test 
them. 
Choice of participants: Why are you asking me? 
We are testing PTQX on children who are your age - between 6 and 16 years old who 
have had eczema for years.  
Participation is voluntary: Do I have to do this?  
You don't have to be in this research if you don't want to be. It’s up to you. If you 
decide not to be in the research, it is okay and nothing changes. Even if you say "yes" 
now, you can change your mind later and it is still okay.  
I have checked with the child and they understand that participation is voluntary 
__ (initial) 
Information on the Trial herbs (PTQX): What is this drug and what do you know 
about it? 
This is a pilot study which means we will only be testing these herbs on a small number 
of children - 30. The project is called a double-blind trial for eczema, lasting only 16 
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weeks. Double blind means we will compare Chinese herbal granules named “PTQX” 
with placebo herbs and test if the Chinese herbal formula is effective in reducing itchy 
skin and skin lesions. You won’t know if you are receiving the real herbs or the placebo 
herbs. We won’t know that either from the sachets of herbs we give you.  
 Procedures: What is going to happen to me? 
If you agree to participate in this project, we will provide PTQX – which is a mixture of 
medicinal herbs in granule form – or placebo granules, that you will swallow 2 times 
each day for 12 weeks. You will be required to attend the clinical trial centre located at 
the RMIT University Bundoora campus 6 times over 16 weeks for about 1 hour on each 
occasion for a check-up.  
You can ask me to stop and explain again at any time and I will explain more about the 
process.  
 
 I have checked with the child and they understand the procedures ________ 
(initial) 
 
Risks: Is this bad or dangerous for me?  
PTQX is considered safe. It has already been tested on adults and on other children in 
China. There has been nothing that has worried us at all. If anything unusual happens to 
you, however, we need to know and you should feel free you to call us anytime with 
your concerns or questions. Another way of us knowing how you are is by having you 
come to the clinic every month for a check-up. If you get sick or have concerns or 
questions in-between the scheduled visits to the clinic, you should let me or Tony who 
is my supervisor know. You don't have to wait for a scheduled visit. 
Discomforts: Will it hurt? 
There are a few other things that I want you to know.  
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The blood collection might hurt for just a second when it goes into your arm. You might 
get a little bit of a bitter taste in your mouth after drinking the trial medication. That 
should go away if you have a drink of water. If you feel bad or strange, tell us. 
Sometimes you may not want to come to the clinic to get your blood checked. It is 
important that you try to come. It won't take very long. You may miss a little bit of 
school - about an hour every month.  
I have checked with the child and they understand the risks and discomforts ____ 
(initial) 
Benefits: Is there anything good that happens to me? 
PTQX may stop you from having itchy skin. Nothing really good might also happen to 
you. But this research might help us to find PTQX now or later that could help other 
children. There is a good thing too if you do decide that you want to do this. You do get 
regular check-ups with us so that if you are sick, we will know very soon and this can 
be important.  
I have checked with the child and they understand the benefits_____ (initial) 
 
Reimbursements: Do I get anything for being in the research?  
No. However, because you might live quite far from the trial centre, we will help your 
parents pay for the trip to our university. 
Confidentiality: Is everybody going to know about this? 
We will not tell other people that you are in this research and we won't share 
information about you to anyone who does not work in the research project. After the 
research is over, you and your parents will be told whether you received the real herbs 
PTQX or the placebo herbs and we will also tell you whether the real herbs helped 
children with this problem in our study. 
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Information about you that will be collected from the research will be put away and no-
one but the researchers will be able to see it. Any information about you will have a 
number on it instead of your name. Only the researchers will know what your number is 
and we will lock that information up with a lock and key. It will not be shared with or 
given to anyone except the project supervisors, consultants and personnel from the 
RMIT ethics committee.  
Compensation: What happens if I get hurt? 
If you become sick during the research, we will look after you. We have given your 
parents information about what to do if you are hurt or get sick during the research. 
Sharing the Findings: Will you tell me the results? 
When we finish the research, I will tell you about what we learnt. I will also give you a 
paper with the results written down. Afterwards, we will be telling more people, 
scientists and others, about the research and what we found. We will do this by writing 
and sharing reports and by going to meetings with people who are interested in the work 
we do.  
Right to Refuse or Withdraw: Can I choose not to be in the research? Can I 
change my mind? 
You do not have to be in this research. No one will be mad or disappointed with you if 
you say no. It is your choice. You can think about it and tell us later if you want. You 
can say "yes" now and change your mind later and it will still be okay. 
Who to Contact: Who can I talk to or ask questions to? 
You can ask me questions now or later. You can ask the other members of this research 
team any questions you have. I am giving you a number and address where you can 
reach us. If you want to talk to someone else that you know like your teacher or doctor 
or auntie, that's okay too. 
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If you choose to be part of this research I will also give you a copy of this paper to 
keep for yourself. You can ask your parents to look after it if you want.  
 
PART 2: Certificate of Assent 
I understand the research is about testing Chinese herbal granules (PTQX) for eczema 
and that I might get either the PTQX or the placebo herbs. I understand that I will 
swallow the granules every day for 12 weeks and that I will come for regular monthly 
check-ups at the clinic where I will give a blood sample by a needle that will be put into 
the vein in my arm. 
 I have read this information (or had the information read to me). I have had my 
questions answered and know that I can ask questions later if I have them.  
 
I agree to take part in the research. 
OR 
I do not wish to take part in the research and I have not signed the assent 
below.___________(initialled by child/minor) 
 
Only if child assents: 
Print name of child ___________________ 
Signature of child: ____________________ 
Date:________________ 
           day/month/year    
 
 
*
 
 
This form was adapted and modified from Informed Assent for Children/Minors template developed by 
WHO ERC http://www.who.int/rpc/research_ethics/informed_consent/en/ accessed on 26 May 2014  
Participant’s Initials:                                    Participant’s ID:                        Date: 
 259 
 
China-Australia International Research Centre for Chinese Medicine and School of 
Health Sciences 
Appendix 10 General Information Questionnaires 
(All Information provided will be strictly confidential abiding to States and 
Commonwealth statues. Please fill in the form carefully and thoroughly.) 
 
 
Title: _______Family Name: __________________________ Given Name: _______________________ 
Date of Birth: _____________________   Gender:  Female  Male.  
Body Height: ____________cm,           Body Weight: ________kg 
Address: ________________________________________________________ Postcode: ____________ 
Phone:___________________(Home)____________________(Work) ____________________(Mobile) 
Contact details of the person you wish to be contacted in an emergency  
 
Name:_______________________________Phone:____________________________ 
Do you have any known Allergies or Alert to adverse drug reactions?  No  Yes 
______________________________(Please indicate) 
Please list all previous illnesses, accidents and surgeries: 
_______________________________________ 
__________________________________________________________________________________  
Do you or any of your parents or siblings have atopic eczema, asthma or allergic rhinitis (hay fever)?  
________________________________________________________________________________ 
Please list your current medical conditions and medications: ____________________________ 
 
Your family doctor (optional) : ___________________________  
 
How do you come to know this trial?  
 Family or Friends    Media    Internet    Others ____________________(Please indicate) 
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 Appendix 11 Inclusion/Exclusion Criteria 
   (Screening Instruments 1) 
Instructions: 
This form should be completed by a trial investigator with consultation of the 
participant or his/her guardian on the screening stage of the trial.  An eligible participant 
must be in keep with Criterion 1 and 2 plus at least 3 out of Criteria 3 to 7 and all of 
Criteria 8 and 9 of the Inclusion criteria. 
 
Inclusion Criteria 
 Questions Yes No 
1 Are you more than 6 year old and under 16 years old   
2 Do you have a history of skin itchiness in the last 12 months   
 Yes No   
3a Did the skin condition start under 2 years old     
3b Do you have a history of flexural involvement     
3c Do you have a history of a generally dry skin     
3d Do you have history of other atopic disorders, 
such as asthma, allergic rhinitis (hay fever) 
    
3e  Do you have visible flexural dermatitis     
4 Are at least 3 of the answers from 3a-3e Yes?   
5 Baseline NESS score ≥ 9   
6 Have you signed the informed consent form and expressed 
your compliance with the requirements of the trial 
  
Exclusion Criteria 
1 Have you been using corticosteroids or other 
immunosuppressives orally in the past 30 days  
  
2 Have you been using any preparation of Chinese herbal 
medicines or other herbs for treatment of the skin eczematous 
changes orally in the past 30 days 
  
3 Has your current skin condition been diagnosed as scabies   
4 Has your current skin condition been diagnosed as allergic 
contact dermatitis  
  
5 Has your current skin condition been diagnosed as seborrhoeic 
dermatitis  
  
6 Has your current skin condition been diagnosed as psoriasis    
7 Do you have any present history of cardiovascular dysfunction   
8 Do you have any present history of  liver or renal dysfunction   
9 Do you have any present history of  lactose intolerance    
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Appendix 12 Assessment Form for NESS

 
   (Screening Instruments 2) 
 
Instructions: 
This form should be completed by a trial investigator with consultation of the 
participant or his/her guardian on the screening stage of the trial.   
 
Nottingham Eczema Severity Score (NESS) 
 
1. Clinical Course (ask the Parent) 
 
In the last 12 months has your child’s skin condition been: Score (please circle 
one answer) 
a) Present for less than 6 weeks in total? 1 
b) Present for between 6 weeks and less than 3 months in total? 2 
c) Present for between 3 months and less than 6 months in total? 3 
d) Present for between 6 months and less than 9 months in total? 4 
e) Present for more than 9 months in total? 5 
 
2. Clinical Intensity (ask the Parent) 
 
In the last 12 months, how often has your child’s sleep usually 
been disturbed by itching or scratching due to their skin 
problem? 
Score (please circle 
one answer) 
a) Sleep is not usually disturbed 1 
b) 1 night per week on average 2 
c) 2 or 3 nights per week on average 3 
d) 4 or 5 nights per week on average 4 
e) 6 or more nights per week on average 5 
 
3. Extent of AE by Examination (see surface diagram) 
 
Score (please circle one answer) 
1 
2 
3 
4 
5 
                                                 

 This form is adapted from R.M. Emersion, H.C. Williams, Department of Dermatology, University 
Hospital, Queen’s Medical Centre, Nottingham NG7 2UH, U.K. with permission of the authors for 
research purpose. 
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4. Final Assessment Severity 
 
Mild: total score 3-8  
Moderate: total score 9-11  
Severe: total score 12-15  
  
Surface area measurement using tick boxes 
Record a tick in each box if more than 2 cm 2 (size of a 10 pence coin) is involved with 
AE. Calculate the total ticks by adding together the number of recorded ticks for both 
the front and back of the surface diagram. The final score is calculated using the tables 
below.  
 
 
 
 
 
 
  
 
Number of ticks Score Final score (tick one) 
0-2 1  
3-5 2  
6-10 3  
11-20 4  
> 20 5  
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Appendix 13 Record Sheet of Withdrawals/Dropouts of the Participants  
 
 
Participant’s 
ID 
Date of 
Withdrawal/ 
Dropout 
Reason(s) of 
Withdrawal/ 
Dropout 
Proper 
Unprocessed Data 
Withdrawn and 
Destroyed 
Signature of the 
Investigator 
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Appendix 14 Instructions for Completing Case Report Forms 
 
Pen:     
 
Always use a black ball-point pen when writing in case report forms. 
 
Text:    
 
Please write clearly in legible English. 
 
Identification of participant:  
 
Please ensure that the participant number & initials are clearly stated on the designated 
portion of each page. 
 
Missing/unavailable data:  
 
Please do not leave data boxes empty. If data is missing, put a single line through the 
blank section and add a comment stating why the data was not available e.g. “not done”.   
 
Abnormal data:  
 
Please give the reason for any abnormal data in the space provided in the Case Report 
Form (CRF). 
 
Corrections:  
 
Please do not make changes with correction fluid. Draw a single line through the 
incorrect value so that it is still legible.  Write the correct value clearly as near as 
possible to the original value.  Initial and date the change. 
 
Dates:  
 
Please write dates using this order: dd/mm/yyyy. 
 
Times:  
 
Please document times using 24-hour notation. 
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Appendix 15 Assessment Form for EASI  
 
 
Instructions: 
This form should be completed by a trial investigator with consultation of the 
participant or his/her guardian on the stages of baseline, treatment, endpoint and 
following up. 
 
 
Eczema Area and Severity Index (EASI) 

 
 
Calculation for patients 8 years of age and older
1 
 
 Body region  EASI Score 
2, 3
 
 
 Head/Neck (H) (E+I+Ex+L) x Area x 0.1 (0.2 for children under 7 years 
old) 
 
 Upper limbs (UL) (E+I+Ex+L) x Area x 0.2 
 
 Trunk (T)  (E+I+Ex+L) x Area x 0.3 
 
Lower limbs (LL) (E+I+Ex+L) x Area x 0.4 (0.3 for children under 7 years old) 
 
EASI =  Sum of the above 4 body region scores  
  
 
Note: 
1
For children aged 0-7 years, proportionate areas were head/neck, 20%; 
 Upper limbs, 20%; trunk 30%; and lower limbs, 30%. 
 
 
2
E=Erythema, I=induration/papulation, Ex=excoriation, L=lichenification. 
 
 
3
Where area is defined on a 7-point ordinal scale: 0=no eruption; 1 ≤ 10%; 
 
 2 ≤ 10-29%; 3 ≤ 30-49%; 4 ≤ 50-69%; 5 ≤ 70-89%; and 6 ≥ 90-100%. 
  
                                                 

 This form is adapted and modified from Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. 
J., & Graeber, M. (2001). The eczema area and severity index (EASI): assessment of reliability in atopic 
dermatitis. EASI Evaluator Group. Experimental Dermatology, 10 (1), 11-18 
Participant’s Initials:                                    Participant’s ID:                        Date: 
 266 
 
1.  Scores of the Head/Neck (H) = Intensity score______ x Area score _______x 
0.1 (or 0.2 for children < 7 years old) = _______  
 
Intensity of AE (please circle one, half points are accepted) 

 
 
 Score 
Erythema 0 1 2 3  
Induration/ 
papulation 
0 1 2 3  
Excoriation 0 1 2 3  
Lichenification 0 1 2 3  
 Total 
score: 
 
 
Area involved (please circle one only) 
*
 
 
Eruption 0 1-9% 10-29% 30-49% 50-69% 70-89% 90-
100% 
Number of 
palm for 
children > 7 
years old 
0 1 2 3-4 5-6 7-8 9-10 
Number of 
palm for 
children < 7 
years old 
0 1 2-5 6-9 10-13 14-17 18-20 
Area score in 
H 
0 1 2 3 4 5 6 
 
 
2. Scores of the Upper limbs (UL) = Intensity score______ x Area score _______x 
0.2 = _______  
 
Intensity of AE (please circle one, half points are accepted) 
 
 Score 
Erythema 0 1 2 3  
Induration/ 
papulation 
0 1 2 3  
Excoriation 0 1 2 3  
Lichenification 0 1 2 3  
 Total 
score: 
 
 
Area involved (please circle one only) 
 
                                                 

 Score of intensity should be assessed with the figures illustrated in 
http://dermnetnz.org/dermatitis/easi.html with author’s permission for this project. 
*
 Palm method developed by the PASI training at http://www.pasitraining.com/bsa_score/ is adopted 
(accessed on 22 August 2014)   
Participant’s Initials:                                    Participant’s ID:                        Date: 
 267 
Eruption 0 1-9% 10-29% 30-49% 50-69% 70-89% 90-100% 
Number 
of palm 
for all 
age 
0 1 2-5 6-9 10-13 14-17 18-20 
Area 
score in 
UL 
0 1 2 3 4 5 6 
 
 
 
3. Scores of the Trunk (T) = Intensity score______ x Area score _______x 0.3 = 
_______  
 
Intensity of AE (please circle one, half points are accepted) 
 
 Score 
Erythema 0 1 2 3  
Induration/ 
papulation 
0 1 2 3  
Excoriation 0 1 2 3  
Lichenification 0 1 2 3  
 Total 
score: 
 
 
Area involved (please circle one only) 
 
Eruption 0 1-9% 10-29% 30-49% 50-69% 70-89% 90-100% 
Number 
of palm 
for all 
age 
0 1-2 3-8 9-14 15-20 21-26 26-30 
Area 
score in 
T 
0 1 2 3 4 5 6 
 
 
 
 
4.  Scores of the Lower limbs (LL) = Intensity score______ x Area score _______x 
0.4 (or 0.3 for children < 7 years old) = _______  
 
Intensity of AE (please circle one, half points are accepted) 

 
 
 Score 
Erythema 0 1 2 3  
Induration/ 
papulation 
0 1 2 3  
Excoriation 0 1 2 3  
                                                 

 Score of intensity should be assessed with the figures illustrated in 
http://dermnetnz.org/dermatitis/easi.html with author’s permission for this project. 
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Lichenification 0 1 2 3  
 Total 
score: 
 
 
Area involved (please circle one only) 
 
Eruption 0 1-9% 10-29% 30-49% 50-69% 70-89% 90-100% 
Number of 
palm for 
children > 7 
years old 
0 1-3 4-11 12-19 20-27 28-35 36-40 
Number of 
palm for 
children < 7 
years old 
0 1-2 3-8 9-14 15-20 21-26 26-30 
Area score in 
LL 
0 1 2 3 4 5 6 
 
 
 
 
Sum of EASI = H (_______) + UL (_______) + T (_______) + LL (_______) = 
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Appendix 16 Assessment Form for POEM  
Patient-oriented eczema measure (POEM) 
 (Infant and young children’s version for parents to complete) 
 
 
Instructions: 
This form should be completed by the participant or his/her guardian on the stages of 
baseline, treatment, endpoint and following up. 
 
Please circle one response for each of the seven questions below about your child’s 
eczema. If your child is old enough to understand the questions then please fill in the 
questionnaire together. Please leave blank any questions you feel unable to answer. 
 
1. Over the last week, on how many days has your child’s skin been itchy because of 
their eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
2.  Over the last week, on how many nights has your child’s sleep been disturbed 
because of their eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
3. Over the last week, on how many days has your child’s skin been bleeding because of 
their eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
4. Over the last week, on how many days has your child’s skin been weeping or oozing 
clear fluid because of their eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
5. Over the last week, on how many days has your child’s skin been cracked because of 
their eczema? 
 
                                                 

 This form is adapted from Charman, C. R., Venn, A. J., & Williams, H. C. (2004). The patient-oriented 
eczema measure: development and initial validation of a new tool for measuring atopic eczema severity 
from the patients' perspective. Archives of dermatology, 140(12), 1513-19 with permssion from the 
authors for reasearch purpose. 
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No days 1-2 days 3-4 days 5-6 days Every day 
 
6. Over the last week, on how many days has your child’s skin been flaking off because 
of their eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
7. Over the last week, on how many days has your child’s skin felt dry or rough because 
of their eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
 
 © CR Charman, AJ Venn, HC Williams, December 2004. 
 
 
 
 
Total POEM score: 
(maximum 28)  
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Appendix 17 Children's Dermatology Life Quality Index (CDLQI) 
1. Instructions: 
The aim of this questionnaire is to measure how much your skin problem has affected you OVER THE 
LAST WEEK.  Please tick  one column for each question. The form is designed for a participant to 
fill it in with the help of the child's parent or guardian.  
 
 Questions Very 
much 
Quite 
a lot 
Only a 
little 
Not at 
all 
1 Over the last week, how itchy, "scratchy", sore 
or painful has your skin been?  
    
2 Over the last week, how embarrassed or self 
conscious, upset or sad have you been because 
of your skin? 
    
3 Over the last week, how much has your skin 
affected your friendships? 
    
4 Over the last week, how much have you changed 
or worn different or special clothes/shoes 
because of your skin? 
    
5 Over the last week, how much has your skin 
trouble affected going out, playing, or doing 
hobbies? 
    
6 Over the last week, how much have you avoided 
swimming or other sports because of your skin 
trouble? 
    
7a If school time: Over the last week, how much 
did your skin problem affect your school work?   
                                        Prevented school      
    
7b If holiday time: How much over the last week, 
has your skin problem interfered with your 
enjoyment of the holiday? 
    
8 Over the last week, how much trouble have you 
had because of your skin with other people 
calling you names, teasing, bullying, asking 
questions or avoiding you? 
    
9 Over the last week, how much has your sleep 
been affected by your skin problem? 
    
                                                 

 CDLQI was adapted from Lewis-Jones, M. S., & Finlay, A. Y. (1995). The children's dermatology life quality index 
(CDLQI): initial validation and practical use. British Journal of Dermatology, 132(6), 942-949 with permission of the 
authors for research purpose. 
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10 Over the last week, how much of a problem has 
the treatment for your skin been? 
    
 
Please check that you have answered EVERY question. Thank you.  
 
CDLQI score:  
 
2. Scoring: 
 
The scoring of each question is as follows:  
 
Very much scored 3 
Quite a lot scored 2 
Only a little scored 1 
Not at all scored 0 
Question unanswered scored 0 
Question 7: "Prevented school" scored 3 
 
The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a 
minimum of 0. The higher the score, the more quality of life is impaired. The CDLQI can also be 
expressed as a percentage of the maximum possible score of 30.  
 
(Please Note: That the scores associated with the different answers on Point 2 Scoring should not be 
printed on the CDLQI itself, as this might cause bias). 
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Appendix 18 Daily Medical Record Sheet 
 
This daily sheet should be recorded by the participant or his/her guardian every day when you are on 
the period of the trial.  Please take the record sheet for evaluation next time when you re-visit the trial 
center. 
You are allowed to use all other medications (concomitant medications) orally or topically for your 
skin or any other medical conditions during the trial period. However, if you have to take 
corticosteroid or other immunosuppressive drugs or herbal medicine orally for treatment of eczema 
during the trial period, you will not be eligible to continue to participate in the trial based on the 
inclusion and exclusion criteria.   
 
If any adverse reaction develops, please fill in the form “Adverse Event Questionnaires” 
separately. 
 
 
 
 
Record sheet for concomitant medications 
 
 
Date Medications Indication Dosage * Route 
     
     
     
     
     
     
     
 
Please add additional sheet if there is not enough space. 
*Fingertip measurement should be used for dosage of cream or ointment used topically.  
 
Record sheet for usage of trial medication 
Date Number of sachets 
you have taken in 
total 
If you have missed taking 
the trial medication, please 
record the reason in this 
column 
Have you return the 
empty sachets in the 
container 
(please √ if you have 
done so) 
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Please add additional sheet if there is not enough space. 
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Appendix 19 Outcome Measures Sheet 
 
Instruction:  This form is designed for recording outcome measures by the trial investigator. 
 
Particip
ant’s ID 
Visit/Week of 
Measurement 
Score of 
EASI 
Score 
of 
POEM 
Score 
of 
QoL 
Usage 
of 
other 
drugs 
Blood 
Tests 
Results 
Adverse 
Event 
 0/-2,-1 
(Screening 
period/run-in) 
      
1/0 
(Baseline) 
      
2/4       
3/8       
4/12 
 (Endpoint) 
      
5/16 
(Follow- up) 
      
 
Note: Shading of a box indicates no measurement is taken, i.e. blood tests will only be conducted on 
the Screening period, Week 4 and Endpoint. 
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Appendix 20 Pathology Tests 
 
 
COMMERCIAL REQUEST FORM 
DOREVITCH PATHOLOGY  
RMIT UNIVERSITY PTQX STUDY 
 
 
DETAILS FOR DATA ENTRY: 
PATIENT IDENTIFICATION -  
SURNAME:         GIVEN NAME:       
 
DATE OF BIRTH:         SEX:  Female  Male  
 
ADDRESS:  c/o- RMIT University PO Box 71 Bundoora Vic 3083 
 
NOTES:                      PTQX STUDY                       RMIT UNIVERSITY             NON REBATABLE  
 
REQUESTED BY: Dr XXXXX Dr Code :         RUYM 
 RMIT University 
 School of Health Sciences 
 PO Box xxxx 
 Bundoora Vic 3083 
  
 
 
COLLECTION DETAILS 
 
 
 
 
     Location 
   C    V    N    H 
       P    O    L 
  Service Date 
           /          /  
Time 
: 
Fee Cat 
MIT 
   
TESTS REQUIRED: 
 
TUBES FOR COLLECTION:    1 x 8.5ml SST (Gold Top) & 1x 4ml EDTA (purple 
top) 
  
   
 
TEST PROFILE 
CODE 
LFT LFT 
U&E, creatinine EUC 
IgE IGE 
FBE FBE 
Collection Fee T5 
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Person drawing blood: I certify that the blood specimen(s) accompanying this request was drawn from the patient named above and I 
established the identity of this patient by direct inquiry and immediately upon the blood being drawn 
I labelled the specimen(s).   
Signature of person collecting blood:  ……………………………………………………………………………….. 
Pathology Collector Name:  …………………………………………………………………………………………… 
 
 
ANY ENQUIRIES PLEASE CONTACT TANYA VASSALLO ON 9244 0292 
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Appendix 21 Adverse Event Questionnaires 
 
Please record any unexpected feelings or symptoms or signs during participation of the trial on the 
following table and report any severe adverse event to the investigator on (03) 9925 7375 and stop 
using the intervention products immediately until further instruction is given. 
Please scale the severity of the event by using the VAS table below and write down the score on the 
Record Sheet of Adverse Event.  0 is not at all, 5 is moderate and 10 is very severe.  
 
 
1. VAS table 
 
 
0 1 2 3 4 5 6 7 8 9 10 
 
2. Record Sheet of Adverse Event 
 
Type of Event 
(symptoms 
and/or signs) 
When did that 
happen? (date 
and time) 
How long did it 
last for? 
Severity of the 
event (0 to 10) 
What action 
did you do for 
the event? 
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Appendix 22 Record Sheet of the Compliance Check 
 
 
Participant’s 
ID 
Visit/Week Sequential 
Number of the 
Container 
Weight of 
Returned 
granules 
Investigator’s 
Signature 
 2/4    
 3/8    
 4/12    
 5/16 
(Follow-up) 
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Appendix 23 Survey for Participation of the Trial 
 
Instruction:  
Please fill in the questions by (√) and return the completed Survey at Visit 5 (Week 16) of the trial. 
 
1. Please indicate whether you could tolerate the colour and smell of trial medication used in this 
trial:  
□ Yes  
 
□ No 
 
□ Not sure 
 
2. If the CHM granules are available in future, would you like to use them again: 
□ Yes 
 
□ No 
 
□ Not sure 
 
3. Please indicate the treatment you believe you have received (this is for the purpose of testing 
the quality of the blinding procedure in this trial):  
□ Real CHM granules treatment 
 
□ Placebo treatment 
 
□ Not sure 
 
4. Do you want to receive a digital copy of the report for the final outcomes when this trial is 
concluded:  
□ Yes, please provide your email address: _________________________ 
 
□ No 
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Thank you again for your participation of this project, your contribution for development of Chinese 
Medicine practice is very much appreciated. 
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Appendix 24 Serious Adverse Event (SAE) Report Form *  
 
Randomised Double-blind Placebo-controlled Clinical Trial of Oral Ingestion of Chinese Herbal 
Medicine Granules for Children with Moderate to Severe Atopic Eczema 
Protocol Number: PTQX 0001 
Site Name: RMIT Health Sciences Research 
Hub 
Pt ID:  
Date Participant Reported: 
            /                   /                        . 
 d d m m m y y y y 
 
SAE onset date: ___ ___ / ___ ___ ___ / ___ ___ ___ ___ 
 d d m m m y y y y 
SAE stop date:  ___ ___ / ___ ___ ___ / ___ ___ ___ ___ 
 d d m m m y y y y 
Location of SAE:  
Was this an unexpected adverse event?  Yes  No 
Brief description of participants with no personal identifiers: 
Sex:   F  M Age:   
Diagnosis for study participation:  
  
Brief description of the nature of the SAE (attach description if more space is needed):  
  
  
Category of the SAE: 
 Date of death
 ___/_____/_______ 
 
 (dd/mmm/yyyy) 
 Life threatening 
 Hospitalisation – initial or prolonged 
 Disability/incapacity 
 Congenital anomaly/birth defect 
 Required intervention to prevent 
permanent impairment 
 Other:
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Intervention type: 
 Medication or nutritional supplement (specify):______________________ 
 Device (specify):___________________________ 
 Surgery (specify):__________________________ 
 Behavioural/lifestyle (specify):_________________________ 
Relationship of event to intervention: 
 Unrelated (clearly not related to the intervention) 
 Possible (may be related to intervention) 
 Definite (clearly related to intervention) 
Was study intervention discontinued due to event?  Yes  No 
What medications or other steps were taken to treat the SAE? 
 
List any relevant tests, laboratory data, and history, including pre-existing medical 
conditions: 
 
Has the event been reported to RMIT HREC and TGA with 7-15 days?     Yes  
No 
 
Type of report: 
 Initial 
 Follow-up 
 Final 
Signature of principal investigator:  __________________________  Date: ______ 
 
 
 
 
 
 
 
*This form is adapted from http://nccam.nih.gov/grants/toolbox with permission from 
the organisation for research purpose.  
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Appendix 25 Script of Introduction to the Trial  
(Initial consultation) 
Thank you for coming and participation of this trial.  
Self introduction 
My name is Xu Ming Gu (Sherman); I am a registered Chinese medicine practitioner 
and have been practising Chinese medicine for many years. I am conducting a project 
to see if a Chinese herbal formula works for eczema.   
About the trial 
This is a pilot study and a total of 30 participants will be recruited. The project is a 
double-blind placebo control trial for eczema which means you have 50:50 chance to 
receive a real treatment or placebo. The study will compare Chinese herbal granules 
named “PTQX” with placebo and test if the Chinese herbal formula is effective in 
reducing itchy skin and skin lesions.   The project has been approved by RMIT 
Human Research Ethics Committee. 
PTQX has been used a lot in clinical practice and there has been some research on 
whether it works. We want to do more research to see if it helps eczema. 
What you need to do 
If you agree to participate in this project, we will provide PTQX – which is a mixture 
of medicinal herbs in granule form and you need to mix up with warm water like a 
cup of tea and drink it twice every day for 12 weeks. You will be required to attend 
the clinical trial centre located at the RMIT University Bundoora campus 6 times over 
16 weeks for about 1 hour on each occasion for assessments of your condition by 
filling out some questionnaires forms.  
Please read the information sheet and consent form carefully and be confident that 
you understand its contents before deciding whether to participate. If you have any 
questions about the project, please feel free to ask me or any of the trial investigators. 
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Script  of introduction to the trial  
(Telephone conversation) 
Hello, thanks for calling. This is Sherman. I am one of the trial investigators.  
Our study will compare Chinese herbal granules prepared like a tea with placebo and 
test if the Chinese herbal formula is effective in reducing itchy skin and  skin lesions.  
This is a pilot study and a total of 30 participants will be recruited. The project is a 
double-blind trial for eczema lasting 16 weeks.  You will be required to attend the 
clinical trial centre located at the RMIT University Bundoora campus 6 times over 16 
weeks for about 1 hour on each occasion for assessments of your condition by filling 
out some questionnaires forms.  The project has been approved by RMIT Human 
Research Ethics Committee. 
 
Please visit our website _________________________________ 
for further information. I can send out an information pack to you. Could I have your 
name and mailing address please. Have a read through the documents, write down any 
questions you may have and feel free to talk to a friend, family member or doctor etc. 
Once you have time to read them, I will give you a call back see if you have any 
questions and to organise an appointment to check whether you are eligible. 
 
Thank you for the calling. 
 
(We may ask the potential participant further following questions if he/she shows 
interest to enrol the trial.) 
How old are you (is your daughter or son)? (6-16 years) 
Have you been diagnosed is eczema by your doctor or specialist? (AE or AD) 
Are you using any medications for eczema? (Exclusion oral usage of steroids or 
Chinese herbal medicines in the past 30 days or tell him/her to contact us after 
stopping using these medications for 30 days) 
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Appendix 26 Task Distribution Checklists for PTQX Trial
1
 
 
Trial investigators: Charlie Xue (CX),  Tony Zhang (TZ), Xu Ming Gu (XG), 
George Lenon (GL), Meaghan Coyle (MC), Noel Cranswick (NC), Xiamen Mo (XM), 
Dacan Chen (DC). 
Tool Summary Sheet 
Tool: Task Distribution Checklist 
Purpose: To identify who (at a group level) will be responsible for each 
of the various tasks associated with planning, executing, 
monitoring, analysing, reporting, and archiving a clinical 
research study 
Audience/User: Lead Investigators and all others responsible for any of the 
delineated tasks on the list 
Details: This document identifies which group will be conducting 
each of the various study tasks but is not intended to be a 
legal transfer of sponsor obligations.  The objective of this 
document is to ensure that all potential study responsibilities 
are considered and clearly assigned.   
Best Practice 
Recommendations: 
This document should be prepared early in a study to ensure 
that all responsibilities are clearly established. 
This tool can be edited to suit the needs and requirements of 
the study.  You can indicate “Not applicable” or remove rows 
at your discretion.  There are additional blank rows included 
for your convenience; add other responsibilities that may be 
important and/or unique to your study in these rows. 
All parties noted in the checklist should agree on the 
delineation of responsibilities and receive a copy of the 
completed document. 
Changes to the grid should be documented and the updated 
version should be made available to all responsible parties. 
For documents being developed, use “Develop (Dev)” for the 
initial author.  If the author is also the person making any 
updates to the master document, then it is not necessary to 
                                                 
1
 The checklist is adapted and modified from 
http://www.nidcr.nih.gov/nidcr2.nih.gov/Templates/Toolkit.aspx?NRMODE=Published&NRNODEG
UID=%7b09426ABC-1182-4433-9A7D-
A57674A5334F%7d&NRORIGINALURL=%2fResearch%2ftoolkit%2f&NRCACHEHINT=Guest#st
artup8 accessed on 9 July 2014 with permission from the authors.  
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have a separate “Update (Upd)” delineation.  It is assumed 
that the authoring group and the approving group will also 
have “Review (Rev)” responsibilities, so you don’t need to 
specify “Review” for those groups.  Use “Review” for other 
groups who have review responsibilities.   
 
Use “Update” if a party other than the author is responsible 
for updating the document.  (It is best to avoid the term 
“Revise” because the abbreviation will be difficult to 
differentiate from “Review.”) Use “Approve (App)” for the 
group with the ultimate approval authority.  This is not 
intended to be the RMIT Human Research Ethics Committee 
(HREC), for example, in the case of a protocol, but rather the 
study team group that approves the document prior to 
delivery to the HERC.  You may need to abbreviate for a 
group that has more than one responsibility (e.g., Upd/App).   
 
You may also choose to be more specific about the role 
responsible for a given task (e.g., Study Coordinator). 
Clinical research operations and management tasks must be 
conducted to ensure human subject safety, data integrity, and 
Good Clinical Practice (GCP). 
Abbreviations and Terms 
Approve (App) Responsible for approval prior to, when required, delivering 
to an external regulatory body such as the HREC or TGA   
Develop (Dev) Responsible for initial development 
Lead (L) Responsible for ensuring that the task is completed 
Review (Rev) Responsible for reviewing a document.  Not necessary to 
indicate for those marked with “Develop” or “Approve” 
responsibilities 
Update (Upd) Responsible for updating an item, if other than the individual 
with “Develop” responsibilities 
X Responsible for some or all of the components of the 
specified activity. 
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Study Management 
 
Not 
applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, 
XM, DC) 
 
1 
Provide overall program 
management and support (e.g., 
establishment of project 
plans/timelines, communication 
plan, execution strategies) 
 
   L X 
2 
Provide administrative support 
for meetings (e.g., agendas, 
minutes, scheduling, dial-in 
numbers) 
 
X X X L  
3 
Participate in teleconferences 
(team meetings) 
 
X X X L X 
4 
Plan/attend face to face 
meetings 
 
X 
X X X 
 
5 
Conduct internal team meetings 
and trainings  
 
X X X L  
6 
Provide status reports (HREC 
reports, timelines, etc.) 
 
X   L  
7 
Oversee herbs manufacturing 
facilities 
 
   L X 
8 Oversee study product supplier    X  L  
9 
Oversee study product 
packaging/labelling/distribution 
center 
 
 X  L  
10 
Oversee central laboratory for 
patients’ blood samples 
 
X L    
11 
Oversee contract research 
organisation 
 
  X L X 
12 Oversee clinical supply vendor  X  X L  
13 Oversee translation vendor X      
14 Oversee archival vendor  X  X L  
15 
Initiate the study in ANZCTR 
and provide updates on study 
progress 
 
X  X L  
16 
Provide final study results to 
ANZCTR 
 
X  X L  
17 Provide study status reports and 
final report to HREC and 
 
X  X L  
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Study Management 
 
Not 
applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, 
XM, DC) 
 update to TGA 
18 Manage site payments X      
19 
Manage submissions, contacts, 
follow-up, and annual updates  
 
X  X L  
20        
 
Footnote:  
 
 
Study Materials 
Not 
Applicable 
 
XG 
 
 GL MC 
Superviso
rs 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
1 
Develop, review, update, 
and approve study 
protocol 
 
Dev 
Upd 
Rev Rev App Rev 
2 
Provide expert support for 
protocol development (list 
clinical/scientific, 
statistical, regulatory, 
safety, & operational (ops) 
separately) 
 
 
  L X 
3 
Develop, review, update, 
and approve protocol 
amendments 
 
Dev 
Upd 
Rev Rev App Rev 
4 
Distribute  protocol to 
sites (may be in electronic 
format) 
 
X 
    
5 
Provide/develop, review, 
update, and approve 
consent document 
templates 
 
Dev 
Upd Rev Rev App Rev 
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Study Materials 
Not 
Applicable 
 
XG 
 
 GL MC 
Superviso
rs 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
6 
Provide/develop, review, 
update, and approve 
assent templates 
 
Dev 
Upd 
Rev Rev App Rev 
7 
Distribute consent 
template to sites (may be 
in electronic format) 
 
X 
  App  
8 
Review and approve 
consent / assent 
customisation from other 
clinical sites 
X 
 
    
9 
Develop, review, update, 
and approve Study 
Manual of Procedures 
(MOP) or Study Specific 
SOPs 
 
Dev 
Upd 
Rev Rev App Rev 
10 
Assemble/distribute study 
MOP or Study SOPs to 
site(s) 
 
X 
    
11 
Provide Investigator 
Brochure to site(s) (may 
be in electronic format) 
X 
 
    
12 
Develop, review, and 
approve study 
advertisements and/or 
patient handouts 
 
Dev 
Upd Rev Rev App Rev 
13 Package/label study herbs  X X X   
14 
Manage provision of study 
herbs  to subjects at the 
site 
 
 
X    
15 
Authorise study herbs and 
materials for 
destruction/return to 
sponsor or inform subjects 
 
X 
X  L  
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Study Materials 
Not 
Applicable 
 
XG 
 
 GL MC 
Superviso
rs 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 to discard study herbs 
16 Provide study aids   X     
17 
Prepare Essential 
Documents Binder  
 
X 
    
18 
Establish and Maintain 
Trial Master File 
 
X 
    
19        
20        
 
 
 
Study Initiation/Activation 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisor
s 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
1 
Conduct feasibility 
assessment 
 
X 
  L  
2 
Conduct PK feasibility 
assessment 
X 
 
    
3 
Develop, review, update, 
and approve subject 
recruitment plan  
 
Dev 
Upd 
Rev Rev App Rev 
4 
Conduct launch meeting 
with full study team 
 
X 
  L  
5 
Conduct ongoing project 
training 
 
X 
  L  
6 
Collect/conduct initial 
review of consent 
documents 
 
X 
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Study Initiation/Activation 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisor
s 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
7 
Collect/conduct initial 
review of essential study 
documents 
 
X 
    
8 
Collect financial 
disclosure information 
X 
 
    
9 
Schedule the initiation 
visits 
 
X 
    
10 
Conduct site initiation 
visits 
 
X 
X X L  
11 
Participate in site 
initiation visits 
 
X 
X X L  
12  
Ensure follow-up on 
action items and 
additional training needs 
identified during initiation 
visits 
 
X 
X X L  
13 
Approve sites for 
activation (to begin 
enrolment) 
 
 
  X/L  
14        
15        
 
 
On-Site Monitoring 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
1 
Conduct on-site 
monitoring and close out 
visits 
 
 
 X X  
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On-Site Monitoring 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
2 
Review and verify data 
recorded on CRFs 
against source 
documents 
 
 
 X X  
3 
Obtain corrections to 
CRFs, resolve queries 
 
 
 X X  
4 Review herbs records   X  X  
5 
Verify compliance with 
the protocol and 
regulations 
 
X 
 X L  
6 
Assess and maintain 
training of site personnel 
X 
 
  L  
7 
Provide written reports 
for all monitoring visits 
 
X 
  App  
8        
9        
 
 
Randomisation 
Not 
Applicable 
 
XG 
 
 
GL 
MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
1 
Develop, review, update, 
and approve 
randomisation plan  
 
Dev 
Upd 
Rev Rev App Rev 
2 
Develop mock 
randomisation tables 
 
X [work 
with an 
independent 
statistician] 
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Randomisation 
Not 
Applicable 
 
XG 
 
 
GL 
MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
3 
Develop and validate 
enrolment/randomisation 
process/system, 
including quality control 
measures 
 
X[work 
with an 
independent 
statistician] 
 
   
4 
Approve randomisation 
system/process 
  
 
 
X [work 
with an 
independent 
statistician] 
 
5 
Deploy and maintain 
randomisation 
system/process 
 
X [work 
with an 
independent 
statistician] 
 
   
6 
Provide support for 
randomisation 
system/process, 
including unmasking 
  
 
X 
L[work with 
an 
independent 
statistician] 
 
7 
Authorise randomization 
code breaks 
  
 
 
X [work 
with an 
independent 
statistician] 
 
8        
9        
 
 
Data Management and 
Database Programming 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
1 
Develop, review, update, 
and approve CRFs 
 
Dev 
Upd 
Rev Rev App Rev 
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Data Management and 
Database Programming 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 2 
Develop CRF completion 
instructions 
 X 
 
   
3 Print CRFs  X     
4 Store/distribute CRFs  X     
5 
Develop, review, update, 
and approve Data 
Management Plan  
 
Dev 
Upd 
Rev Rev App Rev 
6 
Provide document control 
of CRFs (log, track, 
archive) 
 X 
 
   
7 
Design database, edit 
check specifications, and 
perform testing 
 X 
 
   
8 
Prepare source document 
templates 
 X 
 
   
9 
Maintain source 
documents 
 X 
 
   
10 Enter data onto CRFs   X     
11 
Perform data cleaning 
and query generation 
 X 
 
   
12 
Update query responses 
in database 
 X 
 
   
13 
Conduct and approve 
medical coding of 
adverse events and 
concomitant meds  
 X 
 
   
14 Sign CRFs  X   L  
15 
Perform ongoing and 
final database audits  
  
 
X X  
16 Lock database  X  L L  
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Data Management and 
Database Programming 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 17        
18        
 
 
Biostatistics and Statistical 
Programming 
Not 
Applicabl
e 
 
XG 
 
 GL MC 
Supervisor
s 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
1 
Develop, review, update, 
and approve statistical 
analysis plan (SAP)  
 
Dev 
Upd 
Rev Rev App Rev 
2 
Develop mock displays for 
final report 
 X  
 
 L  
3 
Develop analysis database 
specifications 
 
[work with an independent statistician] 
4 
Create and validate analysis 
datasets 
 
5 
Develop, review, update, 
and approve annual report 
displays and analyses  
 
6 
Develop, review, update, 
and approve interim 
analyses, per protocol 
 
7 
Develop, review, update, 
and approve DSMB and 
other Safety Oversight 
analyses, data displays and 
reports 
 
8 
Develop, review, update, 
and approve final, per-
protocol analyses and data 
displays 
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Biostatistics and Statistical 
Programming 
Not 
Applicabl
e 
 
XG 
 
 GL MC 
Supervisor
s 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
9 
Develop, review, update, 
and approve statistical 
report  
 
10 
Provide analysis database 
and supporting 
documentation to PI 
 
11        
12        
 
 
Unanticipated Problem 
(UP) Reporting 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, 
XM, DC) 
 
1 
Collect Unanticipated 
Problem data and report 
UPs to the HREC 
 
X 
 X L  
2 
Report UPs to Program 
Official / Clinical 
Director, as applicable 
 
X 
 X L  
3        
4        
 
 
Safety Oversight 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, 
XM, DC) 
 1 Organise and plan the 
Safety Oversight kick-off 
 X   L  
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Safety Oversight 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, 
XM, DC) 
 meeting 
2 
Attend Safety Oversight 
kick-off meeting via 
teleconference 
 
X 
X X L X 
3 
Draft the Safety 
Oversight Charter 
 
X 
    
4 
Prepare for Safety 
Oversight meeting 
 
X 
    
5 Attend HREC meeting  X   L  
6 
Record HREC meeting 
minutes 
 
X 
    
7 
Develop, review, update, 
and approve Safety 
Analysis Plan 
 
Dev 
Upd 
Rev Rev App Rev 
8 
Provide ongoing Safety 
Oversight support 
 
X 
X X X L 
9 
Provide ongoing SAE 
support 
 
X 
X X X L 
10        
11        
 
 
SAE 
Management/Reporting 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, 
XM, DC) 
 1 
Prepare Safety 
Management Plan 
 
X 
    
2 Receive initial SAE  X   L  
Participant’s Initials:                                    Participant’s ID:                        Date: 
299 
 
SAE 
Management/Reporting 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, 
XM, DC) 
 information from sites 
3 
Obtain follow-up 
information regarding 
SAE/SAE closure from 
site 
 
X 
    
4 
Prepare narrative 
template for Regulatory 
Safety Reports 
 
X 
 X L  
5 
Write SAE narratives for 
Regulatory Safety 
Reports 
 
X 
 X L  
6 Maintain SAE database  X     
7 
Maintain SAE tracking 
database 
 
X 
    
8 
Prepare periodic line 
listings (blinded and 
unblinded) 
 
 
  X  
9 
Distribute periodic line 
listings 
 
 
  X  
10 
Perform unblinding of 
SAEs for 
expedited/SUSAR 
reporting 
 
 
L  X  
11 Report SAEs to HREC   X   L  
12 
Distribute SAE reports to 
HREC/TAG 
 
X 
    
13 
Prepare Dear Doctor 
Letters 
 
X 
    
14 
Distribute Dear Doctor 
Letters 
 
X 
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SAE 
Management/Reporting 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, 
XM, DC) 
 
15 
Conduct SAE database 
and AE clinical database 
reconciliation 
 
X 
    
16 
Conduct SAE database 
and SAE tracking log 
reconciliation 
 
X 
    
17 
Issue queries resulting 
from reconciliation 
 
X 
    
18 
Manage query resolution 
resulting from 
reconciliation 
 
 
  X  
19        
20        
 
Medical Monitoring 
Not 
Applicable 
 
XG 
 
 GL MC 
Supervisors 
(CX, TZ) 
Medical 
experts 
(NC, 
XM, DC) 
 
1 
Provide full medical 
monitoring/management 
services 
 
X 
X X X L 
2 
Provide scheduled 
medical monitoring 
backup  
 
X 
X X X L 
3 Provide CRA support  X X X X L 
4 Provide site support  X X X X L 
5        
6        
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Scientific/Medical Writing 
Not 
Applicabl
e 
 
XG 
 
 GL MC 
Supervisor
s 
(CX, TZ) 
Medical 
experts 
(NC, XM, 
DC) 
 
1 
Develop, review, update, 
and approve Clinical Study 
Report  
 
Dev 
Upd 
Rev Rev App Rev 
2 
Write medical narratives 
for the Clinical Study 
Report 
 
X 
    
3 
Develop, review, update, 
and approve manuscripts 
and presentations for 
submission to journals and 
conferences 
 
Dev 
Upd 
Rev Rev App Rev 
4        
5        
 
 
 
 
Approval and Update Plan 
This checklist will be approved by Charlie Xue or Tony Zhang via signature. 
 
This document will be maintained by PTQX trial group, any changes to 
responsibilities designated herein will be clearly communicated to relevant parties by 
PTQX trial group in a timely manner.  An updated version of the document will be 
distributed by PTQX trial group once it is updated. Changes from one version to the 
next will be outlined in the “Revision History” table by XG.  For updated versions 
that are distributed, signatures will only be collected from groups for which a 
responsibility has changed since the previous version. 
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I acknowledge receipt and review of this document. 
 
Prof. Charlie Xue or Dr Tony Zhang 
 
 
Date: 
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Appendix 27 Instructions for Recording Dosage of Topical Use Medicinal 
Cream or Ointment in the Daily Medical Record Sheet 
1. You are allowed to use any medicinal cream or ointment for your existing skin 
condition during the trial period; 
2. You or your parent/guardian is required to record the information of the 
medicines on section A. Record sheet for concomitant medications of the 
Daily Medical Record Sheet provided. You don’t need to record any 
moisturisers you have used for your skin condition;  
3. To record the dosage of cream or ointment, please write down how many 
finger tip unit (FTU) of the cream or ointment that you have used.  The picture 
below shows how to measure a FTU in an adult’s finger.   
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